=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehab484.pdf",
  "converted_date": "2026-01-31T14:49:06.401008",
  "file_size_bytes": 6895172,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehab484.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
EuropeanHeartJournal(2021)42,3227(cid:2)3337
doi:10.1093/eurheartj/ehab484
2021 ESC Guidelines on cardiovascular disease
prevention in clinical practice
Developed by the Task Force for cardiovascular disease prevention
in clinical practice with representatives of the European Society of
Cardiology and 12 medical societies
With the special contribution of the European Association of
Preventive Cardiology (EAPC)
Authors/Task Force Members: Frank L.J. Visseren* (Chairperson) (Netherlands),
Franc¸ois Mach* (Chairperson) (Switzerland), Yvo M. Smulders† (Task Force
Coordinator) (Netherlands), David Carballo† (Task Force Coordinator)
(Switzerland), Konstantinos C. Koskinas (Switzerland), Maria Ba€ck (Sweden),
Athanase Benetos8 (France), Alessandro Biffi7,10 (Italy), Jose´-Manuel Boavida9
(Portugal), Davide Capodanno (Italy), Bernard Cosyns (Belgium), Carolyn Crawford
(Northern Ireland), Constantinos H. Davos (Greece), Ileana Desormais (France),
Emanuele Di Angelantonio (United Kingdom), Oscar H. Franco (Switzerland), Sigrun
Halvorsen (Norway), F. D. Richard Hobbs13 (United Kingdom), Monika Hollander
(Netherlands), Ewa A. Jankowska (Poland), Matthias Michal11 (Germany), Simona
Sacco6 (Italy), Naveed Sattar (United Kingdom), Lale Tokgozoglu2 (Turkey),
Serena Tonstad (Norway), Konstantinos P. Tsioufis5 (Greece), Inekevan Dis3
(Netherlands), Isabelle C. van Gelder (Netherlands), Christoph Wanner4 (Germany),
Bryan Williams (United Kingdom), ESC Scientific Document Group
*Correspondingauthors:Thetwochairpersonscontributedequallytothedocument.FrankVisseren,DepartmentofVascularMedicine,UniversityMedicalCenterUtrecht,
Heidelberglaan100,3584CXUtrecht,Netherlands.Tel:þ31(0)887557324,E-mail:F.L.J.Visseren@umcutrecht.nl.Franc¸oisMach,CardiologyDepartment,GenevaUniversityHospital,
Perret-Gentil4,1211Geneva,Switzerland.Tel: þ41(0)223727192,E-mail:francois.mach@hcuge.ch.†Thetwotaskforcecoordinatorscontributedequallytothedocument.
Author/TaskForceMemberaffiliations:listedinAuthorinformation.
ESCClinicalPracticeGuidelinesCommittee(CPG):listedintheAppendix.
ESCsubspecialtycommunitieshavingparticipatedinthedevelopmentofthisdocument.Associations:AssociationofCardiovascularNursing&Allied
Professions(ACNAP),EuropeanAssociationofCardiovascularImaging(EACVI),EuropeanAssociationofPreventiveCardiology(EAPC),EuropeanHeartRhythmAssociation
(EHRA),HeartFailureAssociation(HFA).Councils:CouncilforCardiologyPractice,CouncilonHypertension.WorkingGroups:AortaandPeripheralVascularDiseases,
AtherosclerosisandVascularBiology,CardiovascularPharmacotherapy.
PatientForum
ThecontentoftheseEuropeanSocietyofCardiology(ESC)Guidelineshasbeenpublishedforpersonalandeducationaluseonly.Nocommercialuseisauthorized.Nopartof
theESCGuidelinesmaybetranslatedorreproducedinanyformwithoutwrittenpermissionfromtheESC.Permissioncanbeobtaineduponsubmissionofawrittenrequestto
OxfordUniversityPress,thepublisheroftheEuropeanHeartJournalandthepartyauthorizedtohandlesuchpermissionsonbehalfoftheESC(journals.permissions@oup.com).
Disclaimer:TheESCGuidelinesrepresenttheviewsoftheESCandwereproducedaftercarefulconsiderationofthescientificandmedicalknowledgeandtheevidenceavailableat
thetimeoftheirpublication.TheESCisnotresponsibleintheeventofanycontradiction,discrepancyand/orambiguitybetweentheESCGuidelinesandanyotherofficialrecommen-
dationsorguidelinesissuedbytherelevantpublichealthauthorities,inparticularinrelationtogooduseofhealthcareortherapeuticstrategies.Healthprofessionalsareencouraged
totaketheESCGuidelinesfullyintoaccountwhenexercisingtheirclinicaljudgment,aswellasinthedeterminationandtheimplementationofpreventive,diagnosticortherapeutic
medicalstrategies;however,theESCGuidelinesdonotoverride,inanywaywhatsoever,theindividualresponsibilityofhealthprofessionalstomakeappropriateandaccuratedeci-
sionsinconsiderationofeachpatient’shealthconditionandinconsultationwiththatpatientand,whereappropriateand/ornecessary,thepatient’scaregiver.NordotheESC
Guidelinesexempthealthprofessionalsfromtakingintofullandcarefulconsiderationtherelevantofficialupdatedrecommendationsorguidelinesissuedbythecompetentpublic
healthauthorities,inordertomanageeachpatient’scaseinlightofthescientificallyaccepteddatapursuanttotheirrespectiveethicalandprofessionalobligations.Itisalsothehealth
professional’sresponsibilitytoverifytheapplicablerulesandregulationsrelatingtodrugsandmedicaldevicesatthetimeofprescription.
Thisarticlehasbeenco-publishedwithpermissionintheEuropeanHeartJournalandtheEuropeanJournalofPreventiveCardiology.VC TheEuropeanSocietyofCardiology2021.All
rightsreserved.Thearticlesareidenticalexceptforminorstylisticandspellingdifferencesinkeepingwitheachjournal’sstyle.Eithercitationcanbeusedwhencitingthisarticle.
Forermissions,pleaseemail:journals.permissions@oup.com.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 2 ---
3228 ESCGuidelines
DocumentReviewers:GuyDeBacker(CPGReviewCoordinator)(Belgium),VeraRegitz-Zagrosek(CPG
ReviewCoordinator)(Germany),AnneHegeAamodt6(Norway),MagdyAbdelhamid(Egypt),
VictorAboyans(France),ChristianAlbus11(Germany),RiccardoAsteggiano(Italy),MagnusBa€ck
(Sweden),MichaelA.Borger(Germany),CarlosBrotons13(Spain),JelenaC(cid:2)elutkiene_ (Lithuania),Renata
Cifkova(CzechRepublic),MajaCikes(Croatia),FrancescoCosentino(Italy),NikolaosDagres(Germany),
TineDeBacker(Belgium),DirkDeBacquer(Belgium),VictoriaDelgado(Netherlands),
HesterDenRuijter(Netherlands),PaulDendale(Belgium),HeinzDrexel(Austria),VolkmarFalk
(Germany),LaurentFauchier(France),BrianA.Ference(UnitedKingdom),JeanFerrie`res(France),Marc
Ferrini(France),MilesFisher1(UnitedKingdom),DaniloFliser4(Germany),ZlatkoFras(Slovenia),Dan
Gaita3(Romania),SimonaGiampaoli(Italy),StephanGielen(Germany),IanGraham(Ireland),Catriona
Jennings(Ireland),TorbenJorgensen(Denmark),AlexandraKautzky-Willer12(Austria),MaryamKavousi
(Netherlands),WolfgangKoenig(Germany),AleksandraKonradi(Russia),DipakKotecha(United
Kingdom),UlfLandmesser(Germany),MadalenaLettino(Italy),BasilS.Lewis(Israel),Ale(cid:2)sLinhart(Czech
Republic),Maja-LisaLøchen(Norway),KonstantinosMakrilakis9(Greece),GiuseppeMancia5(Italy),
PedroMarques-Vidal(Switzerland),JohnWilliamMcEvoy(Ireland),PaulMcGreavy(UnitedKingdom),
BelaMerkely(Hungary),LisNeubeck(UnitedKingdom),JensCosedisNielsen(Denmark),JoepPerk
(Sweden),SteffenE.Petersen(UnitedKingdom),AnnaSoniaPetronio(Italy),MassimoPiepoli(Italy),
NanaGoarPogosova(Russia),EvaIreneBossanoPrescott(Denmark),KausikK.Ray2(UnitedKingdom),
ZeljkoReiner(Croatia),DimitriosJ.Richter(Greece),LarsRyde´n(Sweden),EvgenyShlyakhto(Russia),
MartaSitges(Spain),MiguelSousa-Uva(Portugal),IsabellaSudano(Switzerland),MonicaTiberi7,10(Italy),
RhianM.Touyz(UnitedKingdom),AndreaUngar8(Italy),W.M.MoniqueVerschuren(Netherlands),
OlovWiklund(Sweden),DavidWood(UnitedKingdom/Ireland),JoseLuisZamorano(Spain)
Allexpertsinvolvedinthedevelopmentoftheseguidelineshavesubmitteddeclarationsofinterest.
Thesehavebeencompiledinareportandpublishedinasupplementarydocumentsimultaneouslytothe
guidelines.ThereportisalsoavailableontheESCwebsitewww.escardio.org/guidelines
Collaboratingandendorsingsocieties:1EuropeanAssociationfortheStudyofDiabetes(EASD);
2EuropeanAtherosclerosisSociety(EAS);3EuropeanHeartNetwork(EHN);4EuropeanRenalAssociation
-EuropeanDialysisandTransplantAssociation(ERA-EDTA);5EuropeanSocietyofHypertension(ESH);
6EuropeanStrokeOrganization(ESO);7EuropeanFederationofSportsMedicineAssociation(EFSMA);
8EuropeanGeriatricMedicineSociety(EuGMS);9InternationalDiabetesFederationEurope(IDFEurope);
10InternationalFederationofSportMedicine(FIMS);11InternationalSocietyofBehaviouralMedicine
(ISBM);12InternationalSocietyofGenderMedicine(IGM);13WorldOrganizationofNationalColleges,
AcademiesandAcademicAssociationsofGeneralPractitioners/FamilyPhysicians(WONCA)(cid:2)Europe
...................................................................................................................................................................................................
Keywords Guidelines (cid:129) prevention (cid:129) personalized (cid:129) population (cid:129) riskestimation (cid:129) lifetimerisk (cid:129) lifetimebenefit (cid:129)
riskmanagement (cid:129) shareddecision-making (cid:129) stepwiseapproach (cid:129) nutrition (cid:129) smoking (cid:129) healthylifestyle (cid:129)
psychosocialfactors (cid:129) bloodpressure (cid:129) lipids (cid:129) diabetes (cid:129) smoking (cid:129) airpollution (cid:129) climatechange
.
. Table of Contents .. 3.2.1.3Cigarettesmoking .................................. 3242
.
.. 3.2.1.4Diabetesmellitus ................................... 3243
1.Preamble ..................................................... 3233 .
.. 3.2.1.5Adiposity .......................................... 3243
2.Introduction .................................................. 3234 .
.. 3.2.2.Sexandgenderandtheirimpactonhealth ............. 3243
2.1.Definitionandrationale ................................... 3235 .
.. 3.2.3.Atheroscleroticcardiovasculardiseaseriskclassification . 3243
2.2.Development ............................................. 3236 .
.. 3.2.3.1Astepwiseapproachtoriskfactortreatmentand
2.3.Cost-effectiveness ........................................ 3236 .
.. treatmentintensification.................................... 3243
2.4.Whatisnew? ............................................. 3236 ..
. 3.2.3.2Riskestimationinapparentlyhealthypeople ........... 3245
3.Riskfactorsandclinicalconditions ............................. 3236 ..
. 3.2.3.3Translatingcardiovasculardiseaseriskto
3.1.Targetpopulationforassessingcardiovasculardiseaserisk .. 3236 ..
. treatmentthresholds ...................................... 3250
3.2.Riskfactorsandriskclassification .......................... 3236 ..
. 3.2.3.4Riskestimationandriskfactortreatmentin
3.2.1.Riskfactors ........................................... 3236 ..
. apparentlyhealthypeople50(cid:2)69yearsofage............... 3253
3.2.1.1Cholesterol ........................................ 3242 ..
. 3.2.3.5Riskestimationandriskfactortreatment
3.2.1.2Bloodpressure ..................................... 3242 ..
. estimationinapparentlyhealthypeople(cid:3)70yearsofage ..... 3253
.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 3 ---
ESCGuidelines 3229
.
.
3.2.3.6Riskestimationandriskfactortreatmentin . 4.2.2.Howtoimprovemotivation? .......................... 3268
.
.
apparentlyhealthypeople<50yearsofage ................. 3254 . 4.2.3.Optimizingdrugadherence ........................... 3268
.
.
3.2.3.7Riskestimationandriskfactortreatmentinpatients . 4.2.4.Treatmentgoals ...................................... 3268
.
.
withestablishedatheroscleroticcardiovasculardisease ......... 3254 . 4.3.Optimizinglifestyle ........................................ 3268
.
.
3.2.3.8Riskestimationandriskfactortreatmentinpersons . 4.3.1.Physicalactivityandexercise .......................... 3268
.
.
withtype2diabetesmellitus ................................ 3256 . 4.3.1.1Physicalactivityprescription .......................... 3269
.
.
3.2.3.9Riskestimationandriskfactortreatmentin . 4.3.1.2Aerobicphysicalactivity ............................. 3269
.
.
personswithtype1diabetesmellitus ........................ 3257 . 4.3.1.3Resistanceexercise ................................. 3269
.
.
3.2.4.Communicationofcardiovasculardiseaserisk .......... 3257 .. 4.3.1.4Sedentarybehaviour ................................ 3269
.
3.3.Potentialriskmodifiers .................................... 3258 .. 4.3.2.Nutritionandalcohol ................................. 4269
.
3.3.1.Psychosocialfactors .................................. 3258 .. 4.3.2.1Fattyacids ......................................... 3270
.
3.3.2.Ethnicity .............................................. 3258 .. 4.3.2.2Mineralsandvitamins............................... 3270
.
3.3.3.Imaging ................................................. 33 .. 4.3.2.3Fibre .............................................. 3270
.
3.3.3.1Coronaryarterycalcium ............................. 3259 .. 4.3.2.4Specificfoodsandfoodgroups ....................... 3270
.
3.3.3.2Contrastcomputedtomographycoronary .. 4.3.2.4.1.Fruits,vegetables,andpulses .................. 3270
.
angiography .............................................. 3259 .. 4.3.2.4.2.Nuts ......................................... 3271
.
3.3.3.3Carotidultrasound .................................. 3259 .. 4.3.2.4.3.Meat ......................................... 3271
.
3.3.3.4Arterialstiffness .................................... 3259 .. 4.3.2.4.4.Fishandfishoilsupplements .................. 3271
.
3.3.3.5Anklebrachialindex ................................ 3259 .. 4.3.2.4.5.Alcoholicbeverages .......................... 3271
. 3.3.3.6Echocardiography .................................. 3259 .. 4.3.2.4.6.Softdrinksandsugar.......................... 3272
.
.
3.3.4.Frailty ................................................ 3259 . 4.3.2.4.7.Coffee ....................................... 3272
.
.
3.3.5.Familyhistory......................................... 3259 . 4.3.2.4.8.Functionalfoods.............................. 3272
.
.
3.3.6.Genetics ............................................. 3260 . 4.3.2.4.9.Dietarypatterns .............................. 3272
.
.
3.3.7.Socioeconomicdeterminants ......................... 3260 . 4.3.3.Bodyweightandcomposition .......................... 3272
.
.
3.3.8.Environmentalexposure .............................. 3260 . 4.3.3.1Treatmentgoalsandmodalities ...................... 3272
.
.
3.3.9.Biomarkersinbloodorurine .......................... 3260 . 4.3.3.2Dietsforweightloss................................. 3272
.
.
3.3.10.Bodycomposition ................................... 3260 . 4.4.Mentalhealthcareandpsychosocialinterventions .......... 3273
.
.
3.3.10.1Whichindexofobesityisthebestpredictorof . 4.5.Smokingintervention ..................................... 3273
.
.
cardiovascularrisk? ........................................ 3261 . 4.5.1.Smokingcessation .................................... 3273
.
.
3.3.10.2Riskreclassification ................................ 3261 . 4.5.2.Evidence-baseddruginterventions .................... 3275
.
.
3.3.10.3Assessriskfactorsandcardiovasculardisease . 4.5.2.1Electroniccigarettes ................................ 3275
.
.
riskinpersonswithobesity .................................. 3262 .. 4.6.Lipids ..................................................... 3275
.
3.4.Clinicalconditions ........................................ 3262 .. 4.6.1.Measurementoflipidsandlipoproteins ................ 3275
.
3.4.1.Chronickidneydisease................................ 3262 .. 4.6.1.1Fastingvs.non-fastingmeasurements ................. 3275
.
3.4.2.Atrialfibrillation....................................... 3262 .. 4.6.1.2Low-densitylipoproteincholesterolmeasurement ........ 50
.
3.4.3.Heartfailure .......................................... 3262 .. 4.6.1.3Non-high-densitylipoproteincholesterol ............... 3276
.
3.4.4.Cancer ............................................... 3263 .. 4.6.1.4ApolipoproteinB ................................... 3276
.
3.4.4.1Diagnosisandscreening ............................. 3264 .. 4.6.2.Defininglipidgoals .................................... 3276
.
3.4.4.2Preventionofcardiotoxicityandcardiovascular .. 4.6.2.1Low-densitylipoproteincholesterolgoals .............. 3276
.
riskfactors................................................ 3264 .. 4.6.2.2Triglyceride-richlipoproteinsandtheirremnants ........ 3276
.
3.4.5.Chronicobstructivepulmonarydisease ................ 3264 .. 4.6.2.3High-densitylipoproteincholesterol ................... 3276
.
3.4.6.Inflammatoryconditions .............................. 3265 .. 4.6.3.Strategiestocontroldyslipidaemias .................... 3278
.
. 3.4.7.Infections(humanimmunodeficiencyvirus,influenza, . 4.6.3.1Strategiestocontrollow-densitylipoproteincholesterol .. 3278
.
.
periodontitis) .............................................. 3265 . 4.6.3.1.1.Dietandlifestylemodifications ................ 3278
.
.
3.4.8.Migraine .............................................. 3265 . 4.6.3.1.2.Drugsfortreatmentofdyslipidaemias ......... 3278
. .
3.4.9.Sleepdisordersandobstructivesleepapnoea .......... 3265 . 4.6.3.1.3.Statins ....................................... 3279
.
.
3.4.10.Mentaldisorders .................................... 3265 . 4.6.3.1.3.1.Adverseeffects,interactions,and
.
.
3.4.11.Non-alcoholicfattyliverdisease ...................... 3266 . adherencetostatintherapy ......................... 3279
.
.
3.4.12.Sex-specificconditions............................... 3266 . 4.6.3.1.4.Cholesterolabsorptioninhibitors(ezetimibe) . 3279
.
.
3.4.12.1Obstetricconditions ............................... 3266 . 4.6.3.1.5.Proproteinconvertasesubtilisin/kexintype9
.
.
3.4.12.2Non-obstetricconditions ........................... 3266 . inhibitors.............................................. 3279
.
.
3.4.12.3Erectiledysfunction ................................ 3266 . 4.6.3.2Strategiestocontrolplasmatriglycerides .............. 3279
.
.
4.Riskfactorsandinterventionsattheindividuallevel ............. 3266 .. 4.6.3.2.1.Fibrates ...................................... 3279
.
4.1.Treatmentrecommendations:classes,grades,and .. 4.6.4.Importantgroups ..................................... 3280
.
freedomofchoice ............................................ 3266 .. 4.6.4.1Women ........................................... 3280
.
4.2.Optimizingcardiovascularriskmanagement ................ 3268 .. 4.6.4.2Olderpatients((cid:3)70years) .......................... 3280
.
4.2.1.Goalsofclinician-patientcommunication .............. 3268 . 4.6.4.3Diabetesmellitus ................................... 3280
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 4 ---
3230 ESCGuidelines
.
.
4.6.4.4Chronickidneydisease .............................. 3281 . 6.5.Chronickidneydisease .................................... 3298
.
.
4.6.4.5Familialhypercholesterolaemia ...................... 3281 . 6.6.Atrialfibrillation........................................... 3298
.
.
4.7.Bloodpressure ........................................... 3281 . 6.7.Multimorbidity ............................................ 3299
.
.
4.7.1.Definitionandclassificationofhypertension ............ 3283 . 7.Keymessages ................................................. 3299
.
.
4.7.2.Bloodpressuremeasurement ......................... 3283 . 8.Gapsinevidence .............................................. 3302
.
.
4.7.2.1Officebloodpressuremeasurement .................. 3283 . 9.‘Whattodo’and‘whatnottodo’messagesfromtheguidelines . 3205
.
.
4.7.2.2Unattendedautomatedofficebloodpressure . 10.Qualityindicators ............................................ 3310
.
.
measurement ............................................. 3283 . 11.Supplementarydata .......................................... 3310
.
.
4.7.2.3Ambulatorybloodpressuremonitoring ................ 3283 .. 12.Authorinformation .......................................... 3310
.
4.7.2.4Homebloodpressuremonitoring ..................... 3283 .. 13.Appendix .................................................... 3311
.
4.7.3.Screeninganddiagnosisofhypertension ............... 3283 .. 14.References .................................................. 3312
.
4.7.3.1White-coatandmaskedhypertension ................. 3284 ..
.
4.7.4.Clinicalevaluationandriskstratificationin .. Recommendations
.
hypertensivepatients ....................................... 3284 ..
.
4.7.5.Treatmentofhypertension ............................ 3285 .. RecommendationsforCVDriskassessment ...................... 3242
.
4.7.5.1Lifestyleinterventionstolowerbloodpressure .. RecommendationsforCVDriskestimation ...................... 3256
.
and/orreducecardiovascularrisk ............................ 3285 .. RecommendationforCVDriskcommunication .................. 3257
.
4.7.5.2Initiationofdrugtreatment .......................... 3285 .. RecommendationsforCVDriskmodifiers........................ 3257
.
4.7.5.3Bloodpressuretreatmenttargets ..................... 3285 .. Recommendationsforcardiovasculardiseaseriskrelatedtoair
. 4.7.5.3.1.Bloodpressuretargetsaccordingtoambulatory .. pollution ........................................................ 3260
.
.
andhomebloodpressuremonitoring .................. 3287 . Recommendationsforcardiovasculardiseaseassessmentinspecific
.
.
4.7.5.4Drugtreatmentofhypertension ...................... 3288 . clinicalconditions ............................................... 3261
.
.
4.7.6.Resistanthypertension ................................ 3288 . Recommendationsforphysicalactivity ........................... 3268
.
.
4.7.7.Managementofhypertensioninwomen ............... 3288 . Recommendationsfornutritionandalcohol ...................... 3269
.
.
4.7.8.Durationoftreatmentandfollow-up .................. 3288 . Recommendationsforbodyweight .............................. 3272
.
.
4.8.Diabetesmellitus ......................................... 3288 .. Recommendationsformentalhealthcareandpsychosocial
.
4.8.1.Keyriskfactorconceptsandnewerparadigms ......... 3289 .. interventionsattheindividuallevel ............................... 3273
.
4.8.1.1Lifestyleintervention ................................ 3289 .. Recommendationsforsmokinginterventionstrategies ............ 3273
.
4.8.1.2Glycaemiccontrol .................................. 3289 .. Recommendationonlow-densitylipoproteincholesterolgoals .... 3276
.
4.8.1.3Newerdiabetesmellitusdrugclasses:cardiovascular .. Recommendationsforpharmacologicallow-densitylipoproteincholesterol
.
diseasebenefits ........................................... 3290 .. lowering for those <70 years of age (for recommendationsfor persons
.
4.8.2.Type1diabetesmellitus............................... 3290 .. aged>_70years,seerespectiverecommendationstables)............ 3278
.
4.9.Antithrombotictherapy ................................... 3290 .. Recommendationsfordrugtreatmentsofpatientswith
.
4.9.1.Antithrombotictherapyinindividualswithout .. hypertriglyceridaemia............................................. 3284
.
atheroscleroticdisease ..................................... 3291 .. Recommendationsforthetreatmentofdyslipidaemiasinolder
.
4.9.2.Antithrombotictherapyinindividualswithestablished .. people(>_70years) .............................................. 3284
.
atheroscleroticdisease ..................................... 3291 .. Recommendationsforthetreatmentofdyslipidaemiasindiabetes
.
4.9.3.Protonpumpinhibitors ............................... 3291 .. mellitus.......................................................... 3284
.
4.10.Anti-inflammatorytherapy ............................... 3291 .. Recommendationsforlipidmanagementinpatientswithmoderate- .
4.11.Cardiacrehabilitationandpreventionprogrammes ........ 3292 .. toseverechronickidneydisease(KidneyDiseaseOutcomes
.
5.Policyinterventionsatthepopulationlevel ..................... 3292 .. QualityInitiativestages3(cid:2)5) ..................................... 3281
.
5.1.Population-levelapproachestothepreventionof .. Summaryofrecommendationsfortheclinicalmanagementof
.
. cardiovasculardisease ......................................... 3293 . hypertension .................................................... 3282
.
.
5.2.Specificriskfactorinterventionsatthepopulationlevel ..... 3293 . Recommendationsforthetreatmentofpatientswithdiabetes
.
.
5.2.1.Physicalactivity ....................................... 3293 . mellitus ......................................................... 3288
. .
5.2.2.Diet .................................................. 3293 . Recommendationsforantithrombotictherapy.................... 3290
.
.
5.2.3.Smokingandtobaccouse ............................. 3293 . Recommendationforanti-inflammatorytherapy .................. 3291
.
.
5.2.4.Alcohol .............................................. 3293 .. Recommendationsforcardiacrehabilitation ...................... 3292
.
5.3.Environment,airpollution,andclimatechange ............. 3293 .. Recommendationsforpolicyinterventionsatthepopulationlevel .. 3292
.
5.3.1.Climatechange ....................................... 3294 .. Recommendationsforpatientswithcoronaryarterydisease ...... 3294
.
5.4.Implicationsforpublichealthpolicyandadvocacyatthe .. Recommendationsregardingpharmacologicalandnon-
.
governmentalandnon-governmentallevel ..................... 3294 .. pharmacologicalinterventionsforpatientswithsymptomatic
.
6.Riskmanagementofdisease-specificcardiovasculardisease ..... 3294 .. (NewYorkHeartAssociationclassII-IV)heartfailurewithreduced
.
6.1.Coronaryarterydisease ................................... 3294 .. ejectionfraction(leftventricularejectionfraction<40%)with
.
6.2.Heartfailure .............................................. 3295 .. provenbenefitsonclinicaloutcomes,includingcardiovascular
.
6.3.Cerebrovasculardiseases ................................. 3296 .. morbidityandmortality.......................................... 3295
.
6.4.Lowerextremityarterydisease ............................ 3297 . Recommendationsforpatientswithcerebrovasculardisease ...... 3297
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 5 ---
ESCGuidelines 3231
.
.
Recommendationsforpatientswithlowerextremityarterydisease: . Figure7Flowchartofcardiovascularriskandriskfactor
.
.
bestmedicaltherapy ............................................ 3297 . treatmentinpatientswithestablishedatherosclerotic
.
.
Recommendationsinpatientswithchronickidneydisease:best . cardiovasculardisease ........................................... 3253
.
.
medicaltherapy ................................................. 3310 . Figure8Flowchartofcardiovascularriskandriskfactortreatment
.
.
Recommendationsforlifestyleinterventionsandmanagementofrisk . inpatientswithtype2diabetesmellitus........................... 3255
.
.
factorsandconcomitantdiseasesinpatientswithatrialfibrillation .. 3310 . Figure9Theroleofriskfactorsandcomorbiditiesinatrialfibrillation 3263
.
.
. Figure10Estimatedpercentagechangeinriskofcoronaryheartdisease
.
.
. associatedwithisocaloricsubstitutionsofsaturatedfatforother
Tables .
.
.. typesoffatorcarbohydrates .................................... 3271
.
Table1Classesofrecommendations ............................. 3234 .. Figure11Lifetimeatheroscleroticcardiovasculardiseasebenefit
.
Table2Levelsofevidence ....................................... 3234 .. fromsmokingcessationforapparentlyhealthypersons,basedon
.
Table3Newrecommendationsandnewandrevisedconcepts .... 3237 .. thefollowingriskfactors:age,sex,systolicbloodpressure,and
.
Table4Patientcategoriesandassociatedcardiovasculardisease .. non-high-densitylipoprotein-cholesterol ......................... 3274
.
risk ............................................................. 3244 .. Figure12Averageyears-free-of-cardiovasculardiseasegainedper
.
Table5Cardiovasculardiseaseriskcategoriesbasedon .. 1mmol/L(40mg/dL)low-densitylipoproteincholesterol
.
SystemicCoronaryRiskEstimation2andSystemicCoronary .. reductioninapparentlyhealthypersons .......................... 3277
.
RiskEstimation2-OlderPersonsinapparentlyhealthypeople ... Figure13Expectedlow-densitylipoproteincholesterolreductions
accordingtoage ................................................. 3251 ... forcombinationtherapies ....................................... 3278
Table6Treatmentgoalsfordifferentpatientcategories ........... 3267 ... Figure14Screeninganddiagnosisofhypertension ................ 3284
Table7Classificationofphysicalactivityintensityandexamplesof ... Figure15Lifetimebenefitfromloweringsystolicbloodpressure
.
absoluteandrelativeintensitylevels ............................. 3269 .. by10mmHgforapparentlyhealthypersons,basedonthe
.
Table8Healthydietcharacteristics............................... 3270 .. followingriskfactors:age,sex,currentsmoking,systolicblood
.
Table9‘Verybriefadvice’forsmokingcessation .................. 3275 .. pressure,non-highdensitylipoproteincholesterol................. 3286
.
Table10Correspondingnon-high-densitylipoproteincholesterol .. Figure16Coredrugtreatmentstrategyforhypertension.......... 3287
.
andapolipoproteinBlevelsforcommonlyusedlow-density ..
.
lipoproteincholesterolgoals ..................................... 3275 ..
Table11DutchLipidClinicNetworkdiagnosticcriteriaforfamilial
... Abbreviations and acronyms
.
.
hypercholesterolaemia .......................................... 3281 .
Table12Categoriesforconventionallymeasuredseatedoffice
... %HR
max
Percentageofmaximumheartrate
.. ABC AtrialfibrillationBetterCare
bloodpressurea ................................................. 3283 .
.. ABI Anklebrachialindex
Table13Definitionsofhypertensionaccordingtooffice, .
.. ABPM Ambulatorybloodpressuremonitoring
ambulatory,andhomebloodpressure ........................... 3283 .
.. ACCORD ActiontoControlCardiovascularRiskin
Table14Considerationsinbloodpressuremeasurement ......... 3283 .
.
. Diabetes
Table15Indicationsforhomebloodpressuremonitoringor .
.
. ACE Angiotensin-convertingenzyme
ambulatorybloodpressuremonitoring ........................... 3284 .
.
. ACR Albumin-to-creatinineratio
Table16Routinetestsforpatientswithhypertension ............. 3285 .
.
. ACS Acutecoronarysyndromes
Table17Patientcharacteristicsthatshouldraisethesuspicionof .
.
. ADA AmericanDiabetesAssociation
secondaryhypertension.......................................... 3285 . .
. ADVANCE ActioninDiabetesandVascularDisease:
Table18Recommendedofficebloodpressuretargetranges.The ..
. preterAxanddiamicroN-MRControlled
firststepinallgroupsisareductiontosystolicbloodpressure ..
. Evaluation
<140mmHg .................................................... 3287 ..
. AF Atrialfibrillation .
.
. AMI Acutemyocardialinfarction Figures ..
.. ARB Angiotensinreceptorblocker
.
Figure1CentralIllustration ...................................... 3235
.. ARNI Angiotensinreceptorneprilysininhibitor
.
Figure2Examplesofastepwiseapproachtoriskstratificationand
.. ASCEND AStudyofCardiovascularEventsinDiabetes
.
treatmentoptions ............................................... 3245
.. ASCVD Atheroscleroticcardiovasculardisease
.
Figure3SystematicCoronaryRiskEstimation2andSystematic
... b.i.d. Bisindie(twiceaday)
CoronaryRiskEstimation2-OlderPersonsriskchartsfor
... BMI Bodymassindex
fatalandnon-fatal(myocardialinfarction,stroke)cardiovascular
... BP Bloodpressure
disease .......................................................... 3246
... b.p.m. Beatsperminute
Figure4RiskregionsbasedonWorldHealthOrganization
... CAC Coronaryarterycalcium
cardiovascularmortalityrates .................................... 3250
... CAD Coronaryarterydisease
Figure5Schematicrepresentationofincreasing10-year
... CANTOS CanakinumabAntiinflammatoryThrombosis
cardiovasculardiseaseriskthresholdsacrossagegroups .......... 3251
... OutcomeStudy
.
Figure6Flowchartofcardiovasculardiseaseriskandriskfactor .. CCB Calciumchannelblocker
.
treatmentinapparentlyhealthypersons .......................... 3252 . CCS Chroniccoronarysyndromes
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 6 ---
3232 ESCGuidelines
.
CCTA Contrastcomputedtomographyangiography .. HR Hazardratio
.
CHD Coronaryheartdisease .. IL Interleukin
.
CI Confidenceinterval .. IMPROVE-IT ImprovedReductionofOutcomes:Vytorin
.
CKD Chronickidneydisease .. EfficacyInternationalTrial
.
CKD-EPI ChronicKidneyDiseaseEpidemiology .. IMT Intima-mediathickness
.
.
COLCOT ColchicineCardiovascularOutcomesTrial . INVEST INternationalVErapamil-SR/TrandolaprilSTudy
.
.
COMPASS CardiovascularOutcomesforPeopleUsing . LDL Low-densitylipoprotein
.
.
AnticoagulationStrategies . LDL-C Low-densitylipoproteincholesterol
.
.
COPD Chronicobstructivepulmonarydisease . LDLR Low-densitylipoproteinreceptor
.
.
CR Cardiacrehabilitation . LEAD Lowerextremityarterydisease
.
.
CTA Computedtomographyangiography . LIFE-CVD LIFEtime-perspectiveCardioVascularDisease
.
.
CV Cardiovascular . LoDoCo Low-dosecolchicine
.
.
CVD Cardiovasculardisease . LV Leftventricular/ventricle
.
.
DAPA-CKD DapagliflozinandPreventionofAdverse . LVEF Leftventricularejectionfraction
.
.
OutcomesinChronicKidneyDisease . MACE Majoradversecardiovascularevents
.
.
DAPT Dualantiplatelettherapy . MET Metabolicequivalentoftask
.
.
DASH DietaryApproachestoStopHypertension .. mHealth Mobiledevice-basedhealthcare
. DBP Diastolicbloodpressure .. MRA Mineralocorticoidreceptorantagonist
.
DCCT DiabetesControlandComplicationsTrial .. MUFA Monounsaturatedfattyacid
.
DIAL Diabeteslifetime-perspectiveprediction .. N/A Notapplicable
.
DM Diabetesmellitus .. NAFLD Non-alcoholicfattyliverdisease
.
e-cigarettes Electroniccigarettes .. NRT Nicotine-replacementtherapy
.
EAPC EuropeanAssociationofPreventiveCardiology .. NYHA NewYorkHeartAssociation
.
EAS EuropeanAtherosclerosisSociety .. o.d. Omnidie(onceaday)
.
EASD EuropeanAssociationfortheStudyofDiabetes .. OARS Open-endedquestions,Affirmation,Reflecting
.
EBCR Exercise-basedcardiacrehabilitation .. listening,andSummarizing
.
ECG Electrocardiographic/electrocardiogram .. OR Oddsratio
.
.
ED Erectiledysfunction . OSA Obstructivesleepapnoea
.
.
eGFR Estimatedglomerularfiltrationrate . PA Physicalactivity
.
.
EORP EURObservationalResearchProgramme . PAD Peripheralarterydisease
.
.
EPIC EuropeanProspectiveInvestigationintoCancer . PAP Positiveairwaypressure
.
.
andNutrition . PCI Percutaneouscoronaryintervention
.
.
ESC EuropeanSocietyofCardiology . PCSK9 Proproteinconvertasesubtilisin/kexintype9
.
.
ESH EuropeanSocietyofHypertension . PM Particulatematter
.
.
ESVS EuropeanSocietyforVascularSurgery . PM Particulatematter<2.5mm
. 2.5
.
EU EuropeanUnion . PUFA Polyunsaturatedfattyacid
.
.
EUROASPIRE EuropeanActiononSecondaryandPrimary . QI Qualityindicator
.
.
PreventionbyInterventiontoReduceEvents . RAAS Renin-angiotensin-aldosteronesystem .
.
EuroHeart EuropeanUnifiedRegistriesOnHeartCare .. RAS Renin-angiotensinsystem
.
EvaluationandRandomizedTrials .. RCT Randomizedcontrolledtrial
.
EXPERT EXercisePrescriptioninEverydaypractice& .. REDUCE-IT ReductionofCardiovascularEventswith
.
RehabilitationTraining .. IcosapentEthyl(cid:2)InterventionTrial
. FEV1 Forcedexpiratoryvolumein1second .. REWIND ResearchingCardiovascularEventsWitha
.
FH Familialhypercholesterolaemia .. WeeklyIncretininDiabetes
.
FITT Frequency,intensity,timeduration,andtypeof .. RPE Ratingofperceivedexertion
.
exercise .. RR Relativerisk
.
GFR Glomerularfiltrationrate .. SAVOR-TIMI53 SaxagliptinAssessmentofVascularOutcomes
.
GLP-1RA Glucagon-likepeptide-1receptoragonist .. RecordedinPatientswithDiabetesMellitus
.
HbA1c Glycatedhaemoglobin .. ThrombolysisinMyocardialInfarction
.
HBPM Homebloodpressuremonitoring .. SBP Systolicbloodpressure
.
.
HDL-C High-densitylipoproteincholesterol . SCORE SystemicCoronaryRiskEstimation
.
.
HF Heartfailure . SCORE2 SystemicCoronaryRiskEstimation2
.
.
HFpEF Heartfailurewithpreservedejectionfraction . SCORE2-OP SystematicCoronaryRiskEstimation2-Older
.
.
HFrEF Heartfailurewithreducedejectionfraction . Persons
.
.
HIV Humanimmunodeficiencyvirus . SCOT-HEART ScottishComputedTomographyoftheHeart
.
.
HMOD Hypertension-mediatedorgandamage . SGLT2 Sodium-glucosecotransporter2
.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 7 ---
ESCGuidelines 3233
.
.
SHARP StudyofHeartandRenalProtection .. providingabetterunderstandingofmedicalpracticeinEuropeand
.
SMART SecondaryManifestationsofArterialDisease .. aroundtheworld,basedonhigh-qualitydatacollectedduringroutine
.
SMART Specific,Measurable,Achievable,Realistic, .. clinicalpractice.
.
Timely .. Furthermore,theESChasdevelopedandembeddedinthisdocu-
.
SMART-REACH SecondaryManifestationsofArterial .. mentasetofqualityindicators(QIs),whicharetoolstoevaluatethe
.
Disease-ReductionofAtherothrombosisfor .. level of implementation of the guidelines and may be used by the
.
ContinuedHealth .. ESC, hospitals, healthcare providers and professionals to measure
.
SNRI Serotonin-noradrenalinereuptakeinhibitor .. clinicalpracticeaswellasusedineducationalprogrammes,alongside
.
SPRINT SystolicBloodPressureInterventionTrial .. thekeymessagesfromtheguidelines,toimprovequalityofcareand
.
SSRI Selectiveserotoninreuptakeinhibitor .. clinicaloutcomes.
.
STAREE STAtinTherapyforReducingEventsinthe .. The Members of this Task Force were selected by the ESC,
.
Elderly .. including representation from its relevant ESC sub-specialty
.
STRENGTH Long-TermOutcomesStudytoAssessStatin .. groups, in order to represent professionals involved with the
.
ResidualRiskwithEpanovainHigh .. medical care of patientswiththis pathology.Selected experts in
.
CardiovascularRiskPatientswith ... thefieldundertookacomprehensivereviewofthepublishedevi-
Hypertriglyceridemia ... dence for management of a given condition according to ESC
SUPRIM SecondaryPreventioninUppsalaPrimary ... Clinical Practice Guidelines Committee (CPG) policy. A critical
HealthCareproject ... evaluation of diagnostic and therapeutic procedures was per-
.
SWITCHD StockholmWomen’sInterventionTrialfor .. formed,includingassessmentoftherisk(cid:2)benefitratio.Thelevel
.
CoronaryHeartDisease .. ofevidenceandthestrengthoftherecommendationofparticular
.
TIA Transientischaemicattack .. managementoptionswereweighedandgradedaccordingtopre-
.
TNF Tumournecrosisfactor .. definedscales,asoutlinedbelow.
.
TOD Targetorgandamage .. Theexpertsofthewritingandreviewingpanelsprovideddecla-
.
UK UnitedKingdom .. ration of interest forms for all relationships that might be per-
.
UKPDS UKProspectiveDiabetesStudy .. ceived as real or potential sources of conflicts of interest. Their
.
VADT VeteransAffairsDiabetesTrial .. declarationsofinterestwerereviewedaccordingtotheESCdec-
.
VITAL VitaminDandOmega-3Trial .. laration of interest rules and can be found on the ESC website
.
VO Oxygenconsumption .. (http://www.escardio.org/guidelines)andhavebeencompiledina
2 .
WHO WorldHealthOrganization .. report and published in a supplementary document simultane-
.
.. ouslytotheguidelines.
.
.. This process ensures transparency and prevents potential
.
1. Preamble .. biasesinthedevelopmentandreviewprocesses.Anychangesin
.
.. declarationsofinterestthatariseduringthewritingperiodwere
.
Guidelinessummarizeandevaluateavailableevidencewiththeaimof .. notified to the ESC and updated. The Task Force received its
.
assisting health professionals in proposing the best management .. entire financial support from the ESC without any involvement
.
strategiesforanindividualpatientwithagivencondition.Guidelines .. fromthehealthcareindustry.
.
and their recommendations should facilitate decision making of .. TheESCCPGsupervisesandcoordinatesthepreparationofnew
.
health professionals in their dailypractice.However,the final deci- .. guidelines.TheCommitteeisalsoresponsiblefortheendorsement
.
sionsconcerninganindividualpatientmustbemadebytheresponsi- .. processoftheseguidelines.TheESCGuidelinesundergoextensive .
ble health professional(s) in consultation with the patient and .. reviewbytheCPGandexternalexperts.Afterappropriaterevisions
.
.
caregiverasappropriate. . theguidelinesaresigned-offbyalltheexpertsinvolvedintheTask
.
.
Agreatnumberofguidelineshavebeenissuedinrecentyearsby . Force.Thefinalizeddocumentissigned-offbytheCPGforpublica-
.
. theEuropeanSocietyofCardiology(ESC),aswellasbyothersoci- . tionintheEuropeanHeartJournal.Theguidelinesweredeveloped
.
.
etiesandorganizations.Becauseoftheirimpactonclinicalpractice, . after careful consideration of the scientific and medical knowledge
.
.
quality criteria for thedevelopmentofguidelines havebeen estab- . andtheevidenceavailableatthetimeoftheirdating.
. .
lishedinordertomakealldecisionstransparenttotheuser.Therec- . ThetaskofdevelopingESCGuidelinesalsoincludesthecreation
.
.
ommendations for formulating and issuing ESC Guidelines can be . ofeducationaltoolsandimplementationprogrammesfortherecom-
.
.
found on the ESC website (https://www.escardio.org/Guidelines). .. mendationsincludingcondensedpocketguidelineversions,summary
.
TheESCGuidelinesrepresenttheofficialpositionoftheESCona .. slides, summary cards for non-specialists and an electronic version
.
giventopicandareregularlyupdated. .. for digital applications (smartphones, etc.). These versions are
.
In additiontothe publicationofClinicalPracticeGuidelines,the .. abridged and thus, for more detailed information, the user should
.
ESC carries out the EURObservational Research Programme of .. alwaysaccesstothefulltextversionoftheguidelines,whichisfreely
.
international registries of cardiovascular diseases and interventions .. available via the ESC website and hosted on the EHJ website. The
.
whichareessentialtoassessdiagnostic/therapeuticprocesses,useof .. NationalCardiac Societies of the ESC are encouraged to endorse,
.
resources and adherence to guidelines. These registries aim at . adopt, translate and implementall ESCGuidelines.Implementation
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 8 ---
3234 ESCGuidelines
Table1 Classesofrecommendations
Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
Class II
Class IIa Weight of evidence/opinion is in Should be considered
Class IIb May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
Table2 Levelsofevidence
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
.
.
programmes are needed because it has been shown that the out- . necessary.It is also the healthprofessional’sresponsibilitytoverify
.
.
comeofdiseasemaybefavourablyinfluencedbythethoroughappli- . therulesandregulationsapplicableineachcountrytodrugsanddevi-
.
.
cationofclinicalrecommendations. . cesatthetimeofprescription.
.
.
HealthprofessionalsareencouragedtotaketheESCGuidelines .
.
.
fullyintoaccountwhenexercisingtheirclinicaljudgment,aswellasin .
.
.
thedeterminationandtheimplementationofpreventive,diagnostic . 2. Introduction
.
.
ortherapeuticmedicalstrategies.However,theESCGuidelinesdo .
.
.
not override inany waywhatsoever theindividualresponsibility of .. Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence
.
health professionalstomake appropriate and accurate decisions in .. andmortalityratesaredeclininginmanycountriesinEurope,butitis
.
considerationofeachpatient’shealthconditionandinconsultation .. stillamajorcauseofmorbidityandmortality.Overthepastfewdeca-
.
withthatpatientorthepatient’scaregiverwhereappropriateand/or . des, major ASCVD risk factors have been identified. The most
snoitadnemmocer
fo
sessalC
1202
CSE©
1202
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 9 ---
ESCGuidelines 3235
Prevention goals for all
Apparently healthy people
10-year CVD risk
Patients with establishedASCVD
Residual CVD risk
Specific risk conditions
Diabetes mellitus, CKD, Familial
Hypercholesterolaemia
Risk modifiers
Psychosocial stress
Ethnicity
CVD risk estimation Imaging (e.g. coronary calcium scoring)
Comorbidity
e.g. cancer, COPD, inflammatory disease,
mental disorders, sex-specific conditions
Informed discussion
About CVD (lifetime) risk and
treatment benefits tailored to individual
needs and preferences considering
age, comorbidities, frailty, polypharmacy
Personalized treatment
decisions
Cost-effectiveness
considerations
Individual-level
Population-level
interventions and
interventions
treatment goals
Lifestyle (physical activity, body
weight,nutrition) Public health policy and advocacy
Psychosocial factors Specific risk factor interventions
Risk factor treatment (smoking, at the population level (physical
lipids, blood pressure, diabetes) activity, diet, alcohol, smoking)
Anti-thrombotic therapy Environment, air pollution,
Disease-specific interventions climate change
Reduction of CVD burden
Figure1 CentralIllustration.ASCVD=atheroscleroticcardiovasculardisease;CKD=chronickidneydisease;COPD=chronicobstructivepulmonary
disease;CVD=cardiovasculardisease
.
importantwaytopreventASCVDistopromoteahealthylifestyle .. cardiovasculardisease(CVD)riskandtreatmentbenefit,aswellas
.
throughoutlife,especiallynotsmoking.Effectiveandsaferiskfactor .. noveltreatmentsandtreatmentgoals,necessitatednew,up-to-date
.
.
treatmentshavebeendeveloped, and most drugsare now generic . guidelines.ThecurrentguidelinesonCVDpreventioninclinicalprac-
. .
andavailableatlowcosts.Nevertheless,theprevalenceofunhealthy . tice concentrate principally but not exclusively on the risk factors,
.
.
lifestyleisstillhigh,andASCVDriskfactorsareoftenpoorlytreated, . riskclassification,andpreventionofASCVD.
.
even in patients considered to be at high (residual) CVD risk.1 .. ThecurrentguidelinesproviderecommendationsonASCVDpre-
.
.
PreventionofCVeventsbyreducingCVDriskisthetopicofthese . ventiontosupportshareddecision-makingbythepatientandtheir
.
.
guidelines. . healthcare professional based on individual patient characteristics.
.
.
. Specialconsiderationshavebeengiventodifferencesinage,sexand
.
2.1. Definition and rationale .. gender,lifeexpectancy,riskfactorprofiles,ethnic,andgeographicdif-
.
.
Thepresentguidelineshavebeendevelopedtosupporthealthcare .. ferences.EstimatingCVDrisknotonlyinapparentlyhealthysubjects,
.
professionalsintheireffortstoreducetheburdenofASCVDinboth .. butalsoinolderpersonsandinpatientswithestablishedASCVDor
.
individual patients, as well as at a population level. The previous .. diabetes mellitus (DM), provides information for tailored interven-
.
European Guidelines on CVD prevention in clinical practice were .. tiononanindividuallevel.Treatmentgoalscanbeindividualizedina
.
published in 2016.2 Recent developments in prediction of . stepwise approach. ‘Residual’ CVD risk is defined as the risk
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 10 ---
3236 ESCGuidelines
.
.
estimatedafterinitiallifestylechangesandriskfactortreatment,and . expensivedrugs,suchasnovellipid-loweringoranti-diabeticdrugs).
.
.
is mostly used in patients with established ASCVD. For younger . For such recommendations, it is inappropriate to ‘unconditionally’
.
.
apparentlyhealthysubjects,lifetimeCVDriskestimatesareavailable . implement them without first considering cost-effectiveness in a
.
.
tosupporttreatmentdecisions,replacing10-yearriskalgorithmsthat . national or regional context or, ideally, to perform formal cost-
.
.
consistentlyestimatelow10-yearriskeveninthepresenceofhigh . effectiveness analyses with country-specific input parameters and
.
.
riskfactorlevels.Inanageingpopulation,treatmentdecisionsrequire . cost-effectivenessthresholds.
.
.
a specific CVD riskscore that takes competing non-CVD riskinto .
.
.
account,aswellasspecificlow-densitylipoproteincholesterol(LDL- . 2.4. What is new?
.
.
C) and blood pressure (BP) treatment considerations. Estimating .. New recommendations, and new and revised concepts, are pre-
.
lifetime benefit in individual patients of smoking cessation, LDL-C .. sentedinTable3.
.
lowering, and BP lowering provides opportunities to communicate ..
.
benefit of treatment in an easy-to-understand way. Personalized ..
.
treatment decisions using CVD risk estimations and a stepwise .. 3. Risk factors and clinical
.
approachtotreatmentismorecomplexthanamoregeneralone- ... conditions
size-fits-allpreventionstrategy, butreflects thediversity in patients ..
.
andpatientcharacteristicsinclinicalpractice. ..
. 3.1. Target population for assessing
RegardingLDL-C,BP,andglycaemiccontrolinpatientswithDM, ..
goals and targets remain as recommended in recent European
... cardiovascular disease risk
.
Society of Cardiology (ESC) Guidelines.3(cid:2)5 These prevention .. CVDriskassessmentorscreeningcanbedoneopportunisticallyor
. guidelinesproposeanew,stepwiseapproachtotreatmentintensifi- .. systematically.Opportunisticscreening,whichmeansscreeningwith-
.
cationasatooltohelpphysiciansandpatientspursuethesetargetsin .. outapredefinedstrategy,isdonewhenapersonpresentsforsome
.
awaythatfitspatientprofileandpreferences.Ofnote,however,new .. otherreason.Systematicscreeningcanbedoneinthegeneralpopu-
.
evidenceand/ornewconsensusmayhaveresultedinsomedifferen- .. lationaspartofaformalscreeningprogramme,withcallandrecallof
.
ceswiththeserecentdomain-specificESCGuidelines.Newevidence .. patients,orintargetedsubpopulationssuchassubjectswithtype2
.
onantithrombotictreatmentregimensforASCVDpreventionisalso .. DM, or family history of premature CVD. Systematic screening
.
presented.Sex-specificaspectsareincluded. .. resultsinimprovementsinriskfactors,buthasnoeffectonCVDout-
.
ASCVDpreventionneedsanintegrated,interdisciplinaryapproach
.. comes.6(cid:2)9OpportunisticscreeningforASCVDriskfactors,suchas
.
including input from several disciplines and areas of expertise. We .. BP orlipids,iseffective atincreasingdetectionratesandisrecom-
.
mustworktogetherinapatient-andfamily-centredwaytoaddress .. mended, although a beneficial effect on clinical outcome is
.
eachofthecorecomponentsofpreventionandrehabilitation,includ-
.. uncertain.10
.
inglifestylemodification,psychosocialfactors,riskfactortreatment, ... Structurednationalprogrammesaimingtoidentifyundocumented
.
andsocialdeterminants(CentralIllustration). .. ASCVDriskfactors in adults over 40 years ofage without DMor
.
. ASCVDandtreatthemhaveshownbetterriskfactorcontrol,but
.
2.2. Development .. thereareconflictingresultsastoclinicaloutcomes.11,12Ahigh-risk
.
.
TheTaskForcechairsandmemberswereappointedbytheESC .. strategyofinvitingthepopulationpredictedtobeatthehighestrisk
.
Clinical Practice Guidelines Committee (CPG). Each member of .. according to anintegrated risk score would be equally effective at
the Task Force was assigned specific writing tasks, which were
... preventingnewcasesofCVDandhavepotentialcostsavings.13One
.
reviewedbyother(sub)sectionwriters,thesectioncoordinators, .. largetrialofmobileultrasoundscreeningforaorticaneurysm,periph-
.
and the chairs. The text was developed over 11 months, during .. eral artery disease (PAD), and hypertension in males aged 65(cid:2)74
which the Task Force members met collectively on three occa-
... yearsshoweda7%mortalityreductionat5years.14
.
sions and corresponded intensively between meetings. The .. A commoncriticism of screeningin general isthepotentialthat
.
review panel consisted of experts selected by all the scientific .. false positive and false negative results may cause harm. However,
.
societies that were involved in the development of these guide- .. evidenceonCVDscreeningshowsthatthosewhoparticipatedonot
.
lines,notonlytheESC.
.. reportmentaldistress.15(cid:2)18
.
.. SystematicCVDriskassessmentassessmentinthegeneralpopula-
. 2.3. Cost-effectiveness .. tion(adultmen>40andwomen>50yearsofage)withnoknown
.
TheTaskForceacknowledgethefactthathealthcarebudgetsare,in .. CVriskfactorsappearsnotcost-effectiveinreducingsubsequentvas-
.
manycircumstances,limitedandthusthatcertainrecommendations .. culareventsandprematuredeath,atleastinshort-termfollow-up,
.
andgoalsmaynotalwaysbeattainable.However,thecurrentguide- .. butdoesincreasedetectionofCVriskfactors.Riskassessmentisnot
.
lines donotprovide cost-effectivenessanalyses. Largenational and ... aone-timeevent;itshouldberepeated,forexample,every5years,
regionaldifferencesinbudgetsandcostsassociatedwithbothinter- ... althoughtherearenoempiricaldatatoguideintervals.
.
ventions and diseases/events preclude valid universal cost- ..
effectiveness analyses. However, some recommendations clearly
... 3.2. Risk factors and risk classification
.
have financial implications, either in terms of costs for individual .. 3.2.1.Riskfactors
.
patientsand/orintermsofbudgetimpact.Someoftheserecommen- .. The main causal and modifiable ASCVD risk factors are blood
.
dationspertaintodiagnosis(e.g.large-scaleuseofexpensiveimaging .. apolipoprotein-B-containinglipoproteins[ofwhichlow-densitylipo-
.
tests such as computed tomography), others to interventions (e.g. . protein(LDL)ismostabundant],highBP,cigarettesmoking,andDM.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 11 ---
ESCGuidelines 3237
Table3 Whatisnew
Newor Recommendationsin2013version Class Recommendationsin2021version Class
revised
Riskfactorsandclinicalconditions(cid:2)section3
New Inapparentlyhealthypeople<70yearsofagewithoutestablished
ASCVD,DM,CKD,genetic/rarerlipidorBPdisorders,estimation
I
of10-yearfatalandnonfatalCVDriskwithSCORE2is
recommended.
New Inapparentlyhealthypeople>_70yearsofagewithoutestablished
ASCVD,DM,CKD,genetic/rarerlipidorBPdisorder,estimation
I
of10-yearfatalandnonfatalCVDriskwithSCORE2-OPis
recommended.
New PatientswithestablishedASCVDand/orDMand/ormoderate-
to-severerenaldiseaseand/orgenetic/rarerlipidorBPdisorders I
aretobeconsideredathighorveryhighCVDrisk.
New Astepwisetreatment-intensificationapproachaimingatintensive
riskfactortreatmentisrecommendedforapparentlyhealthypeo-
pleathighorveryhighASCVDrisk,aswellaspatientswithestab-
I
lishedASCVDand/orDM,withconsiderationofCVDrisk,
treatmentbenefitofriskfactors,riskmodifiers,comorbidities,
andpatientpreferences.
New TreatmentofASCVDriskfactorsisrecommendedinapparently
healthypeoplewithoutDM,CKD,genetic/rarerlipidorBPdisor-
derswhoareatveryhighCVDrisk(SCORE2>_7.5%forage I
under50;SCORE2>_10%forage50(cid:2)69;SCORE2-OP>_15%for
age>_70).
New AninformeddiscussionaboutCVDriskandtreatmentbenefits
I
tailoredtotheneedsofapatientisrecommended.
New Itisrecommendedthatmentaldisorderswitheithersignificant
functionalimpairmentordecreaseduseofhealthcaresystemsbe I
consideredasinfluencing
New TreatmentofASCVDriskfactorsshouldbeconsideredinappa-
rentlyhealthypeoplewithoutDM,CKD,genetic/rarerlipid,orBP
disorderswhoareathighCVDrisk(SCORE22.5to<7.5%for
ageunder50;SCORE25to<10%forage50(cid:2)69;SCORE2-OP IIa
7.5to<15%forage>_70years),takingASCVDriskmodifiers,life-
timeriskandtreatmentbenefit,andpatientpreferencesinto
account.
New Inapparentlyhealthypeople,afterestimationof10-yearfataland
non-fatalCVDrisk,lifetimeriskandtreatmentbenefit,riskmodi-
IIa
fiers,frailty,polypharmacy,andpatientpreferencesshouldbe
considered.
New PresenceofmigrainewithaurashouldbeconsideredinCVDrisk
IIa
assessment.
New AssessmentofCVDriskshouldbeconsideredinmenwithED. IIa
New Inwomenwithahistoryofprematureorstillbirth,periodic
IIb
screeningforhypertensionandDMmaybeconsidered.
New AssessmentoftotalCVDriskmaybeconsideredinadultswith
IIb
chronicinflammatoryconditions.
New Avoidanceofcombinedhormonalcontraceptivesmaybeconsid-
IIb
eredinwomenwithmigrainewithaura.
Riskfactorsandinterventionsattheindividuallevel(cid:2)section4
New Itisrecommendedtoreducesedentarytimetoengageinatleast
lightactivitythroughoutthedaytoreduceall-causeandCVmor- I
talityandmorbidity.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 12 ---
3238 ESCGuidelines
Table3 Continued
Newor Recommendationsin2013version Class Recommendationsin2021version Class
revised
New ItisrecommendedtoadoptaMediterraneanorsimilardietto
I
lowerriskofCVD.
New Itisrecommendedtorestrictalcoholconsumptiontoamaximum
I
of100gperweek.
New Itisrecommendedtoeatfish,preferablyfatty,atleastoncea
I
weekandrestrict(processed)meat.
New Patientswithmentaldisordersneedintensifiedattentionandsup-
porttoimproveadherencetolifestylechangesanddrug I
treatment.
New Smokingcessationisrecommendedregardlessofweightgain,as
I
weightgaindoesnotlessentheASCVDbenefitsofcessation.
New InpatientswithestablishedASCVD,lipid-loweringtreatmentwith
anultimateLDL-Cgoalof<1.4mmol/L(55mg/dL)anda>_50% I
reductionofLDL-Cvs.baselineisrecommended.
New Forsecondarypreventionpatientsnotachievingtheirgoalsona
maximumtolerateddoseofastatinandezetimibe,combination I
therapyincludingaPCSK9inhibitorisrecommended.
New Inpatientswithtype2DMatveryhighrisk(e.g.withestablished
ASCVDand/orsevereTOD),intensivelipid-loweringtherapy,
I
ultimatelyaimingat>_50%LDL-CreductionandanLDL-Cof<1.4
mmol/L(<55mg/dL)isrecommended.
New Inpatientswithtype2DM>40yearsofageathighrisk,lipid-low-
eringtreatmentwithanultimateLDL-Cgoalof>_50%LDL-C
I
reductionandanLDL-Cof<1.8mmol/L(70mg/dL)is
recommended.
New Itisrecommendedthatthefirstobjectiveoftreatmentistolower
BPto<140/90mmHginallpatients,andthatsubsequentBPtar- I
getsaretailoredtoageandspecificcomorbidities.
New Intreatedpatientsaged18(cid:2)69years,itisrecommendedthatSBP
shouldultimatelybeloweredtoatargetrangeof120(cid:2)130 I
mmHginmostpatients.
New Intreatedpatientsaged>_70years,itisrecommendedthatSBP
shouldgenerallybetargetedto<140anddownto130mmHgif I
tolerated.
New Inalltreatedpatients,DBPisrecommendedtobeloweredto
I
<80mmHg.
New Inpersonswithtype2DMandASCVD,theuseofaGLP-1RAor
SGLT2inhibitorwithprovenoutcomebenefitsisrecommended I
toreduceCVand/orcardiorenaloutcomes.
New Inpatientswithtype2DMandCKD,theuseofanSGLT2inhibi-
torisrecommendedtoimproveCVDand/orcardiorenal I
outcomes.
New Inpatientswithtype2DMandHFrEF,useofanSGLT2inhibitor
withprovenoutcomebenefitsisrecommendedtolessenHFhos- I
pitalizationsandCVdeath.
New Participationinamedicallysupervised,structured,comprehen-
sive,multidisciplinaryEBCRandpreventionprogrammefor
patientsafterASCVDeventsand/orrevascularization,andfor I
patientswithHF(mainlyHFrEF),isrecommendedtoimprove
patientoutcomes.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 13 ---
ESCGuidelines 3239
Table3 Continued
Newor Recommendationsin2013version Class Recommendationsin2021version Class
revised
New Lifestyleinterventions,suchasgrouporindividualeducation,
behaviour-changetechniques,telephonecounselling,anduseof
IIa
consumer-basedwearableactivitytrackers,shouldbeconsidered
toincreasePAparticipation.
New Bariatricsurgeryforobesehigh-riskindividualsshouldbeconsid-
eredwhenlifestylechangedoesnotresultinmaintainedweight IIa
loss.
New ASCVDpatientswithstressshouldbeconsideredforreferralto
psychotherapeuticstressmanagementtoimproveCVDout- IIa
comesandreducestresssymptoms.
New PatientswithCHDandmoderate-to-severemajordepression
IIa
shouldbeconsideredforantidepressivetreatmentwithanSSRI.
New AnultimateLDL-Cgoalof<1.4mmol/L(55mg/dL)andLDL-C
reductionof>_50%frombaselineshouldbeconsideredinappa- IIa
rentlyhealthypersons<70yearsatveryhighrisk.
New AnultimateLDL-Cgoalof<1.8mmol/L(70mg/dL)andLDL-C
reductionof>_50%frombaselineshouldbeconsideredinappa- IIa
rentlyhealthypersons<70yearsathighrisk.
New Forthosemotivatedtotry,considerableweightlosswithuseof
low-caloriedietsfollowedbyfoodreintroductionandweight-
IIa
maintenancephasesearlyafterdiagnosiscanleadtoDMremis-
sionandshouldbeconsidered.
New Inpatientswithtype2DMandTOD,theuseofanSGLT2inhibi-
tororGLP-1RAwithprovenoutcomebenefitsmaybeconsid- IIb
eredtoreducefutureCVDandtotalmortality.
New Forprimarypreventionpatientsatveryhighrisk,butwithoutFH,
iftheLDL-Cgoalisnotachievedonamaximumtolerateddoseof
IIb
astatinandezetimibe,combinationtherapyincludingaPCSK9
inhibitormaybeconsidered.
New Inhigh-risk(orabove)patientswithtriglycerides>1.5mmol/L
(135mg/dL)despitestatintreatmentandlifestylemeasures,n-3
IIb
PUFAs(icosapentethyl2X2g/day)maybeconsideredincombi-
nationwithastatin.
New Initiationofstatintreatmentforprimarypreventioninolderpeo-
IIb
pleaged>_70maybeconsidered,ifathighriskorabove.
New Statintherapymaybeconsideredinpersonsaged<_40yearswith
type1ortype2DMwithevidenceofTODand/oranLDL-C
IIb
level>2.6mmol/L(100mg/dL),aslongaspregnancyisnotbeing
planned.
New InpatientswithDMathighorveryhighCVDrisk,low-dose
aspirinmaybeconsideredforprimarypreventionintheabsence IIb
ofclearcontraindications.
New Home-basedCR,telehealth,andmHealthinterventionsmaybe
consideredtoincreasepatientparticipationandlong-termadher- IIb
encetohealthybehaviours.
New InpatientswithHFandmajordepression,SSRIs,SNRIs,andtricy-
III
clicantidepressantsarenotrecommended.
New Inpatientswithdialysis-dependentCKDwhoarefreeofASCVD,
III
commencingstatintherapyisnotrecommended.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 14 ---
3240 ESCGuidelines
Table3 Continued
Newor Recommendationsin2013version Class Recommendationsin2021version Class
revised
Policyinterventionsatthepopulationlevel(cid:2)section5
New Puttinginplacemeasurestoreduceairpollution,includingreduc-
ingPMemissionandgaseouspollutants,reducingtheuseoffossil
I
fuels,andlimitingcarbondioxideemissions,arerecommendedto
reduceCVDmortalityandmorbidity.
Riskmanagementofdisease-specificcardiovasculardisease(cid:2)section6
New ItisrecommendedthatpatientswithHFareenrolledinacom-
prehensiveCRprogrammetoreducetheriskofHFhospitaliza- I
tionanddeath.
New ItisrecommendedtoscreenpatientswithHFforbothCVand
non-CVcomorbiditieswhich,ifpresent,shouldbetreated,pro-
I
videdsafeandeffectiveinterventionsexist,notonlytoalleviate
symptomsbutalsotoimproveprognosis.
New Inpatientswithacerebrovascularevent,improvementoflifestyle
factorsinadditiontoappropriatepharmacologicalmanagementis I
recommended.
New Identificationandmanagementofriskfactorsandconcomitant
diseasesarerecommendedtobeanintegralpartoftreatmentin I
patientswithAF.
New Addingasecondantithromboticdrug(aP2Y inhibitororlow-
12
doserivaroxaban)toaspirinforlong-termsecondaryprevention
IIa
shouldbeconsideredinpatientswithahighriskofischaemic
eventsandwithouthighbleedingrisk.
New InpatientswithDMandchronicsymptomaticLEADwithouthigh
bleedingrisk,acombinationoflow-doserivaroxaban(2.5mg IIb
b.i.d.)andaspirin(100mgo.d.)maybeconsidered.
Addingasecondantithromboticdrugtoaspirinforlong-termsec-
ondarypreventionmaybeconsideredinpatientswithamoderate IIb
riskofischaemiceventsandwithoutahighbleedingrisk.
Riskfactorsandclinicalconditions(cid:2)section3
Revised ABImaybeconsideredasariskmodifierin Theroutinecollectionofotherpotentialmodifiers,suchas
CVDriskassessment. geneticriskscores,circulatingorurinarybiomarkers,orvascular
IIb III
testsorimagingmethods(otherthanCACscoringorcarotid
ultrasoundforplaquedetermination),isnotrecommended.
Riskfactorsandinterventionsattheindividuallevel(cid:2)section4
Revised Drugtreatmentshouldbeconsideredin Forgrade1hypertension,treatmentinitiationbasedonabsolute
patientswithgrade1or2hypertension IIa CVDrisk,estimatedlifetimebenefit,andthepresenceofHMOD I
whoareathighCVDrisk. isrecommended.
Revised Inpatientswithtype2DMandCVD,use Inpersonswithtype2DMandASCVD,theuseofaGLP-1RAor
ofanSGLT2inhibitorshouldbeconsid- SGLT2inhibitorwithprovenoutcomebenefitsisrecommended IIa I
eredearlyinthecourseofthediseaseto toreduceCVand/orcardiorenaloutcomes.
reduceCVDandtotalmortality.
ABI=anklebrachialindex;AF=atrialfibrillation;ASCVD=atheroscleroticcardiovasculardisease;b.i.d.=bisindie(twiceaday);BP=bloodpressure;CAC=coronaryartery
calcium;CHD=coronaryheartdisease;CKD=chronickidneydisease;CR=cardiacrehabilitation;CV=cardiovascular;CVD=cardiovasculardisease;DM=diabetesmelli-
tus;EBCR=exercise-basedcardiacrehabilitation;ED=erectiledysfunction;FH=familialhypercholesterolaemia;GLP-1RA=glucagon-likepeptide-1receptoragonist;HF=
heartfailure;HFrEF=heartfailurewithreducedejectionfraction;HMOD=hypertension-mediatedorgandamage;LDL-C=low-densitylipoproteincholesterol;LEAD=
lowerextremityarterydisease;mHealth=mobiledevice-basedhealthcare;o.d.=omnidie(onceaday);PA=physicalactivity;PCSK9=proproteinconvertasesubtilisin/kexin
type9;PM=particulatematter;PUFA=polyunsaturatedfattyacid;SBP=systolicbloodpressure;SCORE2=SystematicCoronaryRiskEstimation2;SCORE2-OP=
SystematicCoronaryRiskEstimation2-OlderPersons;SGLT2=sodium-glucosecotransporter2;SNRI=serotonin-noradrenalinereuptakeinhibitor;SSRI=selectiveseroto-
ninreuptakeinhibitor;TOD=targetorgandamage.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 15 ---
ESCGuidelines 3241
Newsections
Section3
3.2.2Sexandgenderandtheirimpactonhealth
3.2.3Atheroscleroticcardiovasculardiseaseriskclassification
3.2.3.1Astepwiseapproachtoriskfactortreatmentandtreatmentintensification
3.2.3.2Riskestimationinapparentlyhealthypeople
3.2.3.3Translatingatheroscleroticcardiovasculardiseaserisktotreatmentthresholds
3.2.3.4Riskestimationandriskfactortreatmentinapparentlyhealthypeople50(cid:2)69yearsofage
3.2.3.5Riskestimationandriskfactortreatmentestimationinapparentlyhealthypeople>_70yearsofage
3.2.3.6Riskestimationandriskfactortreatmentinapparentlyhealthypeople<50yearsofage
3.2.3.7Riskestimationandriskfactortreatmentinpatientswithestablishedatheroscleroticcardiovasculardisease
3.2.4Communicationofcardiovasculardiseaserisk
3.3.1Psychosocialfactors
3.3.4Frailty
3.3.8Environmentalexposure
3.4Clinicalconditions
3.4.2Atrialfibrillation
3.4.3Heartfailure
3.4.5Chronicobstructivepulmonarydisease
3.4.6Inflammatoryconditions
3.4.7Infections(humanimmunodeficiencyvirus,influenza,periodontitis)
3.4.8Migraine
3.4.9Sleepdisordersandobstructivesleepapnoea
3.4.10Mentaldisorders
3.4.11Non-alcoholicfattyliverdisease
3.4.12Sex-specificconditions
Section4
• 4.10Anti-inflammatorytreatment
New/revisedconcepts
Section3
• SCORE2andSCORE2-OPriskchartsforfatalandnon-fatal(myocardialinfarction,stroke)ASCVD
• Estimating10-yeartotalCVDriskinapparentlyhealthypeople50(cid:2)69yearsofage
• Estimatinglifetimeriskinapparentlyhealthypeople<50yearsofage
• Estimating10-yeartotalCVDriskinapparentlyhealthypeople>_70yearsofage
• Cut-offsof10-yearCVDrisk,basedonSCORE2/SCORE2-OP,todefinelow(cid:2)moderaterisk,highrisk,andveryhighriskfor
apparentlyhealthypeopleindifferentagegroups(<50,50(cid:2)69,
and>_70years)
• Estimating10-yearCVDriskinpatientswithestablishedCVDand/orDM
• Lifetimebenefitofstoppingsmoking,reducingLDL-C,orloweringSBP(sections3and4)
• Astepwiseapproachtoattainingultimatetreatmentgoals(sections3and4)
• CommunicationofCVDriskandbenefitoftreatmenttopatientsinanunderstandableway
• Stepwiseapproachtoriskfactortreatmentandtreatmentintensification
Section4
• Explicitlyaddressingcost-effectiveness(onaloco-regionalornationallevel)beforeimplementingsomerecommendations
• Non-fastinglipidmeasurement(section4.6.1.1)
• Astepwiseapproachtoattainingtreatmentgoals(sections3and4)
• Anti-inflammatorytreatmentforvery-high-riskpatients
Section5
• TakingintoconsiderationpopulationlevelinterventionstomitigatetheeffectsofpollutiononCVDhealth
Section6
• Riskmanagementofdisease-specificCVD.ThissectionaddressesCVDpreventionwhencertainunderlyingdiseasesarepresentandaimstoprovide
guidanceonhowtopreventtheworseningofexisting,orthedevelopmentoffurther,comorbiditiesthatcouldincreasetheoverallriskofCVD
• Subsectionsinclude:6.1Coronaryarterydisease;6.2Heartfailure;6.3Cerebrovasculardisease;6.4Lowerextremityarterydisease;6.5Chronickidney
disease;6.6Atrialfibrillation;6.7Multimorbidity
ASCVD=atheroscleroticcardiovasculardisease;CVD=cardiovasculardisease;DM=diabetesmellitus;LDL-C=low-densitylipoproteincholesterol;SBP=systolicblood-
pressure;SCORE2=SystematicCoronaryRiskEstimation2;SCORE2-OP=SystematicCoronaryRiskEstimation2-OlderPersons.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 16 ---
3242 ESCGuidelines
.
.
RecommendationsforCVDriskassessment
.. evenasmallabsolutereductioninLDL-Cmaybebeneficialina
.
.. high-orvery-high-riskpatient.22
.
Recommendations Classa Levelb .. • Non-high-density lipoprotein cholesterol (HDL-C) encom-
.
.. passesallatherogenic(apo-B-containing)lipoproteins,andiscal-
SystematicglobalCVDriskassessmentisrecom- ...
culated as: total cholesterol (cid:2) HDL-C = non-HDL-C. The
mendedinindividualswithanymajorvascular ...
relationship between non-HDL-C and CV risk is at least as
riskfactor(i.e.familyhistoryofprematureCVD,
I C
...
strongastherelationshipwithLDL-C.Non-HDL-Clevelscon-
FH,CVDriskfactorssuchassmoking,arterial ...
tain,inessence,thesameinformationasameasurementofapo-
hypertension,DM,raisedlipidlevel,obesity,or ... Bplasmaconcentration.23,24Non-HDL-Cisusedasaninputin
comorbiditiesincreasingCVDrisk). ...
the Systemic Coronary Risk Estimation 2 (SCORE2) and
.
SystematicoropportunisticCVriskassessment .. SCORE2-OlderPersons(SCORE2-OP)riskalgorithms.
.
inthegeneralpopulationinmen>40yearsof .
.
ageandinwomen>50yearsofageorpostme- IIb C .. HDL-CisinverselyassociatedwithCVDrisk.VeryhighHDL-Clevels
.
nopausalwithnoknownASCVDriskfactors .. may signal an increased CVD risk. There is, however, no evidence
. maybeconsidered.9 .. fromMendelianrandomizationstudies,orrandomizedtrialsofcho-
.
.
InthoseindividualswhohaveundergoneCVD .. lesterylestertransferproteininhibitors,thatraisingplasmaHDL-C
riskassessmentinthecontextofopportunistic
... reducesCVDrisk.25(cid:2)28HDL-Cisnonethelessausefulbiomarkerto
.
screening,arepetitionofscreeningafter5years IIb C .. refine risk estimation using the SCORE2 algorithms. The SCORE2
.
(orsoonerifriskwasclosetotreatmentthresh- .. algorithmcannotbeusedforpatientswithageneticlipiddisorder,
. olds)maybeconsidered. .. suchasfamilialhypercholesterolaemia(FH).SpecificLDL-Cthresh-
.
. oldsandtargetsarerecommendedirrespectiveofestimatedCVrisk
OpportunisticscreeningofBPinadultsatrisk .
.
. forpatientswithFHorotherrare/geneticlipiddisorders.
forthedevelopmentofhypertension,suchas .
.
.
thosewhoareoverweightorwithaknownfam- IIa B .
.
. 3.2.1.2Bloodpressure
ilyhistoryofhypertension,shouldbe .
.
considered.19 .. Longitudinalstudies,geneticepidemiologicalstudies,andRCTshave
.
SystematicCVDriskassessmentinmen<40
... shown that raised BP is a major cause of both ASCVD and non-
yearsofageandwomen<50yearsofagewith III C
... atheroscleroticCVD[particularlyheartfailure(HF)],accountingfor
noknownCVriskfactorsisnotrecommended.9
... 9.4 million deaths and 7% of global disability adjusted life-years.29
.. ElevatedBPisariskfactorforthedevelopmentofcoronaryartery
.
ASCVD=atheroscleroticcardiovasculardisease;BP=bloodpressure;CV=car- .. disease(CAD),HF,cerebrovasculardisease,lowerextremityarterial
diovascular;CVD=cardiovasculardisease;DM=diabetesmellitus;FH=familial ...
disease(LEAD),chronickidneydisease(CKD),andatrialfibrillation
hypercholesterolaemia. .
aClassofrecommendation. ... (AF).TheriskofdeathfromeitherCADorstrokeincreaseslinearly
bLevelofevidence. .. fromBPlevelsaslowas90mmHgsystolicand75mmHgdiastolic
.
.. upwards.30,31 The absolute benefit of reducing systolic BP (SBP)
.
.. dependsonabsoluteriskandtheabsolutereductioninSBP,except
Anotherimportantriskfactorisadiposity,whichincreasesCVDrisk ...
thatlowerlimitsofSBPareimposedbytolerabilityandsafetyconsid-
via both major conventional risk factors and other mechanisms. In ...
erations.Managementisdeterminedbythecategoryofhypertension
additiontothese,therearemanyotherrelevantriskfactors,modi- ..
. (optimal, normal, high-normal, stages 1 to 3, and isolated systolic
fiers,andclinicalconditions,whichareaddressedunderriskmodifiers .. . hypertension),definedaccordingtoseatedofficeBP,ambulatoryBP
andclinicalconditions(sections3.3and3.4). ..
. monitoring (ABPM), or home BP average values (see section
.
.
. 4.7).Evidence suggests that lifetime BP evolution differs in women
3.2.1.1 Cholesterol ..
. comparedtomen,potentiallyresultinginanincreasedCVDriskat
ThecausalroleofLDL-C,andotherapo-B-containinglipoproteins, ...
lowerBPthresholds.32(cid:2)34The SCORE2algorithmcannotbe used
inthedevelopmentofASCVDisdemonstratedbeyondanydoubtby ..
. forpatientswithsecondarycausesandrarerformsofhypertension,
genetic, observational, and interventional studies.20 The key attrib- ..
. suchasprimaryhyperaldosteronism.
.
utesofLDL-CasariskfactorforASCVDare: .
.
.
.
• ProlongedlowerLDL-CisassociatedwithlowerriskofASCVD .. 3.2.1.3Cigarettesmoking
.
throughout the range studied, and the results of randomized .. Cigarettesmoking is responsiblefor 50% ofall avoidabledeaths in
.
controlled trials (RCTs) indicate that lowering LDL-C safely .. smokers,withhalfoftheseduetoASCVD.Alifetimesmokerhasa
.
reduces CVD riskeven at low LDL-C levels [e.g. LDL-C <1.4 .. 50%probabilityofdyingduetosmoking,andonaveragewilllose10
.
mmol/L(55mg/dL)].20 .. yearsoflife.35TheCVDriskinsmokers<50yearsofageisfive-fold
.
• TherelativereductioninCVDriskisproportionaltotheabso- .. higherthaninnon-smokers.36Prolongedsmokingismorehazardous
.
lutesizeofthechangeinLDL-C,irrespectiveofthedrug(s)used .. forwomen thanfor men.37 Worldwide, after highSBP, smoking is
.
toachievesuchchange.21 .. theleadingriskfactorfordisabilityadjustedlife-years.38Second-hand
.
• TheabsolutebenefitofloweringLDL-Cdependsontheabso- .. smokeisassociatedwithanincreaseinCVDrisk.39Somesmokeless
.
lute risk of ASCVD and the absolute reduction in LDL-C, so . tobaccoisalsoassociatedwithincreasedriskofCVD.40
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 17 ---
ESCGuidelines 3243
.
.
3.2.1.4 Diabetesmellitus . studiedincludeleftventricular(LV)ejectionfraction(LVEF),adverse
.
.
Type1DM,type2DM,andprediabetesareindependentriskfactors . drugreactions,trendsinASCVDriskfactorsandawareness,sexdis-
.
.
forASCVD,increasingriskofASCVDbyabouttwo-fold,depending . parities in the management of and outcomes after acute coronary
.
on the population and therapeutic control.41 Women with type 2 .. syndromes(ACS).51(cid:2)58Furthermore,CVDhealthaftermenopause
.
DM appear to have a particularly higher risk for stroke.42 Patients .. transition, pregnancy disorders, and gynaecologic conditions have
.
with type 2 DM are likely to have multiple ASCVD risk factors .. recentlybeenreviewed.59
.
.
(includingdyslipidaemiaand hypertension),each ofwhich mediates .
.
.
anincreaseinriskofbothASCVDandnon-ASCVD. .. 3.2.3.Cardiovasculardiseaseriskclassification
.
.. ThecurrentguidelinesonCVDpreventioninclinicalpracticecon-
.
3.2.1.5 Adiposity .. centrate principally, but not exclusively, on risk and prevention of
.
Overrecentdecades,bodymassindex(BMI)—measuredasweight .. ASCVD.Thisincludesriskfactors,riskprediction,riskmodifiers,as
.
(inkg)dividedbysquaredheight(inm2)—hasincreasedsubstantially .. well as clinical conditions that often increase the likelihood of
.
worldwideinchildren,adolescents,andadults.43Mendelianrandom- .. ASCVD.
.
izationanalysessuggestalinearrelationbetweenBMIandmortality .. IdentifyingpatientswhowillbenefitmostfromASCVDriskfactor
.
innon-smokersandaJ-shapedrelationinever-smokers.44All-cause .. treatment is central to ASCVD prevention efforts. In general, the
.
mortality is lowest ata BMI of20(cid:2)25 kg/m2 in apparently healthy .. highertheabsoluteCVDrisk,thehighertheabsolutebenefitofrisk
.
people, with a J-shaped or U-shaped relation.45,46 In HF patients, .. factortreatment,andthusthelowerthenumberneededtotreatto
.
thereisevidenceforanobesityparadox,withlowermortalityriskin .. prevent one CVD event during a period of time.60,61 With this in
.
patientswithhigherBMI.Ameta-analysisconcludedthatbothBMI .. mind,theestimationofCVDriskremainsthecornerstoneofthese
. and waist circumference are similarly, strongly, and continuously .. guidelinesandthusappearsattheforefrontoftheproposedmanage-
.
associatedwithASCVDandtype2DM.47 .. mentschemes,whicharesummarizedinflowcharts.
.
.
. AgeisthemajordriverofCVDrisk.Womenbelow50yearsand
.
.
3.2.2.Sexandgenderandtheirimpactonhealth . menbelow40yearsofagearealmostinvariablyatlow10-yearCVD
.
.
Thecurrentpreventionguidelinesrecognizetheimportanceofinte- . risk,butmayhaveunfavourablemodifiableriskfactorsthatsharply
.
.
gratingsex,gender,andgenderidentityconsiderationsintotherisk . increasetheirlonger-termCVDrisk.Conversely,menover65years
.
.
assessment and clinicalmanagementofindividuals and populations. . andwomenover75yearsofagearealmostalwaysathigh10-year
.
.
These guidelines also acknowledge the complexity of the inter- .. CVDrisk.Onlybetweentheagesof55and75yearsinwomenand
.
relationshipbetweentheseconceptsandCV,aswellaspsychologi- .. 40and65yearsinmendoesthe10-yearCVDriskvaryaroundcom-
.
cal,health.Thereis,atpresent,noofficialESCpositiononthespecific .. monly used thresholds for intervention. The age categories <50,
.
terminology to be used. According to the World Health .. 50(cid:2)69,and>_70yearsshouldbeusedwithcommonsenseandflexi-
.
Organization(WHO),sex‘referstothedifferentbiologicalandphys- .. bility.Differentagerangesmaybeconsideredformenandwomen
.
iologicalcharacteristicsoffemales,males,andintersexpersons,such .. andmaydiffer according togeographic region.Uncertaintyaround
.
aschromosomes,hormonesandreproductiveorgans’.48 .. riskestimationsshouldalsobeconsidered.
.
Thisistobedistinguishedfromgender,which‘referstothechar- .. CVDriskcanalsobeassessedinpatientswithtype2DMandin
.
acteristics of women, men, girls and boys that are socially con- .. patientswithestablishedASCVD.Thepopulationsorpatientgroups
.
structed.Thisincludesnorms,behavioursandrolesassociatedwith .. inwhomCVDriskneedstobeconsideredaresummarizedandpre-
.
beingawoman,man,girlorboy,aswellasrelationshipswitheach .. sentedinTable4.LifetimeCVDriskestimationisavailableforvarious
.
other. As a social construct, gender varies from society to society .. groups of patients, and enables estimation of lifetime benefit from
.
andcanchangeovertime’.48TheGlobalHealth50/50definitionfur- .. preventiveinterventionssuchassmokingcessation(seesection4.5.1), .
.
therstatesthatgenderrefers‘tothesociallyconstructednormsthat . lipid-lowering (see section 4.6.2.1), and BP treatment (see section
.
.
imposeanddetermineroles,relationships,andpositionalpowerfor . 4.7.5.2).Lifetimeriskandbenefitestimationmaybeusedforcommu-
.
allpeopleacrosstheirlifetime’.49 .. nicationintheshareddecision-makingprocess,togetherwithconsid-
.
. Where evidence exists on the risk modifying effect of sex or . eration of comorbidities, frailty, patient preferences for initiating
.
.
wheresex-specificclinicalconditionsandclinicalmanagementstrat- . (STEP1)andintensifying(STEP2)riskfactortreatment(Figure2).
.
egiesexist,thishasbeenincludedintheseguidelines.50Theinfluence ..
. .
ofgender onanindividual’s experience andaccessto healthcare is . 3.2.3.1Astepwiseapproachtoriskfactortreatmentandtreatment
.
paramount.50Thespecifichealthconcernsrelatedtogenderarethus .. intensification
.
.
alsoacknowledgedinthesepreventionGuidelines. . Asexplainedbefore,targetsandgoalsforLDL-C,BP,andglycaemic
.
.
Epigenetic effects of social constructs appear to condition the . controlinDMremainasrecommendedinrecentESCGuidelines.3(cid:2)5
.
.
translation of biological sex into disease pathophysiology. .. Theseguidelinesproposeastepwiseapproachtotreatmentintensifi-
.
Furthermore, social constructs can also be determinants of health .. cationasatooltohelpphysiciansandpatientspursuethesetargetsin
.
access, healthcare utilization, disease perception, decision-making, .. awaythatfitspatientprofilesandpreferences.Thisprinciple(out-
.
andperhapstherapeuticresponse,50includinginthefieldofCVDand .. lined in Figure 2, using the example of a stepwise approach) is not
.
ASCVDprevention.Researchisongoing,butgapsinevidenceremain .. conceptually novel, but rather reflects routine clinical practice, in
.
andthishasalsobeenrecognizedintheguidelines. .. whichtreatmentstrategiesareinitiatedandthenintensified,bothas
.
Examples of specific topics regarding physiological, pathological, .. partofashareddecision-makingprocessinvolvinghealthcareprofes-
.
and clinical differences related to sex and gender that have been . sionalsandpatients.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 18 ---
3244 ESCGuidelines
Table4 Patientcategoriesandassociatedcardiovasculardiseaserisk.
Patient category Subgroups Risk
categories
Apparently healthy persons
Persons without established 10-year CVD risk estimation (SCORE2). Lifetime risk
ASCVD, diabetes mellitus, CKD, Low- to
<50 years
Familial Hypercholesterolemia high-risk (e.g. with the LIFE-CVD lifetime model) to facilitate the
10-year CVD risk estimation (SCORE2). Lifetime
Low- to
50-69 years
very high-risk (e.g. with the LIFE-CVD lifetime model) to facilitate the
10-year CVD risk estimation (SCORE2-OP). Lifetime
Low- to ≥70 years
very high-risk (e.g. with the LIFE-CVD lifetime model) to facilitate the
Patients with CKD
CKD without diabetes or ASCVD Moderate CKD (eGFR 30−44 mL/min/1.73 m2
and ACR <30 or
eGFR 45−59 mL/min/1.73 m2 and High-risk N/A
ACR 30−300 or
eGFR ≥60 mL/min/1.73 m2 and ACR >300)
Severe CKD (eGFR<30 mL/min/1.73 m2 or Very
N/A
eGFR 30−44 mL/min/1.73 m2 and ACR >30) high-risk
Familial Hypercholesterolemia
Associated with markedly elevated
N/A High-risk N/A
cholesterol levels
Patients with type 2 diabetes mellitus
Patients with type 1 DM above Patients with well controlled short-standing
DM (e.g. <10 years), no evidence of TOD Moderate-
N/A
according to these criteria and no additional ASCVD risk factors risk
Patients with DM without ASCVD and/or Residual 10-year CVD risk estimation after general
prevention goals (e.g. with the ADVANCE risk score or
High-risk
risk criteria.
estimation of risk factor treatment (e.g. DIAL model).
Patients with DM with established ASCVD
and/or severe TOD:87, 93-95
• eGFR <45 mL/min/1.73 m2 irrespective
Residual 10-year CVD risk estimation after general
of albuminuria
prevention goals (e.g. with the SMART risk score for
• eGFR 45-59 mL/min/1.73 m2 and
Very established CVD or with the ADVANCE risk score or
microalbuminuria (ACR 30 -300 mg/g)
high-risk with the DIAL model). Consider lifetime CVD risk and
• Proteinuria (ACR >300 mg/g)
• Presence of microvascular disease
model).
microalbuminuria plus retinopathy
plus neuropathy)
Patients with established ASCVD
Documented ASCVD, clinical or
unequivocal on imaging. Documented
clinical ASCVD includes previous
AMI, ACS, coronary revascularization
Residual CVD risk estimation after general prevention
and other arterial revascularization
goals (e.g. 10-year risk with the SMART risk score for
procedures, stroke and TIA, aortic
patients with established CVD or 1- or 2-year risk
aneurysm and PAD. Unequivocally Very
N/A with EUROASPIRE risk score for patients with CHD).
documented ASCVD on imaging high-risk
includes plaque on coronary
risk factor treatment (e.g. SMART-REACH model; or
angiography or carotid ultrasound
DIAL model if diabetes).
or on CTA. It does NOT include
some increase in continuous imaging
parameters such as intima–media
thickness of the carotid artery.
ACR=albumin-to-creatinineratio:(toconvertmg/gtomg/mmol:divideby10);ACS=acutecoronarysyndromes;ADVANCE=ActioninDiabetesandVasculardisease:
preterAxanddiamicroN-MRControlledEvaluation;AMI=acutemyocardialinfarction;ASCVD=atheroscleroticcardiovasculardisease;CKD=chronickidneydisease;CTA
=computedtomographyangiography;CV=cardiovascular;CVD=cardiovasculardisease;DIAL=Diabeteslifetime-perspectiveprediction;DM=diabetesmellitus;FH=
familialhypercholesterolaemia;eGFR=estimatedglomerularfiltrationrate;IMT=intima-mediathickness;LIFE-CVD=LIFEtime-perspectiveCardioVascularDisease;N/A=
notapplicable;PAD=peripheralarterydisease;REACH=ReductionofAtherothrombosisforContinuedHealth;SBP=systolicbloodpressure;SCORE=Systematic
CoronaryRiskEstimation;SMART=SecondaryManifestationsofArterialDisease;TIA=transientischaemicattack.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 19 ---
ESCGuidelines 3245
Categories of individuals considered for prevention
Apparently healthy Patients with Patients with Patients with specific risk
persons establishedASCVD type 2 diabetes mellitus factors such as CKD
(See Figure 6) (See Figure 7) (See Figure 8) and FH (See Table 4)
STEP 1
Prevention goals for all Prevention goals for all Prevention goals for all
Estimate 10-year
CVD risk
Consider risk modifiers,
lifetime CVD risk,
treatment benefit and
patient preferences
Prevention goals based Specific risk factor
on whether patients are prevention and
without or with treatment goals
establishedASCVD based on
Prevention goals and/or severeTOD risk categories
STEP 2
Intensified prevention and Intensified prevention and Intensified prevention and
treatment goals based on: treatment goals based on: treatment goals based on:
10-year CVD risk 10-year CVD risk 10-year CVD risk
Lifetime CVD risk Lifetime CVD risk Lifetime CVD risk
and treatment benefit and treatment benefit and treatment benefit
Comorbidities Comorbidities Comorbidities
Patient preferences Patient preferences Patient preferences
Ultimate prevention goals Ultimate prevention goals Ultimate prevention goals
Figure2Examplesofastepwiseapproachtoriskstratificationandtreatmentoptions.ASCVD=atheroscleroticcardiovasculardisease;CKD=chronic
kidneydisease;DM=diabetesmellitus;FH=familialhypercholesterolaemia;TOD=targetorgandamage.
. Astepwiseapproachstartswithpreventiongoalsforall,regardless .. 3.2.3.2Riskestimationinapparentlyhealthypeople
.
ofCVDrisk.ThisisfollowedbyCVDriskstratificationanddiscussion .. Apparently healthy people are those without established ASCVD,
.
ofpotentialbenefitsoftreatmentwiththepatient.Iftreatmentisiniti- .. type 2 DM, or severe comorbidities. In the 2016 ESC prevention
.
ated,itseffectmustbeevaluated,andsubsequenttreatmentintensifi- .. guidelines,2 the Systemic Coronary Risk Estimation (SCORE) algo- .
.
cationto reach ultimate riskfactorgoalsmustbe considered in all . rithm was used to estimate 10-year risk of CVD death. However,
.
.
patients, taking into account additional benefit, comorbidities, and . CVD morbidity (non-fatal myocardial infarction, non-fatal stroke)
.
. frailty, all of which converge with patient preferences in a shared . combined with CVD mortality better reflects the total burden of
.
.
decision-makingprocess. . ASCVD.TheupdatedSCOREalgorithm—SCORE2—usedinthese
.
.
In the field of DM, studies have shown benefit of a stepwise . guidelines(seeFigure3),estimatesanindividual’s10-yearriskoffatal
.
.
approachtotreatmentintensificationanddonotsupporttheconten- . and non-fatal CVD events (myocardial infarction, stroke) in appa-
.
.
tionof‘therapeuticnihilism’occurringineitherphysiciansorpatients. . rently healthy people aged 40(cid:2)69 years with risk factors that are
.
Infact,itappearsthatattainmentoftreatmentgoalsissimilar,side- .. untreatedorhavebeenstableforseveralyears.68
.
.
effectsare fewer,and patientsatisfactionissignificantlyhigherwith .. Several specific considerations apply to CVD risk estimation in
.
such an approach.66,67 We do, however, emphasize that stopping .. olderpeople.First,thegradientoftherelationshipbetweenclassical
.
assessmentoftreatmentgoalsand/ortreatmentroutinelyafterthe .. risk factors, such as lipids and BP, with CVD risk attenuates with
.
first step is inappropriate. The evidence-based ultimate targets of .. age.69 Second, CVD-free survival dissociates from overall survival
.
treatment intensification are optimal from theperspective of CVD .. progressivelywithincreasingage,becauseriskfornon-CVDmortal-
.
riskreductionandaretobeconsideredinallpatients. .. ity increases (‘competing risk’).70 Forthesereasons, traditional risk
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 20 ---
3246 ESCGuidelines
SCORE2 & SCORE2-OP <50 years 50-69 years ≥70 years
10-year risk of (fatal and non-fatal) CV <2.5% <5% <7.5%
2.5 to <7.5% 5 to <10% 7.5 to <15%
events in populations at low CVD risk ≥7.5% ≥10% ≥15%
Women Men
Non-smoking Smoking Non-smoking Smoking
Non-HDL cholesterol
prS ey ss st uo rl eic
(
mblo mo Hd
g)
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
mmol/L
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
SCORE2-OP 150200250 150200250 mg/dL 150200250 150200250
160-179 28 29 30 31 31 32 33 34 Age 29 35 42 49 29 35 42 49
(y)
140-159 26 27 28 29 29 30 31 32 28 33 40 47 27 33 40 47
85-89
120-139 24 25 26 27 27 28 29 30 26 32 38 45 26 32 38 45
100-119 23 24 25 26 25 26 27 28 25 30 36 43 25 30 36 43
160-179 20 21 22 23 25 26 28 29 23 27 32 37 26 31 36 41
140-159 18 19 20 21 23 24 25 26 21 25 29 34 24 28 33 38
80-84
120-139 16 17 18 19 20 21 22 23 19 22 26 31 22 25 30 34
100-119 15 15 16 17 18 19 20 21 17 20 24 28 19 23 27 31
160-179 15 15 16 17 21 22 23 24 19 21 24 27 24 27 31 34
140-159 13 13 14 15 18 19 20 21 16 18 21 23 21 23 26 30
75-79
120-139 11 11 12 13 15 16 17 18 14 15 18 20 18 20 23 26
100-119 9 10 10 11 13 14 15 15 12 13 15 17 15 17 19 22
160-179 10 11 12 12 17 18 19 20 15 16 18 19 22 24 26 28
140-159 9 9 10 10 14 15 16 16 12 13 14 16 18 19 21 23
70-74
120-139 7 7 8 8 11 12 13 14 10 11 12 13 14 16 17 19
100-119 6 6 6 7 9 10 10 11 8 8 9 10 12 13 14 15
SCORE2
160-179 8 8 9 9 12 12 13 13 11 12 12 13 15 16 17 19
140-159 7 7 7 7 10 10 11 11 9 10 11 11 13 14 15 16
65-69
120-139 5 6 6 6 8 9 9 9 8 8 9 10 11 12 13 13
100-119 5 5 5 5 7 7 7 8 6 7 7 8 9 10 11 11
160-179 6 6 7 7 10 10 11 11 8 9 10 11 13 14 15 17
140-159 5 5 5 6 8 8 9 9 7 8 8 9 10 11 13 14
60-64
120-139 4 4 4 5 6 7 7 8 6 6 7 8 9 10 10 11
100-119 3 3 4 4 5 6 6 6 5 5 6 6 7 8 9 10
160-179 4 5 5 5 8 8 9 10 7 7 8 9 10 12 13 15
140-159 3 4 4 4 6 7 7 8 5 6 7 8 9 10 11 12
55-59
120-139 3 3 3 3 5 6 6 6 4 5 5 6 7 8 9 10
100-119 2 2 3 3 4 4 5 5 4 4 4 5 6 6 7 8
160-179 3 4 4 4 6 7 7 8 5 6 7 8 9 10 11 13
140-159 3 3 3 3 5 5 6 6 4 5 5 6 7 8 9 10
50-54 120-139 2 2 2 3 4 4 5 5 3 4 4 5 6 6 7 8
100-119 2 2 2 2 3 3 4 4 3 3 3 4 4 5 6 7
160-179 2 3 3 3 5 5 6 7 4 5 6 6 7 8 10 11
140-159 2 2 2 3 4 4 5 5 3 4 4 5 6 7 8 9
45-49
120-139 1 2 2 2 3 3 4 4 2 3 3 4 4 5 6 7
100-119 1 1 1 1 2 2 3 3 2 2 3 3 3 4 5 5
160-179 2 2 2 3 4 4 5 6 3 4 5 5 6 7 8 10
140-159 1 2 2 2 3 3 4 4 2 3 3 4 5 5 6 8
40-44
120-139 1 1 1 1 2 3 3 3 2 2 3 3 3 4 5 6
100-119 1 1 1 1 2 2 2 2 1 2 2 2 3 3 4 5
Figure3 SystematicCoronaryRiskEstimation2andSystematicCoronaryRiskEstimation2-OlderPersonsriskchartsforfatalandnon-fatal(myocardial
infarction,stroke)cardiovasculardisease.68,72ASCVD=atheroscleroticcardiovasculardisease;CV=cardiovascular;CVD=cardiovasculardisease;SBP=
systolicbloodpressure;HDL-C=high-densitylipoproteincholesterol;SCORE2=SystematicCoronaryRiskEstimation2;SCORE2-OP=Systematic
CoronaryRiskEstimation2-OlderPersons;TFYR=TheFormerYugoslavRepublic;UK=UnitedKingdom.Forapparentlyhealthypeopleaged40(cid:2)69
years,theSCORE2algorithm68isusedtoestimate10-yearriskoffatalandnon-fatal(myocardialinfarction,stroke)CVD.Forapparentlyhealthypeople
>_70years ofage,the SCORE2-OP is used.72. Low-risk countries: Belgium, Denmark,France, Israel, Luxembourg, Norway, Spain, Switzerland, the
Netherlands, andtheUK. Moderate-risk countries: Austria, Cyprus, Finland, Germany, Greece, Iceland,Ireland,Italy,Malta, Portugal,San Marino,
Slovenia,andSweden.High-riskcountries:Albania,BosniaandHerzegovina,Croatia,CzechRepublic,Estonia,Hungary,Kazakhstan,Poland,Slovakia,
and Turkey. Very-high-risk countries: Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania,
Montenegro,Morocco,RepublicofMoldova,Romania,RussianFederation,Serbia,Syria,TFYR(Macedonia),Tunisia,Ukraine,andUzbekistan.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 21 ---
ESCGuidelines 3247
SCORE2 & SCORE2-OP <50 years 50-69 years ≥70 years
10-year risk of (fatal and non-fatal) CV <2.5% <5% <7.5%
2.5 to <7.5% 5 to <10% 7.5 to <15%
events in populations at moderate CVD risk ≥7.5% ≥10% ≥15%
Women Men
Non-smoking Smoking Non-smoking Smoking
Non-HDL cholesterol
prS ey ss st uo rl eic
(
mblo mo Hd
g)
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
mmol/L
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
SCORE2-OP 150 200 250 150 200 250 mg/dL 150 200 250 150 200 250
160-179 37 39 40 42 41 43 44 46 Age 37 45 53 62 37 45 53 61
(y)
140-159 35 36 38 39 39 40 42 43 36 43 51 59 35 43 51 59
85-89
120-139 32 34 35 37 36 38 39 41 34 41 49 57 34 41 48 57
100-119 30 32 33 34 34 35 37 38 32 39 47 55 32 39 46 55
160-179 27 28 30 31 34 35 37 39 30 35 41 47 34 40 46 53
140-159 24 25 27 28 30 32 33 35 27 32 37 43 31 36 42 48
80-84
120-139 21 22 24 25 27 28 30 31 25 29 34 40 28 33 38 44
100-119 19 20 21 22 24 25 27 28 22 26 31 36 25 30 35 40
160-179 19 20 21 23 27 29 30 32 24 27 31 35 31 35 39 44
140-159 16 17 18 19 24 25 26 28 21 23 27 30 27 30 34 38
75-79
120-139 14 15 15 16 20 21 22 24 17 20 23 26 23 26 29 33
100-119 12 12 13 14 17 18 19 20 15 17 19 22 19 22 25 29
160-179 13 14 15 16 22 23 25 26 19 21 23 25 28 31 34 36
140-159 11 11 12 13 18 19 20 22 15 17 18 20 23 25 28 30
70-74
120-139 9 9 10 11 15 16 17 18 12 13 15 16 19 20 22 24
100-119 7 7 8 8 12 13 13 14 10 11 12 13 15 16 18 20
SCORE2
160-179 10 10 11 12 15 16 17 18 14 15 17 18 20 22 23 25
140-159 8 9 9 9 13 13 14 15 12 13 14 15 17 18 20 21
65-69
120-139 7 7 7 8 10 11 12 12 10 11 12 13 14 15 17 18
100-119 5 6 6 6 9 9 9 10 8 9 10 10 12 13 14 15
160-179 7 8 8 9 12 13 14 15 11 12 13 15 17 18 20 22
140-159 6 6 7 7 10 11 11 12 9 10 11 12 14 15 17 18
60-64
120-139 5 5 5 6 8 9 9 10 7 8 9 10 11 13 14 15
100-119 4 4 4 5 6 7 7 8 6 7 7 8 9 10 11 12
160-179 5 6 6 7 10 11 11 12 9 10 11 12 14 16 17 20
140-159 4 4 5 5 8 8 9 10 7 8 9 10 11 13 14 16
55-59
120-139 3 3 4 4 6 7 7 8 5 6 7 8 9 10 11 13
100-119 3 3 3 3 5 5 6 6 4 5 6 6 7 8 9 10
160-179 4 4 5 5 8 8 9 10 7 8 9 10 11 13 15 17
140-159 3 3 4 4 6 6 7 8 5 6 7 8 9 10 12 14
50-54
120-139 2 2 3 3 5 5 6 6 4 5 5 6 7 8 9 11
100-119 2 2 2 2 3 4 4 5 3 4 4 5 5 6 7 8
160-179 3 3 3 4 6 7 8 9 5 6 7 8 9 11 13 15
140-159 2 2 3 3 5 5 6 6 4 5 5 6 7 8 10 12
45-49
120-139 2 2 2 2 3 4 4 5 3 4 4 5 5 7 8 9
100-119 1 1 1 2 3 3 3 4 2 3 3 4 4 5 6 7
160-179 2 2 3 3 5 5 6 7 4 5 6 7 8 9 11 13
140-159 1 2 2 2 3 4 5 5 3 4 4 5 6 7 8 10
40-44
120-139 1 1 1 2 3 3 3 4 2 3 3 4 4 5 6 8
100-119 1 1 1 1 2 2 2 3 2 2 2 3 3 4 5 6
Figure3Continued.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 22 ---
3248 ESCGuidelines
SCORE2 & SCORE2-OP <50 years 50-69 years ≥70 years
10-year risk of (fatal and non-fatal) CV <2.5% <5% <7.5%
2.5 to <7.5% 5 to <10% 7.5 to <15%
events in populations at high CVD risk ≥7.5% ≥10% ≥15%
Women Men
Non-smoking Smoking Non-smoking Smoking
Non-HDL cholesterol
prS ey ss st uo rl eic
(
mblo mo Hd
g)
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
mmol/L
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
SCORE2-OP 150 200 250 150 200 250 mg/dL 150 200 250 150 200 250
160-179 53 55 57 58 58 59 61 63 Age 42 49 57 65 41 49 56 65
(y)
140-159 50 52 54 55 55 56 58 60 40 47 55 63 40 47 54 62
85-89
120-139 47 49 51 52 52 53 55 57 38 45 53 61 38 45 52 60
100-119 44 46 48 50 49 51 52 54 36 43 51 58 36 43 50 58
160-179 40 42 44 45 49 51 53 55 34 40 45 51 38 44 50 56
140-159 36 38 39 41 44 46 48 50 31 36 42 47 35 40 46 52
80-84
120-139 32 34 36 37 40 42 44 46 29 33 38 44 32 37 42 48
100-119 29 31 32 34 36 38 40 41 26 30 35 40 29 34 39 44
160-179 29 31 32 34 41 43 45 47 28 32 35 39 35 39 44 48
140-159 25 27 28 29 35 37 39 41 24 27 31 34 31 34 38 43
75-79
120-139 22 23 24 25 31 32 34 36 21 24 27 30 27 30 34 37
100-119 18 19 20 22 26 28 29 31 18 20 23 26 23 26 29 33
160-179 21 22 24 25 33 35 37 39 23 25 27 29 33 35 38 41
140-159 17 18 19 20 28 29 31 33 19 20 22 24 27 29 32 34
70-74
120-139 14 15 16 17 23 24 26 27 15 17 18 20 22 24 26 28
100-119 11 12 13 14 19 20 21 22 12 14 15 16 18 20 22 23
SCORE2
160-179 15 16 17 18 26 27 29 30 17 18 20 22 25 28 30 32
140-159 12 13 14 14 21 22 23 24 14 15 16 18 21 23 25 27
65-69
120-139 10 10 11 11 16 17 18 19 11 12 13 15 17 19 20 22
100-119 8 8 8 9 13 14 14 15 9 10 11 12 14 15 17 18
160-179 11 11 12 13 20 21 23 25 13 13 16 18 20 23 25 28
140-159 8 9 9 10 15 16 18 19 10 11 13 14 16 18 20 23
60-64
120-139 6 7 7 8 12 13 14 15 8 9 10 11 13 15 16 18
100-119 5 5 6 6 9 10 11 11 6 7 8 9 10 12 13 15
160-179 7 8 9 10 15 16 18 20 9 11 12 14 16 19 21 24
140-159 5 6 7 7 11 12 14 15 7 8 10 11 13 15 17 19
55-59
120-139 4 4 5 5 8 9 10 11 6 6 7 9 10 11 13 15
100-119 3 3 4 4 6 7 8 8 4 5 6 7 8 9 10 12
160-179 5 5 6 7 11 13 14 16 7 8 10 11 13 15 18 21
140-159 3 4 4 5 8 9 10 12 5 6 7 9 10 12 14 16
50-54
120-139 3 3 3 4 6 7 8 9 4 5 5 6 7 9 10 12
100-119 2 2 2 3 4 5 6 6 3 3 4 5 6 7 8 9
160-179 3 4 4 5 8 10 11 13 5 6 8 9 10 13 15 18
140-159 2 3 3 4 6 7 8 9 4 5 6 7 8 9 11 14
45-49
120-139 2 2 2 2 4 5 6 6 3 3 4 5 6 7 8 10
100-119 1 1 2 2 3 3 4 5 2 2 3 4 4 5 6 7
160-179 2 2 3 4 6 7 9 10 4 5 6 7 8 10 13 16
140-159 1 2 2 2 4 5 6 7 3 3 4 5 6 7 9 11
40-44
120-139 1 1 1 2 3 4 4 5 2 2 3 4 4 5 7 8
100-119 1 1 1 1 2 2 3 3 1 2 2 3 3 4 5 6
Figure3Continued.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 23 ---
ESCGuidelines 3249
SCORE2 & SCORE2-OP <50 years 50-69 years ≥70 years
10-year risk of (fatal and non-fatal) CV <2.5% <5% <7.5%
2.5 to <7.5% 5 to <10% 7.5 to <15%
events in populations at very high CVD risk ≥7.5% ≥10% ≥15%
Women Men
Non-smoking Smoking Non-smoking Smoking
Non-HDL cholesterol
prS ey ss st uo rl eic
(
mblo mo Hd
g)
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
mmol/L
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
SCORE2-OP 150 200 250 150 200 250 mg/dL 150 200 250 150 200 250
160-179 62 63 64 65 65 66 67 68 Age 49 54 59 64 49 54 59 64
(y)
140-159 60 61 62 63 63 64 65 66 48 53 58 63 48 53 58 63
85-89
120-139 58 59 60 61 61 62 63 65 47 52 56 61 47 52 56 61
100-119 56 57 58 60 59 60 61 63 46 50 55 60 46 50 55 60
160-179 53 54 55 57 59 60 62 63 44 48 52 56 47 51 55 59
140-159 50 51 52 54 56 57 59 60 42 46 49 53 45 49 52 56
80-84
120-139 47 48 49 51 53 54 56 57 40 43 47 51 43 46 50 54
100-119 44 45 47 48 50 51 53 54 38 41 45 48 40 44 48 51
160-179 44 46 47 48 53 55 56 58 40 42 45 48 45 48 51 54
140-159 41 42 43 45 49 51 52 53 37 39 42 44 42 44 47 50
75-79
120-139 37 39 40 41 46 47 48 49 34 36 39 41 39 41 44 47
100-119 34 35 36 37 42 43 44 46 31 33 36 38 36 38 41 43
160-179 37 38 39 41 48 49 51 52 35 37 39 40 43 45 47 49
140-159 33 34 35 36 43 44 46 47 32 33 35 36 39 41 42 44
70-74
120-139 29 30 31 32 39 40 41 43 28 30 31 33 35 36 38 40
100-119 26 27 28 29 34 36 37 38 25 26 28 29 31 33 34 36
SCORE2
160-179 27 28 30 31 41 42 44 46 26 28 30 32 36 39 42 44
140-159 22 23 24 26 34 36 37 39 22 24 26 27 31 33 36 38
65-69
120-139 18 19 20 21 28 30 31 33 18 20 21 23 26 28 30 33
100-119 15 16 16 17 23 24 26 27 15 17 18 19 22 24 26 28
160-179 20 21 22 24 33 35 37 39 20 23 25 27 31 33 36 40
140-159 16 17 18 19 27 29 30 32 17 19 20 22 25 28 31 33
60-64
120-139 12 13 14 15 22 23 25 26 14 15 17 18 21 23 25 28
100-119 10 11 11 12 17 18 20 21 11 12 14 15 17 19 21 23
160-179 14 15 17 18 26 28 31 33 16 18 20 23 25 28 32 35
140-159 11 12 13 14 21 23 24 26 13 14 16 18 21 23 26 29
55-59
120-139 8 9 10 11 16 18 19 21 10 11 13 15 17 19 21 24
100-119 7 7 8 9 13 14 15 16 8 9 10 12 13 15 17 19
160-179 10 11 12 14 21 23 25 28 12 14 16 19 21 24 28 31
140-159 8 9 9 11 16 18 19 22 10 11 13 15 17 19 22 25
50-54
120-139 6 6 7 8 12 13 15 17 7 9 10 12 13 15 17 20
100-119 4 5 5 6 9 10 11 13 6 7 8 9 10 12 14 16
160-179 7 8 9 10 16 18 21 23 9 11 13 16 17 20 24 28
140-159 5 6 7 8 12 14 15 17 7 8 10 12 13 16 18 22
45-49
120-139 4 4 5 6 9 10 12 13 5 6 8 9 10 12 14 17
100-119 3 3 4 4 7 8 9 10 4 5 6 7 8 9 11 13
160-179 5 6 7 8 13 15 17 19 7 9 11 13 14 17 20 24
140-159 4 4 5 6 9 11 12 14 5 6 8 10 11 13 16 19
40-44
120-139 3 3 3 4 7 8 9 10 4 5 6 7 8 10 12 14
100-119 2 2 2 3 5 6 6 7 3 4 4 5 6 7 9 11
Figure3Continued.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 24 ---
3250 ESCGuidelines
Low risk Moderate risk High risk Very high risk
Figure4RiskregionsbasedonWorldHealthOrganizationcardiovascularmortalityrates.68,72,73
.
models that do not take into account the competing risk of non- .. rates to fatal and non-fatal CVD events.74 The SCORE2 algorithm
.
CVDmortality,tendtooverestimatetheactual10-yearriskofCVD, .. canbeaccessedintheESCCVDRiskapp(freelyavailablefromapp
.
and hence overestimate the potential benefit of treatment.71 The .. stores)andinriskchartsforthefourclustersofcountries(Figure4).
.
SCORE2-OPalgorithmestimates5-yearand10-yearfatalandnon- .. TheSCORE2chartsdonotapplytopersonswithdocumentedCVD
.
fatalCVDevents(myocardialinfarction,stroke)adjustedforcompet- .. or other high-risk conditions such asDM, FH, or other genetic or
.
ingrisksinapparentlyhealthypeopleaged>_70years.72 .. rarelipidorBPdisorders,CKD,andinpregnantwomen.
.
SCORE2andSCORE2-OParecalibratedtofourclustersofcoun- .. Toestimateaperson’s10-yearriskoftotalCVDevents,onemust
.
. tries(low,moderate,high,andveryhighCVDrisk)thataregrouped . firstidentifythecorrectclusterofcountriesandtheaccompanying
.
.
based on national CVD mortality rates published by the WHO . risktablefortheirsex,smokingstatus,and(nearest)age.Withinthat
.
(Supplementary Table 3 and Figure 4).73 Low-risk countries: .. table, one then finds the cell nearest to the person’s BP and non-
. .
Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain, . HDL-C.Riskestimatesthenneedtobeadjustedupwardsastheper-
.
.
Switzerland, the Netherlands, and the United Kingdom (UK). . sonapproachesthenextagecategory.
.
.
Moderate-risk countries: Austria, Cyprus, Finland, Germany, .
.
.
Greece,Iceland,Ireland,Italy,Malta,Portugal,SanMarino,Slovenia, . 3.2.3.3Translatingcardiovasculardiseaserisktotreatmentthresholds
.
.
and Sweden. High-risk countries: Albania, Bosnia and . Whilenoriskthresholdisuniversallyapplicable,theintensityoftreat-
.
.
Herzegovina,Croatia,CzechRepublic,Estonia,Hungary,Kazakhstan, . ment should increase with increasing CVD risk. In individual cases,
.
.
Poland, Slovakia, and Turkey. Very high-risk countries: Algeria, . however,nolowerthresholdoftotalCVDriskprecludestreatment
.
.
Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, .. of risk factors. Conversely, no high threshold for total CVD risk
.
Latvia,Lebanon,Libya,Lithuania,Montenegro,Morocco,Republicof .. implies‘mandatory’treatment.AcrosstheentirerangeofCVDrisk,
.
Moldova, Romania, Russian Federation, Serbia, Syria, The Former .. the decision to initiate interventions remains a matter ofindividual
.
YugoslavRepublic(Macedonia),Tunisia,Ukraine,andUzbekistan.A .. consideration and shared decision-making (see also section 4.1). In
.
multiplier approach has been used for converting CVD mortality . general, risk factor treatment recommendations are based on
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 25 ---
ESCGuidelines 3251
.
Table5 Cardiovasculardiseaseriskcategoriesbasedon .. categories of CVD risk (‘low-to-moderate’, ‘high’, and ‘very high’).
.
SCORE2andSCORE2-OPinapparentlyhealthypeople .. Thecut-offrisklevelsforthesecategoriesarenumericallydifferent
accordingtoage ...
forvariousagegroupstoavoidundertreatmentintheyoungandto
.
.
<50years 50(cid:2)69 (cid:3)70yearsa .. avoid overtreatment in older persons. As age is a major driver of
.
years .. CVD risk, but lifelong risk factor treatment benefit is higher in
.
. younger people, the risk thresholds for considering treatment are
Low-to-moderateCVD <2.5% <5% <7.5% .
.
. lowerforyoungerpeople(Table5).
risk:riskfactortreatmentgen- .
.
. Riskcategoriesdonot‘automatically’translateintorecommenda-
erallynotrecommended .
.
. tionsforstartingdrugtreatment.Inallagegroups,considerationof
HighCVDrisk:riskfactor 2.5to<7.5% 5to<10% 7.5to<15% ..
. risk modifiers, lifetime CVD risk, treatment benefit, comorbidities,
treatmentshouldbe ..
. frailty, and patient preferences may further guide treatment
considered ..
. decisions.
.
VeryhighCVDrisk:riskfac- >_7.5% >_10% >_15% . . Also, note that many patients can move themselves towards a
.
tortreatmentgenerally .
. lower riskcategory without taking drugs just by stopping smoking. recommendeda ..
.. Finally,notethatpersons>_70yearsoldmaybeatveryhighriskwhilst
C aInVD app= ac rear nd tli yov ha es ac lu thla yr pd eis oe pa ls ee.
>_70yearsold,thetreatmentrecommendationfor
.... beingattargetSBP,andprimarypreventionwithlipid-loweringdrugs
lipid-loweringdrugsisClassIIb(‘maybeconsidered’).
... inolderpersonsisaClassIIb(‘mayconsider’)recommendation;see
Thedivisionofthepopulationintothreedistinctagegroups(<50,50(cid:2)69,and .. section4.6.
.
>_70years)resultsinadiscontinuousincreaseinriskthresholdsforlow-to-mod- .. Inthe50(cid:2)69-yearagerange,a10-yearCVDmortalityriskthresh-
erate,high,andveryhighrisk.Inreality,ageisobviouslycontinuous,andasensi- .
bleapplicationofthethresholdsinclinicalpracticewouldrequiresomeflexibility
... oldof5%estimatedwiththepreviouslyusedSCOREalgorithmcor-
inhandlingtheseriskthresholdsaspatientsmovetowardsthenextagegroup,or .. responds, on average, to a 10-year fatal and non-fatal CVD risk
.
recentlypassedtheagecut-off.Figure5illustrateshowacontinuousincreasein .. threshold of 10% estimated with SCORE2, as approximately the
a pg re acr tie cl ea .testoincreasingriskthresholds,andmaybeusedasaguidefordaily ....
samenumberofpeopleareabovetheriskthresholdandwouldqual-
.. ifyfortreatment.68
.
10-year CVD risk (%)
25
22.5
20
17.5
15
12.5
10
7.5
5
2.5
30 40 50 60 70 80 90
<50 50-69 ≥70
Age groups (years)
CVD risk thresholds (%)
Very high CVD risk
High CVD risk
Low-to-moderate CVD risk
Figure5Schematicrepresentationofincreasing10-yearcardiovasculardiseaseriskthresholdsacrossagegroups.CVD=atheroscleroticcardiovascular
disease.
1202
CSE Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 26 ---
3252 ESCGuidelines
Apparently healthy personsa
STEP 1
Stop smoking, lifestyle recommendations and SBP <160 mmHg (Class I)
Age < 50 years Age 50 – 69 years Age ≥ 70 yearsb
Estimate 10-year CVD risk Estimate 10-year CVD risk Estimate 10-year CVD risk
(SCORE2) (SCORE2) (SCORE2-OP)
<2.5% 2.5 to <7.5% ≥7.5% <5% 5 to <10% ≥10% <7.5% 7.5 to <15% ≥15%
Consider risk modifiers,
Consider risk modifiers, Consider risk modifiers,
lifetime treatment
lifetime CVD risk lifetime CVD risk
benefitb, comorbidities,
and treatment benefitb, and treatment benefitb,
frailty, polypharmacy,
patient preferences patient preferences
patient preferences
No additional No additional No additional No additional
prevention prevention prevention prevention
goals goals goals goals
SBP <140 LDL-C SBP <140 LDL-C
to 130 mmHg <2.6 mmol/L to 130 mmHg <2.6 mmol/L
AND AND
if tolerated (<100 mg/dL) if tolerated (<100 mg/dL)
(Class I) (Class IIa) (Class I) (Class IIb)
STEP 2 STEP 2
Intensified treatment based on:
10-year CVD risk (SCORE2)
Lifetime CVD risk and treatment benefitb
Comorbidities, frailty For specific risk factor
Patient preferences management
in patients ≥70 years,
LDL-C (Class IIa) please see Section 4
SBP
<130 mmHg AND High risk Very high risk
if tolerated <1.8 mmol/L <1.4 mmol/L
(Class I) (<70 mg/dL) (<55 mg/dL)
Figure6 Flowchartofcardiovasculardiseaseriskandriskfactortreatmentinapparentlyhealthypersons.ASCVD=atheroscleroticcardiovasculardis-
ease;CKD=chronickidneydisease;CVD=cardiovasculardisease;DM=diabetesmellitus;ESC=EuropeanSocietyofCardiology;FH=familialhyper-
cholesterolaemia; LDL-C = low-density lipoprotein cholesterol; LIFE-CVD = LIFEtime-perspective CardioVascular Disease; SBP = systolic blood
pressure;SCORE2=SystematicCoronaryRiskEstimation2;SCORE2-OP=SystematicCoronaryRiskEstimation2-OlderPersons.Solidlinesrepresent
defaultoptionsforthemajorityofpeople.Dottedlinesrepresentalternativechoicesforsome,dependingonthepatient-specificcharacteristicsandcondi-
tionsindicatedintheboxes.UltimatetreatmentgoalsforSBP(<130mmHg)andLDL-C(accordingtolevelofrisk)accordingtotherespectiveESC
Guidelinesaretobepursuedasindicated.Thestepwiseapproachhastobeappliedasawhole:afterSTEP1,consideringproceedingtotheintensifiedgoals
ofSTEP2ismandatory.RiskscoresareavailableintheESCCVDRiskCalculatorappformobiledevices(https://www.escardio.org/Education/ESC-
Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app) and at websites such as https://www.u-prevent.com. aDoes not include
patientswithCVD,DM,CKD,orFH.bTheLIFE-CVDmodelforestimatinglifetimeCVDriskandtreatmentbenefitiscalibratedforlow-andmoderate-
riskregions(seeBox1).
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 27 ---
ESCGuidelines 3253
Patients with establishedASCVDa
STEP 1b
Stop smoking SBP <140
and lifestyle to 130 mmHg
recommendations if tolerated
(Class I) (Class I)
AND
LDL-C
≥50% reduction and Antithrombotic
Therapy
<1.8 mmol/L (<70 mg/dL) (Class I)
(Class I)
STEP 2
Intensified treatment based on:
Residual 10-yearCVD riskc
Lifetime CVD risk and treatment benefitd
Comorbidities, frailty
Patient preferences
DAPT, DPI,
SBP LDL-C
novel upcoming
<130 mmHg <1.4 mmol/L
AND AND interventions
if tolerated (<55 mg/dL)
(e.g. colchicine, EPA)
(Class I) (Class I)
(Class IIb)
Figure7 Flowchartofcardiovascularriskandriskfactortreatmentinpatientswithestablishedatheroscleroticcardiovasculardisease.Ultimatetreat-
mentgoalsforSBP(<130mmHg)andLDL-C(accordingtolevelofrisk)accordingtotherespectiveESCGuidelines3,4aretobepursuedasindicated.The
stepwiseapproachhastobeappliedasawhole:afterSTEP1,consideringproceedingtotheintensifiedgoalsofSTEP2ismandatory.ACS=acutecoro-
narysyndromes;ASCVD=atheroscleroticcardiovasculardisease;CR=cardiacrehabilitation;CVD=cardiovasculardisease;DAPT=dualantiplatelet
therapy;DM=diabetesmellitus;ESC=EuropeanSocietyofCardiology;EUROASPIRE=EuropeanActiononSecondaryandPrimaryPreventionby
InterventiontoReduceEvents;LDL-C= low-densitylipoproteincholesterol;SBP= systolicbloodpressure;SMART = SecondaryManifestationsof
ArterialDisease.RiskscoresareavailableintheESCCVDRiskCalculatorappformobiledevices(https://www.escardio.org/Education/ESC-Prevention-
of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app)andatwebsitessuchashttps://www.u-prevent.com.aForpatientswithDMseeDM
flowchart(Figure8).bForpatientswithrecentACS,thesepreventiongoalsarepartofparticipationinCR(ClassI/A).cForpatientsaged>_70years,ahigh
10-year risk may be associated with a lower absolute lifetime benefit from treatment due to limited life expectancy. dLifetime treatment benefit is
expressedasextraCVD-freelifegainedfromacertaininterventionortreatmentintensification.
.
Asthe10-yearCVDriskthresholdsguidetreatmentdecisionsand .. beconsidered,takingCVDriskmodifiers,lifetimeriskandtreatment
.
have an impact on healthcare costs and resources, countries or .. benefit(inlow-andmoderate-riskregions,Box1),andpatientpreferen-
.
regionsmaydecideonusinghigherorlowertreatmentthresholds. .. cesintoaccount.A10-yearCVDrisk<5%isconsidered‘low-to-mod-
.
.. erate risk’, and would generally not qualify for risk factor treatment
.
3.2.3.4 Riskestimationandriskfactortreatmentinapparentlyhealthy .. unlessoneorseveralriskmodifiers(seesection3.3)increaserisk,orthe
.
people50(cid:2)69yearsofage ..
estimatedlifetimeriskandtreatmentbenefitisconsideredsubstantial.
.
Stopping smoking, lifestyle recommendations, and SBP <160 mmHg .
.
.
arerecommendedforall(Figure6).A10-yearCVDrisk(fatalandnon- . 3.2.3.5Riskestimationandriskfactortreatmentestimationinappa-
.
.
fatalASCVDevents)>_10%isgenerallyconsidered‘veryhighrisk’,and . rentlyhealthypeople(cid:3)70yearsofage
.
.
treatmentofCVDriskfactorsisrecommended.A10-yearCVDriskof . Stopsmoking,lifestylerecommendationsandaSBP<160mmHgare
.
.
5to<10%isconsidered‘highrisk’,andtreatmentofriskfactorsshould .. recommendedforall(Figure6).AgeisthedominantdriverofCVD
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 28 ---
3254 ESCGuidelines
.
risk, and estimated 10-year CVD risk of almost all individuals >_70 .. moderate-risk regions), and patient preferences into account. A 10-
.
yearsexceedsconventionalriskthresholds.Also,lifetimebenefitof .. yearCVDrisk<2.5%isconsidered‘low-to-moderaterisk’,andwould
.
treatmentintermsoftimegainedfreeofCVDislowerinolderpeo- .. generallynotqualifyforriskfactortreatmentunlessoneorseveralrisk
.
ple.Therefore,theCVDriskthresholdsforriskfactortreatmentare .. modifiers(seesection3.3)increaseriskortheestimatedlifetimeriskand
.
higherinapparentlyhealthypeople>_70years.A10-yearCVDrisk .. treatmentbenefitisconsideredsubstantial(seeBox1)(Figure6).75(cid:2)78
.
>15% is generally considered ‘very high risk’, and treatment of .. In risk communication with younger people, the lifetime benefit
.
ASCVDriskfactorsisrecommended(note:therecommendationfor .. perspectivemaybeuseful,aswellasdiscussingthepotentialofavoid-
.
lipid-lowering treatment in apparently healthy people >_70 years is .. ing a devastating CVD event in the short-to-intermediate term,
.
.
classIIb;‘maybeconsidered’;seesection4.6).A10-yearCVDriskof . despitethefactthat10-yearCVDriskmaybeverylow.
.
.
7.5 to <15% is considered ‘high risk’, and treatmentofrisk factors . CVDriskpredictions,aswellaspredictionsoflifetimebenefitof
.
.
shouldbeconsideredtakingCVDriskmodifiers,frailty,lifetimetreat- . risk factor treatment, are likely to be imprecise at very young age
.
.
mentbenefit(inlowandmoderateriskregions,Box1),comorbid- . (<40years).Atthatage,lipid-loweringandBP-loweringdrugtreat-
.
.
ities,polypharmacy,andpatientpreferencesintoaccount.Giventhe . mentarenotusuallyconsidered,exceptforpatientswithFHorspe-
.
.
subjectivenatureofmanyofthesefactors,itisnotpossibletodefine . cific BP disorders. A healthy lifestyle that is maintained throughout .
.
strictcriteriafortheseconsiderations.A10-yearCVDrisk<7.5%is . life is more relevant for the very young. Mendelian randomization
.
.
considered ‘low-to-moderate risk’, and would generally not qualify . studiesillustrateverynicelythatrelativelysmalldifferencesinLDL-C
.
.
forriskfactortreatmentunlessoneorseveralriskmodifiers(section . or SBP maintained throughout life have large implications on CVD
.
3.3)increaseriskortheestimatedlifetimeriskandtreatmentbenefit .. riskoveralifespan.80
.
.
isconsideredsubstantial.75(cid:2)79 ..
.
.. 3.2.3.7Riskestimationandriskfactortreatmentinpatientswithestab-
.
3.2.3.6 Riskestimationandriskfactortreatmentinapparentlyhealthy .. lishedatheroscleroticcardiovasculardisease
.
people<50yearsofage .. Patients with clinically established ASCVD are, on average, at very
.
Stoppingsmoking,lifestylerecommendations,andSBP<160mmHgare .. high risk of recurrent CVD events if risk factors are not treated.
.
recommended for all (Figure 6). The 10-year CVD risk in relatively .. Therefore,smokingcessation,adoptionofahealthylifestyle,andrisk
.
young,apparentlyhealthypeopleisonaveragelow,eveninthepres- .. factor treatment is recommended in all patients (STEP 1). Further
.
enceofhighriskfactorlevels,butthelifetimeCVDriskisinthesecir- .. intensificationofriskfactortreatmentbyaimingatlowertreatment
.
cumstancesveryhigh.Inapparentlyhealthypeople<50yearsofage,a .. goals(STEP2)isbeneficialinmostpatientsandmustbeconsidered,
.
10-yearCVDrisk>_7.5%isgenerallyconsidered‘veryhighrisk’asthis .. taking10-yearCVD risk, comorbidities,lifetimeriskand treatment
.
riskrelatestoahighlifetimerisk,andtreatmentofASCVDriskfactors .. benefit (Box 1), frailty, and patient preferences into account in a
.
isrecommended.A10-yearCVDriskof2.5to<7.5% isconsidered .. shareddecision-makingprocess(Figure7).
.
.
‘high risk’, and treatment of risk factors should be considered, taking . After initial risk factor treatment and the achievement of risk
.
.
CVD risk modifiers, lifetime risk and treatment benefit (in low- and . factor treatment goals, the individual residual risk for recurrent
.
Box 1. Lifetime CVD risk and treatment benefit estimation
PreventionofCVDbytreatingriskfactorsisusuallydonewithalifetimeperspective.LifetimeCVDriskcanbeapproximatedbyclinicalexpe-
rience with clinical criteria such as age, (change in) risk factor levels, risk modifiers, etc. or estimated in apparently healthy people, patients
withestablishedASCVD,andpersonswithtype2DMwithspecificlifetimeCVDriskscores.75(cid:2)77Lifetimebenefitfromriskfactormanage-
mentcanbeestimatedbycombininglifetimeriskmodelswithHRsderivedfromRCTs,meta-analysesofRCTs,orMendelianrandomization
studies,whichmayprovideestimatesoftheeffectsoflonger-termtreatmentofriskfactors.Onlinecalculators(suchastheESCCVDRisk
app)canbeusedtoestimatetheaveragelifetimebenefitofsmokingcessation(seealsoFigure11),lipidlowering(seealsoFigure12),andBP
lowering(seealsoFigure15)onanindividualpatientlevelexpressedasextraCVD-freelife-years.78Averagelifetimebenefitiseasytointerpret
andmayimprovethecommunicationofpotentialtherapybenefitstopatientsinashareddecision-makingprocess.Thismayinturnincrease
patientengagement,self-efficacy,andmotivationtoadheretolifestylechangesanddrugtreatment.
Thelifetimeriskisanestimateoftheageatwhichthereisa50%probabilitythatapersonwilleitherhaveexperiencedaCVDeventorhave
died.Lifetimebenefitisthenumericaldifferencebetweenthepredictedageatwhichthereisa50%probabilitythatapersonwilleitherhave
experiencedaCVDeventorhavediedwithandwithoutaproposedtreatment.Currentlytherearenoformaltreatmentthresholdsforaver-
agelifetimebenefit.Inaddition,theestimatedindividuallifetimebenefitshouldbeviewedinthelightoftheestimateddurationoftreatment.
Durationoflifelongtreatmentwillgenerallybelongerinyoungpersonscomparedtoolderpeople.Bothtreatmenteffectandtreatmentdura-
tiondeterminetheindividual‘returnoninvestment’ofriskfactortreatment.Inashareddecision-makingprocessbetweenhealthcareprovider
and patient, the minimum desired benefit of a certain treatment needs to be established, a process in which patient preference, expected
treatmentharms,andcostscanbetakenintoaccount.
BP = blood pressure; CVD = cardiovascular disease; DM = diabetes mellitus; ESC = European Society of Cardiology; HR = hazard ratio;
RCT=randomizedcontrolledtrial.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 29 ---
ESCGuidelines 3255
Patients with type 2 diabetes mellitus
STEP 1
Stop smoking and lifestyle recommendations (Class I) AND HbA1c: <53 mmol/mol (<7.0%) (Class I)
EstablishedASCVD or severeTODa
Without With
Risk
Moderateb Highb
SBP <140 to SBP <140 to
Antithrombotic
130 mmHg 130 mmHg
therapy
Additional if tolerated if tolerated
(Class I)
prevention (Class I) (Class I)
goals
generally not
LDL-C SGLT2-i or GLP-1RA...c
recommended LDL-C ≥50% reduction and
(Class III) <2.6 mmol/
<1.8 mmol/L … for CVD: Class I
(<100 mg/dL)
(<70 mg/dL)
(Class I)
(Class I) … forTOD: Class IIb
STEP 2
Intensified treatment based on: Intensified treatment based on:
10-year CVD risk Residual 10-year CVD risk
Lifetime CVD risk and treatment benefitd Lifetime CVD risk and treatment benefitd
Comorbidities, frailty Comorbidities, frailty
Patient preferences Patient preferences
SBP LDL-C SBP LDL-C
<130 mmHg <1.8 mmol/L <130 mmHg <1.4 mmol/L DAPT, DPI,
if tolerated (<70 mg/dL) if tolerated (<55 mg/dL) novel upcoming
(Class I) (Class I) (Class I) (Class I) interventions
(e.g. colchicine,
SGLT2-i or GLP-1RA SGLT2-i or GLP-1RA EPA)
if not already on it if not already on itc (Class IIb)
(Class IIb) (Class I)
Figure8 Flowchartofcardiovascularriskandriskfactortreatmentinpatientswithtype2diabetesmellitus.UltimatetreatmentgoalsforSBP(<130
mmHg)andLDL-C(accordingtolevelofrisk)accordingtotherespectiveESCGuidelines3,4aretobepursuedasindicated.Thestepwiseapproachhasto
beappliedasawhole:afterSTEP1,consideringproceedingtotheintensifiedgoalsofSTEP2ismandatory.RiskscoresareavailableintheESCCVDRisk
Calculator app for mobile devices (https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-
app)andatwebsitessuchashttps://www.u-prevent.com.ACR=albumin-to-creatinineratio;ASCVD=atheroscleroticcardiovasculardisease;CKD=
chronickidneydisease;CVD=cardiovasculardisease;DAPT=dualantiplatelettherapy;DM=diabetesmellitus;eGFR=estimatedglomerularfiltration
rate;ESC=EuropeanSocietyofCardiology;GLP-1RA=glucagon-likepeptide-1receptoragonist;HbA1c=glycatedhaemoglobin;HF=heartfailure;
LDL-C=low-densitylipoproteincholesterol;SBP=systolicbloodpressure;SGLT2=sodium-glucosecotransporter2;TOD=targetorgandamage(retin-
opathy,nephropathy,neuropathy).aSevereTODisdefinedasatleastoneof:eGFR<45mL/min/1.73m2irrespectiveofthepresenceorabsenceofalbumi-
nuria;eGFR46(cid:2)59mL/min/1.73m2andmicroalbuminuria(ACR30(cid:2)300mg/gor3(cid:2)30mg/mmol);proteinuria(ACR>300mg/gor>30mg/mmol);
presenceofmicrovasculardiseaseinatleastthreedifferentsites(e.g.microalbuminuriaplusretinopathyplusneuropathy).bSeeTable4forCVDriskgroups.
cPatientswithprevalentHForCKDarerecommendedforSGLT2inhibitor,andpatientspoststrokearerecommendedforGLP-1RAtreatment.dLifetime
treatmentbenefitisexpressedasextraCVD-freelifegainedfromacertaininterventionortreatmentintensification.SeeBox1.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 30 ---
3256 ESCGuidelines
CVD varies widely and should be considered.81 It is evident that ..
. RecommendationsforCVDriskestimation
.
patients with a recent ACS or progressive vascular disease, and .
.
.
patientswithDMandvasculardisease,areallatexceptionallyhigh .. Recommendations Classa Levelb
.
riskforrecurrentCVDevents.Forotherpatientswithestablished .
.
. Inapparentlyhealthypeople<70yearswithout
ASCVD, the residual risk may be less evident and could be esti- .
.
. establishedASCVD,DM,CKD,genetic/rarer
matedbasedonclinicalcriteriasuchasage,(changein)riskfactor .
.
. lipidorBPdisorders,estimationof10-yearfatal I B
levels, and risk modifiers, or by calculation of residual CVD risk .
.
. andnon-fatalCVDriskwithSCORE2is
withacalculator. .
.
. recommended.68
TheriskofrecurrentCVDisinfluencedmainlybyclassicalriskfac- ..
tors,vasculardiseasesite,andkidneyfunction.Riskstratificationtools
... Inapparentlyhealthypeople>_70yearswithout
for secondary prevention include the SMART (Secondary
... establishedASCVD,DM,CKD,genetic/rarer
Manifestations of Arterial Disease) risk score (available in the ESC
... lipidorBPdisorders,estimationof10-yearfatal I B
CVDRiskapp)forestimating10-yearresidualCVDriskinpatients
... andnon-fatalCVDriskwithSCORE2-OPis
withstableASCVD,definedasCAD,PAD,orcerebrovasculardis-
... recommended.72
.
ease,81 and the European Action on Secondary and Primary .. Inapparentlyhealthypeople,afterestimationof
.
Prevention by Intervention to Reduce Events (EUROASPIRE) risk .. 10-yearfatalandnon-fatalCVDrisk,lifetime
.
model,whichestimates2-yearriskofrecurrentCVDinpatientswith .. riskandtreatmentbenefit,riskmodifiers,frailty, IIa C
.
stableCAD.82 .. polypharmacy,andpatientpreferencesshould
.
Occasionally, recurrent CVD risk is very high despite maximum .. beconsidered.
. (tolerated) conventional treatments. In such cases, novel but less .. PatientswithestablishedASCVDand/orDM
.
well-established preventive treatments suchasdual antithrombotic .. and/ormoderate-to-severerenaldiseaseand/or
.
pathwayinhibition,83icosapentethyl,84oranti-inflammatorytherapy .. genetic/rarerlipidorBPdisordersaretobe I A
.
withcolchicine(seesection4.10)85,86maybeconsidered. .. consideredathighorveryhighCVD
.
.. risk.75,77,81,88(cid:2)90
.
.
3.2.3.8 Riskestimationandriskfactortreatmentinpersonswithtype2 . Astepwisetreatment-intensificationapproach
.
.
diabetesmellitus . aimingatintensiveriskfactortreatmentisrec-
.
.
Mostadultswithtype2DMareathighorveryhighriskforfuture . ommendedforapparentlyhealthypeopleat
.
.
CVD,particularlyfrommiddleageonwards.Onaverage,type2DM . highorveryhighCVDrisk,aswellaspatients
.. I B
doubles CVD risk and reduces life expectancy by 4-6 years, with .. withestablishedASCVDand/orDM,withcon-
.
absoluteriskshighestinthosewithanytargetorgandamage(TOD). .. siderationofCVDrisk,treatmentbenefitofrisk
.
Type2DMalsoincreasestheriskforcardiorenaloutcomes,inpar- .. factors,riskmodifiers,comorbidities,and
.
ticularHFandCKD.Relativerisks(RRs)forCVDintype2DMare .. patientpreferences.66,67
.
higheratyoungeragesofonsetandaremodestlyhigherinwomen .. TreatmentofASCVDriskfactorsisrecom-
.
comparedwithmen.87Smokingcessationandadoptionofahealthy ..
mendedinapparentlyhealthypeople
.
lifestylearerecommendedforallpeoplewithtype2DM,andriskfac- .. withoutDM,CKD,genetic/rarerlipid,orBP
.
tortreatmentshouldbeconsideredinallpeoplewithDM,atleast .. disorderswhoareatveryhighCVDrisk I C
.
thoseabovetheageof40years(seesections4.6and4.7).Still,there .. (SCORE2>_7.5%forageunder50;SCORE2
.
isawiderangeinindividualriskforCVDevents,especiallyafterinitial .. >_10%forage50(cid:2)69;SCORE2-OP>_15%for .
riskfactormanagement.88 .. age>_70years).68,72
.
Persons with DM with severe TOD (fordefinition: see Table 4) ... TreatmentofASCVDriskfactorsshould
canbeconsideredtobeatveryhighCVDrisk,similartopeoplewith ... beconsideredinapparentlyhealthypeople
establishedCVD(seeTable4).MostotherswithDMareconsidered ... withoutDM,CKD,genetic/rarerlipid,orBP
tobeathighASCVDrisk.64However,anexceptioncanbemadefor ...
disorderswhoareathighCVDrisk(SCORE2
.
patientswithwell-controlledshort-standingDM(e.g.<10years),no .. 2.5to<7.5%forageunder50;SCORE25to
. IIa C
evidenceofTOD,andnoadditionalASCVDriskfactors,whomay .. <10%forage50(cid:2)69;SCORE2-OP7.5to
.
beconsideredasbeingatmoderateCVDrisk. .. <15%forage>_70years),takingCVDrisk
.
Inadditiontothesemi-quantitativedivisionintothreeriskcatego- .. modifiers,lifetimeriskandtreatment
.
ries described above, DM-specific risk models may refine risk esti- .. benefit,andpatientpreferencesinto
.
mates and illustrate the impact of treatments. These models .. account.
.
generally include duration of DM, glycated haemoglobin (HbA1c) .
.
level,andpresenceofTOD.ExamplesaretheADVANCE(Actionin .. ASCVD=atheroscleroticcardiovasculardisease;BP=bloodpressure;CKD=
.
. chronic kidney disease (see definition in Table 4); DM = diabetes mellitus;
Diabetes and Vascular disease: preterAx and diamicroN-MR .
. SCORE2 = Systemic Coronary Risk Estimation 2; SCORE2-OP = Systemic
.
ControlledEvaluation)riskscore,whichpredicts10-yearCVDrisk, .. CoronaryRiskEstimation2-OlderPersons.
andtheUKPDS(UKProspectiveDiabetesStudy)riskengine,which .... a bC Lela vs es lo of fr ee vc ido em nm cee .ndation.
predictsfataland non-fatalCVD riskand isavailablefor useinthe ..
.
UK. However, we recommend cautious use of these calculators, ..
.
sincebotharebasedonoldercohortdata89,90(Figure8). .
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 31 ---
ESCGuidelines 3257
IntensificationofriskfactortreatmentinSTEP2mustbeconsid- .. RecommendationforCVDriskcommunication
.
.
eredinallpatients,takingintoaccount10-yearCVDrisk,comorbid- .
.. Recommendation Classa Levelb
ities, lifetime risk and treatment benefit (Box 1), frailty, and patient .
.
preferencesinashareddecision-makingprocess.75 ...
AninformeddiscussionaboutCVDriskand .
.. treatmentbenefitstailoredtotheneedsofa I C
.
3.2.3.9 Riskestimationandriskfactortreatmentinpersonswithtype1 .. patientisrecommended.96
.
diabetesmellitus .
.
Peoplewithtype1DMareatincreasedCVDrisk,andearliermanifes- .. CVD=cardiovasculardisease.
.. aClassofrecommendation.
tationoftype1DMrelatestomorelife-yearslostinwomenthanmen, .. bLevelofevidence.
.
mostlyduetoCVD.91RRsofCVDare,onaverage,higherintype1vs. ..
.
type2DM,duetoanaverageofthreetofourextradecadesofhyper- ..
.
glycaemia,andusualriskfactorscontributestronglytoCVDoutcomes ..
.
intype 1DM.92 CVD riskshavedeclined overtime,commensurate .. RecommendationsforCVDriskmodifiers
.
withimprovementsinlifeexpectancy.93LifetimeCVDrisksintype1 ..
.
DMarehigherwithpoorerglycaemiccontrol,lowersocialclass,and .. Recommendations Classa Levelb
.
youngerageofonset.TheabsoluteriskofCVDeventsorCVDmor- ..
talityishighestamongthosewithanyevidenceofmicrovasculardis-
... Stresssymptomsandpsychosocialstressors
ease,particularlyrenalcomplications,andisstronglyinfluencedbyage.
... modifyCVDrisk.Assessmentofthesestressors IIa B
CVDriskstratificationinpersonswithtype1DMmaybebasedonthe
... shouldbeconsidered.100(cid:2)102
same risk classification as for type 2 DM, summarized in Table 4,
... CACscoringmaybeconsideredtoimproverisk
.
. classificationaroundtreatmentdecisionthresh-
althoughthelevelofevidencefortype1DMisweaker. .
.. olds.Plaquedetectionbycarotidultrasoundis IIb B
.
.
. analternativewhenCACscoringisunavailable
.
.. ornotfeasible.103,104
.
.
3.2.4.Communicationofcardiovasculardiseaserisk
... MultiplicationofcalculatedriskbyRRforspecific
IIa B
Reducing CVD risk at the individual level begins with appropriate
.. ethnicsubgroupsshouldbeconsidered.105
.
assessmentofindividualriskandeffectivecommunicationofriskand ... Theroutinecollectionofotherpotentialmodi-
anticipated risk reduction by risk factor treatment. Patient-doctor ... fiers,suchasgeneticriskscores,circulatingor
interactionsarecomplexandcommunicatingriskischallenging.94,95 ... urinarybiomarkers,orvasculartestsorimaging
III B
.
Thereisno single ‘correct’ approach; rather,it will depend on the .. methods(otherthanCACscoringorcarotid
.
individual’s preferences and understanding, which may differ with .. ultrasoundforplaquedetermination),isnot
.
education status and numeracy. Risk perception is also strongly .. recommended.
.
affected byemotional factors suchasfear, optimism, etc. (‘patients ...
CVD=cardiovasculardisease;CAC=coronaryarterycalcium;RR=relative
don’tthinkrisk,theyfeelrisk’).96 ..
risk.
.
Itisimportanttoexplorewhetherpatientsunderstandtheirrisk, .. aClassofrecommendation.
theanticipatedriskreduction,andtheprosandconsofintervention,
... bLevelofevidence.
.
andtoidentifywhatisimportanttothem.Forexample,onepatient ..
..
mayfocusonlivingfreeofmedications,whereasanothermaybeless .. .. ofRRstotreatmentdecisionsisnotrecommended,asabsoluterisk
..
abletochangetheirlifestyle.Intermsofoutcomes,reducingmortal- .. .. remainsthekeycriterionforstartingtreatment. ..
ityriskiscrucialtosome,whereasdiseaseriskismoreimportantto .. .. Analternativewayofexpressingindividualriskistocalculateaper-
..
others.Short-termriskmaymotivatesomepatients,whereaslifetime .. .. son’s‘riskage’.96TheriskageofapersonwithseveralASCVDrisk
..
benefit(seeBox1)willhavemoreimpactinothers.Ingeneral,visual .. .. factorsistheageofapersonofthesamesexwiththesamelevelof
..
.. aids (graphsetc.)improve riskunderstanding, absolute risk (reduc- .. riskbutwithlowlevelsofriskfactors.Riskageisanintuitiveandeasily
..
..
tion)isbetterunderstoodthanRR(reduction),andtheuseof‘num- .. understoodwayofillustratingthelikelyreductioninlifeexpectancy
..
..
bersneededtotreat’islesswellunderstood. .. thatayoungpersonwithalowabsolutebuthighRRofCVDwillbe
.. ..
Inapparentlyhealthypeople,thestandardapproachistoreport .. exposedtoifpreventivemeasuresarenotadopted.Riskageisalso
..
..
absolute10-yearriskofaCVDeventwithSCORE2orSCORE2-OP, .. automatically calculated as part of HeartScore (http://www.hearts-
..
which can be found at the ESC CVD Risk Calculator app (https:// .. .. core.org/).97(cid:2)99
..
..
www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/ .. CVDriskmayalsobeexpressedwithalifetimeratherthana10-
..
..
Risk-assessment/esc-cvd-risk-calculation-app) or at http:// .. .. year horizon, for example, the LIFE-CVD (LIFEtime-perspective
..
www.heartscore.orgorhttps://www.u-prevent.com.Inspecificsitua- .. .. CardioVascularDisease)calculator(ESCCVDRiskCalculationapp
..
tions,onemayoptforexpressingriskintermsotherthanabsolute .. .. or https://www.u-prevent.com) (also see Box 1).78 Lifetime CVD
..
10-year risk. Examples of such situations include risks in young or .. .. risk-predictionmodelsidentifyhigh-riskindividualsbothintheshort
..
veryoldpeople.Inyoungpeople,lifetimeriskmightbemoreinfor- .. .. andlongterm.Suchmodelsaccountforpredictedriskinthecontext
..
mative,as10-yearCVDriskisusuallyloweveninthepresenceof .. .. ofcompetingrisksfromotherdiseasesovertheremainingexpected
..
riskfactors.Inolderpersons,specificriskestimationisrequired,tak- .. .. lifespanof anindividual. A similarapproachalsoemployinglifetime
..
ingcompetingnon-CVDmortalityintoaccount.78Directtranslation .. perspective is to calculate lifetime benefit of preventive
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 32 ---
3258 ESCGuidelines
.
.
interventions.78 Lifetime benefit of preventive interventions can be .. 3.3.1.Psychosocialfactors
.
expressedasgaininCVD-freelife(years),whichiseasiertocommu- .. Psychosocialstressisassociated,inadose-responsepattern,withthe
.
nicate to a patient and may support the shared decision-making .. development and progression of ASCVD, independently of conven-
.
process. .. tionalriskfactorsandsex.Psychosocialstressincludesstresssymptoms
.
.. (i.e.symptomsofmentaldisorders),aswellasstressorssuchasloneli-
.
3.3. Potential risk modifiers .. nessandcriticallifeevents.TheRRsofpsychosocialstressarecom-
.
Apart from the conventional CVD risk factors included in the risk
.. monlybetween1.2and2.0108,109(SupplementaryTable4).Conversely,
.
charts,additionalriskfactorsortypesofindividualinformationcan .. indicatorsofmentalhealth,suchasoptimismandastrongsenseofpur-
.
alsomodifycalculatedrisk.Assessmentofapotentialmodifiermay
.. pose,areassociatedwithlowerrisk.109Psychosocialstresshasdirect
.
beconsideredif: ... biologicaleffects,butisalsohighlycorrelatedwithsocioeconomicand
.. behavioural risk factors (e.g. smoking, poor adherence).100,109(cid:2)113
.
• Itimprovesmeasuresofriskprediction,suchasdiscriminationor .
. Although the associations of psychosocial stress with CV health are
.
reclassification(e.g.bycalculationofnetreclassificationindex) .
. robust,only‘vitalexhaustion’hasbeenproventoimproveriskreclassi-
• Publichealthimpactisclear(e.g.numberneededtoscreenor ... fication.101 Owing to the importance of stress symptoms among
.
netbenefit) .
. ASCVD patients, several guidelines and scientific statements recom-
• Itisfeasibleindailypractice ...
mend screening of ASCVD patients for psychological stress113(cid:2)115
• Information is not just available on how risk increases with an ..
. (Box2andSupplementaryTable5).Arecentprospectivecohortstudy
unfavourableresult,butalsoonhowriskdecreasesifthemodi- ..
. with a median follow-up of 8.4 years reported favourable effects of
fiershowsafavourableresult ...
screeningfordepressiononmajorASCVDevents.102
• Theliteratureonthispotentialmodifierisnotdistortedbypubli- ..
.
cationbias. ..
.
.
Very few potential modifiers meet all of these criteria. Meta-
... 3.3.2.Ethnicity
analysesinthisfieldare,forexample,susceptibletosubstantialpubli-
... Europeincludesmanycitizenswhoseethnicbackgroundoriginatesin
cationbias.106Also,theexactwayofintegratingadditionalinforma- ... countriessuchasIndia,China,NorthAfrica,andPakistan.Giventhe
.
tion on top of regular risk calculator input parameters is mostly .. considerable variability in ASCVD risk factors between immigrant
.
unknown.Finally,RCTstodeterminewhethertheaddedriskinfor- .. groups,nosingleCVDriskscoreperformsadequatelyinallgroups.
.
. Rather, the use of a multiplying factor would be helpful to take
mationeventuallyleadstoimprovedhealthoutcomesaregenerally .
.
. accountofCVDriskimposedbyethnicityindependentofotherrisk
lacking. .
.
. factorsintheriskscore.Themostcontemporaryrelevantdatacome
Assessmentofpotentialriskmodifiersseemsparticularlyrelevantif .
.. from the QRISK3 findings in the UK,105 althoughthis focuses on a
the individual’s risk is close to a decision threshold. In low-risk or .
.
. widerrangeofCVDoutcomesandnotsimplyonCVDmortality.
very-high-risk situations, additional information is less likely to alter .
.
. ImmigrantsfromSouthAsia(notablyIndiaandPakistan)present
managementdecisions.Thenumberofindividualsinthis‘greyzone’is .
.
. higher CVD rates independent of other risk factors, whereas
large.Therefore,feasibilitybecomesalimitationasmodifiersbecome .
.
. adjustedCVDrisksappearlowerinmostotherethnicgroups.The
morecomplexorexpensive,suchassomeimagingtechniques. .
.
Careshouldbetakennottouseriskmodifierssolelytoincrease
.. reasonsforsuchdifferencesremaininadequatelystudied,asdothe
.
riskestimateswhenthemodifierprofileisunfavourable,butalsovice
.. risksassociatedwithotherethnicbackgrounds.Basedonsuchdata,
.
versa.Althoughanunfavourableriskmodifiermayincreaseanindi-
.. thefollowingcorrectionfactors,basedondatafromtheUK,could
.
vidual’s estimated risk, a more favourable profile than would be
... beappliedwhenassessingCVDriskusingriskcalculators.105Ideally,
expectedbasedonotherpatientcharacteristicsmusthavetheoppo-
... countryandrisk-calculator-specificRRsshouldbeused,astheimpact
siteeffect.Finally,itisimportanttoacknowledgethatthedegreeto
... ofethnicitymayvarybetweenregionsandriskcalculators.
.
which calculated absolute risk is affected by modifiers is generally .. • Southern Asian: multiply the risk by 1.3 for Indians and
.
muchsmallerthanthe(independent)RRsreportedforthesemodi- .. Bangladeshis,and1.7forPakistanis.
.
fiersintheliterature.107 ..
• OtherAsian:multiplytheriskby1.1.
.
Taking the above into account, we summarize the literature on .. • BlackCaribbean:multiplytheriskby0.85.
.
severalpopularriskmodifiersinthissection. . • BlackAfricanandChinese:multiplytheriskby0.7.
Box 2. Core topics for psychosocial assessment
Simultaneous diagnostic assessment At least one in five patients carries a diagnosis of a mental disorder, usually presenting with bodily
symptoms(e.g.chesttightness,shortnessofbreath).Therefore,physiciansshould be equallyatten-
tivetosomaticastoemotionalcausesofsymptoms.
Screening Screening instruments assessing depression, anxiety, and insomnia are recommended (e.g. Patient
HealthQuestionnaire,116seeSupplementaryTable5).117,118
Stressors Thereare simplequestionstogetinto aconversationaboutsignificantstressors112:Are youboth-
eredbystressatwork,financialproblems,difficultiesinthefamily,loneliness,oranystressfulevents?
Needformentalhealthsupport Areyouinterestedinareferraltoapsychotherapistormentalhealthservice?
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 33 ---
ESCGuidelines 3259
.
.
3.3.3.Imaging . 3.3.3.6Echocardiography
.
.
3.3.3.1 Coronaryarterycalcium . InviewofthelackofconvincingevidencethatitimprovesCVDrisk
.
.
Coronary artery calcium (CAC) scoring can reclassify CVD risk . reclassification, echocardiography is not recommended to improve
.
.
upwardsanddownwardsinadditiontoconventionalriskfactors, . CVriskprediction.
.
.
and may thus be considered in men and women with calculated .
.
risks around decision thresholds.103,104 Availability and cost- .. 3.3.4.Frailty
.
.
effectivenessoflarge-scaleCACscanningmust,however,becon- . Frailtyisamultidimensionalstate,independentofageandmultimor-
.
.
sidered in a locoregional context (see section 2.3 on cost- .. bidity, that makes the individual more vulnerable to the effect of
.
effectiveness).IfCACisdetected,itsextentshouldbecompared .. stressors.Itconstitutesafunctionalriskfactorforunfavourableout-
.
with what would be expected for a patient of the same sex and .. comes, including both high CV and non-CV morbidity and
.
age.Higher-than-expectedCACincreasestheperson’scalculated .. mortality.126,127
.
risk, whereas absent or lower-than-expected CAC is associated .. Frailtyisnotthesameasageingandthetwoshouldnotbecon-
.
with lower than calculated risk. CAC scoring does not provide .. fused.Theincidenceoffrailtyincreaseswithage,butpeopleofthe
.
direct information on total plaque burden or stenosis severity, .. samechronologicalagecandiffersignificantlyintermsofhealthstatus
.
and can be low or even zero in middle-aged patients with soft .. andvitality.‘Biologicalage’ismuchmoreimportantinthecontextof
.
non-calcifiedplaque.Cliniciansareadvisedtoconsultexistingpro- .. clinical status (including frailty features) and hard clinical outcomes
.
tocolsfordetailsofhowtoassessandinterpretCACscores. .. (including CVD events).126,127 Similarly, although the presence of
.
.. comorbiditiescanexacerbatefrailtywithinanindividual,frailtyisnot
.
3.3.3.2 Contrastcomputedtomographycoronaryangiography .. thesameasmultimorbidity(seesection6.7).
. .
Contrast computed tomography angiography (CCTA) allows . Frailtyscreeningisindicatedineveryelderlypatient,butshouldalso
.
.
identification of coronary stenoses and predicts cardiac . beperformedineveryindividualregardlessofhis/herage,whenbeing
.
events.119 In the SCOT-HEART (Scottish Computed .. atriskofacceleratedageing.126,127Mostofthetoolsrelatetofrailfea-
.
.
TomographyoftheHeart)study,5-yearratesofcoronarydeath . tures,includingslowness,weakness,lowphysicalactivity(PA),exhaus-
.
.
ormyocardialinfarctionwerereducedwhenCCTAwasused in . tion, and shrinking (e.g. Fried scale, Short Physical Performance
.
patientswithstablechestpain.120Therelativereductioninmyo- .. Battery, Rockwood Clinical Frailty Scale, handgrip strength, gait
.
cardial infarction was similar in patients with non-cardiac chest .. speed).126(cid:2)129 Frailty assessment is important at each stage of an
.
.
pain. Whether CCTA improves risk classification or adds prog- . ASCVD trajectory. During an acute CVD event, however, frailty
.
.
nosticvalueoverCACscoringisunknown. . assessment is more difficult, and either relies on history taking or
.
.
. shouldbepostponedtowhenpatientsreturntoastablecondition.
.
.
3.3.3.3 Carotidultrasound .. FrailtyisapotentialmodifierofglobalCVDrisk.Theimpactoffrailty
.
Systematic use of intima-media thickness (IMT) to improve risk .. onCVDriskhasbeendemonstratedacrossthespectrumofASCVD,
.
assessmentisnotrecommendedduetothelackofmethodological .. including people with ASCVD risk factors, patients with subclinical
.
standardization,andtheabsenceofaddedvalueofIMTinpredicting .. ASCVD,stableASCVD,acutecerebralandcoronarysyndromes,and
.
futureCVDevents,evenintheintermediate-riskgroup.121 .. HF,126(cid:2)130withfrailtyitselfratherthanclassicalCVDriskfactorspre-
.
Plaqueisdefinedasthepresenceofafocalwallthickeningthatis .. dicting both all-cause and CVD mortality in the very old.130,131
.
>_50%greaterthanthesurroundingvesselwall,orasafocalregion .. Importantly,theabilityoffrailtymeasurestoimproveCVDriskpredic-
.
with an IMT measurement >_1.5 mm that protrudes into the .. tionhasnotbeenformallyassessed.Hence,wedonotrecommend
.
lumen.122AlthoughtheevidenceislessextensivethanitisforCAC, .. thatfrailtymeasuresareintegratedintoformalCVDriskassessment.
.
carotid artery plaque assessment using ultrasonography probably .. Importantly,frailtymayinfluencetreatment.Non-pharmacological
.
also reclassifies CVD risk,104,122 and may be considered as a risk .. interventions (e.g. balanced nutrition, micronutrient supplementa-
.
modifier in patients at intermediate risk when a CAC score is not .. tion,exercisetraining,socialactivation)aimingtoprevent,attenuate,
.
feasible. .. or reverse frailty are of utmost importance.126,127,132 In terms of
.
. . pharmacotherapyanddeviceimplantations,frailtyassessmentisnota
.
.
3.3.3.4 Arterialstiffness . methodtodeterminetheeligibilityforanyparticulartreatment,but
.
.
Arterial stiffness is commonly measured using either aortic pulse . ratherservestobuildanindividualizedcareplanwithpredefinedpri-
. .
wave velocity or arterial augmentation index. Studies suggest that . orities.Frailindividualsoftenhavecomorbidities,polypharmacy,and
.
.
arterialstiffnesspredictsfutureCVDriskandimprovesriskclassifica- . maybemoresusceptibletodrugside-effectsandseriouscomplica-
.
tion.123 However, measurement difficulties and substantial publica- .. tionsduringinvasiveandsurgicalprocedures.126,127
.
tionbias106argueagainstwidespreaduse. ..
.
.
.. 3.3.5.Familyhistory
.
3.3.3.5 Anklebrachialindex .. FamilyhistoryofprematureCVDisasimpleindicatorofCVDrisk,
.
Estimates are that 12(cid:2)27% of middle-aged individuals have an .. reflectingthegeneticandenvironmentinterplay.133Inthefewstudies
.
anklebrachialindex(ABI)<0.9,around50(cid:2)89%ofwhomdonot .. thatsimultaneouslyassessedtheeffectsoffamilyhistoryandgenetics,
.
have typical claudication.124 An individual patient data meta- .. familyhistoryremainedsignificantlyassociatedwithCVDafteradjust-
.
analysis concluded that the reclassification potential of ABI was .. ingforgeneticscores.134,135However,familyhistoryonlymarginally
.
limited, perhaps with the exception of women at intermediate .. improvesthepredictionofCVDriskbeyondconventionalASCVD
.
risk.125 . riskfactors.136(cid:2)141Possibleexplanationsarethevaryingdefinitions
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 34 ---
3260 ESCGuidelines
.
.
offamilyhistoryappliedand thatconventionalASCVD riskfactors . exposuretoPM ;thelong-termeffectsareassociatedmainlywith
. 2.5
.
largelyexplaintheimpactoffamilyhistory. . PM .TheevidencelinkingexposuretoPMandCVDeventsisbased
. 2.5
.
AfamilyhistoryofprematureCVDissimple,inexpensiveinforma- . on large-scale epidemiological studies and experimental studies.
.
.
tion that can trigger comprehensive risk assessment in individuals . AssociationswithASCVDmortalityvary,butthemajorityofcohort
.
withafamilyhistoryofprematureCVD.136 .. studieslinklong-termairpollutionwithanincreasedriskoffatalor
.
.
. non-fatal CAD, and with subclinical atherosclerosis. Evidence sug-
.
.
. gests that reduction of PM is associated with improvements in
3.3.6.Genetics .. 2.5
TheaetiologyofASCVDhasageneticcomponent,butthisinforma-
... inflammation, thrombosis, and oxidative stress, and a decrease in
tionisnotcurrentlyusedinpreventiveapproaches.142Advanceson
... death from ischaemic heart disease.38,160,161 As sufficiently precise
polygenicriskscoresforriskstratificationcouldincreasetheuseof
... individualexposureestimatesarehardtoobtain,formalriskreclassi-
geneticsinprevention.143(cid:2)145ForASCVD,thereis,however,alack
... ficationisdifficulttoquantifyatpresent.
.
ofconsensusregardingwhichgenesandcorrespondingsinglenucleo- ..
.
tide polymorphisms should be included, and whether to use risk .. Recommendationsforcardiovasculardiseaserisk
factor-specific or outcome-specific polygenic risk scores.146 ... relatedtoairpollution
.
PolygenicriskscoringhasshownsomepotentialtoimproveASCVD ..
. Recommendations Classa Levelb
risk prediction for primary prevention,147(cid:2)149 but the incremental ..
.
.
predictionaccuracyisrelativelymodestandneedsfurtherevaluation . Patientsat(very)highriskforCVDmaybe
. inbothmenandwomen.150,151Additionalevidenceisalsoneededto .. encouragedtotrytoavoidlong-termexposure IIb C
.
.
evaluatetheclinicalutilityofpolygenicriskscoresinotherclinicalset- . toregionswithhighairpollution. .
tings,suchasinpatientswithpre-existingASCVD.152 .. Inregionswherepeoplehavelong-termexposure
.
.
.. tohighlevelsofairpollution,(opportunistic)CVD IIb C
.
3.3.7.Socioeconomicdeterminants .. riskscreeningprogrammesmaybeconsidered.
.
.
Lowsocioeconomicstatusandworkstressareindependentlyassoci- .
. CVD=cardiovasculardisease.
atedwithASCVDdevelopmentandprognosisinbothsexes.153,154 ... aClassofrecommendation.
Thestrongestassociationhasbeenfoundbetweenlowincomeand .. bLevelofevidence.
.
.
CVD mortality, with a RR of 1.76 [95% confidence interval (CI) .
.
1.45(cid:2)2.14].155Workstressisdeterminedbyjobstrain(i.e.thecom- ..
.
.
binationofhighdemandsandlowcontrolatwork)andeffort-reward . 3.3.9.Biomarkersinbloodorurine
.
.
imbalance.Thereispreliminaryevidencethatthedetrimentalimpact . Manybiomarkershavebeensuggestedtoimproveriskstratification.
.
.
ofworkstressonASCVDhealthisindependentofconventionalrisk . Somemaybecausal[e.g.lipoprotein(a),reflectingapathogeniclipid
.
.
factorsandtheirtreatment.156 . fraction],whereasothersmayreflectunderlyingmechanisms(e.g.C-
.
.
. reactive protein reflecting inflammation) or indicate early cardiac
.
.
. damage(e.g.natriureticpeptidesorhigh-sensitivitycardiactroponin).
3.3.8.Environmentalexposure ...
Inthe2016Guidelines,2werecommendedagainsttheroutineuse
EnvironmentalexposureswithCVDriskmodifyingpotentialinclude ..
. ofbiomarkersbecausemostdonotimproveriskprediction,andpub-
air and soil pollution as well as above-threshold noise levels. ...
licationbiasseriouslydistortstheevidence.106,162Newstudiescon-
Evaluating individual cumulative exposure to pollutants and noise ..
. firmthatC-reactiveproteinhaslimitedadditionalvalue.103Thereis
remains challenging, but when available, might impact on individual ..
.. renewedinterestinlipoprotein(a),butittooprovideslimitedaddi-
riskassessment. . .. tionalvalueintermsofreclassificationpotential.163,164Cardiacbio-
Componentsofoutdoorairpollutionincludeairborneparticulate .
.. markersarepromising,165,166butfurtherworkisneeded.
matter[PM;ranginginsizefromcoarseparticles2.5(cid:2)10mmindiam- .
.
.
eter,tofine(<2.5mm;PM ),andultrafine(<0.1mm)]andgaseous .
2.5 .
. pollutants(e.g.ozone,nitrogendioxide,volatileorganiccompounds, . 3.3.10.Bodycomposition
.
.
carbonmonoxide,sulphurdioxide),producedprimarilybycombus- . Worldwide,BMIhasincreasedsubstantiallyinrecentdecades,inchil-
.
tionoffossilfuels.SoilandwaterpollutionsarealsoCVDriskmodi- .. dren, adolescents, and adults.43 In observational studies, all-cause
. fiers;increasedexposuretolead,arsenic,andcadmiumisassociated .. mortalityisminimalataBMIof20-25kg/m2,withaJ-orU-shaped
.
withmultipleCVDoutcomesincludinghypertension,coronaryheart .. relation in current smokers.45,46 Mendelian randomization analyses
.
disease(CHD),stroke,andCVDmortality.157AmbientPMpollution .. suggestalinearrelationbetweenBMIandmortalityinnever-smokers
.
.
recentlyrankedasaleadingmodifiablemortalityriskfactorandalso . andaJ-shapedrelationinever-smokers.44Ameta-analysisconcluded
.
.
responsibleforattributabledisabilityadjustedlife-yearsattheglobal .. thatbothBMIandwaistcircumferencearesimilarlystronglyandcon-
.
level.158Arecentmodelestimatedthatlossoflifeexpectancydueto .. tinuouslyassociatedwithASCVDintheelderlyandtheyoungandin
.
ambient air pollution is similar to, if not exceeding, that due to .. menandwomen.47
.
tobacco smoking, and accounts for a global excess mortality esti- .. AmongthosewithestablishedASCVD,theevidenceiscontradic-
.
matedat8.8million/year.159 .. tory.SystematicreviewsofpatientswithACSorHFhavesuggested
.
Theshort-termattributableeffectsonmortalityarelinkedprimar- .. an ‘obesity paradox’ whereby obesity appears protective.167,168 169
.
ilytoexposuretoPM,nitrogendioxide,andozone,withanaverage .. However, this evidence should be interpreted with caution as
.
1.0%increaseofall-causemortalityforanincrementof10lg/m3in . reversecausalityandotherbiasesmaybeoperating.45
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 35 ---
ESCGuidelines 3261
.
3.3.10.1 Whichindexofobesityisthebestpredictorofcardiovascular .
. COPD ItisrecommendedthatallCOPD
.
risk? .
. patientsbeinvestigatedfor I C
.
BMIcanbemeasuredeasilyandisusedextensivelytodefinecatego- .
. ASCVDandASCVDriskfactors.
.
riesofbodyweight(seeSupplementaryTable6).Bodyfatstoredin .
.. Inflammatory AssessmentoftotalCVDriskmay
visceralandotherectopicdepotscarriesahigherriskthansubcuta- .
.. conditions beconsideredinadultswithchronic IIb B
neousfat.Severalmeasuresofglobalandabdominalfatareavailable, .
.. inflammatoryconditions.176
ofwhichwaistcircumferenceisthesimplesttomeasure.TheWHO .
.
. Multiplicationofcalculatedtotal
thresholds for waist circumference are widely accepted in Europe. .
.
. CVDriskbyafactorof1.5should
Twoactionlevelsarerecommended: . IIa B
.
. beconsideredinadultswithrheu-
.
• Waistcircumference>_94cminmenand>_80cminwomen:no .. matoidarthritis.177,178
.
.
furtherweightgain .. Migraine Presenceofmigrainewithaura
• Waistcircumference>_102cminmenand>_88cminwomen: ... shouldbeconsideredinCVDrisk IIa B
.
weightreductionadvised. .. assessment.179(cid:2)181
.
.. Avoidanceofcombinedhormonal
Different cut-offs for anthropometric measurements may be ...
contraceptivesmaybeconsidered
requiredindifferentethnicities. .. IIb B
. inwomenwithmigrainewith
The phenotype of ‘metabolically healthy obesity’, defined by the ...
aura.182,183
presence of obesity in the absence of metabolic risk factors, has ..
. Sleep InpatientswithASCVD,obesity,
.
gainedinterest.Long-termresultssupportthenotionthatmetabol- . .. disorders andhypertension,regularscreen-
icallyhealthyobesityisatransientphasemovingtowardsglucometa- .
bolicabnormalitiesratherthanaspecific‘state’.170
... andOSA ingfornon-restorativesleepis
.. indicated(e.g.bythequestion: I C
.
.. ‘howoftenhaveyoubeenboth-
3.3.10.2 Riskreclassification .
.. eredbytroublefallingorstaying
TheassociationsbetweenBMI,waistcircumference,andwaist-to-hip .
.. asleep,orsleepingtoomuch?’).
ratioandCVDaremaintainedafteradjustmentforconventionalrisk .
.
. Iftherearesignificantsleepprob-
factors.However,thesemeasuresdidnotimproveCVDriskpredic- .
.
tionasassessedbyreclassification.47 .. lems,whicharenotresponding
.
. within4weekstosleephygiene, I C
.
.
. referraltoaspecialistis
.
Recommendationsforcardiovasculardiseaseassess- .
. recommended.
mentinspecificclinicalconditions ..
.. Mental Itisrecommendedthatmentaldis-
.
Clinical Recommendations Classa Levelb .. disorders orderswitheithersignificantfunc-
.
condition .. tionalimpairmentordecreaseduse I C
.
.. ofhealthcaresystemsbeconsidered
.
CKD InallCKDpatients,withorwith- .. asinfluencingtotalCVDrisk.
.
outDM,appropriatescreeningfor .
. Sex-specific Inwomenwithahistoryofpree-
.
ASCVDandkidneydiseasepro- .
I C .. conditions clampsiaand/orpregnancy-
gression,includingmonitoring .
. inducedhypertension,periodic IIa B .
changesinalbuminuriais .
. screeningforhypertensionand recommended.172 ...
DMshouldbeconsidered.184(cid:2)187
.
Cancer Itisrecommendedtomonitor ... Inwomenwithahistoryofpoly-
cardiacdysfunctionusingimaging ... cysticovarysyndromeorgesta-
techniquesandcirculatingbio- I B ...
tionalDM,periodicscreeningfor
IIa B
markersbefore,periodicallydur- ... DMshouldbeconsidered.188(cid:2)191
ing,andaftercancertreatment.173 ..
. Inwomenwithahistoryofpre- .
Cardioprotectioninhigh-risk .
. matureorstillbirth,periodic
patients(thosereceivinghigh .. IIb B
. screeningforhypertensionand
.
cumulativedosesorcombined .. DMmaybeconsidered.192,193
.
radiotherapy)receivinganthracy- IIb B .
.. AssessmentofCVDriskshould
clinechemotherapymaybecon- . IIa C
.. beconsideredinmenwithED.
sideredforpreventionofLV .
.
.
dysfunction.174,175 . ASCVD=atheroscleroticcardiovasculardisease;CKD=chronickidneydisease;
.
ScreeningforASCVDriskfactors
.... C caO rdP ioD va= scc uh lar ron di ic seo asb es ;tr Duc Mtiv =e dp iu ablm eto en sa mry ed llii ts ue sa ;se E; DC =V e= rec ca tr ild eio dv ya ss fucu nl ca tr io; nC ;V LD V==
andoptimizationoftheCVDrisk .. leftventricular;OSA=obstructivesleepapnoea.
I C .
profileisrecommendedin .. aClassofrecommendation.
patientsontreatmentforcancer.
... bLevelofevidence.
.
.
Continued
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 36 ---
3262 ESCGuidelines
.
.
3.3.10.3 Assessriskfactorsandcardiovasculardiseaseriskinpersons . 3.4.2.Atrialfibrillation
.
.
withobesity . Atrialfibrillation(AF)appearstobeassociatedwithanincreasedrisk
.
ComprehensiveCVDriskassessmentshouldbeconsideredinindivid- .. ofdeathandofCVDandkidneydisease.205Furthermore,AFappears
.
ualswithunfavourablebodycomposition.Themainrisk-relatedsequa- .. tobeastrongerriskfactorforCVDinwomenthaninmen.206
.
.
laeofadiposityincludehypertension,dyslipidaemia,insulinresistance, . TheprevalenceofAFrangesbetween2%and4%,anda2.3-fold
.
.
systemicinflammation,aprothromboticstate,albuminuria,aswellasa . riseisexpected,owinginparttoageingofthepopulationandintensi-
.
declineinestimatedglomerularfiltrationrate(eGFR)171andthedevel- .. fiedsearchingforundiagnosedAF,aswellaslowerCVdeath.207The
.
.
opmentoftype2DM,CVDevents,aswellasHFandAF. .. age-adjustedincidence,prevalence,andlifetimeriskofAFarelower
.
.. inwomenvs.menandinnon-whitevs.whitecohorts.208,209Thelife-
.
3.4. Clinical conditions .. timeAFriskestimateisnow1in3individualsofEuropeanancestry
.
.. atanindexageof55years.210ASCVDriskfactorburdenandcomor-
IndividualcalculatedrisksofCVD,asevaluatedbyconventionalrisk .
.. bidities,includinglifestylefactors,andagesignificantlyaffectthelife-
factors in risk scores, are subject to refinement by potential risk .
.. timeriskforAFdevelopment.211(cid:2)213Theobservedeffectofclinical
modifiersashighlightedinsection3.3.Beyondthesepotentialmodi- .
.. ASCVDriskfactorburdenandmultiplecomorbiditiesonthelifetime
fiers,specificclinicalconditionscaninfluenceCVDrisk.Theseclinical .
.. riskofAF(significantlyincreasingfrom23.4%amongindividualswith
conditions often increase thelikelihood ofCVD, orare associated .
.. anoptimalclinicalriskfactorprofileto33.4%and38.4%inthosewith
withpoorerclinicalprognosis.Thecurrentsectionreviewssomeof .
.. borderlineandelevatedclinicalriskfactors,respectively214)suggests
these conditions, which are not often included in traditional risk .
.. thatearlyinterventionandcontrolofmodifiableASCVDriskfactors
scoresbutmaybeintegratedinsomenationalriskscores.Herewe .
.. couldreduceincidentAF.Thecontinuumofunhealthylifestyle,risk
discusshowtheseconditionsincreasethisrisk. . .
. factor(s),and CVDscancontributetoatrialremodelling/cardiomy-
ManyclinicalconditionssharecommonCVDandASCVDriskfac- .
.
. opathyanddevelopmentofAFthatcommonlyresultsfromacom-
torsandthereforetreatingtheseallowsasynergisticreductioninthe ...
bined effect of multiple interacting factors (Figure 9).215 Risk factor
overallburdenofdisease. ..
. and CVD management reduces AF burden. Targeted therapy of
.
.
. underlyingconditionsmaysignificantlyimprovemaintenanceofsinus
.
3.4.1.Chronickidneydisease .. rhythminpatientswithpersistentAFandHF.216However,studies
.
.
Worldwide,thetotalnumberofindividualswithchronickidneydis- . addressing isolated management of specific conditions alone (e.g.
.
ease (CKD) who are nottreated withkidneyreplacementtherapy ... hypertension)yieldedinconsistentfindings.217
.
wasapproximately850millionin2017.194Thisnumberaccountstoa .. TheoverallannualriskofischaemicstrokeinpatientswithAFis
.
prevalence of 10-12% among men and women. CKD is the third .. 5%, but varies considerably according to comorbidities.215
.
fastestgrowingcauseofdeathglobally.195 .. CardioembolicstrokesassociatedwithAFareusuallymoresevere,
.
CKD isdefined asabnormalitiesofkidney structure orfunction, .. and often recurrent.218 Furthermore, AF appears to be a stronger
.
presentfor>3months,withhealthimplications.Criteriaandmarkers .. predictorofstrokeinwomenthaninmen.215AFisalsoassociated
.
ofkidneydamage,especiallykidneydiseaseduetoDM,arealbuminu- .. withimpairedcognitivefunction,rangingfrommildcognitiveimpair-
.
ria[albumin-to-creatinineratio(ACR)>30mg/ginspoturinespeci- .. menttodementia.219AFisindependentlyassociatedwithatwo-fold
.
mens] and glomerular filtration rate (GFR) <60 mL/min/1.73 m2. .. increased risk of all-cause mortality in women and a 1.5-fold
.
GFRcanbeestimated(eGFR)fromcalibratedserumcreatinineand .. increasedriskinmen.220Inonepopulation,themostcommoncauses
.
estimating equations using the CKD-EPI (Chronic Kidney Disease .. ofdeathwereHF(14.5%),malignancy(23.1%),andinfection/sepsis
.
Epidemiology)Collaborationformula.Kidneydiseaseseverityisdif- .. (17.3%),whilestroke-relatedmortalitywasonly6.5%.221Thesedata
.
ferentiatedintostages(categories)accordingtothelevelofGFRand .. indicatethat,inadditiontoanticoagulationandHFtreatment,comor- .
albuminuria;apatientwithaneGFR<60mL/min/1.73m2isclassified .. bidconditionsneedtobeactivelytreatedtoreduceAF-relatedmor-
.
ashavingCKDstage3a,whichrepresentsanadvancedkidneyfunc- .. talityandmorbidity.
.
tionimpairment.172 .. RegardingPA,bothsedentarylifestylesandveryhighlevelsofPA
.
. AmongpersonswithCKD,CVDistheleadingcauseofmorbidity . are associated with development of AF (U-shaped association),
.
anddeath.196EvenafteradjustmentforknownCADriskfactors,includ- .. through different mechanisms. Furthermore, when AF develops in
.
.
ing DM and hypertension, mortality risk progressively increases with . athletesitisnotassociatedwiththesameincreasedriskofstroke.
. worseningCKD.197AsGFRdeclinesbelowapproximately60-75mL/ ..
.
min/1.73m2,theprobabilityofdevelopingCADincreaseslinearly,198 .. 3.4.3.Heartfailure
.
.
withuptotripletheCVDmortalityriskwhenreachinganeGFRof15 . Heart failure (HF) of ischaemic origin constitutes a severe clinical
.
.
mL/min/1.73m2.KidneydiseaseisassociatedwithaveryhighCVDrisk. . manifestation of ASCVD. Conversely, HF itself (predominantly of
.
.
Among persons with CKD, there is a high prevalence of traditional .. ischaemic aetiology) increases the risk of CVD events (myocardial
.
CADriskfactors,suchasDMandhypertension.TheuseofCACscore .. infarction,arrhythmias,ischaemicstroke,CVdeath).
.
to risk stratify patients with CKD might be a promising tool.199(cid:2)203 .. Asymptomatic LV dysfunction (systolic or/and diastolic dysfunc-
.
Furthermore, persons with CKD are also exposed to other non- .. tion)aswellasovertsymptomaticHF[acrossthespectrumofLVEF,
.
traditionalASCVDriskfactorssuchasuraemia-relatedones,including .. i.e. HF with reduced ejection fraction (HFrEF), HF with mid-range
.
inflammation,oxidativestress,andpromotorsofvascularcalcification. .. ejection fraction,222 and HF with preserved ejection fraction
.
CKDandkidneyfailurenotonlyincreasetheriskofCAD,theyalso .. (HFpEF)]increasestheriskofurgentCVhospitalizations(including
.
modifyitsclinicalpresentationandcardinalsymptoms.204 . hospitalizationsduetoHFworsening)andCVandall-causedeaths.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 37 ---
ESCGuidelines 3263
Risk factors forAF
Modifiable Non- or partly modifiable
Lifestyle modification
AF risk factors modification
Hypertension Ageing
Treatment of underlying CV conditions
Obesity Genetics
Diabetes mellitus Heart failure
Physical activity CAD
Reduction of mortality and
OSA Valvular heart
morbidity
Alcohol disease
Primary prevention ofAF
Dyslipidemia COPD
Smoking
LA remodeling
Reversible Non-reversible
Electrical Fibrosis
Biochemical Scarring
Inflammation Dilatation
Stroke prevention Cardioversion
Rate control Catheter ablation
AAD therapy Surgery
AF development and progression
Paroxysmal Persistent Permanent Lifestyle modification
AF risk factors modification
Treatment of underlying CV conditions
Reduction of mortality and
AF outcomes
morbidity
Symptomatic improvement
Mortality Secondary prevention ofAF
Stroke/systemic thromboembolism
Symptoms and quality of life
Heart failure
Dementia
Myocardial infarction
Hospitalizations and healthcare costs
Figure 9 Theroleofriskfactorsandcomorbiditiesinatrialfibrillation.215AF=atrialfibrillation;CAD=coronaryarterydisease;COPD=chronic
obstructivepulmonarydisease;CV=cardiovascular;DM=diabetesmellitus;HF=heartfailure;OSA=obstructivesleepapnoea.
.
. Theseunfavourableeffectsonclinicaloutcomeshavebeendemon- . beneficialinreducingbothCVDaswellascancerrisk.Moreover,the
.
.
stratedinasymptomaticsubjectswithoutovertCVD,inpatientswith . ratesoftheextentofCVDriskdependonboththeCVDtoxicityof
.
.
acuteandpreviousmyocardialinfarction,inpatientswithacuteand . treatments and patient-related factors. Owing to recent improve-
. .
previousstroke,andinpatientswithotherclinicalmanifestationsof . mentsinclinicaloutcomesformanypatientswithcancer,CVDmor-
.
CVD.223 .. tality may ultimately exceed those from most forms of cancer
.
ThediagnosisofischaemicHFpositionsindividualsatveryhighCV .. recurrence.224,225
.
.
risk,andjustifiesrecommendationsasforsecondarypreventionther- . The rapidlyexpandingvarietyofnovel anticancerdrugs/adjuvant
.
.
apeuticstrategies.Additionally,forpatientswithsymptomaticHFrEF, .. therapieshasdemonstratedawiderangeofbothearlyandlateCVD
.
severaldrugsarerecommendedtoreducetheriskofCVmorbidity .. side-effects,includingcardiomyopathy,LVdysfunction,HF,hyperten-
.
andmortality(seesection6.2). .. sion,CAD,arrhythmias,andotherinjuries.Therefore,effectivestrat-
.
.. egies for the prediction and prevention of CVD toxicities are
.
3.4.4.Cancer .. criticallyimportant.Thelatencyandseverityofradiotherapycardio-
.
In patients with cancer, there is an overlap between cancer and .. toxicity,aswellasacceleratedatherosclerosisandcerebralvascular
.
ASCVDriskfactors,withsharedbiologicalmechanismsandgenetic .. disease, is related to multiple factors, including the dose (total per
.
predispositions. Prevention and treatment of these is therefore . fraction), the volume of the heart irradiated, concomitant
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 38 ---
3264 ESCGuidelines
.
.
administrationofothercardiotoxicdrugs,andpatientfactors(which . syndromeandreducedPAispresentin34%ofCOPDpatients,with
.
.
include,amongstotherfactors,youngerage,traditionalriskfactors, . itsmostprevalentcomponentsbeinghypertension(56%),abdominal
.
andhistoryofheartdisease).226,227Furthermore,radio-andchemo- .. obesity(39%),andhyperglycaemia(44%).245CVDmaybecausedby
.
.
therapy may exert direct vascular effects and increase . hypoxiaduringexerciseduetolunghyperinflation,highrestingheart
.
atherosclerosis-relatedCVDoutcomes.227,228 .. rates, impaired vasodilatory capacity, and peripheral, cardiac, and
.
.
. neurohumoral sympathetic stress. Atherosclerosis and coronary
.
.
3.4.4.1 Diagnosisandscreening . arterycalcificationmaybetheresultofoxidativestress,andreduc-
.
.
Signs or symptoms of cardiac dysfunction should be monitored . tionsinantiagingmoleculescausingbothlungandvascularageing.246
.
.
beforeand periodicallyduringand after cancertreatmentforearly .. Systemic inflammationis prominentinCOPD,with circulating bio-
.
detection of abnormalities in patients receiving potentially cardio- .. markersinhighconcentrationsandassociatedwithincreasedmortal-
.
toxic chemotherapy. Detection of subclinical abnormalities using .. ity.247TroponiniselevatedduringanacuteexacerbationofCOPD,
.
imagingandmeasurementofcirculatingbiomarkers(suchascardiac .. and10%ofhospitalizedpatientsmeetthedefinitionofacutemyocar-
.
troponinsandnatriureticpeptides)iscurrentlyrecommended.173,229 .. dial infarction (AMI).248 B-natriuretic peptide level, if elevated,
.
Measuresofmyocardialstrain,particularlysystolicgloballongitudinal .. increasesthemortalityrisk.249
.
strain,mayprecedeasignificantdeclineinLVEF.230(cid:2)233 .. SystemicinflammationandoxidativestresscausedbyCOPDpro-
.
.. motevascularremodelling,stiffness,andatherosclerosis,andinduce
.
3.4.4.2 Preventionofcardiotoxicityandcardiovascularriskfactors .. a‘procoagulant’statethataffectsallvasculaturetypes.250Cognitive
.
RCTsofpreventivetherapywithrenin-angiotensin-aldosteronesys- .. impairmentand dementia duetocerebral microvascular damage is
.
tem (RAAS) inhibitors and/or beta-blockers after trastuzumab or .. correlatedwithCOPDseverity;patientshavea20%increasedrisk
. anthracyclines have reported contradictory results.230,234,235 The .. for both ischaemic and haemorrhagic stroke, which may be up to
.
mainbenefitsarelessmarkedLVremodellingorareduceddeclinein .. seven-foldhigherfollowinganacuteexacerbation.251PADispresent
.
LVEFobservedwithcardiacmagneticresonance,buttranslationinto .. inabout9%ofCOPDpatients,252whohaveanalmostdoubledrisk
.
betteroutcomesremainsspeculative. .. ofdevelopingPAD,253aswellasanincreasedprevalenceofcarotid
.
Exerciseshouldbestronglyadvised.Inparticular,aerobicexerciseis .. plaquesrelatedtothediseaseseverity.254Finally,COPDispositively
.
.
consideredapromisingnon-pharmacologicalstrategytopreventand/ . associated with abdominal aortic aneurysm, regardless of smoking
.
or treat chemotherapy toxicity.236 A study showed a significantly .. status.255
.
.
higherriskofCVDinsurvivorsofchildhoodcancerthaninnon-cancer . Cardiacarrhythmiasarecommonandmaybeduetothehaemo-
.
.
adultcontrols,andparticularlyinsurvivorsofadult-onsetcancerwith . dynamiceffects(pulmonaryhypertension,diastolicdysfunction,atrial
.
underlyingASCVDriskfactors.237Therefore,aggressivemanagement .. structural,andelectricalremodelling)causedbythediseaseincombi-
.
.
ofASCVDriskfactorsinthispopulationisrecommended. . nationwithautonomicimbalanceandabnormalventricularrepolari-
.
.
.. zation.256 AF is frequent, directly associated with FEV1, usually
.
3.4.5.Chronicobstructivepulmonarydisease .. triggeredbyacuteexacerbationsofCOPD,andanindependentpre-
.
Chronicobstructivepulmonarydisease(COPD)isacomplex,pro- .. dictorofin-hospitalCOPDmortality.257,258COPDisalsoariskfac-
.
gressiverespiratorydisorderandcurrentlythefourthleadingcause .. tor for ventricular tachycardia independent of LVEF,259 and for
.
ofdeathworldwide.Itischaracterizedbychronicairflowlimitation .. suddencardiacdeathindependentofCVDriskprofile.260
.
with respiratory symptoms and is associated with an increased .. Unrecognized ventricular dysfunction is common in COPD,261
.
inflammatory response and abnormalities of the airways caused by .. althoughHF is 3.8times more commonin COPD patientsthanin
.
significantexposuretonoxiousparticlesorgases(mainlysmoking). .. controls.262Patientswithfrequentacuteexacerbationshaveahigh
.
AlthoughCOPDisrecognizedandthoroughlyinvestigatedasaCVD .. frequencyofdiastolicdysfunction;HFpEFriskishigherbecauseofa .
comorbidity,itsroleasanASCVDriskfactorisnotwellestablished. .. highprevalenceofhypertensionandDM.263
.
Nevertheless,COPDpatientshaveatwo-tothree-foldincreased .. Consideringthesefacts,itseemsofupmostimportancetoscreen
.
riskofCVDcomparedwithage-matchedcontrolswhenadjustedfor .. COPDpatientsforASCVDandASCVDriskfactors,bearinginmind
.
. tobaccosmoking.Patientswithmild-to-moderateCOPDare8(cid:2)10 . thatCOPDaffectstheaccuracyofCVDdiagnostictests.Achieving
.
.
timesmorelikelytodiefromASCVDthanrespiratoryfailure,having . adequate exercise is difficult, vasodilators for myocardial perfusion
.
.
higher rates of hospitalization and death due to CVD, stroke, and . scanning may be contraindicated because of the risk of broncho-
. HF.238,239CVDalsorunsundiagnosed;lessthanone-thirdofCOPD .. spasm, and stress or transthoracic echocardiography is often dis-
.
.
patients with electrocardiographic (ECG) evidence of myocardial . turbed by poor ultrasound windows. Computed tomography
.
infarction are diagnosed with CVD.240 CVD mortality increases by .. coronaryangiographyormagneticresonanceimagingmaybealterna-
.
.
28%, and the frequency of non-fatal coronary events by 20%, for . tives, but remain expensive, time consuming, and not always
.
.
every 10% decrease in the forced expiratory volume in 1 second .. available.
.
(FEV1).241AcuteCOPDexacerbations,mainlyduetoinfections,are .. TheuseofCOPDmedications(i.e.long-actingmuscarinicantago-
.
frequent and are responsible for a four-fold increase of CVD .. nistsandlong-actingbetaagonists)isnotassociatedwithoverallCV
.
events.242Theriskofbothmyocardialinfarctionandischaemicstroke .. adverseeventsinpatientswithstableCOPD.Olodaterolmayreduce
.
isincreasedduringthe3monthsafteranacuteexacerbation.243 .. theriskofoverallCVadverseeventsandformoterolmaydecrease
.
ThehighprevalenceofCVDinCOPDpatientsmaybeexplained .. theriskofcardiacischaemia.Long-actingbetaagonistsmayreduce
.
by the fact that both diseases share common risk factors, such as .. theincidenceofhypertension,butmayalsoincreasetheriskofHF,
.
smoking, ageing, hypertension, and dyslipidaemia.244 Metabolic . soshouldbeusedwithcautioninHFpatients.264
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 39 ---
ESCGuidelines 3265
.
.
3.4.6.Inflammatoryconditions . migraine with aura, which accounts for about one-third of all
.
.
Inflammatory conditions increase CVD risk both acutely and over . migraines;inmanypatientsthetwoformscoexist.
.
.
time. The best evidence for chronic inflammation increasing CVD . Available data indicate that migraine overall is associated with a
.
.
riskisavailableforrheumatoidarthritis,whichincreasesCVDriskby . two-foldincreasedriskofischaemicstrokeanda1.5-foldincreasein
.
approximately50%beyondestablishedriskfactors.176Hence,alow .. theriskofcardiacischaemicdisease.179(cid:2)181,279,280Theassociations
.
thresholdforassessmentoftotalCVDriskisappropriateinadults .. aremoreevidentformigrainewithaura.179,180,280Giventheyoung
.
.
withrheumatoidarthritis,andoneshouldconsiderincreasingtherisk . mean age of the population affected by migraine, the absolute
.
.
estimatebasedonthelevelofdiseaseactivity.176Thereisalsoevi- .. increaseinriskissmallattheindividuallevel,buthighatthepopula-
.
denceforanapproximately20%increasedCVDriskinpatientswith .. tionlevelbecauseofthehighmigraineprevalence.281
.
activeinflammatoryboweldisease.265 .. Severallinesofevidencealsoindicatethatthevascularriskofsub-
.
Inotherchronicinflammatoryconditions,suchaspsoriasis177and .. jectswithmigrainemaybemagnifiedbycigarettesmoking182andbythe
.
ankylosingspondylitis,178CVDriskmayalsobeincreased.However, .. use of combined hormonal contraceptives.183,281(cid:2)283 Contraception
.
thestrengthoftheevidenceislessstrong,asistheindependenceof .. usingcombinedhormonalcontraceptivesshouldthereforebeavoided
.
such increased risks from the classical ASCVD risk factors. .. inwomenwithmigraine.282,283However,furtherinformationisneeded
.
Nonetheless,itseemsprudenttoatleastconsiderCVDriskassess- .. as good-quality studies assessing risk of stroke associated with low-
.
ment in patients with any chronic inflammatory condition, and to .. doseoestrogenuseinwomenwithmigrainearelacking.
.
take into account the presence of such conditions when there is ..
.
doubtregardinginitiationofpreventiveinterventions.Thecumulative .. 3.4.9.Sleepdisordersandobstructivesleepapnoea
.
disease burden and recent degree of inflammation are important .. Sleepdisturbancesorabnormalsleepdurationsareassociatedwith
. determinantsoftherisk-enhancingeffect. .. increasedCVDrisk.284(cid:2)286Regardingsleepduration,7hseemsto
.
Apart from optimal anti-inflammatory treatment, CVD risk in .. beoptimalforCVhealth.287
.
inflammatoryconditionsshouldbetreatedwithsimilarinterventions .. Inthegeneralpopulation,theprevalenceofgeneralsleepdistur-
.
asinthegeneralhigh-riskpopulation,asthereisevidencethattradi- .. bances is around 32.1%: 8.2% for insomnia, 6.1% for parasomnia,
.
tionalmethodstolessenrisk(e.g.lipid-loweringtreatment)arejust .. 5.9%forhypersomnolence,12.5%forrestlesslegsdisorderandlimb
.
.
asbeneficialinpreventingASCVD. . movementsduringsleep,and7.1%forsleep-relatedbreathingdisor-
.
.. der[e.g.obstructivesleepapnoea(OSA)].288Allsleepdisturbances
.
.
. arestronglyassociatedwithmentaldisordersandsharehyperarousal
3.4.7.Infections(humanimmunodeficiencyvirus, ...
asanunderlyingmechanism.289,290
influenza,periodontitis) ..
. The most important sleep-related breathing disorder is OSA,
.
Infection with human immunodeficiency virus (HIV) is associated .
. whichischaracterizedbyrepetitiveepisodesofapnoea,eachexceed-
.
witha19%increasedriskofLEADandCADbeyondthatexplained .
. ing10seconds.Despite the strongassociationsofOSAwithCVD,
bytraditionalatheroscleroticriskfactors.266,267However,forthose ..
. includinghypertension,stroke,HF,CAD,andAF,treatmentofOSA
withsustainedCD4cellcounts<200cells/mm3,theriskofincident ..
. bypositiveairwaypressure(PAP)hasfailedtoimprovehardCVout-
.
LEADeventsisnearlytwo-foldhigher,whereasforthosewithsus- .
. comesinpatientswithestablishedCVD.291(cid:2)293Therefore,interven-
tained CD4 cell counts >_500 cells/mm3, there is no excess risk of ..
incidentLEADeventscomparedwithuninfectedpeople.268
... tions that include behaviour change (reduction of obesity, alcohol
.. abstinence),sleephygiene,andstressreductioninadditiontoPAPare
CVDandinfluenzahavelongbeenassociated,duetoanoverlapin .
.. needed.290,294 Regarding hypertension and OSA, there are modest
the peak incidence of each disease during winter months. .
.. effectsofPAPonBPlevels,butonlyinpatientswithABPM-confirmed
EpidemiologicalstudieshavenotedanincreaseinCVdeathsduring .
.. resistanthypertensionwhousePAPformorethan5.8h/night.295
influenza epidemics, indicating that CV complications of influenza .
.
.
infection, including acute ischaemic heart disease and, less often, ..
. 3.4.10.Mentaldisorders
stroke,areimportantcontributorstomorbidityandmortalityduring ..
. The12-monthprevalenceofmentaldisordersormentalhealthdis-
influenzainfection. ..
. ordersinthegeneralEuropeanpopulationisbetween27%and38%
TheriskofAMIorstrokeismorethanfourtimeshigheraftera ...
depending on sources and definitions.296 All mental disorders (e.g.
respiratorytractinfection,withthehighestriskinthefirst3daysafter ..
. anxietydisorders,somatoformdisorders,substance disorders, per-
diagnosis.269 Preventing influenza, particularly by means of vaccina- ..
. sonality disorders, mood disorders, and psychotic disorders) are
tion,couldpreventinfluenza-triggeredAMI.270 ..
. associated withthedevelopmentof CVDandreducedlifeexpect-
Studieshavelinkedperiodontaldiseasetobothatherosclerosisand ...
ancyinbothsexes.297(cid:2)300Theriskincreaseswiththeseverityofthe
CVD,271(cid:2)273andserologicalstudieshavelinkedelevatedantibodytitres ..
. mentaldisturbanceandvigilancefor(oftennon-specific)symptomsis
of periodontal bacteria to atherosclerotic disease.274 Nevertheless, if ..
activetreatmentorpreventionofperiodontitisimproves,clinicalprog-
... crucial.301 The onset of CVD is associated with an approximately
nosisrequiresfurtherstudiesdespitepreliminaryevidence.275(cid:2)277
... 2(cid:2)3-foldincreasedriskofmentaldisorderscomparedtoahealthy
.. population.115,302Inthiscontext,screeningshouldbeperformedat
.
.. everyconsultation(or2(cid:2)4times/year).The12-monthprevalenceof
.
3.4.8.Migraine .. mentaldisordersinCVD patientsisaround40%, leadingto signifi-
.
Migraineisahighlyprevalentconditionaffectingaround15%ofthe .. cantlyworseprognosis.100,108,303,304TheonsetofCVDincreasesthe
.
general population.278 There are two main types of migraine— .. risk of committing suicide.305 In this context, awareness of anxiety
.
migraine without aura, which is the most common subtype, and . anddepressionsymptomsshouldbeincreased.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 40 ---
3266 ESCGuidelines
.
.
TheprecisemechanismbywhichmentaldisordersincreaseCVD . Finally, gestational DM confers a sharply elevated risk of future
.
.
remainsuncertain.Thedetrimentaleffectsarepotentiallycausedby . DM, with up to 50% of affected women developing DM within 5
.
.
unhealthylifestyle,increasedexposuretosocioeconomicstressors, . yearsafterpregnancy,andanuptotwo-foldincreasedriskofCVDin
.
andcardiometabolicside-effectsofsomemedications,113butalsoby .. thefuture.188,320ScreeningbyfastingglucoseorHbA1cmaybepref-
.
directeffectsoftheamygdala-basedfear-defencesystemandother .. erabletooralglucosetolerancetesting.191,321
.
direct pathophysiological pathways.303 Abuse of psychostimulants ..
.
(e.g. cocaine) is a powerful trigger of myocardial ischaemia.306 .. 3.4.12.2 Non-obstetricconditions
.
.
Further,thecapacityofthesepatientstoadaptivelyusethehealth- . Polycystic ovary syndrome affects 5% of all women in their fertile
.
.
caresystemsisimpairedduetotheirmentalcondition(e.g.notbeing .. years.322,323IthasbeenassociatedwithanincreasedriskofCVD.314
.
able to trust other people and seek help, impaired capacity to be .. Theriskofdevelopinghypertensionisprobablyincreased,butdata
.
adherent).100Barriersonthepartofhealthcareprovidersarestigma- .. are conflicting.324 Polycystic ovary syndrome is associated with a
.
tizingattitudes,insufficientmentalhealthliteracy,andlackof confi- .. higherriskofdevelopingDM(RR2(cid:2)4),189,190suggestingthatperi-
.
dence in mental healthcare.307(cid:2)309 Although patients with mental .. odicscreeningforDMisappropriate.
.
disordershaveanincreasedCVDrisk,theyreceivealowerrateof .. Prematuremenopauseoccursinroughly1%ofwomen<_40years
.
recognition and treatment of traditional ASCVD risk factors.310 .. ofage.Upto10%ofwomenexperienceanearlymenopause,defined
.
Preliminary evidence suggests that taking mental disorders into .. asthatoccurringby45yearsofage.314,325Earlymenopauseisassoci-
.
accountimprovesclassicalCVDriskmodels.311,312 .. atedwithanincreasedriskofCVD(RR1.5).326(cid:2)328Alinearinverse
.
Certaincategoriesofpatientswithlearningdifficultiesandassoci- .. relationship between earlier menopause and CHD risk has been
.
ateddisorders(suchasDown’ssyndrome)areatincreasedriskof .. found, whereby each 1-year decrease in age at menopause por-
. CVDdisease,butperhapsnotspecificallyASCVD.However,health .. tendeda2%increasedriskofCHD.329
.
.
inequalitiesandtheprevalenceofCVriskfactorsmaybegreaterin .
.
.
thesepopulations,althoughepidemiologyresearchisscarce. . 3.4.12.3 Erectiledysfunction
.
.
. Erectiledysfunction(ED),definedastheconsistentinabilitytoreach
.
.
. andmaintainanerectionsatisfactoryforsexualactivity,hasamulti-
3.4.11.Non-alcoholicfattyliverdisease ..
. factorialcause.Itaffectsalmost40%andmorethan50%ofmenover
Non-alcoholicfattyliverdisease(NAFLD)hasbeenassociatedwith ...
40yearsand60yearsofage,respectively.330,331MenwithEDhave
anincreasedriskofmyocardialinfarctionandstroke.NAFLDrepre- ..
. anincreasedriskofall-causemortality[oddsratio(OR)1.26,95%CI
sents accumulation of ectopic fat; persons with NAFLD are often ..
. 1.01(cid:2)1.57] and CVD mortality (OR 1.43, 95% CI 1.00(cid:2)2.05). ED
overweightorobese,andnotuncommonlyhaveabnormalBP,glu- ..
. andCVDsharecommonriskfactors(hypercholesterolaemia,hyper-
.
cose,andlipidlevels.ArecentstudyinvestigatingwhetherNAFLD .
. tension,insulinresistanceandDM,smoking,obesity,metabolicsyn-
increasesCVriskbeyondtraditionalriskfactors313showsthatafter ..
.. drome, sedentary lifestyle, and depression) and a common
adjustingforestablishedriskfactors,theassociationsdidnotpersist. .
.. pathophysiologicalbasisofaetiologyandprogression.332,333
Nevertheless,patientswithNAFLDshouldhavetheirCVDriskcal- .
.. Medication used to prevent CVD, such as aldosterone receptor
culated,bescreenedforDM,andberecommendedahealthylifestyle .
.. antagonists, some beta-blockers, and thiazide diuretics, can cause
withareductionofalcoholintake. .
.. ED.330,332(cid:2)335EDisassociatedwithsubclinicalvasculardisease,336and
.
.. precedesCAD,stroke,andPADbyaperiodthatusuallyrangesfrom2
.
3.4.12.Sex-specificconditions .. to5years(average3years).MenwithEDhavea44(cid:2)59%higherrisk
.
3.4.12.1 Obstetricconditions .. fortotalCVevents,62%forAMI,39%forstroke,and24(cid:2)33%forall-
.
Pre-eclampsia (defined as pregnancy-related hypertension accompa- .. causemortality,withahigherriskinthosewithsevereED.337(cid:2)341 .
niedbyproteinuria)occursin1(cid:2)2%ofallpregnanciesandisassociated .. ThereisstrongevidencethatCVDriskassessmentisneededinmen
.
withanincreaseinCVDriskbyafactorof1.5(cid:2)2.7comparedwithall .. presenting with ED.336,342 In men with ED and low-to-intermediate
.
women,185,186,314whiletheRRofdevelopinghypertensionis3187and .. CVD risk, detailed risk profiling by, for example, CAC score is sug-
.
DMis2.184,185IthasnotbeenestablishedwhethertheincreasedCVD .. gested,butsofarnotsupportedbyevidence.338,341AssessmentofED
.
.
risk after preeclampsia occurs independently of CV risk factors. The . severityandphysicalexaminationshouldbepartofthefirst-lineCVD
.
rationaleforscreeningthesewomenfortheoccurrenceofhyperten- .. riskassessmentinmen.333,341Lifestylechangesareeffectiveinimproving
. sion and DM is, however, quite strong. At present, no separate risk .. sexualfunctioninmen:theseincludevigorousphysicalexercise,334,343
.
model for women with a history of hypertensive disorders of preg- .. improvednutrition,weightcontrol,andsmokingcessation.343(cid:2)345
.
nancyseemsnecessary,despitetheirhigherbaselinerisk.315 ..
.
.
Pregnancy-relatedhypertensionaffects10(cid:2)15%ofallpregnancies. ..
.
TheassociatedriskoflaterCVDislowerthanforpreeclampsiabutis .. 4. Risk factors and interventions
.
stillelevated(RR1.7(cid:2)2.5).193,314,316,317Also,theriskforsustainedor ..
. at the individual level
future hypertension is elevated (RRs vary, from 2.0 to 7.2 oreven ..
.
higher).187,318Again,however,therewasincompleteadjustmentfor ..
. 4.1. Treatment recommendations:
conventionalriskfactors.TheriskofdevelopingDMisalsoelevated ..
inthesewomen(RR1.6(cid:2)2.0).314,319Bothpreterm(RR1.6)andstill- ... classes, grades, and freedom of choice
.
birth(RR1.5)havebeenassociatedwithamoderateincreaseinrisk .. Clearcommunicationaboutrisksand benefitsiscrucialbeforeany
.
ofCVD.316 . treatmentisinitiated.Riskcommunicationisdiscussedinsection3.2.4,
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 41 ---
ESCGuidelines 3267
Table6 Treatmentgoalsfordifferentpatientcategories
Patientcategory Preventiongoals(STEP1) Intensified/additionalpreventiongoalsa(STEP2)
Apparentlyhealthypersons ForBPandlipids:initiationofdrugtreatmentbasedon
CVDriskassessment(Table5)orSBP>160mmHg
<50years Stopsmokingandlifestyleoptimization SBP<130mmHgiftoleratedb
SBP<140downto130mmHgiftoleratedb LDL-C<1.8mmol/L(70mg/dL)and>_50%reduction
LDL-C<2.6mmol/L(100mg/dL) inhigh-riskpatients
LDL-C<1.4mmol/L(55mg/dL)and>_50%reduction
invery-high-riskpatients
50-69years Stopsmokingandlifestyleoptimization SBP<130mmHgiftoleratedb
SBP<140downto130mmHgiftoleratedb LDL-C<1.8mmol/L(70mg/dL)and>_50%reduction
LDL-C<2.6mmol/L(100mg/dL) inhigh-riskpatients
LDL-C<1.4mmol/L(55mg/dL)and>_50%reduction
invery-high-riskpatients
>_70years Stopsmokingandlifestyleoptimization Forspecificriskfactormanagementinpatients>_70
SBP<140mmHgiftoleratedb yearsold,pleaseseerelevantsectionsinsection4.
LDL-C<2.6mmol/L(100mg/dL)
PatientswithCKD Stopsmokingandlifestyleoptimization LDL-C<1.8mmol/L(70mg/dL)inhigh-riskpatients
SBP<140downto130mmHgiftoleratedb and<1.4mmol/L(55mg/dL)invery-highriskpatients
LDL-C<2.6mmol/L(100mg/dL)and>_50%LDL-C (seeTable4)
reduction
OtherwiseaccordingtoASCVDandDMhistory
PatientswithFH Stopsmokingandlifestyleoptimization LDL-C<1.8mmol/L(70mg/dL)inhigh-riskpatients
SBP<140downto130mmHgiftoleratedb and<1.4mmol/L(55mg/dL)invery-highriskpatients
LDL-C<2.6mmol/L(100mg/dL)and>_50%LDL-C (seeTable4)
reductionOtherwiseaccordingtoASCVDandDM
history
Peoplewithtype2DM
Well-controlledshort-standing Stopsmokingandlifestyleoptimization
DM(e.g.<10years),noevidence
ofTODandnoadditionalASCVD
riskfactors
WithoutestablishedASCVDor Stopsmokingandlifestyleoptimization SBP<130mmHgiftoleratedb
severeTOD(seeTable4for SBP<140downto130mmHgiftoleratedb LDL-C<1.8mmol/L(70mg/dL)and>_50%reduction
definitions) LDL-C<2.6mmol/L(100mg/dL) SGLT2inhibitororGLP-1RA
HbA1c<53mmol/mol(7.0%)
WithestablishedASCVDand/or Stopsmokingandlifestyleoptimisation SBP<130mmHgiftoleratedb
severeTOD(seeTable4for SBP<140downto130mmHgiftoleratedb LDL-C<1.4mmol/L(55mg/dL)and>_50%reduction
definitions) LDL-C<1.8mmol/L(70mg/dL) SGLT2inhibitororGLP-1RAifnotalreadyon
HbA1c<64mmol/mol(8.0%) Mayadditionallyconsidernovelupcomingtreatments:
SGLT2inhibitororGLP1-RA DAPT,dualpathwayinhibition,acolchicine,icosapentethyl
CVD:antiplatelettherapy
Patientswithestablished Stopsmokingandlifestyleoptimization SBP<130mmHgiftoleratedb
ASCVD SBP<140downto130mmHgiftoleratedb LDL-C<1.4mmol/L(55mg/dL)
Intensiveorallipid-loweringtherapyaimingat>_50% Mayadditionallyconsidernovelupcomingtreatments:
LDL-CreductionandLDL-C<1.8mmol/L(70mg/dL) DAPT,dualpathwayinhibition,colchicine,icosapentethyl,
Antiplatelettherapy etc.
ASCVD=atheroscleroticcardiovasculardisease;BP=bloodpressure;CKD=chronickidneydisease;CVD=cardiovasculardisease;DAPT=dualantiplatelettherapy;DBP=
diastolicbloodpressure;DM=diabetesmellitus;EAS=EuropeanAtherosclerosisSociety;ESC=EuropeanSocietyofCardiology;FH=familialhypercholesterolaemia;GLP-
1RA=glucagon-likepeptide-1receptoragonist;HbA1c=glycatedhaemoglobin;LDL-C=low-densitylipoproteincholesterol;SBP=systolicbloodpressure(office);SGLT2=
sodium-glucosecotransporter2;TOD=targetorgandamage.
aDependingon10-year(residual)riskand/orestimatedlifetimebenefit(seeTable4fordetails),comorbidities,andpatientpreference.Levelsofevidenceofintensifiedgoals
vary,seerecommendationtablesinsections4.6and4.7.ForCKDandFH,LDL-Ctargetsaretakenformthe2019ESC/EASGuidelinesforthetreatmentofdyslipidaemias.3
bOfficeDBPtreatmenttargetrange<80mmHg.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 42 ---
3268 ESCGuidelines
.
.
andbenefitsofindividualtreatmentarethetopicofthissection.Inall . about consequences and side-effects, intellectual/cognitive abilities,
.
.
scenarios where recommendations for individual interventions to . mental disorders, physical limitations, financial aspects, and living
.
reduceriskare‘strong’(classIorIIa),itisimportanttorealizethat .. alone.360,362(cid:2)364 Importantly, only substantial risk reduction moti-
.
.
manypatientswhohavereceivedappropriateriskinformationoften . vates patients for preventive drug treatment, which obviates the
.
(in up to 50% of cases, some studies suggest) consciously opt to .. need for appropriate risk communication.365,366 Depression is
.
.
foregothe proposed intervention. This appliesnotonlyto lifestyle . anotherimportantfactor,andadequatetreatmentthereofimproves
.
measures,butalsotodruginterventions.Apparently,whatprofessio- .. adherence.367,368
.
.
nalsfeelissufficientriskreductionforareasonableeffortorinitiation . Mobilephoneapplicationsmayimproveadherencetobothmedi-
.
of a drug with few side-effects does not always correspond to .. cation and behavioural changes.369 Their use is easy and probably
.
.
patients’views.Thereverseisalsotrue:notonlymaysomepatients . cost-effective.370
.
.
at(very)highriskforegointerventions,somepatientswithlow-to- ..
.
moderateriskmaybehighlymotivatedtodecreasetheirriskeven .. 4.2.4.Treatmentgoals
.
further.Hence,treatmentrecommendations are never‘imperative’ .. Inthesubsequentsections,differentdomainsofindividualtreatment
.
for(very) highriskpatients,norare interventions ever‘prohibited’ .. arediscussed.Table6summarizesthetreatmentgoalsandsomekey
.
forpatientsatlow-to-moderaterisk.Thereisevidencethatahigher .. interventionsfordifferentcategoriesofpatients.Foradditionalinfor-
.
proportionofwomen,comparedtomen,havealowawarenessof .. mationonriskcategoriesandtheprincipleofastepwiseapproachto
.
theirCVDriskandtheneedfortherapeuticinterventions.Thiswar- .. treatmenttargets,pleaserefertosection3.2.3.1.Fordetailsontreat-
.
rantseffortstoimproveawareness,riskassessment,andtreatmentin .. mentgoals,howtoachievethem,strengthsofrecommendationsand
.
women.52,346(cid:2)351 ..
levelsofsupportingevidence,pleasegototherelevantsubsections.
. .
.
.
4.2. Optimizing cardiovascular risk .. 4.3.Optimizing lifestyle
.
.
management .. 4.3.1.Physicalactivityandexercise
.
.
4.2.1.Goalsofclinicianpatientcommunication .
.. Recommendationsforphysicalactivity
Cliniciansshouldprovideapersonalizedpresentationofguidelinesto .
.
.
improve understanding, encourage lifestyle changes, and support .. Recommendations Classa Levelb
.
adherencetodrugtherapy.Applyingthisindailypracticefacesdiffer- ..
entbarriers.352Patients’ability to adoptahealthylifestyledepends ... Itisrecommendedforadultsofallagestostrive
oncognitiveandemotionalfactors,theimpactofadiagnosisorsymp-
... foratleast150-300minaweekofmoderate-
toms, socioeconomic factors, educational level, and mental health.
... intensityor75-150minaweekofvigorous-
I A
Perceivedsusceptibilitytoillnessandtheanticipatedseverityofthe
... intensityaerobicPA,oranequivalentcombina-
consequences are also prominent components of patients’
... tionthereof,toreduceall-causemortality,CV
motivation.353
... mortality,andmorbidity.371,372
.
. Itisrecommendedthatadultswhocannotper-
.
.
. form150minofmoderate-intensityPAaweek
4.2.2.Howtoimprovemotivation? .. I B
. shouldstayasactiveastheirabilitiesandhealth
Communicationstrategiessuchasmotivationalinterviewingareuse- ..
. conditionallow.373,374
ful.354Consultationsessionsmayincludeafamilymemberorfriend, ..
especiallyforelderlypatients.Connectionisparamount:focusbefore
... Itisrecommendedtoreducesedentarytimeto
.. engageinatleastlightactivitythroughoutthe
greeting;listenintently;agreeonwhatmattersmost;connectwiththe . I B
person’s story; and explore emotions.355 The OARS (Open-ended ... daytoreduceall-causeandCVmortalityand
.. morbidity.375(cid:2)377
questions,Affirmation,Reflectivelistening,andSummarizing)principle .
.
. Performingresistanceexercise,inadditionto
helpspatientstopresenttheirperceptions,andclinicianstosumma- .
.
. aerobicactivity,isrecommendedon2ormore
rize.TheSMART(Specific,Measurable,Achievable,Realistic,Timely) .. I B
principle may help with setting goals for behavioural change.353,356 .. daysperweektoreduceall-cause
.
. mortality.378,379
Healthcareprofessionalsmustconsidercapability,opportunity(physi- .
.
cal, social, or environmental) and motivation for behavioural .. Lifestyleinterventions,suchasgrouporindivid-
.
change.357Multidisciplinarybehaviouralapproachesthatcombinethe .. ualeducation,behaviour-changetechniques,tel-
.
knowledgeandskillsofdifferentcaregiversarerecommended.358 .. ephonecounselling,anduseofconsumer-based IIa B .
.. wearableactivitytrackers,shouldbeconsidered
.
.. toincreasePAparticipation.380(cid:2)382
4.2.3.Optimizingdrugadherence ..
.
Medicationadherencerangesfrom50%forprimaryASCVDpreven- .. CV=cardiovascular;PA=physicalactivity.
tionto66%forsecondaryprevention.359Physiciansshouldconsider .... a bC Lela vs es lo of fr ee vc ido em nm cee .ndation.
non-adherenceineverypatientandinquirenon-judgmentallyabout ..
.
it.360Approximately9%ofcasesofASCVDinEuropecanbeattrib- ..
.
uted to poor medication adherence.361 Contributors to non- .. PAreducestheriskofmanyadversehealthoutcomesandriskfactors
.
adherenceincludepolypharmacy,complexityofdrug/doseregimes, .. inallagesandbothsexes.Thereisaninverserelationshipbetween
.
poordoctor-patientrelationship,lackofdiseaseacceptance,beliefs . moderate-to-vigorousPAandall-causemortality,CVmorbidityand
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 43 ---
ESCGuidelines 3269
Table7 Classificationofphysicalactivityintensityandexamplesofabsoluteandrelativeintensitylevels.
Absoluteintensity Relativeintensity
................................................................................................................ ................................................................................................
Intensity METa Examples %HR RPE(Borg Talktest
max
scalescore)
Light 1.1(cid:2)2.9 Walking<4.7km/h,lighthouseholdwork 57(cid:2)63 10(cid:2)11
Moderate 3(cid:2)5.9 Walkingatmoderateorbriskpace(4.1(cid:2)6.5km/h), 64(cid:2)76 12(cid:2)13 Breathingisfasterbutcompatiblewith
slowcycling(15km/h),painting/decorating,vacuuming, speakingfullsentences
gardening(mowinglawn),golf(pullingclubsintrolley),
tennis(doubles),ballroomdancing,wateraerobics
Vigorous >_6 Race-walking,jogging,orrunning,cycling>15km/h, 77(cid:2)95 14(cid:2)17 Breathingveryhard,incompatible
heavygardening(continuousdiggingorhoeing),swim- withcarryingonaconversation
minglaps,tennis(singles) comfortably
%HRmax=percentageofmeasuredorestimatedmaximumheartrate(220(cid:2)age);MET=metabolicequivalentoftask;RPE=ratingofperceivedexertion(Borg-scale6(cid:2)20);
VO2=oxygenconsumption.
aMETisestimatedastheenergycostofagivenactivitydividedbyrestingenergyexpenditure:1MET=3.5mLoxygenkg(cid:2)1min(cid:2)1VO2.
Modifiedfrom392
. mortality, as well as incidence of type 2 DM.371(cid:2)373,383(cid:2)387 The .. Relativeintensityisdeterminedbasedonanindividual’smaximum
.
.
reductioninriskcontinuesacrossthefullrangeofPAvolumes,and . (peak) effort, e.g. percentage of cardiorespiratory fitness (%VO
. 2
.
the slope of risk decline is steepest for the least active individu- . max),percentageofmaximum(peak)heartrate(%HR )orusing
. max
als.371(cid:2)374,386,387MoreinformationonPAprescriptioncanbefound .. ratingofperceivedexertionaccordingtotheBorgscale.Lessfitindi-
.
.
inarecentESCGuideline.388 . vidualsgenerallyrequireahigherlevelofeffortthanfitterpeopleto
.
.
.. performthesameactivity.Arelativeintensitymeasureisnecessary
.
4.3.1.1 Physicalactivityprescription .. toprovideanindividualizedPAprescription.389
.
PA should be individually assessed and prescribed in terms of fre- .. Classificationforbothabsoluteandrelativeintensityandexamples
.
quency, intensity, time (duration), type, and progression.389 .. arepresentedinTable7.
.
Recommendations regarding pre-participation screening can be ..
.
foundinpreviousESCGuidelines.388Interventionsshowntoincrease .. 4.3.1.3Resistanceexercise
.
PA level or reduce sedentary behaviour include behaviour theory- .. ResistanceexerciseinadditiontoaerobicPAisassociatedwithlower
.
basedinterventions,suchasgoal-setting,re-evaluationofgoals,self- .. risksoftotalCVeventsandall-causemortality.378,379,393(cid:2)395Thesug-
.
monitoring,andfeedback.372,380,381Usingawearableactivitytracker .. gested prescription is one to three sets of 8(cid:2)12 repetitions at the
.
mayhelpincreasePA.382Mostimportantistoencourageactivitythat .. intensityof60(cid:2)80%oftheindividual’s1repetitionmaximumatafre-
.
peopleenjoyand/orcanincludeintheirdailyroutines,assuchactiv- .. quencyofatleast2daysaweekinavarietyof8(cid:2)10differentexercises
.
itiesaremorelikelytobesustainable. .. involvingeachmajormusclegroup.Forolderadultsordeconditioned
.
.
. individuals,itissuggestedtostartwithonesetof10(cid:2)15repetitionsat
.
4.3.1.2 Aerobicphysicalactivity .. 40(cid:2)50%of1repetitionmaximum.389Inaddition,olderadultsarerec-
.
Examples of aerobic PA include walking, jogging, cycling, etc.389 .. ommended to perform multicomponent PA that combines aerobic,
.
Adultsarerecommendedtoperformatleast150(cid:2)300minaweek .. muscle-strengthening,andbalanceexercisestopreventfalls.372
.
.
ofmoderate-intensityPA,or75(cid:2)150minofvigorous-intensityPA, .
.
.
or an equivalent combination of both, spread throughout the . 4.3.1.4Sedentarybehaviour
.
week.371,372 Additional benefits are gained with even more PA. .. Sedentary time is associated with greater risk for several major
.
PractisingPAshouldstillbeencouragedinindividualsunabletomeet .. chronic diseases and mortality.371,372,375(cid:2)377,396(cid:2)399 For physically
.
.
theminimum.Insedentaryindividuals,a gradualincrease inactivity . inactiveadults,light-intensityPA,evenaslittleas15minutesaday,is
. .
levelisrecommended.Whenolderadultsorindividualswithchronic . likelytoproducebenefits.Thereismixedevidencetosuggesthow
.
.
conditionscannotachieve150minofmoderate-intensityPAaweek, .. activityboutsthatinterruptsedentarybehaviourareassociatedwith
.
they should be as active as their abilities and conditions .. healthoutcomes.375,398,400
.
allow.371(cid:2)375,384,385 PA accumulated in bouts of even <10 min is ..
.
associatedwithfavourableoutcomes,includingmortality.371,390 ..
4.3.2.Nutritionandalcohol
PA can be expressed in absolute or relative terms.389 Absolute ... Recommendationsfornutritionandalcohol
.
intensity is the amount of energy expended per minute of activity, .
.
.
assessedbyoxygenuptakeperunitoftime(mL/minorL/min)orby .. Recommendations Classa Levelb
.
metabolic equivalent of task (MET). A compendium of the energy ..
. Ahealthydietisrecommendedasacornerstone
costinMETvaluesforvariousactivitiesisavailable.391Anabsolute ...
ofCVDpreventioninallindividuals.401,402
I A
measure does not consider individual factors such as body weight, ..
sex,andfitnesslevel.389 .. Continued
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 44 ---
3270 ESCGuidelines
.
. Table8 Healthydietcharacteristics
ItisrecommendedtoadoptaMediterraneanor .
I A .
similardiettolowerriskofCVD.403,404 ..
. Adoptamoreplant-andlessanimal-basedfoodpattern
.
Itisrecommendedtoreplacesaturatedwith .
. Saturatedfattyacidsshouldaccountfor<10%oftotalenergy
.
unsaturatedfatstolowertheriskof I A .
. intake,throughreplacementbyPUFAs,MUFAs,andcarbohydratesfrom
.
CVD.405(cid:2)409 ...
wholegrains
Itisrecommendedtoreducesaltintaketolower
I A
...
Transunsaturatedfattyacidsshouldbeminimizedasfaraspossible,with
BPandriskofCVD.410 ...
nonefromprocessedfoods
.
Itisrecommendedtochooseamoreplant- .
. <5gtotalsaltintakeperday
.
basedfoodpattern,richinfibre,thatincludes .
I B .. 30(cid:2)45goffibreofperday,preferablyfromwholegrains
wholegrains,fruits,vegetables,pulses,and .
.. >_200goffruitperday(>_2(cid:2)3servings)
nuts.411,412 .
.
. >_200gofvegetablesperday(>_2(cid:2)3servings)
Itisrecommendedtorestrictalcoholconsump- ..
tiontoamaximumof100gperweek.413(cid:2)415
I B ... Redmeatshouldbereducedtoamaximumof350-500gaweek,inpar-
.. ticularprocessedmeatshouldbeminimized
Itisrecommendedtoeatfish,preferablyfatty,at .
.
. Fishisrecommended1(cid:2)2timesperweek,inparticularfattyfish
leastonceaweekandrestrict(processed) I B .
.
meat.406,416(cid:2)418 .. 30gunsaltednutsperday
.
Itisrecommendedtorestrictfreesugarcon-
... Consumptionofalcoholshouldbelimitedtoamaximumof100gper
sumption,inparticularsugar-sweetenedbever-
... week
I B . ages,toamaximumof10%ofenergy .. Sugar-sweetenedbeverages,suchassoftdrinksandfruitjuices,mustbe .
intake.419,420 .. discouraged
.
.. MUFA=monounsaturatedfattyacid;PUFA=polyunsaturatedfattyacid.
CVD=cardiovasculardisease;BP=bloodpressure. .
.
aClassofrecommendation. ..
bLevelofevidence. ..
.
.. TheDASH(DietaryApproachestoStopHypertension)trialshowed
.
DietaryhabitsinfluenceCVrisk,mainlythroughriskfactorssuchas .. a dose(cid:2)response relation between sodium reduction and BP
.
lipids,BP,bodyweight,andDM.401,402Table8summarizesthechar- .. reduction.423Inameta-analysis,saltreductionof2.5g/dayresultedin
.
acteristics of a healthy diet. Although recommendations about .. a 20% reductionofASCVDevents(RR 0.80).410 A U- orJ-shaped
.
nutrientsandfoodsremainimportantforCVhealth,thereisagrow- .. relation between a low salt intake and ASCVD is debated.424
.
.
ing concern about environmental sustainability, supporting a shift . Underlying illnessandmalnutritionmayexplainbothlowfoodand
.
fromananimal-toamoreplant-basedfoodpattern.411,412 .. saltintakesaswellasincreasedASCVD.410,425,426Thetotalityofevi-
.
.
. dencewarrantssaltreductiontopreventCHDandstroke.
.
.
4.3.2.1 Fattyacids . In most Western countries, salt intake is high ((cid:4)9(cid:2)10 g/day),
.
.
Risk of CHD is reduced when dietary saturated fats are replaced . whereas the recommended maximum intake is 5 g/day. Optimal
.
.
appropriately(Figure10).Thisisalsothecasewhenreplacingmeat .. intakemightbeaslowas(cid:4)3g/day.Saltreductioncanbeachievedby
.
anddairyfoods.406,407Polyunsaturatedfats(-25%),monounsaturated .. dietary choices (fewer processed foods) and the reformulation of
.
fats(-15%),andtoalesserextentcarbohydratesfromwholegrains .. foodsbyloweringtheirsaltcontent(seesection5.2.2).
.
(-9%),wereallassociatedwithreducedCHDriskwhenisocalorically .. Potassium(e.g.infruitsandvegetables)hasfavourableeffectson
substitutedfordietarysaturatedfat.408,409 ... BPandriskofstroke(RR0.76).427
.
Reducing saturated fatty acid intake to less than 10% of energy .. Asforvitamins,observationalstudieshavefoundinverseassocia-
.
mayhaveadditionalbenefits.405However,theLDL-C-loweringeffect .. tionsbetweenvitaminsAandEandriskofASCVD.However,inter-
.
ofsubstitutingpolyunsaturatedfattyacids(PUFAs)forsaturatedfatty .. vention trials have failed to confirm these findings. Also, trials of
.
acids may be less in obese (5.3%) than in normal-weight persons .. supplementationwithBvitamins(B6,folicacid,andB12),andvita-
.
(9.7%).421 .. minsCandDhavenotshownbeneficialeffects.428,429
.
Transfattyacids,formedduringindustrialprocessingoffats,have ..
. unfavourable effects on total cholesterol (increase) and HDL-C .. 4.3.2.3Fibre
.
(decrease). On average, a 2% increase in energy intake from trans .. Each7g/dayhigherintakeoftotalfibreisassociatedwitha9%lower
.
fattyacidsisassociatedwitha23%higherCHDrisk.422Aregulation .. riskofCAD(RR0.91).430A10g/dayhigherfibreintakewasassoci-
.
oftheEuropeanUnion(EU)Commissionhassettheupperlimitto2 .. atedwitha16%lowerriskofstroke(RR0.84)anda6%lowerriskof
.
gper100goffat(April2019)(https://ec.europa.eu/food/safety/label- .. type2DM(RR0.94).431,432Ahighfibreintakemayreducepostpran-
.
ling_nutrition/trans-fat-food_en). .. dialglucoseresponsesaftercarbohydrate-richmealsandalsolower
.
Whenguidelinestolowersaturatedfatintakearefollowed,reduc- .. triglyceridelevels.433
.
.
tionsindietarycholesterolintakefollow. .
.
.
. 4.3.2.4Specificfoodsandfoodgroups
.
.
4.3.2.2 Mineralsandvitamins .
.
.
A reduction in sodium intake may reduce SBP by, on average, 5.8 . 4.3.2.4.1. Fruits,vegetables,andpulses.Ameta-analysisreporteda
.
.
mmHginhypertensive,and1.9mmHginnormotensivepatients.410 . 4% lower risk in CV mortality for each additional serving of fruits
1202 CSE 1202 CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 45 ---
ESCGuidelines 3271
Trans fat (2%)
MUFA (5%)
PUFA (5%)
Carbohydrates from refined
starches/sugars (5%)
Carbohydrates from whole
grains (5%)
-35 -30 -25 -20 -15 -10 -5 0 5 10 15 20
Changes in risk (%)
Figure10 Estimatedpercentagechangeinriskofcoronaryheartdiseaseassociatedwithisocaloricsubstitutionsofsaturatedfatforothertypesoffat
orcarbohydrates.ReproducedfromSacksetal.409MUFA=monounsaturatedfattyacid;PUFA=polyunsaturatedfattyacid.
.
.
(equivalentto77g)andvegetables(equivalentto80g)perday,while .. althougha7%lowerriskofCHDeventswasobserved.Ameta-anal-
.
all-cause mortality was not reduced further with intakes of more .. ysis of 13 RCTs included the results of VITAL (Vitamin D and
.
thanfiveservings.434Ameta-analysisreportedan11%lowerriskfor .. Omega-3 Trial), ASCEND (A Study of Cardiovascular Events in
.
strokeassociatedwiththreetofivedailyservingsoffruitsandvegeta- .. Diabetes), and REDUCE-IT (Reduction of Cardiovascular Events
.
blesandof26%withfiveservingsadaycomparedwithfewerthan .. withIcosapentEthyl(cid:2)InterventionTrial).444Intheanalysisexcluding
.
threeservings.435,436Asingleportionofpulses(legumes)adaylow- .. REDUCE-IT,fishoilreducedtotalASCVD(RR0.97)andCHDdeath
.
ers LDL-C by 0.2 mmol/L and is associated with a lower risk of .. (RR0.92).444IncludingREDUCE-IT(astudydoneinparticipantswith
.
CHD.437,438 .. hightriglycerides,comparingveryhighicosapentethyldosesvs.min-
.
.. eral oil placebo) strengthened the results.444 However, this is the
.
4.3.2.4.2. Nuts. A meta-analysisof prospective cohortstudies sug- .. onlystudythattestedahighicosapentethyldoseandquestionshave
.
gestedthatdailyconsumptionof30gof(mixed)nutswasassociated .. been raised regarding the choice of placebo. Very recently,
.
witha(cid:4)30%lowerriskofASCVD.437Bothpulsesandnutscontain .. STRENGTH(Long-TermOutcomesStudytoAssessStatinResidual
.
fibreandotherbioactivecomponents.438 .. Risk with Epanova in High Cardiovascular Risk Patients with
.
.
. Hypertriglyceridemia) failed to demonstrate benefit of a combined
.
4.3.2.4.3. Meat. Frombothahealthandanenvironmentalpointof ... eicosapentaenoicacidanddocosahexaenoicacidpreparation.445
. view,alowerconsumptionofmeat,especiallyprocessedmeat,isrec- ..
.
ommended.411Arestrictionofredmeatmayhavelittleornoeffect .. 4.3.2.4.5. Alcoholicbeverages.Theuppersafelimitofdrinkingalco-
.
on major cardiometabolic outcomes.416 However, substituting red .. holicbeveragesisabout100gofpurealcoholperweek.Howthis
.
meatwithhigh-qualityplantfoods(i.e.nuts,soy,andlegumes)does .. translatesintonumberofdrinksdependsonportionsize,thestand-
.
improve LDL-C concentrations.406 A recent analysis showed that .. ards of which differ per country, mostly between 8 and 14 g per
.
higherintakeofprocessedmeatandunprocessedredmeatisassoci- .. drink.Thislimitissimilarformenandwomen.413Drinkingabovethis
.
atedwitha7%and3%,respectively,increasedriskofASCVD.417 .. limitlowerslifeexpectancy.
.
Byreducingprocessedmeats,saltintakewillalsobereduced.The .. Resultsfromepidemiologicalstudieshavesuggestedthat,whereas
.
WorldCancerResearchFundrecommends limitingred meatcon- .. higher alcohol consumption is roughly linearly associated with a
.
sumptionto350(cid:2)500gperweek.439 .. higherriskofallstrokesubtypes,coronarydisease,HF,andseveral
.
.. lesscommonCVDsubtypes,itappearedapproximatelylog-linearly
.
4.3.2.4.4. Fish and fish oil supplements. Studiesindicatethateating .. associated with a lower riskof myocardial infarction.413 Moreover,
.
fish,particularlyfishrichinn-3PUFA,atleastonceaweek,isassoci- .. Mendelianrandomizationstudiesdonotsupporttheapparentlypro-
.
.
atedwitha16% lowerriskofCAD,418andeatingfishtwotofour .. tectiveeffectsofmoderateamountsvs.noalcoholagainstASCVD,
.
times a week is associated with a 6% lower risk of stroke.440 The .. suggestingthatthelowestrisksforCVDoutcomesareinabstainers
.
highestriskwasobservedintherangeofnoorverylowintakes. .. and that any amount of alcohol uniformly increases BP and
Severalmeta-analysesandarecentCochranereviewshowedno
... BMI.414,415Thesedatachallengetheconceptthatmoderatealcohol
.
benefits of fish oils on CV outcomes and/or mortality,441(cid:2)443 .. consumptionisuniversallyassociatedwithlowerCVDrisk.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 46 ---
3272 ESCGuidelines
.
4.3.2.4.6. Soft drinks and sugar. Regular consumption of sugar- .
. Bariatricsurgeryforobesehigh-riskindividuals .
sweetenedbeverages(i.e.twoservingsperdaycomparedwithone .
. shouldbeconsideredwhenlifestylechangedoes IIa B
.
servingpermonth)wasassociatedwitha35%higherriskofCADin .. notresultinmaintainedweightloss.455
.
womenintheNurses’HealthStudy,whereasartificiallysweetened .
.
beverages were not associated with CAD. In the EPIC (European .. CVD=cardiovasculardisease;BP=bloodpressure;DM=diabetesmellitus.
.. aClassofrecommendation.
ProspectiveInvestigationintoCancerandNutrition)cohort,botharti- .
.. bLevelofevidence.
ficiallyandsugar-sweetenedsoftdrinkswereassociatedwithall-cause .
.
.
mortality,whileonlytheformerwasassociatedwithcirculatorydis- .
.. 4.3.3.1Treatmentgoalsandmodalities
eases.419TheWHOguidelinerecommendsamaximumintakeof10% .
.. Although diet, exercise, and behaviour modification are the main
ofenergyfromfreesugars(mono-anddisaccharides),whichincludes .
.. therapiesforoverweightandobesity,theyareoftenunsuccessfulin
addedsugarsaswellassugarspresentinfruitjuices.420 ...
the long term. Yet, maintaining even a moderate weight loss of
.
.. 5-10%frombaselinehassalutaryeffectsonriskfactorsincludingBP,
4.3.2.4.7.Coffee.Non-filteredcoffeecontainsLDL-C-raisingcafestol ... lipids,andglycaemiccontrol,450,451aswellasonprematureall-cause
andkahweol,andmaybeassociatedwithanupto25%increasedrisk ... mortality.456 Weight loss is associated with lower morbidity but
ofASCVDmortalitybyconsumptionofnineormoredrinksaday.446 ...
highermortalityin(biologically)olderadults(the‘obesityparadox’).
Non-filtered coffee includes boiled, Greek, and Turkish coffee and ...
Inthisgroup,emphasisshouldbelessonweightlossandmoreon
.
some espresso coffees. Moderate coffee consumption (3(cid:2)4 cups .. maintainingmusclemassandgoodnutrition.
. per day) is probably not harmful, perhaps even moderately .
.
beneficial.447 ..
. 4.3.3.2Dietsforweightloss .
.
. Energyrestrictionisthecornerstoneofmanagement.PAisessential
.
4.3.2.4.8. Functionalfoods.Functionalfoodscontainingphytosterols .. tomaintainweightlossandpreventreboundweightgain,butisnot
.
(plantsterolsandstanols)areeffectiveinloweringLDL-Clevelsby .. reviewedhere.Hypocaloricdietsmaybecategorizedas:
.
an average of 10% when consumed in amounts of 2 g/day.448 The ..
effectisinadditiontothatobtainedwithalow-fatdietoruseofsta-
... 1.DietsthataimtoreduceASCVD,includingplant-based457,458and
tins.Nostudieswithclinicalendpointshavebeenperformedyet. ... hypocaloric Mediterranean diets,458,459 with modifications to suit
.
Redyeastricesupplementsarenotrecommendedandmayeven .. localfoodavailabilityandpreferences.
.
causeside-effects.449 .. 2.Changestothefatandcarbohydratemacronutrientcompositionof
.
. the diet, including low or very low carbohydrate diets (with
.
.
4.3.2.4.9. Dietarypatterns.Studyingtheimpactofatotaldietarypat- .. 50(cid:2)130gand20(cid:2)49gcarbohydrates/day,respectively),moderate
.
ternshowsthefullpreventivepotentialofdiet.TheMediterranean .. carbohydratediets (>130(cid:2)225 g carbohydrates/day),andlow-fat
.
diet includes high intakes of fruits, vegetables, pulses, wholegrain .. diets(<30%ofenergyfromfat).
.
products,fish,andoliveoil,moderateconsumptionofalcohol,and .. 3.High-protein diets to preserve lean muscle mass and enhance
.
lowconsumptionof(red)meat,dairyproducts,andsaturatedfatty .. satiety.
.
acids.GreateradherencetoaMediterraneandietisassociatedwitha .. 4.Dietsfocusingonspecificfoodgroups(e.g.increasingfruitandvege-
.
10%reductioninCVincidenceormortalityandan8%reductionin .. tablesoravoidingrefinedsugars).
.
all-causemortality.403FollowingaMediterraneandietenrichedwith .. 5.Diets that restrict energy intake for specified time periods, for
.
nutsovera5-yearperiod,comparedwithacontroldiet,loweredthe .. exampleon2daysaweekoralternatedays(intermittentfasting)or
.
riskofASCVDby28%andby31%withadietenrichedwithextra- ... duringcertainhoursoftheday(time-restrictedeating).
.
virginoliveoil.404 ..
Also,ashiftfromamoreanimal-basedtoaplant-basedfoodpat-
... Thesedietsgivebroadlysimilarshort-termweightloss.452(cid:2)454By
ternmayreduceASCVD.411 ... 12 months, the effects tend to diminish.453 Benefits of the
.
. Mediterraneandiet,however,tendtopersist.Thequalityofnutrients
.
. . inadiet,forexamplesubstitutingunsaturatedforsaturatedfats(see
4.3.3.Bodyweightandcomposition ...
section4.3.2.1)andincludingfibre-richcarbohydrates460determines
.
.
. whetheradietishealthyinthelongterm.
Recommendationsforbodyweight . .
. Loworverylowcarbohydratedietsmayhaveadvantagesregard-
.
.
Recommendations Classa Levelb .. ingappetitecontrol,loweringtriglycerides,andreducingmedications
.. fortype2DM.461Suchdietsmaybeketogenicandneedmedicalor
.
Itisrecommendedthatoverweightandobese .
. at least dietetic supervision. Studies beyond 2 years are scarce.
.
peopleaimforareductioninweighttoreduce .
I A .. Extreme carbohydrate intakes should be avoided in the long term
BP,dyslipidaemia,andriskoftype2DM,and .
.. and plant substitutions of fat and protein for carbohydrates are
thusimprovetheirCVDriskprofile.450,451 ...
advantageousoveranimalones.462
Whilearangeofdietsareeffectiveforweight ... Intermittentfastingdietsproduceequivalentweightlosstocontin-
loss,itisrecommendedthatahealthydietin
I A
... uousenergyrestrictionwhenmatchedforenergyintake.463
regardtoCVDriskismaintainedover ... Medications approved in Europe as aids to weight loss (orlistat,
time.452(cid:2)454 ...
naltrexone/bupropion, high-dose liraglutide) may supplement
.
Continued . lifestyle change to achieve weight loss and maintenance, although
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 47 ---
ESCGuidelines 3273
.
.
sometimes at the expense of side-effects. Meta-analysis of . fatalandnon-fatalfirstrecurrentASCVDevents[hazardratio(HR
.
medication-assistedweightlossfoundfavourableeffectsonBP,gly- .. 0.59)] and fewer recurrent AMIs (HR 0.55).467 In SWITCHD
.
.
caemiccontrol,andASCVDmortality.464 . (Stockholm Women’s Intervention Trial for Coronary Heart
.
.
Averyeffectivetreatmentoptionforextremeobesityorobesity .. Disease),theinterventionyieldedasubstantialreductioninall-cause
.
withcomorbiditiesisbariatricsurgery.Ameta-analysisindicatedthat .. mortality(OR0.33).468ArecentRCTreportedthatcardiacrehabili-
.
patients undergoing bariatric surgery had over 50% lower risks of .. tation (CR) enhanced by stress management produced significant
.
total,ASCVD,andcancermortalitycomparedwithpeopleofsimilar .. reductionsinASCVDeventscomparedwithstandardCRalone(HR
.
weightwhodidnothavesurgery.455 .. 0.49).469ConcerningpsychopharmacotherapyofpatientswithCHD
.
.. anddepression, selective serotonin reuptake inhibitor(SSRI)treat-
.
.. mentlowersratesofCHDreadmission(riskratio0.63)andall-cause
4.4. Mental healthcare and psychosocial ... mortality(riskratio0.56).470ArecentRCTreportedthat,inpatients
.
interventions .. with ACS and depression, treatment with the SSRI, escitalopram,
.
Recommendationsformentalhealthcareandpsychoso- .. resultedinalowerrateofthecompositeendpointofall-causemor-
.
cialinterventionsattheindividuallevel .. tality,myocardialinfarction,orpercutaneouscoronaryintervention
.
.. (PCI) (HR 0.69).471 Collaborative care for patients with CHD and
Recommendations Classa Levelb ... depressionhassmallbeneficialeffectsondepression,butsignificantly
.
Patientswithmentaldisordersneedintensified
... reducesshort-termmajorcardiacevents.485
.
attentionandsupporttoimproveadherenceto I C .. Concerning side-effects of psychopharmacological treatments,
.
lifestylechangesanddrugtreatment.3,465 .. manypsychiatricdrugsareassociatedwithanincreasedriskofsud-
.. dencardiacdeath.486InpatientswithHF,antidepressantsareassoci-
InASCVDpatientswithmentaldisorders,evi- .
.
. atedwithincreasedriskofcardiacandall-causemortality(HR1.27;
dence-basedmentalhealthcareandinterdiscipli- I B ..
narycooperationarerecommended.100,113,466
.... .... fordetailsseesupplementarymaterialforsection4.4).472Therefore,
.. ASCVD patients with complex mental disorders, and particularly
A
e
m
rerS
ae
dC
nd
uaV
cf
g
eoD
er
sm
tp
r
reea ent
f
sei te
sr
tn
r
soat ys
l
mimtw
o
ppi tt
p
r
oh
os
mys vct ser
h
.4e
Co
6s
7t
Vs
h
(cid:2)s
e
o
4h
r
6uo
a
9tpu cel od
u
mtb
i
ee
c
ssc ato
r
nn
e
ds si sd-
IIa B
............. .............
t
c
4h
o
.o
o
5s pe .ern Sae te
i
mod nin
.
og kp is nyc ghia it nric tedr rug vetr nea ttm ioen nt, require interdisciplinary
PatientswithCHDandmoderate-to-severe .
.
majordepressionshouldbeconsideredforanti- IIa B ..
. Recommendationsforsmokinginterventionstrategies
depressivetreatmentwithanSSRI.470,471 ..
.
.
InpatientswithHFandmajordepression,SSRIs, .. Recommendations Classa Levelb
.
SNRIs,andtricyclicantidepressantsarenotrec- III B ..
. Allsmokingoftobaccoshouldbestopped,as
ommended.472,473c ..
.. tobaccouseisstronglyandindependentlycausal I A
.
ASCVD=atheroscleroticcardiovasculardisease;CHD=coronaryheartdisease; .. ofASCVD.487,488
C taV ke= inc ha ibr id ti oo rv ;a Ss Sc Ru Ila =r; sH elF ec= tivh ee sa ert rofa toilu nr ine; reS uN pR taI k= eis ne hr io bt io ton rin .-noradrenalinereup- ....
Insmokers,offeringfollow-upsupport,nicotine
aClassofrecommendation. .. replacementtherapy,varenicline,andbupropion
. IIa A
bLevelofevidence. .. individuallyorincombinationshouldbe
cDetails explaining this recommendation are provided in the supplementary ...
considered.489(cid:2)494
materialsection2.1. .
. . Smokingcessationisrecommendedregardless
.
.
. ofweightgain,asweightgaindoesnotlessenthe I B
TreatmentofanunhealthylifestylewillreduceCVDriskaswellas . .
. ASCVDbenefitsofcessation.495
improvementalhealth.Smokingcessation,forinstance,hasapositive ..
.
effect ondepression outcomes,474,475 asdo exercise therapy113,476 .. ASCVD=atheroscleroticcardiovasculardisease.
.
and healthy dietary practices.477 Evidence-based interventions for .. aClassofrecommendation.
smokingcessation,andimprovingPAanddiet,areconsidereduseful
... bLevelofevidence.
. andapplicableforpersonswithmentaldisorders.465,478(cid:2)480 ..
.
MentaldisordersareassociatedwithanincreasedriskofCVDand .. 4.5.1.Smokingcessation
.
aworseprognosisinpatientswithASCVD,duetoCVDeventsor .. Stoppingsmoking is potentially the most effective ofall preventive
.
other death causes, including suicide.100,113,305 Mental-health treat- .. measures,withsubstantialreductionsin(repeat)myocardialinfarc-
.
mentseffectivelyreducestresssymptomsandimprovequalityoflife. .. tionsordeath.487,488LifetimegainsinCVD-freeyearsaresubstantial
.
Severalobservationalstudiesindicatethattreatmentorremissionof .. atallages,andbenefitsareobviouslyevenmoresubstantialifother
.
depressionreducesCVDrisk.113,481(cid:2)484Psychologicalinterventions .. complicationsfromsmokingwouldbeaccountedfor.Fromage45
.
in patients with CHD may reduce cardiac mortality (RR 0.79) and .. years,gainsof3-5yearspersistinmentoage65andinwomento
.
alleviate psychological symptoms.466 Psychotherapy focusing on .. age75years(Figure11).Eveninheavysmokers(>_20cigarettes/day),
.
stressmanagementinASCVDpatientsimprovesCVDoutcomes.In .. cessation lowers CVD risk within 5 years, althoughit remains ele-
.
SUPRIM (Secondary Prevention in Uppsala Primary Health Care .. vated beyond 5 years. Total health benefits will be even larger
.
project),patientsintheinterventiongrouphada41%lowerrateof .. becauseofgaininnon-CVDhealth.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 48 ---
3274 ESCGuidelines
LIFE-CVD model
CVD-free lifetime gain from smoking cessation (in years)
< 0.5 years 0.5- 0.9 years 1.0-1.4 years 1.5 - 2.0years ≥2.0 years
Women Men
Systolic blood pressure Non-HDL cholesterol
(mmHg) 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 mmol/L 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
150 200 250 mg/dL 150 200 250
160-179 0.8 0.8 0.9 0.9 Age 0.5 0.5 0.5 0.6
(y)
140-159 0.8 0.8 0.8 0.8 0.5 0.5 0.6 0.6
90+
120-139 0.8 0.8 0.8 0.8 0.5 0.6 0.6 0.7
100-119 0.8 0.8 0.8 0.8 0.5 0.7 0.7 0.7
160-179 1.6 1.7 1.9 1.9 0.7 0.9 0.9 1.0
140-159 1.7 1.8 1.9 1.9 0.8 0.9 1.0 1.0
85-89
120-139 1.8 1.8 1.8 1.8 0.8 0.9 1.0 1.1
100-119 1.7 1.7 1.8 1.8 0.8 1.0 1.0 1.1
160-179 2.0 2.3 2.4 2.4 1.2 1.3 1.4 1.4
140-159 2.2 2.3 2.4 2.5 1.2 1.3 1.4 1.4
80-84
120-139 2.2 2.3 2.5 2.5 1.2 1.3 1.4 1.5
100-119 2.2 2.4 2.5 2.5 1.2 1.3 1.4 1.5
160-179 2.6 2.8 2.8 2.9 1.6 1.7 1.9 1.9
140-159 2.6 2.7 2.9 3.0 1.7 1.8 1.9 1.9
75-79
120-139 2.6 2.7 2.9 3.0 1.6 1.8 1.9 2.0
100-119 2.6 2.7 2.9 3.0 1.7 1.8 1.9 1.9
160-179 3.0 3.2 3.4 3.4 2.1 2.3 2.4 2.5
140-159 3.1 3.2 3.3 3.4 2.1 2.2 2.4 2.4
70-74
120-139 3.0 3.1 3.3 3.4 2.0 2.2 2.3 2.4
100-119 3.0 3.1 3.2 3.3 2.1 2.2 2.3 2.3
160-179 3.4 3.6 3.8 3.9 2.6 2.7 2.9 2.9
140-159 3.4 3.6 3.7 3.8 2.5 2.7 2.8 2.8
65-69
120-139 3.3 3.5 3.6 3.7 2.4 2.6 2.7 2.7
100-119 3.6 3.6 3.8 3.9 2.7 2.7 2.9 2.9
160-179 3.7 4.0 4.1 4.3 3.0 3.1 3.3 3.4
140-159 3.7 3.9 4.1 4.2 2.9 3.0 3.2 3.3
60-64
120-139 3.6 3.7 4.0 4.0 2.8 2.9 3.0 3.1
100-119 3.6 3.6 3.8 3.9 2.7 2.7 2.9 2.9
160-179 4.1 4.3 4.5 4.6 3.3 3.5 3.7 3.8
140-159 4.0 4.2 4.4 4.5 3.1 3.2 3.5 3.6
55-59
120-139 3.9 4.0 4.3 4.3 2.9 3.1 3.3 3.4
100-119 3.8 3.9 4.0 4.1 2.8 3.0 3.1 3.2
160-179 4.3 4.5 4.8 4.9 3.5 3.7 3.9 4.2
140-159 4.2 4.4 4.6 4.7 3.3 3.5 3.7 3.9
50-54
120-139 4.1 4.3 4.4 4.5 3.1 3.3 3.4 3.6
140-159 3.9 4.0 4.2 4.3 2.9 3.1 3.2 3.3
100-119 4.5 4.7 5.0 5.1 3.7 3.9 4.2 4.4
120-139 4.4 4.5 4.8 4.9 3.4 3.7 3.9 4.1
45-49
160-179 4.2 4.4 4.6 4.7 3.3 3.4 3.6 3.7
100-119 4.1 4.2 4.4 4.5 3.1 3.2 3.3 3.5
160-179 4.5 4.8 5.1 5.2 3.7 4.0 4.3 4.5
140-159 4.4 4.6 4.9 5.0 3.5 3.7 4.0 4.2
40-44
120-139 4.3 4.5 4.6 4.8 3.3 3.5 3.7 3.9
100-119 4.1 4.3 4.5 4.5 3.2 3.3 3.4 3.6
Figure11 Lifetimeatheroscleroticcardiovasculardiseasebenefitfromsmokingcessationforapparentlyhealthypersons,basedonthefollowingrisk
factors:age,sex,systolicbloodpressure,andnon-high-densitylipoprotein-cholesterol.Themodeliscurrentlyvalidatedforlow-andmoderate-riskcoun-
tries.CVD=cardiovasculardisease;ESC=EuropeanSocietyofCardiology;HDL-C=high-densitylipoproteincholesterol;HR=hazardratio;LIFE-CVD
=LIFEtime-perspectiveCardioVascularDisease;SBP=systolicbloodpressure.Thelifetimebenefitisexpressedas‘yearsofmedianlifeexpectancyfree
frommyocardialinfarctionorstroke’gainedfromsmokingcessation.ThelifetimebenefitiscalculatedbyestimatinglifetimeCVDriskwiththeLIFE-CVD
model76multipliedbytheHRcomparedtosustainedsmoking(0.60)fromameta-analysisofstudiesontheCVDriskofsmoking496andmultipliedbythe
HR(0.73)fornon-CVDcompetingmortality.497Forindividualizedestimationsoflifetimebenefit,thistablecanbeusedortheelectronicversionofLIFE-
CVD,assessableviatheESCCVDriskapporhttps://u-prevent.com/.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 49 ---
ESCGuidelines 3275
.
.. deliver nicotine without most of the tobacco chemicals, and are
Table9 ‘Verybriefadvice’forsmokingcessation ...
probablylessharmfulthantobacco.
.
‘Verybriefadvice’onsmokingisaproven30-secondclinicalintervention, ... Recent evidence suggests that e-cigarettes are probably more
developedintheUK,whichidentifiessmokers,advisesthemonthebest
... effectivethanNRTintermsofsmokingcessation.503(cid:2)505Thelong-
.
methodofquitting,andsupportssubsequentquitattempts.Thereare .. termeffectsofe-cigarettesonCVandpulmonaryhealth,however,
threeelementstoverybriefadvice: ... require more research.506 Dual use with cigarettes should be
.
• ASK-establishingandrecordingsmokingstatus .. avoided.Furthermore,ase-cigarettesareaddictive,theiruseshould
.
. besubjecttosimilarmarketingcontrolsasstandardcigarettes,espe-
• ADVISE-advisingonthebestwaysofstopping .
.. ciallytheflavouredvarietiesthatappealtochildren.507Despitebeing
• ACT-offeringhelp ..
. lowerintoxicantsthanregularcigarettes,‘heat-not-burn’cigarettes
.
.
. docontaintobaccoandshouldbediscouraged.
.
UK=UnitedKingdom. .
.
.
.
. 4.6. Lipids
.
.
. . This section covers recommendations for the diagnosis and treat-
Quittingmustbeencouragedinallsmokers,andpassivesmoking .
.
. mentofunfavourablebloodlipidlevels.Moredetailandguidancefor
should be avoided as much as possible. Very brief advice may be .
.
. complex cases/tertiary care, including genetic lipid disorders, are
advantageouswhentimeislimited(Table9).Amajorimpetusforces- .
.
. available in the 2019 ESC/European Atherosclerosis Society (EAS)
sation occurs at the time of diagnosis or treatment of CVD. .
.. Guidelinesforthemanagementofdyslipidaemias.3
Promptingapersontotrytoquit,briefreiterationofCVandother .
.
. Recentevidencehasconfirmedthatthekeyinitiatingeventinathe-
benefitsofquitting,andagreeingonaspecificplanwithafollow-up .
.
. rogenesisistheretentionofLDLandothercholesterol-richlipopro-
arrangementareevidence-basedinterventions. .
.
. teinswithinthearterialwall.ThecausalroleofLDL-C,andotherapo-
Smokerswhoquitmayexpectanaverageweightgainof5kg,but .
.
. B-containinglipoproteins,inthedevelopmentofASCVDisdemon-
thehealthbenefitsoftobaccocessationoutweighrisksfromweight .
.
gain.495Persistentorreuptakeofsmokingiscommoninpatientswith .. strated beyond any doubt by genetic, observational, and interven-
.
CHD,inparticularinthosewithseveredepressionandenvironmen-
... tional studies.20 Meta-analysis of clinical trials has indicated that the
tal exposures.498 Mood-management therapies may improve out- ... relativereductioninCVDriskisproportionaltotheabsolutereduc-
comesinpatientswithcurrentorpastdepression.499 ... tion of LDL-C, irrespective of the drug(s) used to achieve such
.. change,withnoevidenceofalowerlimitforLDL-Cvaluesor‘J-curve’
.
.. effect.21 The absolute benefit of lowering LDL-C depends on the
.
4.5.2.Evidence-baseddruginterventions .. absolute risk of ASCVD and the absolute reduction in LDL-C, so
.
Drugsupportforstoppingsmokingshouldbeconsideredinallsmokers .. evenasmallabsolutereductioninLDL-Cmaytranslatetosignificant
.
whoarereadytoundertakethisaction.Evidence-baseddruginterven- .. absoluteriskreductioninahigh-orvery-high-riskpatient.22Arecent
.
tionsincludenicotine-replacementtherapy(NRT),bupropion,vareni- .. LDL-Ctarget-drivenRCTinpatientsafterischaemicstrokeortransi-
.
cline, and cytisine (not widely available).489(cid:2)491 All forms of NRT .. entischaemicattack(TIA)demonstratedatargetLDL-Clevelof<1.8
.
(chewinggum,transdermalnicotinepatches,nasalspray,inhaler,sublin- .. mmol/L(70mg/dL)withtheuseofstatinand,ifrequired,ezetimibe,
.
gualtablets)areeffective.Combinationvs.single-formNRTand4mg .. wasassociatedwithalowerCVDriskthanthosewhohadatarget
.
vs.2mggumcanincreasesuccess.492NRTshowsnoadverseeffectsin .. rangeof2.3(cid:2)2.8mmol/L(90(cid:2)110mg/dL).508Studiesontheclinical
.
patientswithASCVD,493butevidenceofefficacyinthisgroupisincon- ..
safetyof(very)lowachievedLDL-Cvalueshavenotcausedparticular
.
clusive.494InpatientswithASCVD,varenicline(RR2.6),bupropion(RR ..
concerns,althoughmonitoringforlongerperiodsisrequired. .
1.4),telephonetherapy(RR1.5),andindividualcounselling(RR1.6)all ..
.
increase success rates.494 The antidepressant, bupropion, aids long- ... 4.6.1.Measurementoflipidsandlipoproteins
termsmokingcessationwithsimilarefficacytoNRT.490 ... 4.6.1.1Fastingvs.non-fastingmeasurements
Varenicline1mgb.i.d.(twiceaday)increasesquittingratesmore ... Non-fastingsamplingoflipidparametersisrecommendedforgeneral
thantwo-foldcomparedwithplacebo.491TheRRforabstinencevs. ...
riskscreening,sinceithasthesameprognosticvalueasfastingsam-
.
NRTwas1.25andvs.bupropion,1.4.Lowerorvariabledosesare .. ples.509,510Inpatientswithmetabolicsyndrome,DM,orhypertrigly-
.
also effective and reduce side-effects. Varenicline beyond the 12- .. ceridaemia, calculated LDL-C from non-fasting samples should be ..
weekstandardregimeniswelltolerated.Vareniclineinitiatedinhos- ... interpretedwithcare.
pitalfollowingACSisefficaciousandsafe.500 ..
.
.
Themainside-effectofvareniclineisnausea,butthisusuallysub- .
.
sides.Acausallinkbetweenvareniclineandneuropsychiatricadverse
.. Table10 Correspondingnon-high-densitylipoprotein
.
. cholesterolandapolipoproteinBlevelsforcommonlyused
events is unlikely.501 Varenicline, bupropion, and NRT do not ...
low-densitylipoproteincholesterolgoals
increaseseriousCVadverseeventrisksduringoraftertreatment.502 ..
.
Cytisineiseffectiveforsmokingcessation,butevidencetodateis .. LDL-C Non-HDL-C ApolipoproteinB
.
limited.491 .. 2.6mmol/L(100mg/dL) 3.4mmol/L(131mg/dL) 100mg/dL
.
.. 1.8mmol/L(70mg/dL) 2.6mmol/L(100mg/dL) 80mg/dL
.
4.5.2.1 Electroniccigarettes .. 1.4mmol/L(55mg/dL) 2.2mmol/L(85mg/dL) 65mg/dL
.
Electronic cigarettes (e-cigarettes) simulate combustible cigarettes ...
HDL-C=high-densitylipoproteincholesterol;LDL-C=low-densitylipoprotein
by heatingnicotine and other chemicalsintoa vapour. E-cigarettes . cholesterol.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 50 ---
3276 ESCGuidelines
.
.
4.6.1.2 Low-densitylipoproteincholesterolmeasurement . Asexplainedearlierintheseguidelines(section3.2.3.1),wepropose
.
.
LDL-Ccanbemeasureddirectly,butinmoststudiesandmanylabo- . astepwiseapproachtotreatmentgoals,alsoforLDL-C(Figures6(cid:2)8).
.
.
ratories,LDL-CiscalculatedusingtheFriedewaldformula: . Thisapproachmayseemnovelbut,inreality,resemblesclinicalprac-
.
.
. tice,wheretreatmentintensificationisconsideredbasedonanticipated
• Inmmol/L:LDL-C=totalcholesterol(cid:2)HDL-C(cid:2)(0.45(cid:5)trigly- ..
. benefit,side-effects,and—importantly—patientpreferences.Theulti-
cerides) ..
. matelipidgoalsare the same asinthe2019ESC/EASdyslipidaemia
• Inmg/dL:LDL-C=totalcholesterol(cid:2)HDL-C(cid:2)(0.2(cid:5)trigly- ...
Guidelines.3 Evidence from glucose-lowering treatment studies indi-
cerides) ..
. catesthatstepwisetreatmentdoesnotcompromisegoalattainment,
.
.
Thecalculationisonlyvalidwhentheconcentrationoftriglycer-
... and is associated with fewer side-effects and higher patient satisfac-
idesis<4.5mmol/L((cid:6)400mg/dL),andnotprecisewhenLDL-Cis
... tion.66,67Inspecificcases(atveryhighrisk),thephysicianmayoptto
verylow[<1.3mmol/L(50mg/dL)].InpatientswithlowLDL-Clev-
... mergebothstepsandproceeddirectlytothelowLDL-Ctargetlevel
elsand/orhypertriglyceridaemia(<_800mg/dL),alternativeformulae
... ofSTEP2.Inapparentlyhealthypeople,lifetimetreatmentbenefitof
areavailable511,512orLDL-Ccanbemeasureddirectly.
... LDL-Creductionmayplayaroleinshareddecision-making,together
.. withriskmodifiers,comorbidities,patientpreference,andfrailty.Figure
.
.. 12 may support decision-making, as it shows the estimated lifetime
4.6.1.3 Non-high-densitylipoproteincholesterol .
.. benefitsinyears-free-of-CVDinrelationtothetotalCVDriskprofile,
Thenon-HDL-CvalueiscalculatedbysubtractingHDL-Cfromtotal .
.. calibratedinlow-to-moderateCVDriskcountries.
cholesterol.Non-HDL-C,unlikeLDL-C,doesnotrequirethetrigly- .
.. AfterSTEP1,treatmentintensificationwithSTEP2mustbecon-
cerideconcentrationtobe<4.5mmol/L(400mg/dL).Italsohasan .
.. sideredinallpatients.Giventhatlowerisbetter,weencourageliberal
advantage in that it is accurate in a non-fasting setting, and may be . .. intensificationoftreatment,particularlyifsubmaximaldosesof(low-
more accurate in patients with DM. There is evidence for a role .
.
. cost)genericstatinsareusedandside-effectsarenotapparent.
of non-HDL-C as a treatment target as it captures the information .
.
regardingallapolipoprotein-B-containinglipoproteins.513Wesuggest .. ThetreatmentgoalofLDL-C<1.4mmol/L(55mg/dL)inSTEP2,
.
. inpatientswithestablishedASCVDorwithoutASCVDbutatvery
itasareasonablealternativetreatmentgoalforallpatients,particularly .
.
. highrisk,islowerthanthelowestLDL-Cgoalof1.8mmol/L(70mg/
forthosewithhypertriglyceridaemiaorDM.Hownon-HDL-Clevels ...
dL)inthe2016ESCpreventionGuidelines.2Thislowgoalwasestab-
correspondtocommonlyusedLDL-CgoalsisshowninTable10. ...
lishedbasedondatafromrecentMendelianrandomizationstudies,80
.
.
. meta-analyses from the Cholesterol Treatment Trialists’
4.6.1.4 ApolipoproteinB ...
Collaboration,21RCTssuchasIMPROVE-IT(ImprovedReductionof
ApolipoproteinBprovidesadirectestimateofthetotalconcentra- ...
Outcomes: Vytorin Efficacy International Trial),515 and—more
tion of atherogenic lipid particles, particularly in patients with ele- ..
. recently—proprotein convertase subtilisin/kexin type 9 (PCSK9)
vatedtriglycerides.However,onaverage,theinformationconferred ..
by apolipoprotein B is similar to that of calculated LDL-C.514
... inhibitorclinicaloutcomestudies.516(cid:2)518Theclassandlevelofevi-
HowapolipoproteinBlevelscorrespondtocommonlyusedLDL-C
... dencesupportingthisLDL-Ctargetof<1.4mmol/L(55mg/dL)for
goalsisshowninTable10.
... patientswithASCVDisidenticaltothatintherecentESC/EASdysli-
.. pidaemia guidelines.3 For primary prevention in very-high-risk
.
.. patients,however,theclassofrecommendationislower(ClassIin
.
4.6.2.Defininglipidgoals .. the dyslipidaemia guidelines, Class IIa in the current guidelines),
.
4.6.2.1 Low-densitylipoproteincholesterolgoals .. becausetheTaskForcewaslessunanimouswithregardstothislow
.
Recommendationonlow-densitylipoproteincholes- .. LDL-Ctargetintheprimarypreventioncontext. .
terolgoalsa .. ForpatientswithASCVDwhoexperienceasecondvascularevent
.
Recommendation Classb Levelc .. within2years(notnecessarilyofthesametypeasthefirst)whiletak-
.
Astepwisetreatment-intensificationapproachis ... ingmaximumtoleratedstatin-basedtherapy,anevenlowerLDL-C
recommendedforapparentlyhealthypeopleat ... goal of <1.0 mmol/L (40 mg/dL) may be considered. Importantly,
. highorveryhighCVDrisk,aswellaspatients .. there are no differences in the RR reductions between men and
.
withestablishedASCVDand/orDMwithcon- I C .. womenandbetweenyoungerandolderpatients(atleastuptoage
siderationofCVDrisk,treatmentbenefit,risk
... 75years),orbetweenthosewithandwithoutDM.3
.
modifiers,comorbidities,andpatient ..
.
preferences. .. 4.6.2.2Triglyceride-richlipoproteinsandtheirremnants
.
. Therearenotreatmentgoalsfortriglycerides,but<1.7mmol/L(150
.
ASCVD=atheroscleroticcardiovasculardisease;DM=diabetesmellitus. .. mg/dL) is considered to indicate lower risk, whereas higher levels
aRecommendationfromsection3.2. ..
. indicateaneedtolookforotherriskfactors.
bClassofrecommendation. ..
cLevelofevidence. ..
.
. 4.6.2.3High-densitylipoproteincholesterol
.
.
LDL-Cgoalsaresummarizedintherecommendationsbelow.Asnot . Todate,nospecificgoalsforHDL-Clevelshavebeendeterminedin
.
.
alldrugsaretoleratedoravailable/affordable,treatmentshouldfocus . clinicaltrials,althoughlowHDL-Cisassociatedwith(residual)riskin
.
.
on achieving LDL-C levels as close as possible to the given goals. .. ASCVD patients. PA and other lifestyle factors, rather than drug
.
Treatment should be a shared decision-making process between .. treatment,remainimportantmeansofincreasingHDL-Clevels.
.
physiciansandthepatient. .
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 51 ---
ESCGuidelines 3277
LIFE-CVD model < 0.5years 1.5 - 2.0years
CVD-free lifetime gain from 1 mmol/L 0.5 - 0.9years ≥2.0 years
LDL-C reduction (in years) 1.0 - 1.4years
Women Men
Non-smoking Smoking Non-smoking Smoking
Non-HDL cholesterol
prS ey ss st uo rl eic
(
mblo mo Hd
g)
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 mmol/L 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
150200250 150200250 mg/dL 150200250 150200250
160-179 0.3 0.4 0.4 0.4 0.1 0.1 0.2 0.2 Age 0.2 0.3 0.3 0.3 0.1 0.0 0.1 0.1
(y)
140-159 0.3 0.3 0.4 0.4 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.0 0.0 0.0 0.0
90+
120-139 0.2 0.3 0.3 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.0 0.0 0.1
100-119 0.2 0.2 0.2 0.2 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1
160-179 0.8 0.8 0.9 0.9 0.2 0.2 0.3 0.4 0.4 0.5 0.5 0.5 0.1 0.1 0.1 0.2
140-159 0.6 0.7 0.8 0.8 0.1 0.2 0.2 0.3 0.3 0.4 0.5 0.5 0.1 0.1 0.1 0.1
85-89 120-139 0.5 0.6 0.7 0.7 0.1 0.2 0.2 0.2 0.3 0.4 0.4 0.4 0.0 0.0 0.1 0.1
100-119 0.4 0.4 0.5 0.6 0.0 0.1 0.1 0.1 0.2 0.2 0.3 0.3 0.0 0.0 0.0 0.1
160-179 1.0 1.1 1.2 1.3 0.2 0.4 0.4 0.5 0.5 0.6 0.7 0.7 0.1 0.2 0.2 0.2
140-159 0.9 1.0 1.1 1.1 0.2 0.3 0.3 0.4 0.4 0.5 0.6 0.7 0.1 0.1 0.2 0.2
80-84
120-139 0.7 0.8 0.9 1.0 0.2 0.2 0.3 0.2 0.4 0.4 0.5 0.5 0.0 0.1 0.1 0.1
100-119 0.5 0.6 0.7 0.8 0.1 0.1 0.2 0.2 0.2 0.3 0.4 0.4 0.0 0.0 0.0 0.1
160-179 1.2 1.3 1.4 1.4 0.4 0.5 0.5 0.6 0.7 0.8 0.9 1.0 0.2 0.2 0.3 0.3
140-159 1.0 1.2 1.3 1.4 0.2 0.3 0.5 0.5 0.6 0.6 0.7 0.9 0.2 0.2 0.3 0.3
75-79
120-139 0.8 1.0 1.1 1.2 0.2 0.2 0.3 0.4 0.4 0.5 0.6 0.7 0.1 0.2 0.2 0.2
100-119 0.6 0.8 0.9 1.0 0.2 0.2 0.2 0.3 0.3 0.4 0.5 0.6 0.1 0.1 0.2 0.1
160-179 1.3 1.4 1.5 1.6 0.5 0.6 0.7 0.8 0.8 0.9 1.1 1.1 0.3 0.4 0.5 0.5
140-159 1.1 1.3 1.4 1.5 0.4 0.5 0.6 0.6 0.7 0.8 1.0 1.0 0.2 0.3 0.4 0.4
70-74
120-139 0.9 1.1 1.3 1.3 0.2 0.3 0.5 0.5 0.5 0.6 0.7 0.9 0.2 0.2 0.3 0.4
100-119 0.7 0.9 1.0 1.1 0.2 0.3 0.3 0.3 0.4 0.5 0.6 0.6 0.1 0.2 0.3 0.2
160-179 1.3 1.5 1.6 1.7 0.6 0.7 0.9 0.9 0.9 1.1 1.2 1.3 0.5 0.5 0.7 0.7
140-159 1.2 1.4 1.5 1.6 0.5 0.6 0.7 0.7 0.8 1.0 1.0 1.1 0.4 0.5 0.5 0.6
65-69
120-139 1.0 1.2 1.4 1.5 0.3 0.5 0.5 0.6 0.6 0.8 0.8 1.0 0.3 0.4 0.4 0.4
100-119 0.9 1.0 1.2 1.3 0.3 0.4 0.4 0.6 0.5 0.7 0.7 0.8 0.3 0.4 0.5 0.4
160-179 1.4 1.6 1.7 1.8 0.6 0.8 0.9 1.1 1.1 1.2 1.4 1.4 0.6 0.7 0.9 0.9
140-159 1.3 1.4 1.6 1.7 0.5 0.7 0.8 0.9 0.8 1.0 1.2 1.2 0.5 0.6 0.7 0.8
60-64
120-139 1.1 1.3 1.5 1.6 0.4 0.5 0.7 0.7 0.7 0.8 1.0 1.1 0.4 0.5 0.6 0.6
100-119 0.9 1.0 1.2 1.3 0.3 0.4 0.4 0.6 0.5 0.7 0.7 0.8 0.3 0.4 0.5 0.4
160-179 1.5 1.7 1.8 1.9 0.8 1.0 1.1 1.2 1.1 1.3 1.4 1.6 0.8 0.9 1.0 1.1
140-159 1.3 1.6 1.7 1.8 0.6 0.8 0.9 1.1 0.9 1.1 1.3 1.4 0.6 0.7 0.8 0.9
55-59
120-139 1.1 1.3 1.5 1.6 0.5 0.6 0.8 0.8 0.7 0.9 1.1 1.2 0.4 0.6 0.7 0.8
100-119 0.9 1.1 1.3 1.4 0.4 0.4 0.6 0.6 0.6 0.6 0.8 0.9 0.3 0.5 0.5 0.6
160-179 1.5 1.7 1.8 1.9 0.9 1.0 1.3 1.4 1.2 1.4 1.5 1.6 0.9 1.0 1.2 1.3
140-159 1.4 1.5 1.8 1.9 0.7 0.9 1.1 1.1 1.0 1.2 1.3 1.5 0.7 0.8 0.9 1.1
50-54
120-139 1.2 1.4 1.6 1.7 0.6 0.7 0.8 0.9 0.8 1.0 1.1 1.2 0.6 0.7 0.7 0.8
140-159 0.9 1.1 1.3 1.5 0.4 0.5 0.6 0.7 0.6 0.7 0.9 1.0 0.4 0.5 0.6 0.6
100-119 1.5 1.7 1.9 2.0 0.9 1.1 1.3 1.4 1.2 1.4 1.6 1.6 0.9 1.1 1.3 1.4
120-139 1.4 1.5 1.7 1.8 0.8 0.9 1.1 1.2 1.0 1.2 1.4 1.5 0.7 0.9 1.1 1.2
45-49 160-179 1.2 1.4 1.6 1.7 0.6 0.7 0.9 0.9 0.8 1.0 1.1 1.3 0.6 0.7 0.9 0.9
100-119 0.9 1.2 1.4 1.5 0.5 0.6 0.7 0.8 0.6 0.8 0.9 1.0 0.5 0.6 0.6 0.8
160-179 1.6 1.7 1.9 2.0 0.9 1.1 1.3 1.4 1.3 1.4 1.6 1.7 0.9 1.2 1.4 1.5
140-159 1.4 1.5 1.7 1.8 0.8 0.9 1.1 1.2 1.0 1.2 1.4 1.5 0.8 0.9 1.1 1.3
40-44
120-139 1.2 1.4 1.6 1.7 0.6 0.8 0.9 1.0 0.8 1.0 1.1 1.3 0.6 0.8 0.9 1.0
100-119 1.0 1.2 1.4 1.5 0.5 0.6 0.7 0.8 0.6 0.8 0.9 1.0 0.5 0.6 0.7 0.8
Figure12 Averageyears-free-of-cardiovasculardiseasegainedper1mmol/L(40mg/dL)low-densitylipoproteincholesterolreductioninapparently
healthypersons.Themodeliscurrentlyvalidatedforlow-andmoderate-riskcountries.Lifetimebenefitof1mmol/LLDL-Cloweringforapparently
healthypersons,basedonthefollowingriskfactors:age,sex,currentsmoking,SBP,andnon-HDL-C.Thelifetimebenefitisexpressedas‘yearsofmedian
lifeexpectancyfreefrommyocardialinfarctionorstroke’gainedfrom1mmol/LLDL-Clowering.For2mmol/LLDL-Clowering,theaverageeffectis
almosttwiceaslarge,andsoon.ThelifetimebenefitiscalculatedbyestimatinglifetimeCVDriskwiththeLIFE-CVDmodel76multipliedbytheHR(0.78)
fromameta-analysisoftheeffectoflipidlowering.22Forindividualizedestimationsoflifetimebenefit,thistablecanbeusedortheelectronicversionof
LIFE-CVD,assessableviatheESCCVDriskapporhttps://u-prevent.com/.CVD=cardiovasculardisease;ESC=EuropeanSocietyofCardiology;HDL-C
= high-density lipoprotein cholesterol; HR = hazard ratio; LDL-C = low-density lipoprotein cholesterol; LIFE-CVD = LIFEtime-perspective
CardioVascularDisease;SBP=systolicbloodpressure.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 52 ---
3278 ESCGuidelines
Intensity of lipid-lowering treatment
Treatment Average LDL-C reduction
Moderate-intensity statin 30%
High-intensity statin 50%
High-intensity statin plus ezetimibe 65%
PCSK9 inhibitor 60%
PCSK9 inhibitor plus high-intensity statin 75%
PCSK9 inhibitor plus high-intensity statin plus ezetimibe 85%
Figure13 Expectedlow-densitylipoproteincholesterolreductionsforcombinationtherapies.LDL-C=low-densitylipoproteincholesterol;PCSK9=
proproteinconvertasesubtilisin/kexintype9.AdaptedfromMachetal.3
.
. 4.6.3.Strategiestocontroldyslipidaemias . approved in several European countries. Results from the ASCVD
.
.
Thepresenceofdyslipidaemiassecondarytootherconditionsmust . outcomestrialareexpectedfor2023.
.
.
beexcludedbeforebeginningtreatment,astreatmentofunderlying . The expected LDL-C reductions in response to therapy are
.
.
disease may improve hyperlipidaemia without requiring lipid- . shown in Figure 13, and may vary widely among individuals.
.
.
lowering therapy. This is particularly true for hypothyroidism. .. Therefore,monitoringtheeffectonLDL-Clevelsisrecommended,
.
Secondarydyslipidaemiascanalsobecausedbyalcoholabuse,DM, .. with assessment of LDL-C levels 4-6 weeks after any treatment
.
Cushing’ssyndrome,diseasesoftheliverandkidneys,aswellasby .. strategyinitiationorchange.
.
drugs(e.g.corticosteroids).Inaddition,lifestyleoptimizationiscrucial ..
.
inallpatientswithhigherthanoptimallipidlevels. .. Recommendationsforpharmacologicallow-densitylip-
.
. oproteincholesterolloweringforthose<70yearsofage
.
.
4.6.3.1 Strategiestocontrollow-densitylipoproteincholesterol . (forrecommendationsforpersonsaged(cid:3)70years,see
.
.. respectiverecommendationstables).
.
.
4.6.3.1.1. Diet and lifestyle modifications. Dietaryfactorsinfluence ...
Recommendations Classa Levelb
thedevelopmentofASCVD,eitherdirectlyorthroughtheiraction ..
.
ontraditionalriskfactors,suchasplasmalipids,BP,orglucoselevels. .. Itisrecommendedthatahigh-intensitystatinis
.
Consistent evidence from epidemiological studies indicates that .. prescribeduptothehighesttolerateddoseto
. I A
higher consumption of fruit, non-starchy vegetables, nuts, legumes, .. reachtheLDL-Cgoalssetforthespecificrisk
.
fish, vegetable oils, yoghurt, and wholegrains, along with a lower .. group.21,520,521
.
intakeofredandprocessedmeats,foodshigherinrefinedcarbohy- .. AnultimatecLDL-Cgoalof<1.4mmol/L(55mg/
. drates,andsalt,isassociatedwithalowerincidenceofCVevents.519 .. dL)andLDL-Creductionof>_50%frombaseline
.. IIa C
Moreover, the replacement of animal fats, including dairy fat, with . shouldbeconsideredinapparentlyhealthypersons
.
vegetable sources of fats and PUFAs may decrease the risk of .. <70yearsatveryhighrisk.21,22,522
.
ASCVD.407Moredetailonlifestylerecommendationscanbefound ... AnultimatecLDL-Cgoalof<1.8mmol/L(70
.
earlierinthissection. .. mg/dL)andLDL-Creductionof>_50%from
. IIa C
.. baselineshouldbeconsideredinapparently
.
4.6.3.1.2. Drugs for treatment of dyslipidaemias. The currently .. healthypersons<70yearsathighrisk.21,22,522
. availablelipid-loweringdrugsincludeinhibitorsof3-hydroxy-3-meth- .. InpatientswithestablishedASCVD,lipid-lowering
.
ylglutaryl-coenzymeAreductase(statins),fibrates,bileacidseques- .. treatmentwithanultimatecLDL-Cgoalof<1.4
trants, selective cholesterol absorption inhibitors (e.g. ezetimibe),
...
mmol/L(55mg/dL)anda>_50%reductioninLDL-
I A
.
and—more recently—PCSK9 inhibitors. Bempedoic acid, an oral .. Cvs.baselineisrecommended.21,508,515(cid:2)517,522
.
cholesterolsynthesisinhibitor,hasrecentlybeenapprovedinseveral ...
Ifthegoalsarenotachievedwiththemaximum
countries.Usageismainlyintendedincombinationwithezetimibein ...
tolerateddoseofastatin,combinationwitheze- I B
patients with statin intolerance. ASCVD outcome trials are not ... timibeisrecommended.515
expectedbeforetheendof2022.Additionally,inclisiran,anewsmall ..
. Forprimarypreventionpatientsatveryhighrisk,
interferingribonucleicacid,hasshowntoreduceLDL-Cby50(cid:2)55% ..
. butwithoutFH,iftheLDL-Cgoalisnot
when applied subcutaneously twice a year. These results were ..
. achievedonamaximumtolerateddoseofasta- IIb C
.
obtained either on top of statin or without other lipid-lowering .
. tinandezetimibe,combinationtherapyincluding
.
therapies, and with almost no side-effects. Inclisiran has been .
aPCSK9inhibitormaybeconsidered.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 53 ---
ESCGuidelines 3279
.
.
. pharmacological therapy for concomitant conditions. In practice,
Forsecondarypreventionpatientsnotachieving .
.
. managementofapatientwithmyalgiabutwithoutamajorincreasein
theirgoalsonamaximumtolerateddoseofa .
.
. creatinekinaseisbasedontrialanderror,andusuallyinvolvesswitch-
statinandezetimibe,combinationtherapy I A .
.
. ing toa differentstatin oruseofa verylow dosage severaldays a
includingaPCSK9inhibitoris .
.
recommended.516,517 .. week, witha gradualincrease infrequencyand dosage. A manage-
.. mentalgorithmmayhelptomanagethesepatients.3
Forvery-high-riskFHpatients(thatis,with ..
.
ASCVDorwithanothermajorriskfactor)who ..
donotachievetheirgoalsonamaximumtoler-
... 4.6.3.1.4. Cholesterolabsorptioninhibitors(ezetimibe).Thecom-
ateddoseofastatinandezetimibe,combination
I C ... binationofstatinwithezetimibebringsabenefitthatisinlinewith
therapyincludingaPCSK9inhibitoris
... meta-analysesshowingthatLDL-Creductionhasbenefitsindepend-
recommended.
... entoftheapproachused.3,21Thebeneficialeffectofezetimibeisalso
.. supported by genetic studies.528 Together, these data support the
Ifastatin-basedregimenisnottoleratedatany .
.. positionthatezetimibeshouldbeconsideredassecond-linetherapy,
dosage(evenafterrechallenge),ezetimibe IIa B .
shouldbeconsidered.515,523(cid:2)525
... eitherontopofstatinswhenthetherapeuticgoalisnotachieved,or
.
. whenastatincannotbeprescribed.
Ifastatin-basedregimenisnottoleratedatany ..
.
dosage(evenafterrechallenge),aPCSK9inhibitor IIb C ..
. 4.6.3.1.5. Proprotein convertase subtilisin/kexin type 9 inhibitors.
addedtoezetimibemaybeconsidered.523,524,526 ..
. PCSK9inhibitors(monoclonalantibodiestoPCSK9)decreaseLDL-C
.
Ifthegoalisnotachieved,statincombination .
IIb C .. byupto60%,eitherasmonotherapyorinadditiontothemaximum
withabileacidsequestrantmaybeconsidered. .
. tolerateddoseofstatinand/orotherlipid-loweringtherapies,suchas
.
Statintherapyisnotrecommendedin ..
ezetimibe.Their efficacyappears to be largelyindependent of back-
.
premenopausalfemalepatientswhoareconsid-
III C
...
groundtherapy.Incombinationwithhigh-intensityormaximumtoler-
eringpregnancyorarenotusingadequate ..
atedstatins,alirocumabandevolocumabreducedLDL-Cby46(cid:2)73%
.
contraception. .. morethanplacebo,andby30% morethanezetimibe.516,517Among
.
.
. patients in whom statins cannot be prescribed, PCSK9 inhibition
ASCVD=atheroscleroticcardiovasculardisease;FH=familialhypercholestero- .
.
laemia;LDL-C=low-densitylipoproteincholesterol;PCSK9=proproteincon- .. reducedLDL-Clevelswhenadministeredincombinationwithezeti-
v aCer lata ssse os fu rb et ci olis min m/k ee nx din att ioyp ne
.
9. .... mibe.529 Both alirocumab and evolocumab effectively lower LDL-C
bLevelofevidence. ... levelsinpatientswhoareathighorveryhighCVDrisk,includingthose
cAstepwiseapproachtoLDL-Ctargetsisrecommended;seesection3.2.3.1and .. with DM, with a large reduction in future ASCVD events.516,517
.
Figures6and7. .. PCSK9inhibitorsalsolowertriglycerides,raiseHDL-Candapolipo-
Adaptedfrom3 .
.. proteinA-I,andlowerlipoprotein(a),althoughtherelativecontribu-
.
.. tionsoftheselipidmodificationsremainunknown.PCSK9inhibitors
.
4.6.3.1.3. Statins.StatinsdecreaseLDL-C,therebyreducingASCVD .. arecostly,andtheircost-effectiveness,long-termsafety,andeffectin
.
morbidityandmortalityaswellastheneedforcoronaryarteryinter- .. primarypreventionareasyetunknown.Werecommendconsidering
.
ventions.Statinsalsolowertriglycerides,andmayreducepancreatitis .. cost-effectivenessinaloco-regionalcontextbeforeimplementingrec-
.
risk. Therefore, they are the drug of first choice in patients at .. ommendationsthatinvolvetheiruse.Recommendationsfortheuseof
increasedriskofASCVD.3 ..
. PCSK9inhibitorsaredescribedintheRecommendationsforpharma-
.
.
. cologicalLDL-Clowering.Inclisiranisalong-actinghepaticPCSK9syn- .
4.6.3.1.3.1. Adverse effects, interactions, and adherence to statin .. thesisinhibitorthatalsolowersLDL-Clevelsconsiderably.530Itseffect
.
therapy .. onclinicaloutcomesremainstobeestablished.
.
Themostfrequentadverseeffectofstatintherapyismyopathy,but ..
.
thisisrare.Ameta-analysisruledoutanycontributiontoanincrease .. 4.6.3.2Strategiestocontrolplasmatriglycerides
.
innon-CVmortality.522IncreasedbloodsugarandHbA1clevels(i.e. .. AlthoughCVD risk is increased when fastingtriglycerides are >1.7
.
increasedriskoftype2DM)canoccuraftertreatmentinitiationand .. mmol/L(150mg/dL),531theuseofdrugstolowertriglyceridelevels
.
aredosedependent,inpartlinkedtoslightweightgain,butthebene- .. mayonlybeconsideredinhigh-riskpatientswhentriglyceridesare
. fits of statins outweigh the risks for the majority of patients.527 .. >2.3mmol/L(200mg/dL)andtriglyceridescannotbeloweredbylife-
.
Adheringtolifestylechangeswhenprescribedastatinshouldlessen .. stylemeasures.The available pharmacologicalinterventionsinclude
.
theriskofDM.Increasedlevelsofliverenzymesmayoccurduring .. statins,fibrates,PCSK9inhibitors,andn-3PUFAs(inparticularicosa-
.
.
statintherapy,andareusuallyreversible.Routinemonitoringofliver . pentethylindosesof2(cid:2)4g/day;seesection4.3.2.4.4).
.
.
enzymevaluesisnotindicated. . Recommendationsforthetreatmentofhypertriglyceridaemiaare
.
.
Although5(cid:2)10%ofpatientsreceivingstatinscomplainofmyalgia, . shownintheRecommendationsbelow.
.
inmostcasesitisnotattributabletostatins.3Theriskofmyopathy ..
.
.
(severemuscularsymptoms)canbeminimizedbyidentifyingvulner- . 4.6.3.2.1. Fibrates.Fibratesareusedprimarilyfortriglyceridelower-
.
.
ablepatientsand/orbyavoidingstatininteractionswithspecificdrugs. .. ingand,occasionally,forincreasingHDL-C.Evidencesupportingthe
.
Rhabdomyolysis is extremely rare. As statins are prescribed on a .. useofthesedrugsforCVDeventreductionislimited,andgiventhe
.
long-termbasis,possibleinteractionswithotherdrugsdeservepar- .. strongevidencefavouringstatins,routineuseofthesedrugsinCVD
.
ticular and continuous attention, as many patients will receive . prevention is not recommended.3 To prevent pancreatitis, when
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 54 ---
3280 ESCGuidelines
.
.
triglyceridesare>10mmol/L(900mg/dL),theymustbereducednot .. RecentevidencehasstrengthenedtheroleofLDL-CasanASCVD
.
onlyby drugs, but alsoby restrictionofalcohol,treatmentofDM, .. riskfactorinolderpatients.537Evidencefromtrialsindicatesthatstatins
.
withdrawalofoestrogentherapy,etc.Inpatientswithsevereprimary .. andotherlipid-loweringdrugsproducesignificantreductionsinmajor
.
hypertriglyceridaemia,referraltoaspecialistmustbeconsidered. .. vasculareventsirrespectiveofage.538,539However,thereislessdirect
.
An evidence-based approach to the use of lipid-lowering nutra- .. evidenceofstatinbenefitinthosewithoutevidenceofASCVD.Under
.
ceuticalscouldimprovethequalityofthetreatment,includingther- .. theageof70years,statinsarerecommendedforprimaryprevention
.
apy adherence, and achievement of the LDL-C goal in clinical .. dependingonthelevelofrisk.Abovethatage,initiationofstatintreat-
.
practice.However,ithastobeclearlystressedthattherearestillno .. mentforprimarypreventionmaybeconsideredwhenat(very)high
.
outcomestudiesprovingthatnutraceuticalscanpreventCVDmor- .. risk, but we explicitly recommend also taking other arguments into
.
bidityormortality.532 .. account, such as risk modifiers, frailty, estimated life-time benefit,
.
.
. comorbidities, and patient preferences (see section 3.2.3.3 and Figure
.
.
. 12).Incaseofrenalfunctionimpairmentorriskfordruginteractions,
.
.
4.6.4.Importantgroups . thestatindoseshouldbeup-titratedcarefully.IntermsofLDL-Ctar-
.
Recommendationsfordrugtreatmentsofpatientswith .. gets,thereisinsufficientevidencetosupporttargetsforprimarypre- .
hypertriglyceridaemia. .
. ventioninolderpatients.AlthoughtheconventionalLDL-Ctargetof
.
.
. <2.6mmol/L(100mg/dL)mayseemreasonable,theresultsofongoing
Recommendations Classa Levelb ..
. primarypreventiontrialsinolderpatientsmustbeawaited[STAREE
.
.
Statintreatmentisrecommendedasthefirst . (STAtinTherapyforReducingEventsintheElderly)trial;clinicatrials.
.
.
drugofchoiceforreducingCVDriskinhigh-risk . gov registration: NCT02099123]. Frailty, polypharmacy, and muscle
I A ..
individualswithhypertriglyceridaemia[triglycer- .. symptomsremainrelevantfactorstoconsiderinolderpatients.
.
ides>2.3mmol/L(200mg/dL)].533 ..
.
InpatientstakingstatinswhoareatLDL-Cgoal .. Recommendationsforthetreatmentofdyslipidaemias
.
withtriglycerides>2.3mmol/L(200mg/dL),fenofi- IIb B .. inolderpeople((cid:3)70years).
.
brateorbezafibratemaybeconsidered.534(cid:2)536 ..
Inhigh-risk(orabove)patientswithtriglycerides
... Recommendations Classa Levelb
.
>1.5mmol/L(135mg/dL)despitestatintreat- ... Treatmentwithstatinsisrecommendedfor
mentandlifestylemeasures,n-3PUFAs(icosa- IIb B ... olderpeoplewithASCVDinthesamewayas I A
.
pentethyl2(cid:5)2g/day)maybeconsideredin .. foryoungerpatients.538,539
combinationwithastatin.84 ..
. Initiationofstatintreatmentforprimarypreven-
.
CVD = cardiovascular disease; LDL-C = low-density lipoprotein cholesterol; ... tioninolderpeopleaged>_70maybeconsid- IIb B
PUFA=polyunsaturatedfattyacid. .. ered,ifathighriskorabove.538,539
.
aClassofrecommendation. .
bLevelofevidence. ... Itisrecommendedthatthestatinisstartedata
Adaptedfrom3 .. lowdoseifthereissignificantrenalimpairment I C
.
.. and/orthepotentialfordruginteractions.
4.6.4.1 Women ..
.
The proportional reductions per mmol/L reduction in LDL-C in .. ASCVD=atheroscleroticcardiovasculardisease.
majorvascularevents,majorcoronaryevents,coronaryrevasculari-
.... a bC Lela vs es lo of fr ee vc ido em nm cee .ndation.
zation,andstrokearesimilarinwomenandmen.Inaddition,therela- .. Adaptedfrom3
.
tive effects of non-statin drugs that lower LDL-C (ezetimibe and ..
.
. 4.6.4.3Diabetesmellitus
PCSK9inhibitors,ontopofhigh-intensitystatintherapy)arealsosim- .
.
ilarinbothwomenandmen.3 .. Lowering of LDL-C in patients with DM is consistently associated
.
. with lower CVD risk. Similar to prevention in apparently healthy
.
4.6.4.2 Olderpatients((cid:3)70years) .. individuals, we propose a stepwise approach to lipid control,
.
Comparedtothe2019ESC/EASdyslipidaemiaguidelines,3wepro- .. dependent on risk, estimated lifetime benefit, comorbidities, and
.
videasinglecut-offforidentifying‘olderpersons’asthose>_70years .. patientpreferences(Figure8).PCSK9inhibitorscanalsobeusedin
. .
ofage,asopposedto75years,forreasonsofconsistencywithother . patientswithDMnotreachingtheirLDL-Ctargetswithstatinsand/
.
.
partsofthecurrentguidelines.Asaresult,classandlevelofevidence . orezetimibe.
.
.
havebeenmodifiedinsomeagegroups,inparticularthecategoryof .
.. Recommendationsforthetreatmentofdyslipidaemias
patients between 70 and 75 years. Although a single age cut-off is .
. indiabetesmellitus.
.
nowused,itisimportanttostressthatallsuchagecut-offsarerela- .
.
.
tivelyarbitrary,andbiologicalageinfluencesthisthresholdinclinical .. Recommendations Classa Levelb
.
practice.Forexample,averyfit75-year-oldpersonmayqualifyfora .
.
treatmentnormallyreservedforthose<70and,conversely,avery
.. Inpatientswithtype2DMatveryhighrisk(e.g.
.
frail 65-year-old person should sometimes be considered ‘older’.
.. withestablishedASCVDand/orsevereTODc),
.
General recommendations for lipid-lowering treatment in older
... intensivelipid-loweringtherapy,ultimatelydaim-
I A
patientsaresummarizedbelow.
... ingat>_50%LDL-CreductionandanLDL-Cof
.. <1.4mmol/L(55mg/dL)is
recommended.21,22,522,540,541
Continued
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 55 ---
ESCGuidelines 3281
.
Inpatientswithtype2DM>40yearsathigh .. Table11 DutchLipidClinicNetworkdiagnosticcriteria
.
risk,lipid-loweringtreatmentwithanultimate . forfamilialhypercholesterolaemia
.
.
LDL-Cgoalof>_50%LDL-Creductionandan I A .
.. Criteria(chooseonlyonescorepergroup,the Points
LDL-Cof<1.8mmol/L(70mg/dL)is .
. highestapplicable;diagnosisisbasedonthetotal
recommended.540,541 ...
numberofpointsobtained)
.
Statintherapymaybeconsideredinpersons .. 1)Familyhistory
.
aged<_40yearswithtype1ortype2DMwith .. First-degreerelativewithknownpremature(menaged 1
.
evidenceofTODand/oranLDL-Clevel>2.6 IIb C .. <55years;women<60years)coronaryorvasculardis-
.
mmol/L(100mg/dL),aslongaspregnancyisnot .. ease,orfirst-degreerelativewithknownLDL-Cabove
.
beingplanned. .. the95thpercentile
.
.
IftheLDL-Cgoalisnotreached,statin .. First-degreerelativewithtendinousxanthomataand/or 2
.
combinationwithezetimibeshouldbe IIa B .. arcuscornealis,orchildrenaged<18yearswithLDL-C
considered.515,542 ...
abovethe95thpercentile
.
.
ASCVD=atheroscleroticcardiovasculardisease;DM=diabetesmellitus;eGFR .. 2)Clinicalhistory
.
=estimatedglomerularfiltrationrate;LDL-C=low-densitylipoproteincholes- .. Patientwithpremature(menaged<55years;women 2
t aCer lo asl; sT oO frD ec= omta mrg ee nt do ar tg ioan n.damage. ....
<60years)CAD
bLevelofevidence. .. Patientwithpremature(menaged<55years;women 1
.
cSevereTODinthisspecificcontextincludeseGFR<45mL/min/1.73m2;eGFR ..
<60years)cerebralorperipheralvasculardisease
46(cid:2)79mL/min/1.73m2plusmicroalbuminuria;proteinuria;presenceofmicro- ..
vasculardiseaseinatleastthreedifferentsites(e.g.albuminuriaplusretinopathy .. 3)Physicalexamination
.
plusneuropathy).SeeTable4fordetails. .. Tendinousxanthomata 6
dAstepwiseapproachtoLDL-Ctargetsisrecommended;seesection3.2.3.1and ..
Figure8. .. Arcuscornealisbeforeage45years 4
Adaptedfrom3 .. 4)LDL-Clevels(withouttreatment)
.
.
.. LDL-C>_8.5mmol/L(326mg/dL) 8
.
.
. LDL-C6.5(cid:2)8.4mmol/L(251(cid:2)325mg/dL) 5
4.6.4.4 Chronickidneydisease ..
PatientswithCKDareathighorveryhighriskofASCVD,andhavea
... LDL-C5.0(cid:2)6.4mmol/L(191(cid:2)250mg/dL) 3
characteristic dyslipidaemia (high triglycerides, normal LDL-C, and
... LDL-C4.0(cid:2)4.9mmol/L(155(cid:2)190mg/dL) 1
.
low HDL-C). Statin therapy or statin therapy in combination with .. 5)DNAanalysis
.
ezetimibe(whichallowslargerLDL-Creductionswithoutincreasing .. FunctionalmutationintheLDLR,apolipoproteinB,or 8
.
the statin dose) has a beneficial effect on ASCVD outcomes in .. PCSK9genes
.
CKD.543Forpatientswithend-stagerenaldisease,however,werec- .. A‘definite’FHdiagnosisrequires>8points
.
.
ommend that hypolipidaemic therapy should not be initiated (see . A‘probable’FHdiagnosisrequires6(cid:2)8points
.
.
Recommendationsbelow).IfpatientswithCKDalreadyonahypoli- .. A‘possible’FHdiagnosisrequires3(cid:2)5points
.
pidaemictherapyenterend-stagerenaldisease,thetherapymaybe .
. CAD=coronaryarterydisease;DNA=deoxyribonucleicacid;FH=familialhyper-
.
maintained. .. cholesterolaemia;LDL-C=low-densitylipoproteincholesterol;LDLR=low-density
.. lipoproteinreceptor;PCSK9=proproteinconvertasesubtilisin/kexintype9.
.
Recommendationsforlipidmanagementinpatients ..
.
withmoderate-to-severechronickidneydisease(Kidney .
. DiseaseOutcomesQualityInitiativestages3(cid:2)5). .. 4.6.4.5FamilialHypercholesterolaemia
.
.
. Patientswhocouldhavegeneticdyslipidaemias,suchasheterozygous
Recommendations Classa Levelb ..
. FH,canbeidentifiedbyextremelipidabnormalitiesand/orfamilyhis- .
.
Theuseofstatinsorstatin/ezetimibecombina- .. tory (Table 11). An LDL-C >4.9 mmol/L (190 mg/dL) in therapy-
.
tionisrecommendedinpatientswithnon-dialy- I A .. na¨ıvepatientsrequirescarefulevaluationforpossibleFH.However,
.
sis-dependent,stage3(cid:2)5CKD.525,544,545 .. inthepresenceofprematureASCVDorfamilyhistory,possibleFH
.
Inpatientsalreadyonstatins,ezetimibe,orasta-
.. shouldbeconsideredatlowerLDL-Clevels.Besidesgenetictesting
.
tin/ezetimibecombinationatthetimeofdialysis
.. (notalwaysaffordable),useoftheDutchClinicalLipidNetworkcri-
initiation,continuationofthesedrugsshouldbe
IIa C ...
teria (Table 11) is recommended to identify possible FH.
.
considered,particularlyinpatientswithASCVD.
... HomozygousFHisrareandshouldalwaysbeplacedunderthecare
Inpatientswithdialysis-dependentCKDwho
... oflipidexperts.
arefreeofASCVD,commencingstatintherapy III A
... TreatmentguidelinesforpeoplewithFHcanbefoundinthe2019
isnotrecommended.546,547
... ESC/EASdyslipidaemiaGuidelines.3
.
.
.
ASCVD=atheroscleroticcardiovasculardisease;CKD=chronickidneydisease. .. 4.7. Blood pressure
aClassofrecommendation. ..
bLevelofevidence. ..
.
Adaptedfrom3 .. Hypertension is one of the most important preventable causes of
.
. prematuremorbidityandmortality.Itaffectsmorethan150million
1202
CSE
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 56 ---
3282 ESCGuidelines
.
.
Summaryofrecommendationsfortheclinicalmanage- . Treatmentofhypertension:drugtreatment
.
mentofhypertension ...
Itisrecommendedtoinitiateantihypertensive
.
Recommendations Classa Levelb
... treatmentwithatwo-drugcombinationinmost
... patients,preferablyasasingle-pillcombination.
I B
ClassificationofBP .. Exceptionsarefrailolderpatientsandthose
.
ItisrecommendedthatBPshouldbeclassified .. withlow-risk,grade1hypertension(particularly
.
asoptimal,normal,high-normal,orgrades1-3 I C .. ifSBP<150mmHg).560(cid:2)565
.
.
hypertension,accordingtoofficeBP. . Itisrecommendedthatthepreferredcombina-
.
.
Diagnosisofhypertension .. tionsincludeaRASblocker(i.e.anACEinhibitor
.
Itisrecommendedtobasethediagnosisof ... orARB)withaCCBordiuretic,butothercom- I A
hypertensionon: .. binationsofthefivemajorclassescanbeused
.
(cid:7)RepeatedofficeBPmeasurements,onmore .. (ACEinhibitor,ARB,beta-blocker,CCB,thia-
thanonevisit,exceptwhenhypertensionis I C
... zide/thiazide-likediuretic).566(cid:2)569
.
severe(e.g.grade3andespeciallyinhigh-risk .. Itisrecommended,ifBPremainsuncontrolled
.
patients) .. withatwo-drugcombination,thattreatmentbe
.
or .. increasedtoathree-drugcombination,usuallya I A
.
(cid:7)Out-of-officeBPmeasurementwithABPMand/ I C .. RASblockerwithaCCBandadiuretic,prefera- .
orHBPMwhenfeasible.
.. blyasasingle-pillcombination.563,570,571
.
. AssessmentofHMOD .. Itisrecommended,ifBPisnotcontrolledbya
.
ToevaluateforthepresenceofHMOD,meas- .. three-drugcombination,thattreatmentshould
.
urementofserumcreatinine,eGFR,electrolytes, .. beincreasedbytheadditionofspironolactone,
.
andACRisrecommendedforallpatients.A12- .. orifnottolerated,otherdiureticssuchasami- I B
.
leadECGisrecommendedforallpatients,and .. lorideorhigherdosesofotherdiuretics,an
.
echocardiographyisrecommendedforthose .. alpha-blockerorbeta-blocker,or
withECGabnormalitiesorsigns/symptomsof
I B ... clonidine.555,572(cid:2)574
.
LVdysfunction.Fundoscopyorretinalimagingis .. ThecombinationoftwoRASblockersisnot
. III A
recommendedforpatientswithgrades2or3
.. recommended.575,576
.
.
hypertensionandallhypertensivepatientswith . ManagementofCVDriskinhypertensivepatients
.
DM.548(cid:2)551 ... Statintherapyisrecommendedformany Section4.6
.
Thresholdsforinitiationofdrugtreatmentofhypertension .. patientswithhypertension.d
.
Forgrade1hypertension,treatmentinitiation .. Antiplatelettherapyisindicatedforsecondary Section4.9
.
basedonabsoluteCVDrisk,estimatedlifetime .. preventioninpatientswithhypertension.e
I C ..
benefit,andthepresenceofHMODis .
recommended.552,553
... ABPM=ambulatorybloodpressuremonitoring;ACE=angiotensin-converting
. enzyme;ACR=albumin-to-creatinineratio;ARB=angiotensinreceptorblocker;
.
F do rur gp ta rt eie an tmts ew ni tth isg rr ea cd oe m2 mh ey np de er dte .4n ,5s 5io 2norhigher,
I A
...... A
c Ea
CS lcC GiuV
m
=D ec=
lh ea
ca
n
tt rnh oee clr abo rls doc
ic
ole
k
gr
e
ro
r
a;t mi Dc ;Bc ePa Gr =d FRio dv
i
=aa ss etc
o
su
tli
il
c
mar
b
ald
to
eis
o
de da gs
lp
oe
r
m; eB
s
esP
ru
ur=
le a;
rb
D
filo
lM
to rad
=
tip odr niae bs rs
e
au
tt
eere ;s; HmC BeC
Pll
MiB
tu
==
s;
OfficeBPtreatmenttargets .. homebloodpressuremonitoring;HMOD=hypertension-mediatedorgandam-
.
. age;LV=leftventricular;RAS=renin(cid:2)angiotensinsystem;SBP=systolicblood Itisrecommendedthatthefirstobjectiveof .
.. pressure.
t ar lle pat am tiee nn tt si ,s at no dl to hw ater suB bP seto qu< e1 n4 t0 B/ P90 tam rgm etH sg arin
e
I A .... a bC Lela vs es lo of fr ee vc ido em nm cee .ndation.
.
tailoredtoageandspecificcomorbidities.552,554
.. cSeesection4.3fordetails.
.. dSeesection4.6fordetails.
Intreatedpatientsaged18(cid:2)69years,itisrec- .. eSeesection4.9fordetails.
.
ommendedthatSBPshouldultimatelybelow- ..
I A ..
eredtoatargetrangeof120-130mmHgin .. .. people across Europe, over 1 billion globally, with a prevalence of
..
mostpatients.552,554(cid:2)556 .. .. (cid:6)30(cid:2)45%inadults,increasingwithagetomorethan60%inpeople
..
..
Intreatedpatientsaged>_70years,itisrecom- .. aged>60years,andaccountingfor(cid:6)10milliondeathsgloballyper
..
mendedthatSBPshouldgenerallybetargetedto .. .. annum.577 Despite extensive evidence for the effectiveness of BP-
I A .. ..
<140anddownto130mmHgif .. loweringtreatmentsatreducingCVDriskanddeath,thedetection,
..
..
tolerated.552,554,557 .. treatment, and control of BP in Europe and globally remains
..
Inalltreatedpatients,DBPisrecommendedto
... ... suboptimal.578
I A ..
beloweredto<80mmHg.555,558,559 .. .. Thissectioncoversrecommendationsforthediagnosisandtreat-
..
.. mentofhypertensiontobeappliedinroutineprimaryandsecondary
Treatmentofhypertension:lifestyleinterventions ..
..
.. care. More detail and guidancefor complex cases/tertiary care are
L pi efe os pt ly ele wi in tt he hrv ige hn -t nio on rmsa ar le Br Pe oco rm him ghe en rd .cedfor
I A
..... .....
availableinthe2018ESC/EuropeanSocietyofHypertension(ESH)
.. Guidelinesforthemanagementofarterialhypertension.4
Continued ..
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 57 ---
ESCGuidelines 3283
.
.
4.7.1.Definitionandclassificationofhypertension . dictorofhypertension-mediatedorgandamage(HMOD)andclinical
.
.
BPisclassifiedaccordingtoseatedofficeBP(Table12),withapproxi- .. outcomesthanofficeBP,andidentifies‘white-coat’hypertensionand
.
matelycorrespondingvaluesaccordingtoABPMorhomeBPaverage .. maskedhypertension(seebelow).Diagnosticthresholdsforhyper-
.
valuesinTable13. .. tensionarelowerwithABPMthanofficeBP(Table12).4
.
.
.
.. 4.7.2.4Homebloodpressuremonitoring
4.7.2.Bloodpressuremeasurement .
.. HomeBPistheaverageofallBPreadingsperformedwithavalidated
4.7.2.1Officebloodpressuremeasurement .
.. semiautomaticmonitor,foratleast3consecutivedays(ideally6-7
Office BP should be measured in standardized conditions using .
.. days), with readings in the morning and evening, taken seated in a
validated auscultatory or (semi)automatic devices, as described in .
.
. quietroomafter5minofrest.HomeBPmonitoring(HBPM)thresh-
Table14. .
.
. oldsforthediagnosisofhypertensionarelowerthanthoseforoffice
.
.
. BP(Table12).Patientself-monitoringmayhaveabeneficialeffecton
4.7.2.2Unattendedautomatedofficebloodpressuremeasurement ...
medicationadherenceandBPcontrol.4
RepeatedautomatedofficeBPreadingsmayimprovethereproduci- ..
. Clinicalindicationsforambulatoryorhomemonitoringareshown
bility of BP measurement. If the patient is seated alone and unob- ..
. inTable15.
served, unattended automatedofficeBP measurement may reduce ..
.
oreliminatethe‘white-coat’effect,andunattendedautomatedoffice ..
.
BP measurements are usually lower than conventional office BP ..
.
measurements,andmoresimilartoambulatorydaytimeBPorhome .. 4.7.3Screeninganddiagnosisofhypertension
.
BP values. There is limited information on the prognostic value of .. Ideally,alladultsshouldbescreenedforthepresenceofhyperten-
.
unattendedautomatedofficeBPmeasurements.4 .. sion,578,579butmostcountrieslacktherequiredresourcesandinfra-
.
.. structure. Formally, these guidelines recommend opportunistic
.
4.7.2.3Ambulatorybloodpressuremonitoring .. screening at least in susceptible individuals, such as those who are
.
ABPM is the average of repeated automated measurements of BP .. overweightorhaveafamilyhistoryofhypertension(seesection3.1).
.
duringthedaytime,night-time,andover24h.ABPMisabetterpre- ..
.
.
.
. Table14 Considerationsinbloodpressure
.
Table12 Categoriesforconventionallymeasuredseated .. measurement
officebloodpressurea ..
.
.. Patientsshouldbeseatedcomfortablyinaquietenvironmentfor5min
Category SBP(mmHg) DBP(mmHg) ...
beforeBPmeasurements.
Optimal <120 and <80 ..
. ThreeBPmeasurementsshouldberecorded,1(cid:2)2minapart,andaddi-
.
Normal 120(cid:2)129 and/or 80(cid:2)84 .
. tionalmeasurementsifthefirsttworeadingsdifferby>10mmHg.BPis
.
High-normal 130(cid:2)139 and/or 85(cid:2)89 .. recordedastheaverageofthelasttwoBPreadings.
.
Grade1hypertension 140(cid:2)159 and/or 90(cid:2)99 ... Additionalmeasurementsmayhavetobeperformedinpatientswith
.
Grade2hypertension 160(cid:2)179 and/or 100(cid:2)109 .. unstableBPvaluesduetoarrhythmias,suchasinpatentswithAF,in
.
Grade3hypertension >_180 and/or >_110 .. whommanualauscultatorymethodsshouldbeusedasmostautomated
.
Isolatedsystolic >_140 and <90 .. deviceshavenotbeenvalidatedforBPmeasurementinAF.
.
hypertensionb .. Useastandardbladdercuff(12(cid:2)13cmwideand35cmlong)formost
.
. BP=bloodpressure;DBP=diastolicbloodpressure;SBP=systolicbloodpressure. .. patients,butuselargerandsmallercuffsforlarger(armcircumference
aBPcategoryisdefinedaccordingtoseatedclinicBPandbythehighestlevelof .. >32cm)andsmaller(armcircumference<26cm)arms,respectively.
.
BP,whethersystolicordiastolic. .
bIsolatedsystolichypertensionisgraded1,2,or3accordingtoSBPvaluesinthe .. Thecuffshouldbepositionedattheleveloftheheartwiththebackand
.
rangesindicated. .. armsupported,toavoidmusclecontractionandisometric-exercise-
.
.. dependantincreasesinBP.
.
.. Whenusingauscultatorymethods,usephaseIandV(suddenreduction/
.
Table13 Definitionsofhypertensionaccordingtooffice, .. disappearance)KorotkoffsoundstoidentifySBPandDBP,respectively.
.
ambulatory,andhomebloodpressure .. MeasureBPinbotharmsatthefirstvisittodetectpossiblebetween-arm
.
.
Category SBP DBP .. differences.Usethearmwiththehighervalueasthereference.
.
(mmHg) (mmHg) .. MeasureBP1minand3minafterstandingfromtheseatedpositioninall
.
OfficeBPa >_140 and/or >_90 .. patientsatthefirstmeasurementtoexcludeorthostatichypotension.
.
AmbulatoryBP .. LyingandstandingBPmeasurementsshouldalsobeconsideredinsubse-
.
Daytime(orawake)mean >_135 and/or >_85 .. quentvisitsinolderpeople,inpeoplewithDM,andinotherconditions
.
Night-time(orasleep)mean >_120 and/or >_70
... inwhichorthostatichypotensionmayfrequentlyoccur.Initialorthostatic
24-hmean >_130 and/or >_80
... hypotensionmayoccur<1minafterstandingandmaybedifficultto
.. detectwithconventionalmeasurementtechniques.
HomeBPmean >_135 and/or >_85 . .
. Recordheartrateandusepulsepalpationtoexcludearrhythmia.
.
BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic blood .
pressure. .. AF=atrialfibrillation;BP=bloodpressure;DBP=diastolicbloodpressure;DM
.
aReferstoconventionalofficeBPratherthanunattendedofficeBP. . =diabetesmellitus;SBP=systolicbloodpressure.
1202
CSE
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 58 ---
3284 ESCGuidelines
.
.
.. When hypertension is suspected, the diagnosis of hypertension
Table15 Indicationsforhomebloodpressuremonitor- .
ingorambulatorybloodpressuremonitoring
... should be confirmed, either by repeated office BP measurements
.. overanumberofvisits,orby24-hABPMorHBPM(Figure14).
.
Conditionsinwhichwhite-coathypertensionismorecommon,for ..
.
example: .. 4.7.3.1White-coatandmaskedhypertension
.
• Grade1hypertensiononofficeBPmeasurement .. White-coat hypertensionreferstoBPthatiselevated in the office
.
• MarkedofficeBPelevationwithoutHMOD .. butisnormalwhenmeasuredbyABPMorHBPM.Itoccursinupto
.
Conditionsinwhichmaskedhypertensionismorecommon,forexample: .. 30(cid:2)40%ofpatients.Theriskassociatedwithwhite-coathyperten-
.
• High-normalofficeBP .. sion is lower than sustained hypertension but may be higher than
.
• NormalofficeBPinindividualswithHMODorathightotalCVrisk .. normotension.Peoplewithwhite-coathypertensionshouldreceive
.
Posturalandpost-prandialhypotensioninuntreatedandtreatedpatients ... lifestyleadvicetoreducetheirCVriskandbeofferedBPmeasure-
.
Evaluationofresistanthypertension .. mentatleastevery2yearsbyABPMorHBPMbecauseofhighrates
.
. oftransitiontosustainedhypertension.Routinedrugtreatmentfor
EvaluationofBPcontrol,especiallyintreatedhigher-riskpatients .
.
. white-coathypertensionisnotindicated. ExaggeratedBPresponsetoexercise ..
. MaskedhypertensionreferstopatientswithanormalofficeBPbut
.
WhenthereisconsiderablevariabilityintheofficeBP .
. an elevated BP on ABPM or HBPM. These patients often have
.
Evaluatingsymptomsconsistentwithhypotensionduringtreatment .
. HMOD and are at a CV risk level at least equivalent to sustained
.
SpecificindicationsforABPMratherthanHBPM: .. hypertension.Itismorecommoninyoungerpeopleandinthosewith
.
• AssessmentofnocturnalBPvaluesanddippingstatus(e.g.suspicion .. high-normalofficeBP.Inmaskedhypertension,lifestylechangesare . ofnocturnalhypertension,suchasinsleepapnoea,CKD,DM, .. recommended,anddrugtreatmentshouldbeconsideredtocontrol
.
endocrinehypertension,orautonomicdysfunction) .. ‘out-of-office’BP,withperiodicmonitoringofBP,usuallywithHBPM.
.
.
ABPM=ambulatorybloodpressuremonitoring;BP=bloodpressure;CKD= ..
chronickidneydisease;CV=cardiovascular;DM=diabetesmellitus;HBPM= ..
home blood pressure monitoring; HMOD = hypertension-mediated organ .. 4.7.4.Clinicalevaluationandriskstratificationin
.
damage. .. hypertensivepatients
.
.. Theroutinework-upforhypertensivepatientsisshowninTable16.
.
. Alongsideclinicalexamination,thisisdesignedto:
Screening and diagnosis of hypertension
Blood pressure measurement
Normal High-normal
Optimal Hypertension
<120/80 mmHg 120–129 mmHg / 130–139 mmHg / ≥140/90 mmHg
80–84 mmHg 85–89 mmHg
Consider
masked
hypertension
Out-of-office Repeat visits
BP measurement for office
(ABPM or HBPM) BP measurement
Indications
forABPM
OR
or HBPM
Repeat BP Repeat BP Repeat BP Out-of-office
measurement a measurement at measurement a BP measurement
least every 5 years least every 3 years least annually (ABPM or HBPM)
Figure14 Screeninganddiagnosisofhypertension.ABPM=ambulatorybloodpressuremonitoring;BP=bloodpressure;HBPM=homebloodpres-
suremonitoring.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 59 ---
ESCGuidelines 3285
.
Table16 Routinetestsforpatientswithhypertension .. Table17 Patientcharacteristicsthatshouldraisethe
.
. suspicionofsecondaryhypertension.
.
Routinetests .
.
Haemoglobinand/orhaematocrit .. Characteristics
.
Fastingbloodglucoseand/orHbA1c
... Youngerpatients(<40years)withgrade2hypertensionoronsetofany
.. gradeofhypertensioninchildhood
Bloodlipids:totalcholesterol,LDL-C,HDL-C,triglycerides .
.
. Acuteworseningofhypertensioninpatientswithpreviouslydocumented
Bloodpotassiumandsodium .
.
. chronicallystablenormotension
Blooduricacid ..
.. Resistanthypertension(BPuncontrolleddespitetreatmentwithoptimal
BloodcreatinineandeGFR .
.. orbest-tolerateddosesofthreeormoredrugsincludingadiuretic,and
Bloodliverfunctiontests ...
confirmedbyABPMorHBPM)
Urineanalysis:microscopic;urinaryproteinbydipstickor,ideally,ACR ..
. Severe(grade3)hypertensionorahypertensionemergency .
12-leadECG .
.. PresenceofextensiveHMOD
ACR=albumin-to-creatinineratio;ECG=electrocardiogram;eGFR=estimated ... Clinicalorbiochemicalfeaturessuggestiveofendocrinecausesofhyper-
glomerularfiltrationrate;HbA1c=glycatedhaemoglobin;HDL-C=high-density .
lipoproteincholesterol;LDL-C=low-densitylipoproteincholesterol. .. tensionorCKD
.
.
. ClinicalfeaturessuggestiveofOSA
. .
.. Symptomssuggestiveofpheochromocytomaorfamilyhistoryof
.
• AssessriskfactorsforASCVD(seesection3.2),orthepresence .. pheochromocytoma
.
ofcardiac,vascular,orrenaldisease .. ABPM=ambulatorybloodpressuremonitoring;BP=bloodpressure;CKD=
.
• DetectevidenceofHMOD,e.g.LVhypertrophy,renaldisease, .. chronickidney disease; HBPM =homeblood pressuremonitoring; HMOD =
orretinopathy .... h Ay dp ae pr tt ee dns frio on m-m 4ediatedorgandamage;OSA=obstructivesleepapnoea.
• Considerpotentialsecondarycausesofhypertension,e.g.reno- .
.
.
vascular disease, hyperaldosteronism, or pheochromocytoma ..
.
(see Table 17). Also, carefully evaluate substance abuse (e.g. ..
.. reductioninSBPisatleastmoderatetohigh[Figure15(lifetimebene-
cocaine),drugsthatmayincreaseBP(e.g.cyclosporine,sympati- ..
. fitcalibratedinlow-to-moderateCVDriskcountries].Also,thepres-
comimetics),liquorice,etc.Moredetailonwork-upofsuspected ..
. ence of HMOD mandates treatment of grade 1 hypertension. For
secondaryhypertensionisprovidedelsewhere.4 ..
. grade2hypertensionorhigher(SBP>160mmHg),treatmentisrec-
.
.
Echocardiography is recommended inpatientswith ECGabnor- .. ommended,becausenotonlyisthelifetimebenefitofreducingBP
.
malities,andshouldbeconsideredwhentheresultwillinfluenceclini- .. almostuniversallyhighinsuchpatients,thereisalsotheimportance
.
cal decision-making. Fundoscopy is recommended in grade 2 or 3 .. ofreducingtheriskofHMODresultinginothermorbiditiessuchas
.
hypertensionandinallpatientswithDM.Theroutinemeasurement .. renaldisease,haemorrhagiccerebrovasculardisease,andHF.
.
of other biomarkers and use of vascular imaging are not ..
.
recommended.548(cid:2)551 .. 4.7.5.3Bloodpressuretreatmenttargets
.
. When drug treatment is used, the aim is to control BP to target
.
.
4.7.5.Treatmentofhypertension
... within 3 months.Evidencenowsuggests thatthe BPtargets in the
Thetreatmentofhypertensioninvolveslifestyleinterventionsforall
... previousiterationofthisguideline2weretooconservative,especially
patientsanddrugtherapyformostpatients.
... forolderpatients.Inlinewiththestepwiseapproach(section3.2.3.1),
.. it is now recommended that the first step in all treated patients
.
4.7.5.1Lifestyleinterventionstolowerbloodpressureand/orreducecar-
... should achieve a treated SBP <140 mmHg and diastolic BP (DBP)
diovascularrisk
... <80mmHg.552,554TherecommendedultimateSBPtreatmenttarget
Lifestyleinterventionsareindicatedforallpatientswithhigh-normal ... range for younger patients (18(cid:2)69 years) is 120(cid:2)130 mmHg,
BPorhypertensionbecausetheycandelaytheneedfordrugtreat-
... althoughsomepatientsmaysafelyachievelowertreatedSBPlevels
ment or complement the BP-lowering effect of drug treatment.
... than this and, if they are well tolerated, there is no need to back-
Moreover, most lifestyle interventions have healthbenefitsbeyond
... titratetreatment.552,554(cid:2)556TheultimatetargetSBPforpatientsaged
theireffectonBP.Lifestyleisdiscussedextensivelyinsection4.3.
... >_70 years is <140 mmHg and down to 130 mmHg if toler-
.. ated.552,554,557,580ThischangeintheBPtargetrangeforolderpeople
.
4.7.5.2 Initiationofdrugtreatment
.. comparedwiththe2016ESCpreventionguidelines2issupportedby
.
.
Drug treatment decisionsinCVD preventionare mostlybased on . evidence that these treatment targets are safely achieved in many
.
.
absoluteCVDrisk,riskmodifiers,comorbidities,estimatedbenefitof .. older patients and are associated with significant reductions in the
treatment, frailty, and patient preferences. The same is true for ... risk of major stroke, HF, and CV death.557,580 It also takes into
.
hypertension. Drug treatment of grade 1 hypertension (SBP .. accountthattheevenlowerSBPintheintensivelytreatedgroupin
.
140-159 mmHg) has level A evidence for reducing CVD risk. In .. SPRINT (Systolic Blood Pressure Intervention Trial) (mean 124
.
youngerpatients,however,the absolute 10-yearCVDriskis often .. mmHg) probably reflects a conventional office SBP range of
low,andlifetimebenefitoftreatmentshouldbeconsideredandcom-
... 130(cid:2)139mmHg.555Itisrecognized,however,thattheevidencesup-
.
municatedbeforeinstitutingtreatment(Figure6andsection3.2.3.6). .. porting more strict targets is less strong for very old people (>80
.
In many such cases, the absolute lifetime benefit per 10-mmHg . years)andthosewhoarefrail.Also,intheseolderandespeciallyfrail
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 60 ---
3286 ESCGuidelines
LIFE-CVD model < 0.5years 1.5 - 2.0years
CVD-free lifetime gain from 10 mmHg 0.5 - 0.9years ≥2.0 years
Systolic Blood Pressure reduction (in years) 1.0 - 1.4years
Women Men
Non-smoking Smoking Non-smoking Smoking
Non-HDL cholesterol
prS ey ss st uo rl eic
(
mblo mo Hd
g)
3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 mmol/L 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9
150200250 150200250 mg/dL 150200250 150200250
160-179 0.3 0.3 0.4 0.4 0.1 0.1 0.2 0.2 Age 0.2 0.2 0.3 0.3 0.1 0.0 0.0 0.1
(y)
140-159 0.3 0.3 0.3 0.3 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.0 0.0 0.0 0.0
90+
120-139 0.2 0.3 0.3 0.3 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.0 0.0 0.0 0.1
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 0.7 0.8 0.8 0.8 0.2 0.2 0.3 0.3 0.3 0.4 0.5 0.5 0.1 0.1 0.1 0.2
140-159 0.6 0.6 0.7 0.8 0.1 0.2 0.2 0.3 0.3 0.3 0.4 0.5 0.1 0.1 0.1 0.1
85-89
120-139 0.4 0.5 0.6 0.6 0.1 0.2 0.2 0.2 0.3 0.3 0.3 0.4 0.0 0.0 0.1 0.1
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 0.9 1.0 1.1 1.2 0.2 0.3 0.4 0.4 0.5 0.5 0.6 0.7 0.1 0.2 0.2 0.2
140-159 0.8 0.9 1.0 1.0 0.2 0.3 0.3 0.4 0.4 0.5 0.6 0.6 0.1 0.1 0.2 0.1
80-84 120-139 0.6 0.7 0.8 0.9 0.2 0.1 0.3 0.2 0.3 0.4 0.4 0.5 0.0 0.1 0.1 0.1
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 1.1 1.2 1.3 1.3 0.3 0.5 0.5 0.5 0.6 0.7 0.8 0.9 0.2 0.2 0.3 0.3
140-159 0.9 1.1 1.2 1.2 0.2 0.3 0.4 0.5 0.5 0.6 0.7 0.8 0.2 0.2 0.3 0.3
75-79
120-139 0.7 0.9 1.0 1.1 0.2 0.2 0.3 0.4 0.4 0.5 0.6 0.6 0.1 0.2 0.2 0.2
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 1.2 1.3 1.4 1.5 0.4 0.5 0.7 0.7 0.7 0.8 1.0 1.0 0.3 0.4 0.5 0.5
140-159 1.0 1.3 1.4 1.5 0.4 0.4 0.5 0.6 0.6 0.7 0.9 0.9 0.2 0.3 0.4 0.4
70-74
120-139 0.8 1.0 1.1 1.2 0.2 0.3 0.4 0.5 0.4 0.6 0.7 0.8 0.1 0.2 0.3 0.3
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 1.2 1.3 1.5 1.5 0.5 0.7 0.8 0.9 0.8 1.0 1.1 1.1 0.5 0.5 0.7 0.6
140-159 1.0 1.3 1.4 1.5 0.4 0.5 0.6 0.7 0.7 0.9 0.9 1.0 0.3 0.5 0.5 0.5
65-69
120-139 0.9 1.1 1.2 1.3 0.3 0.4 0.5 0.5 0.5 0.7 0.8 0.9 0.2 0.4 0.4 0.4
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 1.3 1.4 1.5 1.6 0.6 0.7 0.9 1.0 1.0 1.1 1.2 1.3 0.6 0.7 0.8 0.8
140-159 1.2 1.3 1.4 1.5 0.5 0.6 0.7 0.8 0.8 0.9 1.1 1.1 0.5 0.5 0.7 0.7
60-64
120-139 1.0 1.1 1.3 1.4 0.4 0.4 0.6 0.6 0.7 0.7 0.9 1.0 0.4 0.4 0.5 0.5
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 1.3 1.5 1.6 1.7 0.7 0.9 1.0 1.1 1.0 1.2 1.3 1.4 0.7 0.9 0.9 1.0
140-159 1.1 1.4 1.6 1.6 0.6 0.7 0.8 1.0 0.8 1.0 1.2 1.2 0.5 0.6 0.8 0.9
55-59
120-139 1.0 1.2 1.4 1.5 0.4 0.5 0.7 0.7 0.7 0.8 1.0 1.0 0.4 0.5 0.6 0.7
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 1.3 1.5 1.7 1.7 0.8 1.0 1.1 1.2 1.0 1.3 1.4 1.5 0.8 0.9 1.0 1.2
140-159 1.3 1.4 1.6 1.7 0.6 0.8 1.0 1.0 0.9 1.1 1.2 1.3 0.7 0.7 0.8 1.0
50-54 120-139 1.1 1.2 1.4 1.5 0.5 06 0.7 0.8 0.7 0.9 1.0 1.1 0.5 0.6 0.7 0.7
140-159 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
100-119 1.3 1.6 1.7 1.8 0.8 1.0 1.2 1.3 1.1 1.3 1.5 1.5 0.8 1.0 1.2 1.3
120-139 1.3 1.4 1.6 1.6 0.7 0.8 1.0 1.1 0.9 1.1 1.3 1.3 0.7 0.8 1.0 1.1
45-49
160-179 1.1 1.2 1.4 1.5 0.5 0.7 0.8 0.8 0.8 0.9 1.0 1.2 0.6 0.7 0.8 0.8
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
160-179 1.4 1.6 1.7 1.8 0.8 1.0 1.2 1.3 1.1 1.3 1.4 1.6 0.9 1.1 1.3 1.4
140-159 1.3 1.4 1.6 1.7 0.7 0.8 1.0 1.1 0.9 1.1 1.3 1.4 0.7 0.9 1.0 1.2
40-44
120-139 1.1 1.3 1.4 1.5 0.6 0.7 0.8 0.9 0.7 0.9 1.0 1.2 0.6 0.7 0.8 0.9
100-119 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Figure15 Lifetimebenefitfromloweringsystolicbloodpressureby10mmHgforapparentlyhealthypersons,basedonthefollowingriskfactors:age,
sex,currentsmoking,systolicbloodpressure,non-high-densitylipoproteincholesterol.Themodeliscurrentlyvalidatedforlow-andmoderate-riskcoun-
tries.Thelifetimebenefitisexpressedas‘yearsofmedianlifeexpectancyfreefrommyocardialinfarctionorstroke’gainedfrom10mmHgSBPlowering.
ThelifetimebenefitiscalculatedbyestimatinglifetimeCVDriskwiththeLIFE-CVDmodelmultipliedbytheHR(0.80)fromameta-analysisoftheeffectof
BPlowering.For20mmHgSBPlowering,theaverageeffectisalmosttwiceaslarge,etc.Forindividualizedestimationsoflifetimebenefit,thistablecanbe
usedortheelectronicversionofLIFE-CVD,assessableviatheESCCVDriskapporhttps://u-prevent.com/.BP=bloodpressure;CVD=cardiovascular
disease;ESC=EuropeanSocietyofCardiology;HDL-C=high-densitylipoproteincholesterol;HR=hazardratio;LIFE-CVD=LIFEtime-perspective
CardioVascularDisease;N/A=notapplicable;SBP=systolicbloodpressure.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 61 ---
ESCGuidelines 3287
Table18 Recommendedofficebloodpressuretargetranges.Thefirststepinallgroupsisareductiontosystolicblood
pressure<140mmHg.Thesubsequentoptimalgoalsarelistedbelow.
Agegroup OfficeSBPtreatmenttargetranges(mmHg)
.........................................................................................................................................................
Hypertension 1DM 1CKD 1CAD 1Stroke/TIA
18269years 120(cid:2)130 120(cid:2)130 <140(cid:2)130 120(cid:2)130 120(cid:2)130
LowerSBPacceptableiftolerated
(cid:3)70years <140mmHg,downto130mmHgiftolerated
LowerSBPacceptableiftolerated
DBPtreatmenttarget(mmHg) <80foralltreatedpatients
CAD=coronaryarterydisease;CKD=chronickidneydisease;DBP=diastolicbloodpressure;DM=diabetesmellitus;SBP=systolicbloodpressure;TIA=transientischae-
micattack.
1 pill Initial therapy
ACEi orARB + CCB or diuretic
Dual combination
Consider monotherapy in low-risk grade 1 hypertension (systolic
BP <150mmHg), or in very old (≥80 years) or frailer patients
1 pill
Step 2
ACEi orARB + CCB + diuretic
Triple combination
2 pills Step 3 Resistant hypertension
Triple combination
Add spironolactone (25-50 mg o.d.) or other
+ spironolactone
diuretic, alpha-blocker or beta-blocker
or other drug
Consider referral to a specialist centre for further investigation
Beta-blockers
Consider beta-blockers at any treatment step, when there is a specific indication for their use,
e.g. heart failure, angina, post-myocardial infarction, atrial fibrillation,
or younger women with, or planning, pregnancy
Figure16 Coredrugtreatmentstrategyforhypertension.Thisalgorithmisappropriateformostpatientswithhypertension-mediatedorgandamage,
diabetesmellitus,cerebrovasculardisease,andperipheralarterydisease.ACE=angiotensin-convertingenzyme;AF=atrialfibrillation;ARB=angiotensin
receptorblocker;BP=bloodpressure;CCB=calciumchannelblocker;HF=heartfailure;o.d.=omnidie(onceaday).
.
.
patients,it may be difficultto achievetherecommended target BP . example, a very fit 75-year-old person mayqualify for a treatment
.
.
range due to poor tolerability or adverse effects, and high-quality .. policy normallyreserved for those <70and,viceversa,a veryfrail
.
measurement and monitoringfor tolerability and adverse effects is .. 65-year-oldpersonshouldsometimesbeconsidered‘older’.
.
especiallyimportantinthesegroups.580 .. BP targets for patient subgroups with various comorbidities are
.
Compared to previous ESC/ESH Hypertension Guidelines,4 we .. showninTable18.
.
changedthecut-offforidentifyingwhois’older’from65to70years ..
forreasonsofconsistencywithotherpartsofthecurrentguidelines.
... 4.7.5.3.1. Blood pressure targets according to ambulatory and
Althoughasingleagecut-offisprovided,itisimportanttostressthat
... homebloodpressuremonitoring.Therearenooutcome-basedtri-
biological age influences this threshold in clinical practice. For
.. alsthat have usedABPM or HBPM to guidetreatment.Therefore,
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 62 ---
3288 ESCGuidelines
.
ABPM and HBPM BP targets are extrapolated from observational .. CKD and eGFR <45 mL/min/m2 and blood potassium levels >4.5
.
data.AtreatedofficeSBPof130mmHglikelycorrespondstoa24-h .. mmol/L.555,572 Potassium-bindingdrugsreducetheriskofhyperka-
.
SBPof125mmHgandhomeSBP<130mmHg.4 .. laemia.573 When spironolactone is not tolerated, amiloride, alpha-
.
.. blockers,beta-blockers,orcentrallyactingdrugs,suchasclonidine,
.
4.7.5.4Drugtreatmentofhypertension .. haveevidencesupportingtheiruse.555,572,574Renaldenervationand
.
ThemostimportantdriverofbenefitisthemagnitudeofBPlowering. .. device-basedtherapymaybeconsideredforspecificcases,andare
.
Single-drugtherapywillrarelyachieveoptimalBPcontrol. .. discussedinthe2018ESC/ESHhypertensionguidelines.4
.
.
.
.
Initial therapy with a combination of two drugs should be ..
4.7.7.Managementofhypertensioninwomen
.
considered usual care for hypertension.560(cid:2)563,565,581 The only ..
Thediagnosisandtreatmentofhypertensioninwomenissimilarto
.
exceptionswouldbepatientswithabaselineBPclosetotherecom- ..
thatinmen,exceptforwomenofchild-bearingpotentialorduring
.
mendedtarget,whomightachievethattargetwithasingledrug,or ...
pregnancy,becauseofpotentialadverseeffectsofsomedrugsonthe
veryold(>80years)orfrailpatientswhomaybettertolerateamore ...
foetus,especiallyinthefirsttrimester.Inaddition,theeffectoforal
gentle reduction of BP. Initial combination therapy, even low-dose ...
contraceptivepillsontheriskofdevelopingorworseninghyperten-
combination therapy, is more effective at lowering BP than mono- ... sionshouldbeconsidered.4
therapy,560,561,565andwillreduceBPfasterandreduceheterogeneity ..
.
in response.560,565 Moreover, initial combination therapy does not ...
4.7.8.Durationoftreatmentandfollow-up
increaseriskofadverseeffects.560(cid:2)563,565Initiatingtherapywithtwo ..
. Treatmentofhypertensionisusuallymaintainedindefinitelybecause
drugs will also help overcome treatment inertia where patients ..
. cessationoftreatmentusuallyresultsinareturnofBPtopretreat-
remainononedruglongtermdespiteinadequateBPcontrol.562 ..
. mentlevels.Insomepatientswithsuccessfullifestylechanges,itmay
.
.
. bepossibletograduallyreducethedoseornumberofdrugs.After
.
Single-pillstrategytotreathypertension:pooradherenceto .
. BPisstableandcontrolled,visitsshouldbescheduledatleastannu-
.
BP-lowering medicationis a major cause ofpoor BP control rates, .
. ally,andincludethecontrolofotherriskfactors,renalfunction,and
andisdirectlyrelatedtothenumberofpills.581Single-pillcombina- ..
. HMOD,aswellasreinforcelifestyleadvice.Whenthereisalossof
.
tiontherapy(ifavailable)isthepreferredstrategy.Thisstrategywill .
. BP control in a previously well-controlled patient, non-compliance
controlBPinmostpatients.560(cid:2)565 ..
. with therapy should be considered. Self-measurement of BP using
.
.
. HBPM helps engage the patient in their ownmanagementand can
.
Recommendeddrugtherapyandtreatmentalgorithm:five .
. improve BP control. HBPM is essential to monitor BP control in
.
major classes of BP-lowering drug therapy have shown benefit in .
.. patientswithasignificant‘white-coateffect’ormaskedhypertension.
reducingCVevents;angiotensin-convertingenzyme(ACE)inhibitors, .
.. Supervision of patient follow-up increasingly involves nurses and
angiotensinreceptorblockers(ARBs),beta-blockers,calciumchan- .
.. pharmacistsandislikelytobecomeincreasinglysupportedbytele-
nelblockers(CCBs),andthiazideorthiazide-likediuretics.582Arec- ...
medicineandapp-basedtechnologies.
ommended treatment algorithm based on best available evidence, ..
.
pragmaticconsiderations(e.g.combinationpillavailability),andpath- .. 4.8. Diabetes mellitus
.
ophysiologicalreasoningisshowninFigure16.4Acombinationofan ..
.
ACEinhibitororARBwithaCCBorthiazide/thiazide-likediureticis .. Recommendationsforthetreatmentofpatientswith
.
the preferred initial therapy for most patients with hyper- . diabetesmellitus
.
tension.566(cid:2)569Forthoseinwhomtreatmentrequiresescalationto ..
. threedrugs,acombinationofanACEinhibitororARBwithaCCB .. Recommendations Classa Levelb
. and a thiazide/thiazide-like diuretic should be used.563,570,571 Beta- ..
.. Screening
blockers should be used when there is a specific indication (e.g. .
.. WhenscreeningforDMinindividualswithor
angina,postmyocardialinfarction,arrythmia,HFrEF,orasanalterna- . .. withoutASCVD,assessmentofHbA1c(which
tivetoanACEinhibitororARBinwomenofchild-bearingpoten- . IIa A .. canbedonenon-fasting)orfastingbloodglu-
tial).582 Combinations of an ACE inhibitor and an ARB are not ...
coseshouldbeconsidered.583
recommended because of no added benefit on outcomes and ..
. Lifestyle increasedriskofharm.575,576 ..
Specific modifications to the treatment algorithm are recom-
... Lifestylechangesincludingsmokingcessation,a
mendedforpatientswithCHD,CKD,HF,andAF.4 ... lowsaturatedfat,high-fibrediet,aerobicPA,and I A
.. strengthtrainingarerecommended.584
.
.
. Reductioninenergyintakeisrecommendedto
4.7.6.Resistanthypertension ..
. patients,tohelpachievelowerbodyweightor I B
Resistant hypertension is defined as BP being uncontrolled despite ...
preventorslowweightgain.584
treatment with optimal or best-tolerated doses of three or more ..
drugs including a diuretic, and confirmed by ABPM or HBPM. The
... Forthosemotivatedtotry,considerableweight
prevalenceofresistanthypertensionislikelytobe<10%oftreated
... losswithuseoflow-caloriedietsfollowedby
hypertensivepatients.Spironolactoneisthemosteffectivedrugfor
... foodreintroductionandweight-maintenance IIa A
loweringBPinresistanthypertensionwhenaddedtoexistingtreat-
... phasesearlyafterdiagnosiscanleadtoDM
ment;however,theriskofhyperkalaemiaisincreasedinpatientswith
.. remissionandshouldbeconsidered.585,586
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 63 ---
ESCGuidelines 3289
.
.
. 4.8.1.Keyriskfactorconceptsandnewerparadigms
Glycaemiatargets .
.
. Exceptforglucosemanagement,preventionofASCVDfollowsthe
AtargetHbA1cforthereductionofCVDrisk ..
. sameprinciplesasforpeoplewithouttype2DM.AchievingBPand
andmicrovascularcomplicationsofDMof ..
. LDL-Ctargetsisparticularlyimportant.Morerecently,trialevidence
<7.0%(53mmol/mol)isrecommendedforthe I A ..
. has shown that drugs in the sodium-glucose cotransporter 2
majorityofadultswitheithertype1ortype2 ..
. (SGLT2)inhibitororglucagon-likepeptide-1receptoragonist(GLP-
DM.587,588 ..
. 1RA) classes lower ASCVD, HF, and renal risks independently of
.
ForpatientswithalongdurationofDMandin .
oldorfrailadults,arelaxingoftheHbA1ctar- IIa B
... baselineHbA1candwhetherpatientsareonmetformin.Suchbene-
gets(i.e.lessstringent)shouldbeconsidered.588
... fitsaremostevidentinthosewithexistingASCVD,HF,orCKD,but
.. appeartoextendtogroupsatelevatedrisk.Thishasledtonewer
AtargetHbA1cof<_6.5%(48mmol/mol)should .
.. treatmentalgorithms.
beconsideredatdiagnosisorearlyinthecourse
IIa B
...
oftype2DMinpersonswhoarenotfrailand ...
4.8.1.1Lifestyleintervention
donothaveASCVD.587,588 ...
Lifestyle management is a first priority for ASCVD prevention and
TreatmentofhyperglycaemiaandASCVD/cardiorenalrisks ...
management of DM. Most persons with DM are obese, so weight
.
Metforminisrecommendedasfirst-linetherapy, .. controliscrucial.Severaldietarypatternscanbeadopted,wherethe
.
followingevaluationofrenalfunction,inthe
I B
... predominance of fruits, vegetables, wholegrain cereals, and low-fat
majorityofpatientswithoutpreviousASCVD, .. proteinsourcesismoreimportantthanthepreciseproportionsof
.
CKD,orHF.589 .. totalenergyprovidedbythemajormacronutrients.Saltintakeshould
. Inpersonswithtype2DMwithASCVD,metfor- .. be restricted. Specific recommendations include limiting saturated
.
minshouldbeconsidered,unlesscontraindica- IIa B .. andtransfatsandalcoholintake,monitoringcarbohydrateconsump-
.
tionsarepresent.5,590(cid:2)592 .. tion,andincreasingdietaryfibre.AMediterranean-typediet,where
.
.
Avoidanceofhypoglycaemiaandexcessive . fatsourcesarederivedprimarilyfrommonounsaturatedoils,ispro-
weightgainshouldbeconsidered.559,588,593
IIa B ...
tectiveagainstASCVD.Moredetailisprovidedinsection4.3.2.
.
.
Inpersonswithtype2DMandASCVD,theuse .. Acombinationofaerobicandresistanceexercisetrainingiseffec-
.
ofaGLP-1RAorSGLT2inhibitorwithproven .. tiveinpreventingtheprogressionoftype2DMandforthecontrol
I A .
outcomebenefitsisrecommendedtoreduce .. ofglycaemia.Smokersshouldbeofferedcessationsupport(seesec-
.
CVand/orcardiorenaloutcomes.590(cid:2)592 .. tion4.5).Lifestyleinterventionlowersfuturemicrovascularandmac-
.
Inpatientswithtype2DMandTOD,ctheuseof .. rovascularrisksaswellasmortalityinthelongerterm.603Intensive
.
anSGLT2inhibitororGLP-1RAwithproven .. lifestylechangeswithlow-caloriedietsandmeanweightlossesinthe
outcomebenefitsmaybeconsideredtoreduce
IIb B ...
regionof10kgleadstoremissionoftype2DMinaround46%of
.
futureCVandtotalmortality.594(cid:2)597 .. cases at 1 year and 36% by 2 years.585 In those with prediabetes,
.
Inpatientswithtype2DMandCKD,theuseof
... otherASCVDriskfactorsshouldbeassessedbothbefore(toincen-
anSGLT2inhibitorisrecommendedtoimprove I A
... tivizeimprovements)andafterlifestylechangeshavetakenplace.604
.
ASCVDand/orcardiorenaloutcomes.598,599 ..
.. 4.8.1.2Glycaemiccontrol
Inpatientswithtype2DMandHFrEF,useofan .
.. TheUKPDS587establishedtheimportanceofintensiveglucoselow-
SGLT2inhibitorwithprovenoutcomebenefits .
I A .. eringwithrespecttoCVDriskreductioninpersonsnewlydiagnosed
isrecommendedtolessenHFhospitalizations .
andCVdeath.600,601
... with DM, with better evidence to support metformin, which cor-
.. rectly remains thefirstagentofchoice for themajority of patients
Inpatientswithtype2DMbutwithoutASCVD, ...
diagnosedwithDM.ThreetrialswereconductedtoseeifCVevents
HF,orCKD,useofanSGLT2inhibitororGLP- ..
. could be reduced further with more intensive glycaemia treat-
1RAshouldbeconsideredbasedonestimated
IIa B
...
ment.559,588,593However,therewereunexpectedincreasesintotal
futurerisks(e.g.withtheADVANCEriskscore ..
. and ASCVD deaths in the ACCORD (Action to Control
orDIALmodel)foradverseCVDorcardiorenal ...
CardiovascularRiskinDiabetes)trial559andasimilartrendinVADT
outcomesfromriskfactorprofiles.602 ...
(VeteransAffairsDiabetesTrial).593Theresultspromptedconcerns
.
.
ACR = albumin-to-creatinine ratio; ADVANCE = Action in Diabetes and .. aboutpursuingtightglucosecontrol,particularlyinolderpeoplewith
Vasculardisease:preterAxanddiamicroN-MRControlledEvaluation;ASCVD= .. DMandinthosewithexistingASCVD.Subsequentmeta-analysesof
.
atheroscleroticcardiovasculardisease;CKD=chronickidneydisease;CV=car- .
. relevanttrialsshowedreductionsinnon-fatalAMIandCADevents,
diovascular; DIAL = Diabetes lifetime-perspective prediction; DM = diabetes .
mellitus;eGFR=estimatedglomerularfiltrationrate;GLP-1RA=glucagon-like ... butnoeffectonstrokeortotalmortality.605,606Themeta-analyses
peptide-1receptoragonist;HbA1c=glycatedhaemoglobin;HF=heartfailure; .. suggestedthatCVDbenefitsforanaverageHbA1creductionof0.9%
.
HFrEF = heart failure with reduced ejection fraction; PA = physical activity; .
SGLT2=sodium-glucosecotransporter2;TOD=targetorgandamage.
.. over 5 years were less than via treatment of cholesterol and BP.
.
aClassofrecommendation. .. HbA1c targets should be personalized to individual characteristics
b cSL ee eve Tl ao bf leev 4id foe rnc de e.
tails.
.... andpreferences.
.. Four trials of dipeptidyl peptidase-4 inhibitors607(cid:2)610 in patients
.
.. with DM and existing ASCVD or at high risk demonstrated non-
.
. inferiority(i.e.safety)butnotsuperioritywithrespecttoCVDrisk.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 64 ---
3290 ESCGuidelines
.
Therewas,however,anincreaseintherateofhospitalizationforHF .. (EASD)consensusreport,592recommendthatmetforminshouldbe
.
with saxagliptin in the SAVOR-TIMI 53 (Saxagliptin Assessment of .. usedasfirst-linetreatment,whiletheESCGuidelines5recommended
.
Vascular Outcomes Recorded in Patients with Diabetes Mellitus .. in2019thatSGLT2inhibitorsandGLP-1RAsmaybeusedwithout
.
ThrombolysisinMyocardialInfarction)trial.608 .. metformininpeoplewithDMandCVDorathighriskofCVD,as
.
.. reviewed.602AsubsetofthewritinggroupsoftheADA/EASDcon-
.
4.8.1.3 Newerdiabetesmellitusdrugclasses:cardiovasculardisease .. sensusreportandtheESCGuidelines616wasconvenedasanexpert
.
.
benefits . panel. The expert panel emphasized the overall commonalities of
.
.
Recenttrialsfromtwoclassesofdrugs(SGLT2inhibitorsandGLP- . approachandtheneedtoensurethatpeoplewithtype2DM,CVD,
.
.
1RAs) have shown CVD benefits that appear independent of . HF, or CKD are treated appropriately with an SGLT2 inhibitor or
.
.
glycaemic control and, where examined, of baseline metformin . GLP-1RA.Thepanelconcludedthatthisapproachshouldbeinitiated
.
use.596,597,611 Their results have recently been systematically meta- .. independentofbackgroundtherapy,glycaemiccontrol,orindividual-
.
analysed(SupplementaryFigures1(cid:2)4).590,591 .. ized treatment goals.616 The view of the ESC is that metformin
.
.
ForSGLT2inhibitors,threetrialsdemonstratedtheCVbenefitsof . should be considered, but is not mandatory first-line treatment in
.
.
empagliflozin, canagliflozin, and dapagliflozin.611(cid:2)613 Major adverse . patientswithASCVDorevidenceofTOD.Certainly,theinitiationof .
.
CVevents(MACE)werereducedmodestly,by14%,withnoclear .. metformininsuchpatientsshouldnotforegoordelaytheinitiation
.
effect on stroke and an unclear effect on myocardial infarction.590 .. ofevidence-basedSGLT2inhibitorsorGLP-1RAs.Ariskscoreplus
.
However, reductions in incident HF hospitalization/CVD death by .. cost-effectiveanalyseswouldbeusefultodeterminewhichpatients
.
24%andrenalendpointsby44%wereseen.590TheMACEbenefits .. free fromASCVD orevidence ofTODmaybe recommended for
.
wereevidentonlyinthosewithbaselineASCVD,butHFandrenal .. thesenewerdrugs.Inalltheabove,thereisnoevidenceofanysex
.
benefitsappearedtoextendtothosewithtype2DMwithmultiple .. interaction in benefits. Finally, people with type 2 DM should be
.
riskfactors.However,amorerecenttrialinpeoplewithtype2DM .. involvedindecision-makingafterexplanationofthepotentialbenefits
.
andASCVDshowedertugliflozintobenon-inferiortoplacebowith .. andside-effectsofthedrugs.
.
respect to MACE outcomes.614 Whether the results represent a ..
.
classeffectis,therefore,notclear.FourfurtherSGLT2inhibitortrials ..
. 4.8.2.Type1diabetesmellitus
demonstrated the benefit of canagliflozin598 and dapagliflozin599 in ..
. TheDCCT(DiabetesControlandComplicationsTrial)established
patientswithCKD[withDAPA-CKD(DapagliflozinandPrevention ..
. the importanceoftightglucose controltolessen the risksofboth
.
of Adverse Outcomes in Chronic Kidney Disease) showing similar .
benefitsinpeoplewithoutDM],anddapagliflozin600andempagliflo-
... microvascular and macrovascular disease in both men and women
zin601inpatientswithHFrEF,withbothtrialsshowingsimilarbenefits
... withtype1DM.617A27-yearfollow-upofthistrialshowedthat6.5
.. yearsofintensiveDMtherapywasassociatedwithamodestlylower
inthosewithouttype2DM. .
.. all-cause mortality rate.617 A glycaemic target for HbA1c of
Thespecificpatternoftrialresults(e.g.earlyseparationofcurves .
.. 6.5(cid:2)7.5% (48(cid:2)58 mmol/mol) appears to be a balanced approach
forHFhospitalization)suggeststhatthebenefitsofSGLT2inhibitors .
.. forlong-termcare.
mayrelatemoretocardiorenalhaemodynamiceffectsthantoathe- .
rosclerosis.600Otherthangenitourinaryinfections,ratesofadverse
... Recently,metforminwasshownnottolowerprogressionofcaro-
.. tidIMTinpersonswithtype1DMconsideredtobeatelevatedCVD
events(includingdiabeticketoacidosis)weregenerallylow.Onetrial .
showedanexcessofamputationsandfractures,612butnoneofthe
... risk.618Itsuseisnotrecommendedintype1DMforthisindication.
.. SGLT2inhibitorsimprovemetaboliccontrolintype1DMandmay
other trials noted imbalances. Patients should be advised on the ...
complementinsulintherapyinselectedpatients.
importanceofgenitourinary hygiene before being prescribed these ..
.
medications. ..
GLP-1RAs reduce MACE, CV death, and all-cause mortality by ... 4.9. Antithrombotic therapy
.
around12%,witharounda9%reductioninmyocardialinfarctionand .
.
a16%reductioninstroke.591Furthermore,HFisloweredby9%and .. Recommendationsforantithrombotictherapy
.
. acompositerenaloutcomewasloweredby17%.Theresultscannot .
.. Recommendations Classa Levelb
be explained by lowering of glucose levels and, in multiple SGLT2 .
.
.
inhibitorandGLP-1RAtrials,subgroupanalysessuggestedthatthese .. Aspirin75-100mgdailyisrecommendedfor
benefitscouldbeindependentofmetforminuse.594(cid:2)597Mosttrials ... secondarypreventionofCVD.619 I A
.
wereconductedinpatientswithexistingASCVDor,intheREWIND .
. Clopidogrel75mgdailyisrecommendedasan
.
(Researching Cardiovascular Events With a Weekly Incretin in .
. alternativetoaspirininsecondarypreventionin I B
.
Diabetes)trial,withasignificantproportionofpatientsathighriskfor .. caseofaspirinintolerance.620
CVD.615Side-effectsofthisclassmainlyincludenauseaandvomiting, ..
.. Clopidogrel75mgdailymaybeconsideredin
which can lessen with gradual up-titration. Risks of hypoglycaemia .
.. preferencetoaspirininpatientswithestablished IIb A
canbereducedbyloweringdosesofsulphonylureasorinsulin. .
.. ASCVD.620,621
Thelargelypositiveresultsofthesetwoclassesofdrugs(SGLT2 .
.
. Concomitantuseofaprotonpumpinhibitoris
inhibitors and GLP-1RAs) have led to rapid changes in DM algo- ..
. recommendedinpatientsreceivingantiplatelet
rithms, but with some differences in interpretation.602 Most DM .. I A
. therapywhoareathighriskofgastrointestinal
guidelines, including those within the 2020 American Diabetes ...
bleeding.622,623
Association(ADA)/EuropeanAssociationfortheStudyofDiabetes .
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 65 ---
ESCGuidelines 3291
.
.
. Subgroup analysis suggested a greater benefit of clopidogrel in
InpatientswithDMathighorveryhighCVD .
.
. patients with LEAD. A meta-analysis showed a clinically modest
risk,low-doseaspirinmaybeconsideredforpri- .
marypreventionintheabsenceofclear
IIb A .... riskreductionwithP2Y 12inhibitormonotherapy(numberneeded
contraindications.5,624,625 ... totreat:244),andnoeffectonall-causeorvascularmortalityand
Antiplatelettherapyisnotrecommendedinindi-
... majorbleeding.621Moreguidanceonantithrombotictreatmentin
vidualswithlow/moderateCVriskduetothe III A
... thespecificsettingsofCAD,cerebrovasculardisease,andLEAD,
increasedriskofmajorbleeding.624,626(cid:2)630
... including possible indications for dual pathway inhibition in
.. patientswithLEAD,isgiveninsection6.
.
ASCVD=atheroscleroticcardiovasculardisease;CV=cardiovascular;DM=dia- ..
.
betesmellitus. .
aClassofrecommendation. .. 4.9.3.Protonpumpinhibitors
.
bLevelofevidence. .. Protonpumpinhibitorsreducetheriskofgastrointestinalbleedingin
.
. patientstreatedwithantiplateletdrugsandmaybeausefuladjunctive
.
.
. therapytoimprovesafety.634,635Protonpumpinhibitorsthatspecifi-
.
.
.. cally inhibit CYP2C19 (omeprazole or esomeprazole) may reduce
.
4.9.1.Antithrombotictherapyinindividualswithout .. thepharmacodynamicresponsetoclopidogrel.Althoughthisinterac-
.
atheroscleroticdisease .. tionhasnotbeenshowntoaffecttheriskofischaemicevents,coad-
.
In 2009, a meta-analysis in patients with low CVD risk reported a .. ministrationofomeprazoleoresomeprazolewithclopidogrelisnot
.
12% reduction in ASCVD with aspirin but a significant increase in .. recommended.622
.
majorbleeding.619CVDriskreductionandbleedingrisksweresimilar .
. .
inmenandwomen.631Morecontemporaryprimarypreventiontrials .. 4.10. Anti-inflammatory therapy
.
reportednoorlittlebenefitinpatientswithoutASCVDandaconsis- ..
tentincreaseinbleeding.624,626,627Anupdatedmeta-analysisdidnot ..
. Recommendationforanti-inflammatorytherapy
.
showareductioninall-cause orCVmortalitywithaspirin,butdid .
.
.
showa lowerriskofnon-fatal myocardialinfarction(RR 0.82)and .. Recommendation Classa Levelb
.
ischaemic stroke (RR 0.87).628 Conversely, aspirin was associated .
.
. Low-dosecolchicine(0.5mgo.d.)maybeconsid-
withahigherriskofmajorbleeding(RR1.50),intracranialbleeding .
.
. eredinsecondarypreventionofCVD,particu-
(RR1.32),andmajorgastrointestinalbleeding(RR1.52),withnodif- ..
. larlyifotherriskfactorsareinsufficiently IIb A
ferenceintheriskoffatalbleeding(RR1.09).Bleedingriskswerepar- ..
. controlledorifrecurrentCVDeventsoccur
ticularly increased in older persons. Other recent meta-analyses ..
. underoptimaltherapy.85,86
found verysimilarresults.629,630Overall,althoughaspirin should ..
.
notbegivenroutinelytopatientswithoutestablishedASCVD,we .. CVD=cardiovascular;o.d.=omnidie(onceaday).
.
cannot exclude that in some patients at high or very high CVD .. aClassofrecommendation.
risk, the benefits outweigh the risks.632,633 In patients with DM
... bLevelofevidence.
.
andnoevidentASCVD,theASCENDstudyreporteda12%risk ..
.
reductionandasignificantincreaseinmajorbleeding,butnotin .. Acknowledgingthattheprocessofatherosclerosishasinflamma-
.
fatal or intracranial bleeding.624 A meta-analysis of aspirin for .. tory components has led to the investigation of various anti-
.
primary prevention in DM found a number needed to treat of .. inflammatorytherapiesinrecentyears.Thefirststudytoexamine
.
95 to prevent one major adverse ischaemic event in 5 years.625 .. theeffectsofreducinginflammationwithoutimpactinglipidlevels
.
Hence, as in patients without DM, aspirin may be considered if .. was CANTOS (Canakinumab Antiinflammatory Thrombosis .
CVD risk is exceptionally high. Only one in four patients in the .. Outcome Study), in which the monoclonal antibody, canakinu-
.
ASCENDstudywerebeingtreatedwithaprotonpumpinhibitor. .. mab,providedproof-of-conceptforanti-inflammatorytherapyin
.
Widerusethanthiscouldpotentiallyamplifythebenefitofaspirin .. high-risk patients.636 This particular drug was, however, not fur-
.
. inprimarypreventionforpatientsathigheratheroscleroticrisk. . therdevelopedforthisindicationbecauseoftheriskoffatalinfec-
.
.
In apparently healthy persons <70 years of age with (very) high . tions and high costs. Methotrexate was the second anti-
.
.
CVDrisk,furtherstudiesareneeded.Untilthen,decisionsinthese . inflammatory drug studied for this purpose, but was not proven
. high-riskpersonsshouldbemadeonacase-by-casebasis,takingboth .. effectiveinreducingCVDoutcomes.637
.
.
ischaemicriskandbleedingriskintoconsideration. . In 2019, COLCOT (Colchicine Cardiovascular Outcomes Trial)
.
.
. reported a significant reduction (HR 0.77) in CVD outcomes with
.
.
4.9.2.Antithrombotictherapyinindividualswith . low-dose colchicine [0.5 mg o.d. (once a day)] in patients with a
.
.
establishedatheroscleroticdisease .. recentAMI. Themore recent LoDoCo2 (secondlow-dose colchi-
.
Inestablishedatheroscleroticdisease,aspirinisassociatedwithsignifi- .. cine)trialreinforcedtheseresultsinpatientswithchronicCAD(HR
cantreductionsinseriousvascularevents,includingstrokeandcoro- ... 0.69).85Thisstudyobservedatrendtowardsincreasednon-CVmor-
.
naryevents,anda10%reductionintotalmortality.619Thesebenefits .. tality,whichrequiresfurtherattention.
.
outweighthebleedinghazards. .. The useof colchicinein dailypracticeremainsto be established
.
In patients with previous myocardial infarction, stroke, or .. basedonfurtherclinicalstudydataandexperiencesindailypractice.
.
LEAD, clopidogrel showed a slight superiority for ischaemic .. Nonetheless, the encouraging results justify consideration of low-
.
events with respect to aspirin, with a similar safety profile.620 . dosecolchicineinselected,high-riskpatients.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 66 ---
3292 ESCGuidelines
.
.
4.11. Cardiac rehabilitation and . Recently, the European Association of Preventive Cardiology
.
.
prevention programmes .. (EAPC)proposed minimal and optimalstandards for improvement
.. ofsecondarypreventionthroughCRprogrammesinEurope.657
.
.
Recommendationsforcardiacrehabilitation .. AlthoughexercisetrainingprescriptionshouldadopttheFITT(fre-
.
. quency,intensity,timeduration,andtypeofexercise)model,inter-
.
Recommendations Classa Levelb .. clinician variance and disagreement exists.658 To optimize exercise
.
.
. training,theEAPChasintroducedadigital,interactivedecisionsup-
Participationinamedicallysupervised,struc- ..
. porttool;theEXPERT(EXercisePrescriptioninEverydaypractice&
tured,comprehensive,multidisciplinaryEBCR ..
. Rehabilitation Training) Tool (https://www.escardio.org/Education/
andpreventionprogrammeforpatientsafter ..
ASCVDeventsand/orrevascularization,andfor
I A ... Practice-Tools/CVD-prevention-toolbox/expert-tool).659 No single
patientswithHF(mainlyHFrEF),isrecom-
... exercisecomponentisasignificantpredictorofmortality;onlyadher-
mendedtoimprovepatientoutcomes.638(cid:2)642
... encetothefullinterventionimprovesoutcome.660
.. Despiteprovenbenefits,ratesofreferral,participation,andimple-
MethodstoincreaseCRandpreventionreferral .
.. mentationare low.653,660,661 Uptake seemslower in women,buta
anduptakeshouldbeconsidered(i.e.electronic .
.. varietyofotherintrapersonal,interpersonal,clinical,logistical,health
promptsorautomaticreferrals,referralandliai- .
IIa B .. system, and CRprogramme-related factors affectparticipationand
sonvisits,structuredfollow-upbynursesor .
.. adherence.662 CR enrolment is higher if trained nurses or allied
healthprofessionals,andearlyprogrammeinitia- ...
healthcareprovidersinterveneface-to-face,whereasadherencemay
tionafterdischarge).643(cid:2)646 ...
be higherwhen remote interventions are implemented (i.e. home-
Home-basedCR,telehealth,andmHealthinter- ... based).643 Nurse-coordinated programmes can increase
ventionsmaybeconsideredtoincreasepatient IIb B ... effectiveness.644(cid:2)646Home-basedCRwithorwithouttelemonitor-
participationandlong-termadherenceto ..
. ing may increase participation and appear similarly effective as
healthybehaviours.647,648 ...
centre-basedCR.647Telehealthinterventionsaremoreeffectivethan
.
ASCVD = atherosclerotic cardiovascular disease; CR = cardiac rehabilitation;
... nointervention,648butmayalsocomplementconventionalCR.Also,
.
EBCR=exercise-basedcardiacrehabilitation;HF=heartfailure;HFrEF=heart . mobile device-based healthcare (mHealth) delivery through smart-
.
failure with reduced ejection fraction; mHealth = mobile device-based .
. phonesmaybeaseffectiveastraditionalcentre-basedCR,showing
h aCea lalt sh sc oa fre re.
commendation.
....
significant improvements in health-related quality of life.663 These
bLevelofevidence. .. novel interventions may support thepatientto maintain long-term
.
.. healthybehavioursafterspecializedCRprogrammes.664
.
CRisacomprehensive,multidisciplinaryinterventionnotjustinclud- ..
.
.
ingexercisetrainingandPAcounselling,butalsoeducation,riskfac- .
.
.
tor modification, diet/nutritional counselling, and vocational and . 5. Policy interventions at the
.
psychosocialsupport.358 Prevention and rehabilitation programmes ..
.. population level
afterASCVDeventsorrevascularizationreduceCVhospitalizations, .
.
.
myocardial infarction, CV mortality and, in some programmes, all- .
.
causemortality.638,640(cid:2)642Theymayalsoreducedepressive/anxiety ..
. Recommendationsforpolicyinterventionsatthepopu-
symptoms.649InpatientswithchronicHF(mainlyHFrEF),exercise- ...
lationlevel
.
basedcardiacrehabilitation(EBCR)mayimproveall-causemortality, .
. .
reducehospitaladmissions,andimproveexercisecapacityandquality . Recommendations Classa Levelb,c
. .
oflife.639,650CRisgenerallycost-effective.651 .
.
. PoliciesandpopulationapproachestoPA,diet,
Clinicaltrialsandregistriesarehighlyheterogeneous,whichinflu- ..
. smokingandtobaccouse,andalcoholingov-
encesnationalguidelines,legislation,andreimbursement.652,653The ..
. ernmentalrestrictionsandmandates,mediaand
results of recent reviews provide clinicians with minimal require- ..
. education,labellingandinformation,economic
mentsforsuccessfulCRafterACSorcoronaryarterybypassgraft: ..
. incentives,schools,worksites,andcommunity
.
• CRisacomprehensivemultidisciplinaryintervention466,649,654,655 .. settingsfollowdifferentlevelsofrecommenda- .
.
• CR is supervised and carried out by adequately trained health . tions(seespecifictablesinthesupplementary
.
professionals,includingcardiologists649 .. materialforsection5).
.
• CRstartsassoonaspossibleaftertheinitialCVevent649 ...
Puttinginplacemeasurestoreduceairpollution,
• EBCRincludesaerobicandmuscularresistanceexercise,which ...
includingreducingPMemissionandgaseouspol-
shouldbeindividuallyprescribedbasedonpre-exercisescreen- ...
lutants,reducingtheuseoffossilfuels,andlimit- I C ingandexercisetesting656 ...
ingcarbondioxideemissions,arerecommended,
• The dose of EBCR (number of weeks of exercise training (cid:5) ...
toreduceCVDmortalityandmorbidity.
averagenumberofsessions/week(cid:5)averagedurationofsession ..
.
inminutes)exceeds1000638 .. CVD=cardiovasculardisease;PA=physicalactivity;PM=particulatematter.
• ThenumberofEBCRsessionsneedstoexceed36641 .... a bC Lela vs es lo of fr ee vc ido em nm cee .ndation.
• DuringCR,allindividuallyrecognizedCVriskfactorsneedtobe .
.. cLevelofevidenceapplieslesswelltopolicyinterventions,andthetypeofempir-
addressedandtreated.642 . icalevidencevarieswidelyacrosstheseparateapproachessuggested.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 67 ---
ESCGuidelines 3293
.
.
5.1. Population-level approaches to the . professionals play an important role in advocating evidence-based
.
.
prevention of cardiovascular disease .. population-levelinterventions.Bymodifyingthegeneralcontext,one
.
. caninducehealthydecisionsasadefaultinentirepopulations(allage
Population level approaches to CVD prevention centre around ..
. groupsandparticularlyvulnerableones).Thetaskforbothnational
upstreammeasuresrequiringbroadpublic-healthinterventionstar- ..
. and local authorities is to create social environments that provide
getinglifestyleandpromotingmonitoringofCVD.Thesemeasures ...
healthierdefaults,takinghealthliteracy intoaccount.669,670 Theevi-
are designed to address populations and are intended to shift the ..
. dencepresentedherebuildsonrecentcomprehensivereviewsand
populationattributable risk.This isbasedona preventionparadox ..
. individualstudies,notingthatitisrarelyfeasibletouseanRCTtoeval-
describedbyGeoffreyRosein1981.665Thepopulationattributable ..
riskdependsontheRRandontheprevalenceofariskfactorinthe
... uate population-level interventions (in contrast to individual-level
generalpopulation.IftheprevalenceofasignificantRRfactorislow,
... interventions).671,672Theimportanceofheartdiseaseinwomenhas
thenthepopulationattributableriskmaybemodest.Conversely,ifa
... become apparent and sex differences in CVD prevention have
low-impact RR factor is common, the population attributable risk
... promptedsex-specificawarenesscampaignswiththeaimofreducing
maybehigh.ThispreventionapproachfollowingtheGeoffreyRose
... sex disparities in research and clinical care. While interpreting this
paradigm665,666statesthatsmallshiftsintheriskofdiseaseacrossa ... section,itisimportanttorecognizethatthereareoftenvestedinter-
.. ests,whichmayinfluencepolicydecisionsonhealthpromotion.
wholepopulationconsistentlyleadtogreaterreductionsindisease .
burden than does a large shift in high-risk individuals only.667,668 In
... Thesupplementarymaterialforthissectionpresentsevidencefor
.. population-levelstrategiesdealingwithspecificriskfactorinterven-
other words, many people exposed to a small risk may generate .
.. tionsforPA(section5.2.1),diet(section5.2.2),smokingandtobacco
more disease than a few exposed to a conspicuous risk. This .
.. use(section5.2.3),andalcoholconsumption(section5.2.4).Lifestyle
population-wideapproach—asopposedtostrategiestargetinghigh- . .. changes at the population level take time, may be expensive, and
riskindividuals—hasmajoradvantagesatthepopulationlevelwhilst .
.
. needtobe sustained overtime.Furthermore, thebenefits maybe
sometimes having only a modest benefit at the individual level, .
.
. slow to manifest; however, they persist over the long term and
becauseitaddressestheCVhealthofalargenumberofindividuals .
.
. improvehealth-relatedqualityoflifeandwell-being.
over the entire life course. It should be noted that high-risk and .
.
.
population-levelpreventionstrategiesarenotmutuallyexclusiveand .
.
mustthereforecoexist. ... 5.2.1.Physicalactivity
Prevalenceofhigh-riskconditionsandincidenceratesofCVDvary ... Pleaseseethesupplementarymaterialsection3.1.
.
across countries. Many of their underlying causes are known, and ..
.
they are closely related to dietary habits, PA, smoking, alcohol, .. 5.2.2.Diet
.
employment,socialdeprivation,andtheenvironment.Theobjective .. Pleaseseethesupplementarymaterialsection3.2.
.
of population approaches to prevention of CVD is to control the ..
.
underlyingdeterminantsofCVhealthand,inthisway,reducepopula- .. 5.2.3.Smokingandtobaccouse
.
tionincidencerates.Thepopulationapproachmaybringnumerous .. Pleaseseethesupplementarymaterialsection3.3.
.
benefits,suchasnarrowingthegapinhealthinequalities,preventing ..
.
otherconditionssuchascancer,pulmonarydiseases,andtype2DM, ...
5.2.4.Alcohol
and savingcostsfromthe avoidedCVevents and earlyretirement ..
. Pleaseseethesupplementarymaterialsection3.4.
.
duetohealthproblems. .
.
.
Individualbehaviourisenactedinanenvironmentwithhierarchical .. 5.3. Environment, air pollution, and
. levels,whichencompassindividualchoice,familyinfluence,culturaland .
. climate change
. ethnicgrouping,workplace,healthcare,andpolicyattheregional,state .
.
. Air pollution contributes to mortality and morbidity. It specifically
andgloballevels(e.g.EUpoliciesandinternationaltradeagreements). .
.
. increasestheriskofrespiratoryandCVdiseases,notablyCAD,HF,
Theaimofthissectionoftheguidelinesistoprovideevidence-based .
.
. cardiacarrhythmiasandarrest,cerebrovasculardisease,andvenous
suggestionsforthemosteffectiveinterventionstoreduceCVDriskat .
.. thromboembolism.158,673,674Lossoflife-expectancyduetoambient
the population level, improve CVD health, and promote healthy .
.
. airpollutionhasbeenestimatedat2.9years,accountingforanesti-
choicesatthecommunity,regional,andgloballevel.Healthchallenges .
.. matedglobalexcessmortalityof8.8million/year.159Plausiblemecha-
cannotbesolvedbythehealthcaresystemsaloneandrequirepolitical . .
. nisms by which air pollution is linked to CVD include promoting
support.Toadvancethiscause,theWHOhasbeenorganizingGlobal .
.
. atherosclerosis,inflammation,thrombosis,systemicvasculardysfunc-
ConferencesonHealthpromotionsince1990. ..
. tion, myocardial fibrosis, epigenetic changes, and interactions with
.
.
. traditionalriskfactors.158
.
5.2. Specific risk factor interventions at .
.. Importantsourcesoffineparticlesareroadtraffic,powerplants,
the population level ...
andindustrialandresidentialheatingusingoil,coal,andwood.Main
.
Population-levelinterventionsaimtoalterthesocietalenvironment, .. componentsofoutdoorairpollutionincludeairbornePM(rangingin
.
modifycertainsocialdeterminantsofhealth,andprovideincentives ... sizefromcoarseparticles2.5(cid:2)10mm,fineparticles<2.5mm(PM 2.5),
toencouragechangesinindividualbehaviourandexposuretoriskfac- .. andultrafineparticles<0.1mmindiameter)andgaseouspollutants
.
tors.Socialdeterminantsofhealthincludesocioeconomicstatus(edu- .. suchasozone,nitrogendioxide,volatileorganiccompounds,carbon
.
cation,occupation,andincome),wealthinequalities,neighbourhood .. monoxide, and sulphur dioxide, produced primarily by fossil fuel
.
andurbandesign,andsocialnetworks,tonamebutafew.Healthcare . combustion.158,675Uptoone-thirdofEuropeanslivinginurbanareas
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 68 ---
3294 ESCGuidelines
.
are exposed to levels exceeding EU air-quality standards. The EU .. 6.1.Coronaryartery disease
.
Commissionreleasedapolicypackagetobeimplementedby2030, ..
Disease-specific acute management of coronary syndromes is cov-
.
with measures to reduce harmful emissions from traffic, energy .. eredindetailinrecentguidelines.677(cid:2)680
.
plants,andagriculture. ..
As for antithrombotic therapy, dual antiplatelet therapy (DAPT)
.
Indoorairpollutionandexposuretonoisemustalsobehighlighted. ...
for12months,preferablywithprasugrelorticagrelor,isthestandard
Householdairpollution,suchasthatproducedfromburningbiomass, ... antithrombotic treatment after ACS.681(cid:2)683 There are conflicting
accountsforover3milliondeathsworldwide.38Ithasbeenestimated ...
data astowhetherprasugrel is preferableto ticagrelor.684,685 A 6-
by the WHO that 30% of the European population is exposed to ... month duration of DAPT after ACS is generally too short,686 but
nightly levels of noise exceeding 55 dB.161 These levels have been ...
maybeconsideredinselectedpatientsathighbleedingrisk.
associated with hypertension, arteriosclerosis, CAD, CV mortality, ...
In patients with chronic coronary syndromes (CCS) undergoing
andstroke.Itshouldbenotedthatmitigatingeffortstoreducenoise ...
electivePCI,thestandarddurationofDAPTis6months,butshort-
exposurehavenot,asyet,proventohaveabeneficialhealtheffect.161 ...
ening this to 1-3 months is an option when bleeding risk is very
.
conT th re ibue tx ete tn ot t Co Vw Dhi hc ah se an lv soiro bn em enen eta sl tae bx lip so hesu dr .1e 5s 7in Ints eo ri vl ea nn td iow nsat te or ..... ah nig dh. t6 ic22 agC relo lop rid mo ag yre bl eis cot nh se idP e2 rY
ed12
afi tn eh rib ci oto mr po lef xc ih no teic re v, enb tu iot np sr .6a 2s 2ugrel
.
reducethispollutionarerequired,includingfactoryregulationsand .. ProlongedDAPT(>12months)followingPCIforeitherACSor
drinkingwatercontrols.157 ...
CCSisanoptionforpatientswhotolerateDAPTwellandhavefea-
.
Patient organizationsand health professionalshave animportant .. turesofhighischaemicrisk.687,688InpatientswithstableCAD,dual-
.
role in supporting education and policy initiatives. Information on .
. pathway inhibition with low-dose rivaroxaban (2.5 mg b.i.d.) and
.
patients’ behaviour during smog peaks is needed. Economic .
. aspirinimprovedCVoutcomesatthepriceofmoremajorbleeding .
incentives,suchasreducedtaxesonelectricandhybridcars,cancon- .. eventsthanaspirinalone.83
.
tributetotheimprovementofairqualityaswellasincentivesencour- .. Basedontheabove,andinlinewiththeCCSGuidelines,622adding
.
aging the use of public transport. Urban design promoting the .
. asecondantithromboticdrug(P2Y inhibitororlow-doserivaroxa-
. 12
constructionofnewhousesandschoolsinareasremotefromhigh- .
. ban)toaspirinforlong-termsecondarypreventionshouldbeconsid-
.
waysandpollutingindustriesneedstobeurged. ..
eredforpatientswhoareathighischaemicriskanddonothavea
.
‘Cleanair’legislationaimedatpromotingdecreasedparticleemissions, ..
highriskofbleeding.Itmayalsobeconsideredinpatientswhoareat
.
and promotion of public transport should also be encouraged. The ..
moderateischaemicriskandwithoutahighriskofbleeding,butthe
.
urgencyofacceptingwhatmightappearas‘comfortsacrifices’fordistant ... benefits are lower.622 More details on antithrombotic treatment
healthbenefits,andthetransitoryhighcostsofreorganizingentiresec- ... optionsarefoundintheESCGuidelinesforCCS.622
tionsofindustry,probablyremainamajordilemmatothepopulation- .
.
basedapproach.AnexampleofsuchlegislationistheEuropeanGreen .. Recommendationsforpatientswithcoronaryartery
.
. disease
Deal,bywhichtheEUaimstobeclimateneutralby2050. .
.
.
.
.. Recommendations Classa Levelb
.
5.3.1.Climatechange .
.
Climate change resulting from the increasing use of fossil fuels, as a
.. Aspirin75-100mgdailyisrecommendedfor
.
majorsourceofbothairpollutionand‘greenhouse’gases,isbecoming
.. patientswithapreviousmyocardialinfarctionor I A
.
amajorpublichealthandenvironmentalconcern.Societalmeasuresto
.. revascularization.619
.
.
reducesuchfuels,andtransfertowardsrenewablesources,arebecom- .. Aspirin75-100mgdailymaybeconsideredin
.
ingurgenttoreduceairpollutionandclimatechange.676Theimpactof .. patientswithoutahistoryofmyocardialinfarc- IIb C
.
diet, notably long-term non-sustainable meat-based food production .. tionorrevascularization,butwithdefinitiveevi-
chains,aswellastheimpactofsedentarylifestylesonclimate-altering
... denceofCADonimaging.622
.
variables,willalsoneedtobeaddressedbypolicymakers. .. InACS,DAPTwithaP2Y 12inhibitorinaddition
. ... toaspirinisrecommendedfor12months,unless
I A 5.4. Implications for public health policy .. therearecontraindicationssuchasexcessive
.
and advocacy at the governmental and
.. riskofbleeding.681(cid:2)683
.
.
non-governmental level .. InpatientswithCCS,clopidogrel75mgdailyis
.
. recommended,inadditiontoaspirin,for6
Pleaseseethesupplementarymaterialsection3.5. ..
. monthsfollowingcoronarystenting,irrespective
.. I A
. ofstenttype,unlessashorterduration(1-3
.
.
6. Risk management of disease- .. months)isindicatedduetoriskoroccurrence
.. oflife-threateningbleeding.622
.
specific cardiovascular disease .
.. Addingasecondantithromboticdrug(aP2Y
12
.
.. inhibitororlow-doserivaroxaban)toaspirinfor
ThissectionaddressesCVDpreventioninspecificclinicalcontexts. ...
long-termsecondarypreventionshouldbecon-
A significant number of patients already have such comorbidities, ...
sideredinpatientswithahighriskofischaemic
IIa A
whichputthematadditionalrisk.Thegeneralprinciplesoflifestyle ...
eventsandwithouthighbleeding
modificationandtreatmentofmajorriskfactorsareoutlinedinsec- ...
risk.83,622,687(cid:2)689
tion4.Inthissection,onlydisease-specificaspectsareadded. ..
. Continued
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 69 ---
ESCGuidelines 3295
.
.
Addingasecondantithromboticdrugtoaspirin
... risk of CV events in patients with symptomatic HFrEF.702(cid:2)719
forlong-termsecondarypreventionmaybecon-
... Importantly,thesedrugsshouldbeup-titratedtothemaximumtoler-
sideredinpatientswithamoderateriskof IIb A
... ateddoses,whichmaybedifferentformenandwomen,particularly
ischaemiceventsandwithoutahighbleeding
... inpatientsrecentlydischargedafterHFhospitalization.690,720,721
risk.83,622,687(cid:2)689 ... SGLT2inhibitors(currentlydapagliflozinandempagliflozin)added
.. ontopofneurohormonalblockadereducestheriskofCVdeathand
ACEinhibitors(orARB)arerecommendedifa .
.. worseningHFinpatientswithsymptomaticHFrEF,withorwithout
patienthasotherconditions(e.g.HF,hyperten- I A .
sion,orDM).622
... DM,600,601andarerecommendedforallpatientswithsymptomatic
.. HFrEF already treated with an ACE inhibitor (or ARNI), a beta-
Beta-blockersarerecommendedinpatientswith
I A
...
blocker,andanMRA.
LVdysfunctionorsystolicHF.622 ..
. Recently, an oral soluble guanylate cyclase receptor stimulator
InpatientswithestablishedASCVD,orallipid- ..
. (vericiguat),administeredalongwithstandardneurohormonalblock-
.
loweringtreatmentwithanultimateLDL-Cgoal . I A . adeinsymptomaticpatientswithHFrEFwithrecentHFhospitaliza-
.
of<1.4mmol/L(55mg/dL)anda>_50%reduc- .
. tion, reduced the composite of death from any cause or HF .
tioninLDL-Cvs.baselineisrecommended. .. hospitalization.722
.
.
ACE=angiotensin-convertingenzyme;ACS=acutecoronarysyndromes;ARB .. Other drugs bring additional moderate benefits for selected
=angiotensinreceptorblocker;ASCVD=atheroscleroticcardiovasculardisease; .. patientswithsymptomatic HFrEF.Diuretics,723,724ivabradine,725,726
.
CAD=coronaryarterydisease;CCS=chroniccoronarysyndromes;DAPT= .. andhydralazine727,728shouldbeconsidered,anddigoxin729maybe
dualantiplatelettherapy;DM=diabetesmellitus;HF=heartfailure;LDL-C= ..
low-densitylipoproteincholesterol;LV=leftventricular. .. considered as complementary therapies in specific patients with
aClassofrecommendation. .. symptomaticHFrEF.SomeofthesetherapiesreduceCVmorbidity
.
bLevelofevidence. ...
andmortality(e.g.ivabradine).
.
.. Additionally,forselectedpatientswithsymptomaticHFrEF,there
.
.. areindicationsforanimplantablecardioverterdefibrillatortoreduce
The management of dyslipidaemia and hypertension in patients .
.. the risk of sudden death and all-cause mortality, and for cardiac
withCADisdiscussedinsections4.6and4.7,respectively.ForACE .
.. resynchronization therapy to reduce morbidity and mortality (for
inhibitors (or ARBs) and beta-blockers, see also the 2019 ESC .
GuidelinesfordiagnosisandmanagementofCCS.622
... details,see2021HFGuidelines).690
.
.
.
.
6.2. Heart failure
... Recommendationsregardingpharmacologicalandnon-
. pharmacologicalinterventionsforpatientswithsymp-
.
The management of HF aims to improve mortality, hospitalization .. tomatic(NewYorkHeartAssociationclassII2IV)heart
.
rate,andqualityoflife.690Toachievethis,multidisciplinarymanage- .. failurewithreducedejectionfraction(leftventricular
.
mentprogrammesandstructuredfollow-upwithpatienteducation, .. ejectionfraction<40%)withprovenbenefitsonclinical
optimizationofmedicaltreatment,usingtelehealthfacilities,lifestyle
... outcomes,includingcardiovascularmorbidityand
. mortality.
changes, psychosocial support, and improved access to care are ..
.
fundamental.691(cid:2)694 ...
Recommendations Classa Levelb
RegardingthemanagementofCVDriskfactors,similarbasicrules ..
.
applyforthosewithandwithoutHF.However,inHF,lowcholes- .. ItisrecommendedthatpatientswithHFare
.
terollevels695,696andlowbodyweightareassociatedwithincreased ... enrolledinacomprehensiveCRprogrammeto
I A
mortality.697,698 Initiation of lipid-lowering therapy is not recom- .. reducetheriskofHFhospitalizationanddeath.c .
mendedinpatientswithHFwithoutcompellingindicationsfortheir .. 691-694
.
use.3Whereasunintentionalweightlossisassociatedwithaworse .. EBCRisrecommendedinstablesymptomatic
.
prognosisregardlessofbaselineBMI,theeffectsofintentionalweight .. patientswithHFrEFtoreducetheriskofHF I A
.
lossremainunclear. .. hospitalization.700,701
.
.
Conversely,regularexercisetraining(particularlycombinedaero- . ItisrecommendedtoscreenpatientswithHF
.
.
bic and resistance exercises) improves clinical status in all patients . forbothCVandnon-CVcomorbiditieswhich,if
. with HF650,699,700 and improves CVD burden and prognosis in .. present,shouldbetreated,providedsafeand I A
.
HFrEF.700,701 .. effectiveinterventionsexist,notonlytoalleviate
.
.
ItisrecommendedtoscreenallpatientswithHFforbothCVand . symptomsbutalsotoimproveprognosis.c
.
.
non-CVcomorbidities;ifpresent,theyshouldbetreated.690These .. AnACEinhibitorisrecommended,inaddition
.
diseases include CAD, hypertension, lipid disorders, DM, obesity, .. toabeta-blockerandanMRA,forpatientswith
. I A
cachexiaandsarcopenia,thyroiddisorders,CKD,anaemia,irondefi- .. symptomaticHFrEFtoreducetheriskofHF
.
ciency,andsleepapnoea.690 .. hospitalizationanddeath.702(cid:2)705
.
ForpatientswithsymptomaticHFrEF,neurohormonalantagonists .. Abeta-blockerisrecommended,inadditiontoan
.
[ACE inhibitors,702(cid:2)705 ARBs,706 angiotensin receptor neprilysin .. ACEinhibitor(oranARNI)andanMRA,for
inhibitors (ARNIs),707(cid:2)710 beta-blockers,711(cid:2)717 and mineralocorti- ... patientswithstable,symptomaticHFrEFtoreduce I A
.
coid receptor antagonists (MRAs)718,719] improve survival and .. theriskofHFhospitalizationanddeath.711(cid:2)717
.
reducetheriskofHFhospitalizations.690Thesedrugsalsoreducethe .
Continued
1202
CSE Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 70 ---
3296 ESCGuidelines
.
AnMRAisrecommendedforpatientswith .. Digoxinmaybeconsideredinpatientswith
.
HFrEFalreadytreatedwithanACEinhibitor(or .. symptomaticHFrEFinsinusrhythmdespite
I A .
anARNI)andabeta-blocker,toreducetherisk .. treatmentwithanACEinhibitor(orARNI),a IIb B
.
ofHFhospitalizationanddeath.718,719 .. beta-blocker,andanMRA,toreducetheriskof
.
Sacubitril/valsartanisrecommendedasa .. hospitalizations(all-causeandHF).729
.
.
replacementforanACEinhibitortoreducethe .
I B .. ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker;
riskofHFhospitalizationanddeathinpatients .. ARNI=angiotensinreceptorneprilysininhibitor;b.p.m.=beatsperminute;CR
withHFrEF.707,730 .. = cardiac rehabilitation; CV = cardiovascular; EBCR = exercise-based cardiac
.
. rehabilitation;HF=heartfailure;HFrEF=heartfailurewithreducedejection
AnARBisrecommendedtoreducetheriskof ...
fraction;LV=leftventricle;LVEF=leftventricularejectionfraction;MRA=min-
HFhospitalizationorCVdeathinsymptomatic .. eralocorticoidreceptorantagonist;NYHA=NewYorkHeartAssociation.
patientswithHFrEFwhoareunabletotolerate I B ... aClassofrecommendation.
anACEinhibitorand/orARNI(patientsshould
.... b cALe pv pe lil eo sf te ov aid lle pn ac te ie.
ntswithHF,regardlessofLVEF.
alsoreceiveabeta-blockerandanMRA).706 .. Forimplantablecardioverter-defibrillatorandcardiacresynchronizationrecom-
.
Dapagliflozinorempagliflozinarerecom-
.. mendations,see690
.
.
mended,inadditiontooptimaltreatmentofan .
.
.
ACEinhibitor(orARNI),abeta-blocker,andan I A .
MRA,forpatientswithHFrEFtoreducetherisk
... 6.3. Cerebrovascular diseases
.
ofHFhospitalizationanddeath.600,601,730 .. Interventions for cerebrovascular diseases depend on the type of
.
. event, i.e. ischaemic or haemorrhagic.732,733 Ischaemic events are Vericiguatmaybeconsideredinpatientswithsymp- .
.
. mainlycausedbyatherothrombosis,cardiacembolism,orsmallves-
tomaticHFrEFwhohaveexperiencedHFworsen- .
.
ingdespitetreatmentwithanACEinhibitor(oran IIb B
.. seldisease.734Othermechanisms(e.g.arterialdissection,patentfora-
.
ARNI),abeta-blocker,andanMRA,toreducethe
.. men ovale, thrombophilia, inherited diseases) are relatively rare.
.
riskofHFhospitalizationorCVdeath.722 ... Intracerebralhaemorrhageismostlycausedbyhypertensiveangiop-
Diureticsarerecommendedinpatientswith
... athyand/orcerebralamyloidangiopathy.735Bleedingcanbeprecipi-
HFrEFwithsignsand/orsymptomsofcongestion I C
... tated by surges in BP values, use of anticoagulants, or diseases
toreducetheriskofHFhospitalization.723,724
... impairingcoagulation.733,735
.. InpatientswithischaemicstrokeorTIA,antithromboticsprevent
Ivabradineshouldbeconsideredinsymptomatic .
.. further vascular events. Cardioembolic ischaemia, which occurs
patientswithLVEF<_35%,insinusrhythm,andwith .
.. mainly in AF, requires anticoagulation (see sections 3.4.3 and
arestingheartrate>_70bpmdespitetreatment .
.. 6.6).736(cid:2)742Innon-cardioembolicmechanism,plateletinhibitorsare
withanevidence-baseddoseofabeta-blocker(or IIa B .
.. recommended.619,620,743(cid:2)753
maximumtolerateddosebelowthat),anACE ...
Innon-cardioembolicischaemicstroke,aspirinisthemoststudied
inhibitor(oranARNI),andanMRA,toreducethe ...
antithrombotic drug. Aspirin 75(cid:2)150 mg/day reduces the risk of
riskofHFhospitalizationorCVdeath.725 ...
recurrent ischaemic stroke and serious vascular events.619,743
Ivabradineshouldbeconsideredinsymptomatic ... Clopidogrel shows slight superiority to aspirin.620 In patients with
patientswithLVEF<_35%,insinusrhythm,and ...
ischaemic stroke or TIA and ipsilateral carotid stenosis, ticagrelor
.
witharestingheartrate>_70b.p.m.whoare .. addedtoaspirincomparedtoaspirinalonereducedtheriskofstroke
unabletotolerateorhavecontraindicationsfor IIa C ... ordeathat1month,withoutanincreaseofseverebleeding.754Adding
.
abeta-blockertoreducetheriskofHFhospital- .. aspirintoclopidogrelwasassociatedwithanon-significantreductionin
.
izationorCVdeath.Patientsshouldalsoreceive .. majorvasculareventsandanincreasedlong-termbleedingrisk.747(cid:2)749
anACEinhibitor(orARNI)andanMRA.726 .. . However, in patients with minor ischaemic stroke or TIA, a short
.
Hydralazineandisosorbidedinitrateshouldbe .. course of DAPT with aspirin and clopidogrel is beneficial.750,751
. consideredinself-identifiedblackpatientswith .. Similarly,ticagrelorandaspirinvs.aspirinalonereducesstrokeordeath
.
LVEF<_35%orwithLVEF<45%combinedwith .. at30daysaftermild-to-moderateischaemicstrokeorTIAnottreated
.
adilatedLVinNYHAclassIII(cid:2)IVdespitetreat- IIa B .. withthrombolysisorthrombectomy.However,DAPTwithticagrelor .
mentwithanACEinhibitor(orARNI),abeta- .. andaspirindidnotimprovetheincidenceofdisabilityandcontributed
.
blocker,andanMRA,toreducetheriskofHF .. to severe bleeding.755 DAPT with dipyridamole plus aspirin also
.
hospitalizationanddeath.731 .. showed superiority over aspirin alone.744 In patients with ischaemic
.
.
Hydralazineandisosorbidedinitratemaybecon- . stroke, however, dipyridamole plus aspirin vs. clopidogrel alone
.
.
sideredinpatientswithsymptomaticHFrEFwho . showed similar rates of recurrent stroke, including haemorrhagic
.
cannottolerateACEinhibitors,ARBs,orARNIs IIb B .. stroke,745butmoremajorhaemorrhagicevents.Inpatientswithnon-
.
.
(oriftheyarecontraindicated),toreducethe . cardioembolic ischaemic stroke, oral vitamin K antagonists are not
.
riskofdeath.728 .. superiortoaspirinandcarryahigherbleedingrisk.752,753Intheabsence
.
.
Continued .. ofadefinitecauseofischaemiaandapresumedoccultcardioembolic
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 71 ---
ESCGuidelines 3297
.
source(e.g.embolicstrokeofundeterminedcause),neitherdabigatran .. 6.4. Lower extremity artery disease
.
norrivaroxabanarebetterthanaspirin.756,757 ...
SymptomaticorasymptomaticLEAD(ABI<_0.90)isassociatedwith
RecommendationsforBPandlipidmanagementarecongruentto ...
adoublingofthe10-yearrateofcoronaryevents,CVmortality,and
.
the general recommendations outlined in sections 4.6 and 4.7.4. In .. total mortality.125 Within 5 years of LEAD diagnosis, 20% develop
.
patients with either ischaemic or haemorrhagic cerebrovascular .. AMIorstroke,andmortalityis10(cid:2)15%.767
.
disease who have a BP of 140/90 mmHg or higher, lowering BP .. AllLEADpatientsrequirelifestyleimprovementandpharmacolog-
reduces the risk of recurrent stroke.758,759 Optimal BP targets ..
. icaltherapy.Smokingcessationincreaseswalkingdistanceandlowers
in these patients are uncertain, as is the optimal drug regimen.760 ... amputation risk.2 In patients with DM, glycaemic control improves
.
Most evidence is available for ACE inhibitors, ARBs, and diuretics. .. limboutcomes.768Statinsprovidemodestimprovementsinwalking
.
Comorbidities may guide the choice of antihypertensive agent. In .. distance,andlowertheriskofadverselimbevents.769,770Combining
patientswithrecentlacunarstroke,thetargetSBPis<130mmHg.761 ...
a statin with ezetimibe771 or a PCSK9 inhibitor also has beneficial
.
Inpatientswithstroke(ischaemicorhaemorrhagic)orTIAwithan .. effects.772
.
LDL-Clevelof100-190mg/dL,atorvastatin80mg/dayreducedthe .
. Plateletinhibitorsareusedtopreventlimb-relatedandgeneralCV
overall incidence of strokes and CV events.762 A recent trial sup- ... events.Theoptimalantiplateletstrategyremainsunclear.773DAPTis
portedanLDL-Ctargetof<1.8mmol/L(70mg/dL).508 ..
. currentlyrecommendedonlyafterintervention(irrespectiveofthe
.
Evidenceofcerebrovascularlesions(e.g.whitematterhyperinten- .
. stenttype)foratleast1month.
.
sities,lacunes, non-lacunar ischaemia) in theabsence ofany stroke .
.. In the COMPASS (Cardiovascular Outcomes for People Using
historyisarelativelycommonfindingatneuroimaging,especiallyin . .. AnticoagulationStrategies)trial,low-doserivaroxabanaddedtoaspirin
olderpatients.Silentcerebrovasculardiseaseisamarkerofincreased ...
inCVDpatientswithanABI<0.90reducednotonlyASCVDevents,
riskofstroke.763,764Arterialhypertension,DM,andcigarettesmok- ...
butalsomajoradverse limbevents,includingamputation(HR0.54),
ingcontributetotheselesionsandshouldbeattendedto.Thereare ..
.
nostudiesaddressingthebesttreatmentoptionsforsilentcerebral .. Recommendationsforpatientswithlowerextremity
.
ischaemia.765 .. arterydisease:bestmedicaltherapy
.
.
.
.. Recommendations Classa Levelb
.
Recommendationsforpatientswithcerebrovascular ..
. Smokingcessationisrecommendedinall
disease ...
patientswithLEAD.29,781
I B
.
.
Recommendations Classa Levelb .. HealthydietandPAarerecommendedforall
. I C
.. patientswithLEAD.
Inpatientswithacerebrovascularevent, .
.
. Inpatientswithintermittentclaudication:
improvementoflifestylefactorsinadditionto .
I A .. (cid:7)Supervisedexercisetrainingis I A
appropriatepharmacologicalmanagementis ...
recommended782(cid:2)784
recommended.732,733,741 ..
InpatientswithischaemicstrokeorTIA,preven-
... (cid:7)Non-supervisedexercisetrainingisrecom-
tionwithantithromboticsisrecommended;
... mendedwhensupervisedexercisetrainingisnot I C
choiceofantithromboticdependsonthemecha-
... feasibleoravailable.
.. Antiplatelettherapyisrecommendedinpatients
nismofevent.Useofanantiplateletisrecom- . I C
I A .. withsymptomaticLEAD.c
mendedforpatientswithnon-cardioembolic .
. . InpatientswithLEADandhypertension,itis
ischaemicstrokeorTIA,anduseofananticoa- .
. . recommendedtocontrolBPat<140/90 I A
gulantisrecommendedinpatientswithcardi- .
.
oembolicischaemicstrokeorTIA.732,741 .. mmHg.776,785,786
.
Inpatientswithnon-cardioembolicischaemic
... InpatientswithLEADandDM,strictglycaemic
I A
strokeorTIA,preventionwithaspirinonly,or
... controlisrecommended.768
I A .
dipyridamoleplusaspirin,orclopidogrelaloneis .. ACEinhibitorsorARBsshouldbeconsideredas
.
recommended.620,743(cid:2)745 .. first-linetherapyinpatientswithPADand IIa B
InpatientswithminorischaemicstrokecorTIA,
... hypertension.d575,787
.
DAPTwithaspirinandclopidogrelorwith .. InpatientswithDMandchronicsymptomatic
aspirinandticagrelor,for3weeksaftertheacute
IIa A ...
LEADwithouthighbleedingrisk,acombination
. IIb B
eventshouldbeconsidered.750,751,755 .. oflow-doserivaroxaban(2.5mgb.i.d.)and
.
InpatientswithstrokeorTIAwhohaveBPof
... aspirin(100mgo.d.)maybeconsidered.774
.
140/90mmHgorhigher,BPloweringis I A ...
ACE=angiotensin-convertingenzyme;ARB=angiotensinreceptorblocker;b.i.d.
recommended.757,766 .. =bisindie(twiceaday);BP=bloodpressure;CCB=calciumchannelblocker;
.
. DM=diabetesmellitus;LEAD=lowerextremityarterydisease;o.d.=omnidie
.
BP=bloodpressure;DAPT=dualantiplatelettherapy;TIA=transientischaemic . (onceaday);PA=physicalactivity;PAD=peripheralarterydisease.
.
attack. .. aClassofrecommendation.
aClassofrecommendation. .. bLevelofevidence.
bLevelofevidence. .. cEvidenceisnotavailableforallsites.Whenevidenceisavailable,recommenda-
.
cMinorischaemicstrokedefinedasscoreatNationalInstitutesofHealthStroke .. tionsspecificforthevascularsitearepresentedincorrespondingsections.
Scale<_3,or<_5dependingonthetrial. dCCBsshouldbeproposedinblackindividuals.
1202
CSE
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 72 ---
3298 ESCGuidelines
albeitatthecostofhighermajorbleedingrisk.774Theseresults,com- ...
Recommendationsinpatientswithchronickidneydis-
binedwithsimilarbenefitsofrivaroxabanvs.aspirinmonotherapy,sug- .. ease:bestmedicaltherapya
.
gestabenefitofanticoagulantsinLEAD.However,furtherstudiesare ..
.
needed.Optimalantithrombotictherapyisaddressedinmoredetailin .. Recommendations Classb Levelc
.
the 2017 ESC/European Society for Vascular Surgery (ESVS) ..
. TreatmentwithanACEinhibitororanARBis
Guidelines.775 Importantly, in patients with isolated asymptomatic ..
. recommendedinpatientswithDM,hyperten-
LEAD(e.g.lowABI),antiplatelettreatmentisnotrecommended.775 ..
. sion,andalbuminuria.Thesemedicationsshould I B
.
RecommendationsforBPandlipidmanagementarecongruentto .
. betitratedtothehighestapproveddosethatis
.
the general recommendations outlined in sections 4.6 and 4.7. .
.. tolerated.
Hypertension targets are based mainly on INVEST (INternational .
VErapamil-SR/TrandolaprilSTudy).776AnSBPbelow110(cid:2)120mmHg
... AnSGLT2inhibitorwithprovenoutcome
mayincreaseCVeventsinpatientswithLEAD.776ACEinhibitorsand
... benefitsshouldbeconsideredfortheprevention
IIa B
ARBs reduce CV events in patients with LEAD,575,777 and are pre-
... ofrenaldeteriorationandmortalityinpatients
ferred(asmonotherapyoraspartofacombinationdrugregimen).778
... withCKD.599
.
. CombinationtreatmentwithACEinhibitorsand
Beta-blockersare notcontraindicated inmild-to-moderateLEAD as .. III C
theydonotaffectwalkingcapacityoradverselimbevents,779andsig- .. ARBsisnotrecommended.
.
.
nificantly reduce coronary events.780 Nevertheless, beta-blockers .. ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker;
.
shouldbecarefullyconsideredincriticallimb-threateningischaemia. .. CKD=chronickidneydisease;DM=diabetesmellitus;SGLT2=sodium-glucose
.. cotransporter2.
6.5. Chronic kidney disease ... aRecommendationsonCKDmanagementinpatientswithDMarefoundinsec-
. tion4.8.
.
SevereCKDisassociatedwithaveryhighriskofCVDandisconsid- .. bClassofrecommendation.
eredaCADriskequivalent(seesection3.2).AsGFRdeclines,non-
.. cLevelofevidence.
.
.
traditionalriskfactors emerge and non-atherosclerotic CVD event .
.
riskincreases.204 Trials often exclude patientswith eGFR<30mL/ ..
.
min/1.73m2.Inpatientsondialysis,coronarysyndromesmaypresent .. 6.6. Atrial fibrillation
.
.
atypically, and angina equivalents—such as shortness of breath or . Thesimple‘AtrialfibrillationBetterCare’(ABC)holisticpathway
.
.
fatigue—arefrequent.788StandardCVDriskmanagementiseffective .. (‘A’=Anticoagulation/Avoidstroke;‘B’=Bettersymptomman-
.
inpatientsondialysis,butuniquehaemodialysis-specificsyndromes .. agement; ‘C’ = Cardiovascular and Comorbidity optimization)
.
(i.e. intradialytic hypotension and myocardial stunning) associated .. streamlinesintegratedcareofpatientswithAF.215TheABCpath-
.
withmortalitycomplicatetreatmentandmodifyoutcomes. .. way lowers risk of all-cause death and the composite of stroke,
.
RiskclassificationofpatientswithvariousdegreesofCKDissum- .. major bleeding, CV death, or first hospitalization,791 and lowers
.
marizedinTable4.Treatmentwithastatinorstatin/ezetimibecombi- .. ratesofCVevents792,793andhealth-relatedcosts.794
.
nationisrecommendedinCKDpatientswithsufficientlyhighCVD .. The‘C’componentoftheABCpathwayreferstoidentification
.
risk,butnotinthosetreatedwithkidneyreplacementtherapy.This .. and management of concomitant diseases, cardiometabolic risk
.
recommendationisbuiltonevidencefromSHARP(StudyofHeart .. factors,andunhealthylifestylefactors.Therapyofunderlyingcon-
.
and Renal Protection), which demonstrated a reduction of major .. ditions improves rhythm control in persistent AF and HF.216 In
.
atherosclerotic events.525 Statins should be dosed according to a .. obese patients, weight reduction prevents AF recurrences and
.
moderate-intensity regimen based on limited experience and risks .. symptoms.795(cid:2)802GiventhathypertensionprecipitatesAF,treat-
.
associated with high-intensity regimens.543 Subgroup analysis of a .. mentofhypertensionismandatory.Alcoholexcessisariskfactor .
recent study with a PCSK9 inhibitor has shown that the benefits .. forincidentAF,803,804andabstinencereducedAFrecurrencesin
.
may extend to those with earlier CKD stages (60(cid:2)90 as well as .. regular drinkers.798 Many studies have demonstrated beneficial
.
30(cid:2)60mL/min/1.73m2).789 .. effects of moderate exercise/PA.805(cid:2)807 The incidence of AF
.
. TreatmentwithanACEinhibitororanARBisrecommendedin . appears,however,tobeincreasedineliteathletes,mainlyrelated
.
patientswithDM,hypertension,andalbuminuria.Thesemedications .. to endurance sports.808(cid:2)811 Patients should be encouraged to
.
.
shouldbetitratedtothemaximumtolerateddose(KidneyDisease . practisemoderate-intensityexerciseandremainphysicallyactive
. .
ImprovingGlobalOutcomesgrading1B). . to prevent AF incidence or recurrence, but avoid excessive
.
.
Individualized HbA1c targets, ranging from 6.5% to <8.0% in . endurance exercise. CR is a universally recommended pro-
.
.
patients with DM and non-dialysis-dependent CKD, are recom- . gramme for patients with ACS and/or revascularization, and for
.
.
mendedinparallel.TheroleofSGLT2inhibitorsandGLP-1RAsin . patientswithHF.639,640,655ThebenefitsofEBCRaremoreuncer-
.
.
CKDassociatedwithDMisaddressedinsection4.8.Dapagliflozinhas .. taininpatientswithAF,butCRremainsrecommendedinpatients
.
shown promising reno- and cardioprotective effects,599 and more .. with the aforementioned indications.812 Continuous PAP may
.
studiesinvestigatingSGLT2inhibitorsinCKDpatientswithoutDM .. improve rhythm control and attenuate AF recurrences in OSA
.
areongoing.790 .. patients.813(cid:2)816 Intensive glycaemic control does not affect the
.
Overall, the management of CAD in CKD patients must be .. rateofnew-onsetAF.817Optimalglycaemiccontrolduringthe12
.
informedbythemodificationofitsclinicalpresentationinCKD,as .. monthsbeforeAFablationdoes,however,reduceAFrecurrence
.
wellascomorbidityandrisksoftreatmentside-effects.Treatmentof .. after ablation.818 All patients with HF and AF should receive
.
establishedriskfactorsisoftensuboptimalinpatientswithCKD. . guideline-adherentHFtherapy.819
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 73 ---
ESCGuidelines 3299
.
.
. Sofar,guidanceforthetreatmentofCVDhasfocusedmainlyon
Recommendationsforlifestyleinterventionsandman- .
.
agementofriskfactorsandconcomitantdiseasesin .. singleCVDs.Inmultimorbidpatients,applicationofasingleguideline
patientswithatrialfibrillation215 .. foroneCVDisoftennotfeasibleastherapeuticcompetitionishighly
.
.. prevalent(22.6%)820andtreatmentforoneconditioncanworsena
.
Recommendations Classa Levelb .. coexisting condition. The challenges for managing CVD and multi-
.
.
. morbidity are disease-disease, disease-drug, and drug-drug interac-
Identificationandmanagementofriskfactors .
.. tions.820Further,pharmacokineticscanbedifferentinpatientswith
andconcomitantdiseasesarerecommendedto I B .
.
beanintegralpartoftreatment.795 .. comorbidities,andlifeexpectancyhastobetakenintoaccountwhen
.
Modificationofunhealthylifestyleandtargeted
... startinganewmedication.Avalue-basedapproachshouldalwaysbe
therapyofintercurrentconditionsisrecom-
... discussedandproposedwhenpossible.820Theincrementalbenefitof
mendedtoreduceAFburdenandsymptom
I B ... medication when added to an already complex regimen is often
severity.216,795(cid:2)802
... uncertain.828Moreover,careformultimorbidCVDpatientsisoften
.. fragmented and given by multiple providers, complicating decision-
AttentiontogoodBPcontrolisrecommended .
.. makingandadherencetorecommendedtreatment.820
inAFpatientswithhypertensiontoreduceAF .
I B .. MultimorbidCVDpatientshavebeenunderrepresentedinmost
recurrencesandriskofstrokeand .
bleeding.800,801
... clinicaltrialsthatunderlietheguidelines.Trialsincludingpatientswith
.. multimorbidityandendpointsthatmattertopatients,pragmatictri-
InobesepatientswithAF,weightlosstogether ...
als,andtheuseofregistriesandbigdatacouldhelpelucidatehowto
withmanagementofotherriskfactorsshouldbe
IIa B
...
optimize treatment and care for patients with CVD and
consideredtoreduceAFincidence,AFprogres- ...
multimorbidity.820
sion,AFrecurrences,andsymptoms.795(cid:2)797 ..
. There is a plea for a paradigm shift from disease-focused to
.
Adviceandmanagementtoavoidalcoholexcess .
. patient-centred care for multimorbid CVD patients, with a central
.
shouldbeconsideredforAFpreventionandin IIa B ... place for patients’ overarching goals of care.828 ‘What matters to
AFpatientsconsideredfororalanticoagulant .
. you?’shouldbethecentralquestion,insteadof‘whatisthematter?’.
therapy.798,803,804 ..
. Patient-centredcareshouldincludeassessmentofpatients’prefer-
.
PAshouldbeconsideredtohelppreventAF .. ences,interpretationoftheevidenceanditsapplicationtothespe-
.
incidenceorrecurrence,withtheexceptionof .. cific patient, consideration of overall prognosis, including life
IIa C .
excessiveenduranceexercise,whichmaypro- .. expectancy,functionalstatus,andqualityoflife,andclinicalfeasibility.
.
moteAF.805(cid:2)812 ..
Adherencetotreatment,theoccurrenceofadversedrugevents,the
.
.
OptimalmanagementofOSAmaybeconsid- . economicburden,andthestressexperiencedbycaregiversshould .
.
eredtoreduceAFincidence,AFprogression,AF IIb C .. be taken into account when optimizing therapies and care plans
recurrences,andsymptoms.813(cid:2)816 ... where adherence to essential medication is emphasized and non-
.
AF=atrialfibrillation;BP=bloodpressure;OSA=obstructivesleepapnoea;PA
... essentialdrugsarestopped.828Furthermore,advancedcareplanning
=physicalactivity. .. shouldbeinitiatedearly.Multidisciplinaryteamsandclosecollabora-
.
aClassofrecommendation. .. tionbetweenprimarycareworkersandspecialistsisneeded.Finally,
bLevelofevidence. ...
automated decision support systems for multimorbidity and CVD
.
.. could help in aligning the relevant evidence and making adequate
.
.. decisions.829
.
.
. .
6.7. Multimorbidity .
.
.
. 7. Key messages
The older adult population is growing fast and survival after acute .
.
CVD has improved,820 leading to an increasing number of older ..
.
patients with CVD and multimorbidity.821,822 This development is .. Riskfactorsandriskclassification
.
associated with high healthcare costs,823,824 worse outcome meas- ... • ThemajorriskfactorsforASCVDarecholesterol,BP,cigarette
ures,higherreadmissionrates,825andmortality.826 ..
. smoking,DM,andadiposity. .
Upto70%ofpatientsaged>_70yearshaveatleastoneCVDand .. • Riskfactorsaretreatedinastepwiseapproachtoreachtheulti-
.
two-thirds also develop non-CVD comorbidities. Multimorbidity is .. matetreatmentgoalsinapparentlyhealthypeople,patientswith
importantinpatientswithCVD.823 ...
establishedASCVD,andpatientswithDM.
.
TheprevailingCVconditionsinpatientsaged>60yearsarehyper- .. • 10-yearCVDriskisestimatedinapparentlyhealthypeopleaged
.
tension, hyperlipidaemia, ischaemic heart disease, arrhythmia, DM, .. 40(cid:2)69yearswithSCORE2,andinpeopleaged>_70yearswith
.
and CAD.823 Other frequent comorbidities include anaemia and .. SCORE2-OP.
.
arthritis.Lowvision,backandneckproblems,osteoarthritis,COPD, .. • Age-specific10-yearCVDriskthresholds—togetherwithcon-
.
depression,andcancerarethemostcommonnon-CVcomorbidities .. siderationofriskmodifiers,frailty,comorbidities,lifetimeCVD
.
inCVDpatients.Moststudieshavefoundnosexdifferencesinthe .. risk,treatmentbenefit,polypharmacy,andpatientpreferences—
.
numberofcomorbidities.However,menhavemoreCVDcomorbid- .. guidetreatmentdecisionsforlipidandBPtreatment.
.
ities and women have more non-CVD comorbidities (in particular .. • Therearevariousoptionsofcommunicatingthe(residual)CVD
.
moredepression).822,826,827 . risk,andthisshouldbetailoredtotheindividualpatient.
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 74 ---
3300 ESCGuidelines
.
Riskmodifiers .. • Migraine,particularlymigrainewithaura,isanindependentrisk
.
.
. factorforstrokeandischaemiccardiacdisease.
• PsychosocialstressisassociatedwithriskofASCVD. ...
• Theriskofischaemicstrokeinsubjectswithmigrainewithaura
• Currentriskscoresmayunder-oroverestimateCVDriskindif- ...
is magnified by the use of combined hormonal contraceptives
feringethnicminoritygroups. ..
. andcigarettesmoking.
• CACscoringisthebest-establishedimagingmodalitytoimprove .
.. • Non-restorative sleep and a sleep duration that varies signifi-
CVDriskstratification. ...
cantlyupordownfromtheoptimumof7hareassociatedwith
• FrailtyisafunctionalriskfactorofbothCVandnon-CVmorbid- .
.. increasedCVrisk.
ityandmortality. .
.. • Mental disorders are common in the general population (12-
• Frailtyassessmentisnotamethodtodetermineeligibilityforany .
.. month prevalence of 27%) and are associated with excess
particulartreatment,butratherservestobuildanindividualized .
.. mortality.
careplanwithpredefinedpriorities. .
.. • TheonsetofCVDincreasestheriskofmentaldisordersby2.2-
• Familyhistoryshouldbeenquiredaboutroutinely,andapositive .
.. fold,leadingtoaworseprognosis.
familyhistoryofprematureASCVDshouldbefollowedbycom- .
.. • Somementaldisorders—evensymptomsofanxietyanddepres-
prehensiveCVDriskassessment. .
.. sion—areassociatedwiththedevelopmentofCVDandwitha
• Currentdatadoesnotsupporttheuseofgenomicriskscoresin .
.. worse prognosis in those with existing CVD (CHD, arterial
CVDriskassessmentinprimaryprevention. .
• ASCVD development and prognosis are linked to social
... hypertension,AF,HF).
.. • Excessmortalityis mainlycaused bybehaviour-dependentrisk
gradients. .
• AirpollutionisstronglyassociatedwithASCVD.
... factors(e.g.smokingaddiction)andanimpairedcapacityforself-
• Additionalcirculatingandurinebiomarkersshouldnotberou-
... care(e.g.treatmentadherence).
tinelymeasured.
... • NAFLDisassociatedwithothercardiometabolicriskfactors.
. • PatientswithNAFLDshouldbeevaluatedforothercardiometa-
• AssessCVDriskinpersonswithobesity. ..
. bolicriskfactors.
.
.
Clinicalconditions .. • Sex-specificconditions:
.
. • Preeclampsiaandpregnancy-relatedhypertensionareasso-
.
• CKDisanindependentriskfactorforASCVD,andASCVDis .
. ciatedwithahigherriskofCVD.
.
theleadingcauseofdeathinCKD. .. • Polycystic ovary syndrome confers a significant risk for
.
• A short-term reduction in albuminuria by approximately 30% .
. futuredevelopmentofDM.
.
uponstarting RAAS inhibitionis associated withimproved CV .. • ED is associated with future CV events and mortality in
.
andkidneyoutcomes. .. men.
.
• Similarly,SGLT2inhibitorsareassociatedwithlong-termbene- .. • CVDriskshouldbeassessedinmenwithED.
.
fitsinCVandrenalrisks. .. • AskingaboutEDshouldbeastandardprocedureinroutine
• AFisassociatedwithanincreasedriskofdeathandanincreased ... CVriskassessmentinmen.
.
riskofCVD. .
.
• IschaemicHFconstitutesthemostadvancedclinicalmanifesta- .. Riskfactorsandinterventionsattheindividuallevel
.
tionofatherosclerosiswithinthemyocardium. ..
. • RegularPAisamainstayofASCVDprevention.
• ThediagnosisofovertHF,aswellasasymptomaticpresentation ..
. • Aerobic PA in combination with resistance exercise and the
withLVdysfunction,increasestheriskofCVDevents(myocar- ..
. reductionofsedentarytimearerecommendedforalladults.
dialinfarction,ischaemicstroke,CVdeath). ...
• A healthy diet lowers the risk of CVD and other chronic
• ThereisanoverlapbetweencancerandCVriskfactors;CVrisk ..
. diseases. inpatientswithcancerdependsonboththeCVtoxicityoftreat- ...
• A shift from a more animal- to plant-based food pattern may
mentsandpatient-relatedfactors. ...
reduceCVD.
• Signsorsymptomsofcardiacdysfunctionshouldbemonitored ...
• Achieving and maintaining a healthy weight through lifestyle
before,periodicallyduring,andaftertreatment. ...
changeshasfavourableeffectsonriskfactors(BP,lipids,glucose
• Exerciseshouldbestronglyadvised,inparticularaerobicexer- ...
metabolism)andlowersCVDrisk.
cise,topreventcardiotoxicity. ...
• When changes in diet and PA—aswell asother conventional,
• COPDisamajorriskfactorforCVD,especiallyASCVD,stroke, ...
non-invasive interventions—are unsuccessful, bariatric surgery
andHF. ...
shouldbeconsideredforhigh-riskindividuals.
• COPD patients are prone to arrhythmias (AF and ventricular .
.. • Anti-obesity medications with protective ASCVD effects may
tachycardia)andsuddencardiacdeath. .
.. alsobeconsidered.
• AllCOPDpatientsshouldbeinvestigatedforCVD. .
.. • Patients with mental disorders have sharply increased lifestyle
• Common COPD medications are usually safe in terms of CV .
.. risksthatneedrecognitionandtreatment.
adverseevents. .
• ChronicinflammatoryconditionsincreaseCVDrisk.
... • Mentalhealthcareimprovesstresssymptomsandqualityoflife,
• InfectionwithHIVisassociatedwithanincreasedriskofLEAD
... reducestheriskofsuicide,andmayimproveCVoutcomes.
. • The treatment of ASCVD patients with mental disorders
andCAD. ..
. requiresinterdisciplinarycooperationandcommunication.
• There is an association between influenza and periodontitis ..
. • Stopping smoking rapidly reduces CVD risk and is the most
infectionsandASCVD. ..
. cost-effectivestrategyforASCVDprevention.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 75 ---
ESCGuidelines 3301
.
• Thereisstrongevidence formedication-assistedinterventions: .. • Targetingotherriskfactors,inparticularsmoking,BP,andcho-
.
.
NRT, bupropion, varenicline, and drugs in combination. The . lesterollevels,remainsanimportantmeanstolowerCVDriskin
.
.
most effective are assistance using drug therapy and follow-up . type1DM.
.
support. .. • All patients with established ASCVD require some form of
.
• Lowerisbetter:theeffectofLDL-ContheriskofCVDappears .. antithrombotictherapy.
.
tobedeterminedbyboththebaselinelevelandthetotaldura- .. • Anti-inflammatory therapy is a promising strategy in CVD
.
tionofexposuretoLDL-C. .. prevention.
.
• Lowering LDL-C with statins, ezetimibe, and—if needed .. • Patients after ACS and/or coronary artery bypass graft/PCI, or
.
and cost-effective—PCSK9 inhibitors, decreases the risk of .. with chronic HFrEF, should participate as early as possible in
.
ASCVD proportionally to the absolute achieved reduction in .. structured,multidisciplinaryEBCRandpreventionprogrammes.
.
LDL-C. .. • EBCR and prevention programmes must comply with certain
.
• WhenLDL-Cgoalsaccordingtolevelofriskcannotbeattained, .. qualitystandardsandbeindividualizedtoeachpatient’sprofile.
.
aimtoreduceLDL-Cby>_50%andthenstrivetoreduceother .. • Participationandlong-termadherencetotheseprogrammeshas
.
riskfactorsaspartofashareddecision-makingprocesswiththe .. tobeencouragedandenhanced.TelerehabilitationandmHealth
.
patient. .. mayhelptowardsachievingthistarget.
.
• Whenhypertensionissuspected,thediagnosisshouldbecon- ..
firmedbyrepeatedofficeBPmeasurementatdifferentvisits,or
... Population-level approaches to cardiovascular disease
.. prevention
ABPMorHBPM. . .
• Lifestyleinterventionsareindicatedforallpatientswithhyper- .. Physicalactivity
.
tensionandcandelaytheneedfordrugtreatmentorcomple- ..
menttheBP-loweringeffectofdrugtreatment.
... • Asignificantpercentageoftheworldwidepopulation,inparticu-
• BP-lowering drug treatment is recommended in many adults
... lar the European population, shows high levels of sedentary
whenofficeBPis >_140/90 mmHg and in all adultswhen BPis
... behaviourandphysicalinactivity.
>_160/100mmHg.
... • Thepercentageofthoseexercisingataregularlevelisgreaterin
• BPtreatmentgoalsarelowerthaninthepreviousESCCVDpre-
... menthaninwomen.
ventionguidelines forallpatientgroups,including independent
... • Global progress to increase PA has been slow, largely due to
olderpatients.
... lackofawarenessandinvestment.
• Wideruseofsingle-pillcombinationtherapyisrecommendedto
... • TheoptimaldoseofdifferenttypesofPAforCVDandgeneral
reducepooradherencetoBPtreatment.
... prevention is still controversial and subjected to frequent
• Asimpledrugtreatmentalgorithmshouldbeusedtotreatmost
... updates.Increasingmoderate-to-vigorous PA and reducingsit-
patients,basedoncombinationsofarenin(cid:2)angiotensinsystem
... tingtime,however,isbeneficialandanylevelofPAisconsidered
(RAS)blockerwithaCCBorthiazide/thiazide-likediuretic,orall
... betterthannone.
three. Beta-blockers may also be used where there is a
... • PAforhealthpromotionshouldbeimplementedbyphysicians
guideline-directedindication.
... in the same way as drug prescription and should alsobe pro-
• Manypatientswithhypertensionwillbeatsufficientrisktobene-
... motedbyotherhealthcareprofessionals.
fitfromstatintherapyforprimaryprevention.Antiplateletther-
... • Population-based interventions are effective in promoting
apyisindicatedforsecondaryprevention.
... PAforgroupsbasedonage,sex,andrace,forhigh-,middle-,and
• Amultifactorialapproach,includinglifestylechanges,iscriticalin
... low-income populations, and for different environments
personswithtype2DM.
... (e.g. kindergarten, school, gyms, companies, and worksites in
• Managementofhyperglycaemiareducestheriskofmicrovascu-
... general).
lar complications and, to a lesser extent, the risk of CVD.
... • DailyPAatschoolshouldbepractisedforatleast3h/week,and
Glycaemic targets should be relaxed in older adults and frail ... preferablyfor60minutesperday.
. • Population-basedapproachesarecomplementarytoindividual- individuals. ..
• Newantihyperglycaemicdrugsareparticularlyimportantforper- ... centredinterventions.
. • Diet
sonswithtype2DMwithexistingASCVDand(heightenedrisk ..
. • Structuralmeasuressuchaschangesinagriculturalsupplychain
of)HForrenaldisease,broadlyirrespectiveofglycaemialevels. ..
. andfoodindustry,productreformulation,limitationson(digital)
.
.
Type1diabetesmellitus .. marketing to children, taxes on unhealthy foods/nutrients, and
.
. consumer-friendly nutrition labellingwillimprovehealthy food
.
• IntensivemanagementofhyperglycaemiainDMreducestherisk .
. choices.
.
ofmicro-andmacrovascularcomplicationsandprematuremor- .
. • Healthyenvironmentsinthecommunity,onpublictransport,at
.
tality; a target of 6.5(cid:2)7.5% (48(cid:2)58 mmol/mol) HbA1c is .
. schools,andinworkplaceswillstimulateahealthierlifestyle.
.
recommended. .. • TheWHOGlobalActionPlanforthePreventionandControl
.
• Metformin is not recommended in type 1 DM to lower CVD .
. ofNon-CommunicableDiseases2013(cid:2)2020extendedto2025
.
risk. .
. recommends to develop goals in global, regional, and national
.
• Dapagliflozin has been recommended for use in type 1 DM, .
. agendas.Withinthe10voluntarytargets toreachin2025isa
.
althoughthereisanincreasedriskofdiabeticketoacidosiswith .
. 30% relative reduction in mean population intake of sodium/
.
suchtherapies. .. salt.830
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 76 ---
3302 ESCGuidelines
.
.
Smokingandtobaccouse . haemorrhage is mostly caused by hypertensive angiopathy or
.
.
. cerebralamyloidangiopathy.
• Adolescence is the most vulnerable period for the uptake of ...
• Platelet inhibitors are recommended for non-cardioembolic
smoking,withlifelongconsequences. ..
. eventsandanticoagulantsforcardioembolicevents.
• Previous prevention campaigns reduced tobacco use in girls ...
• InpatientswithapreviousstrokeorTIAandhighBP,BPlower-
muchlessthaninboys. ...
ingreducestherecurrencerisk.
• Teenagers should be informed that smoking is not helpful in ...
• InpatientswithstrokeorTIA,statinspreventCVDandcerebro-
weightcontrol. ...
vascularevents.
• Hightaxesonalltobaccoproductsisthemosteffectivepolicy .
.. • Lowerextremityarterydisease
measuretoreducesmokinguptakebytheyoung. ...
• LEADisassociatedwithanincreasedCVDrisk.
• There should be restrictions on smokeless tobacco due to .
. • Antiplatelet therapy (alone or in combination with low-dose
.
strongevidenceofharm. .
. oralanticoagulation)reducestheriskofadverselimbeventsand
.
• Also,restrictionsone-cigarettesduetoevidenceofharm. .
. overallCVDriskinpatientswithLEAD.
.
• Plain packaging is effective in reducing the attractiveness of .
. • Smoking cessation and control of other CVD risk factors
.
tobaccoproducts. .
. improveprognosis.
• There should be restrictions on advertising, promotion, and ..
.
sponsorshipbythetobaccoindustry. .. Chronickidneydisease
.
• A goal would be to make a common European decision to ..
achieveasmoking-freeEuropeby2030.
... • Hypertension,dyslipidaemia,andDMareprevalentamongindi-
.
. viduals with CKD and require a high-risk treatment strategy
.
Alcohol .. approach.
.
.. • Riskmanagementincludeslifestyle,smokingcessation,nutrition,
• Alcohol intake is associated with increased CV mortality, and ..
. sufficientRAASblockade,targetBPcontrol,lipidmanagement,
alcoholuseistheleadingriskfactorforprematuredeathanddis- ..
. and—inestablishedCVD—aspirin.
abilityamongpeopleaged15(cid:2)49years. ...
• A high value is placed on self-management education pro-
• Theinterventionsforaddressingtheharmfuluseofalcoholare ...
grammesand team-basedintegratedcareinpatientswithDM,
cost-effective,withagoodreturn(i.e.increasingalcoholicbever- ...
CKD,andCVD.
ageminimumunitpricingandexcisetaxes,restrictingaccessto ..
.
alcoholic beverages, and implementing comprehensive restric- .. Atrialfibrillation
.
tions and bans on advertising and the promotion of alcoholic ..
beverages).
... • Holistic management of patients with AF improves prognosis
• Healthcareprovidersmayinquireaboutalcoholintakeinevery
... andreduceshealth-relatedcosts.
medical evaluation and should inform patients that alcohol is
... • Comprehensiverisk-factormodificationandtargetingunderlying
energy-dense:itprovides7kcal/gandnonutrients.
... conditionsreduceAFburdenandrecurrence.
.
.
Environment,airpollution,andclimatechange
... Multimorbidity
.
.
. • ThenumberofpatientswithmultipleCVandnon-CVcomor-
• Airpollutioncontributestomortalityandmorbidity,andspecifi- .
.
. biditiesisrapidlyincreasing.
callyincreasestheriskofrespiratoryandCVdiseases. .
.
. • Therapeutic competitionshouldbe considered in multimorbid
• Environmentalexposurehastakenonnewurgency,asairpollu- .
.
. patients,asthetreatmentofoneconditionmightworsenacoex-
tion,inadditiontoitshealtheffects,hasalsobeenascribedasa . .
. istingcondition.
majorcontributortoclimatechanges,notablythroughtheburn- . .
. • A paradigm shift from disease-focused to patient-centred care
ing of fossil fuels leading to increasing emissions of carbon .
.
. formultimorbidCVDpatientsisrecommended.
dioxide. ..
.
.
.
Riskmanagementofdisease-specificcardiovasculardisease ..
.
Coronaryarterydisease .. 8. Gaps in evidence
.
.
.
• Multidimensionalpreventioniscrucialforshort-andlong-term . .. CVDriskclassification
outcomesinCAD. .
.
.
. • Country-specific risk algorithms for patients with established
.
Heartfailure .
. CVDandpeoplewithDM.
.
• PatientswithHFbenefitfrommultidisciplinarycaremanagement
... • Formal comparison of effectiveness and cost-effectiveness of
.
. CVD risk-guidedtreatmentvs.treatmentguided byrisk factor
programmes. .
.
• Severalneurohormonalantagonists,aswellasnovelmolecules, .. level.
improveclinicaloutcomesinsymptomaticpatientswithHFrEF.
... • Comparison of the precision of competing risk-adjusted CVD
.
. riskmodelsvs.standardCVDriskmodels.
.
Cerebrovasculardiseases .. • Incorporatingpotentialriskmarkersintoconventionalriskmod-
.
.. els,suchassocioeconomicstatusandethnicity.
• Ischaemiceventsaremainlycausedbyatherothrombosis,cardi- ...
• Comparisonoftreatmentbenefit-guidedstrategyvs.risk-guided
oembolism, or small vessel disease, whereas intracerebral ..
strategyinreducingriskfactorlevelsandCVDrisk.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 77 ---
ESCGuidelines 3303
.
• Management of CVD risk in older people (>85 years) with .. • Emerging evidence suggests that stroke can occur in patients
.
.
markedfragility,forwhomnodatacurrentlyexist. . withAFevenaftersinusrhythmisrestored.
.
• Comparisonofdifferentmethodsfortheestimationoflifetime ..
.
CVDriskandlifetimebenefitofriskfactortreatment. .. Heartfailure
.
.
.. • ItremainsunknownwhetherpatientswithHFrEFofischaemic
Riskmodifiers .
.. originshouldhavedifferenttargetLDL-Clevelsthanthoserec-
Psychosocialfactors .
.. ommendedforsecondarypreventioninindividualswithoutHF.
.
• Moreevidencethatpsychosocialfactorsimproveriskprediction ..
beyondtheclassicalrisk-factormodels.
... Cancer
.
.
Ethnicity
... • RCTsusingpreventivetherapytodemonstrateacleareffecton
.. preventionofCVevents.
.
• Whetherrecalibrationoffactorsforethnicityarehomogeneous ..
invariousEuropeancountries.
... Chronicobstructivepulmonarydisease
.
• Risksassociatedwithotherethnicbackgrounds. .
. • AlthoughcommonpathophysiologicalpathwaysbetweenCVD
.
.
. andCOPDareprobable,theyremaintobeclarified.
Frailty .
.
.
.
• Consensusonaclinicallyorientatedscreeningtoolforfrailtyto .. Inflammatoryconditions
. .
beappliedacrossthespectrumofASCVD. .
. • Theoptimalwayofintegratinginformationonchronicinflamma-
• Quantitative contribution of frailty to the global CVD risk- .. . toryconditionsintoCVDriskassessment.
predictionscheme. ...
• The effect of modernanti-inflammatorydrugsonCV risk[e.g.
• At which degree of frailty treatment of specific risk factors ..
. anti-tumournecrosisfactor(TNF),interleukin(IL)-1,IL-17,IL-23
shouldbelessaggressive. ..
. biologics].
.
.
Familyhistory ..
. Infections
.
.
• Disentangletheroleand(genetic,socioeconomic,etc.)mecha- ...
• Large-scalestudiestoassesstheefficacyofinfluenzavaccination
nismsoffamilyhistoryonCVDrisk. ...
orperiodontitistreatmentinpreventingCVD.
.
Genetics .. • TheassociationofinfectionwithHIVandtotalCVDrisk.
.
.
.
• The potential of polygenic risk scores to complement existing .. Migraine
.
riskscores. ..
.. • Therearenodatathatallowreliableidentificationofsubgroups
.
Socioeconomicdeterminants .. ofmigraineursatparticularhighrisk(e.g.activemigraine,high-
.
.. frequencyauras,youngsubjects,women).
• Moreevidencefromdifferentriskregionsthattheinclusionof .
.. • Theroleofcomorbidfactors(e.g.patentforamenovale,throm-
socioeconomicfactorsimprovesriskpredictionbeyondclassical .
.. bophilicfactors)isunclear,andatthemomentthereisnoindica-
riskfactormodelsinbothmenandwomen. .
.. tiontoscreenortomanageforthesefactors.
.
Environmentalexposure ..
.. Sleepdisorders
. • Whetherairpollutionreclassifiesriskinindividualpatients. .
.
.. • Thereislackofevidencethattheinclusionofsleepimprovesrisk
Biomarkers ...
prediction.
.
• Addedvalueofbiomarkersinriskclassification.
... • Trialsareneededthattargetthecomplexpathwayslinkingsleep
.. disturbanceswithCVD.
. Clinicalconditions .
.
Chronickidneydisease .. Mentaldisorders
.
.
.
• Identificationofagoodbiomarker,besidesalbuminuria,andper- .. • The precise mechanism by which mental disorders increase
.
hapstheuseofCACscoretosubclassifyCVriskinCKD. .. CVDremainsuncertain.
.
• Earlyand preciseidentificationofprogressiveCKD withnovel .. • How the consideration of mental disorders improves CV risk
.
biomarkersthataremoresensitivethaneGFRandalbuminuria. .. models.
.
.
.
Atrialfibrillation .. Non-alcoholicfattyliverdisease
.
.
.
• Evaluatetheeffectofinterventionsaimedatreducingoutcomes . • Whether NAFLD increases CV risk beyond traditional risk
.
.
beyondstroke. . factors.
.
.
• Is AF a causal factor for increased CVD morbidity and .
.
mortality? .. Sex-specificconditions
.
.
• Strokeriskpredictionforlow-riskAFpatients. .
. • ThedegreetowhichincreasedCVDriskassociatedwithseveral
.
.
. of the female-specific conditions occurs independently of
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 78 ---
3304 ESCGuidelines
.
conventionalCVDriskfactors,althoughdatainwomenarestill .. • Thecost-effectivenessofusinglifetimeCVDriskandmorepre-
.
.
underpoweredcomparedtomen. . cise CVD risk scores to target interventions needs further
.
• Informationonwhetherfemale-specificconditionsimproverisk .. investigation.
.
classification. .. • The value of triglycerides or HDL-C values as a target for
.
• There are insufficient data to draw conclusions on a possible .. therapy.
.
increased risk of hypertension or DM with premature .. • Whetherlipoprotein(a)loweringagainstbackgroundstatin,eze-
.
menopause. .. timibeandPCSK9itherapycanreducetheriskofASCVD.
.
• Studies on the specificities of CVD disease in the transgender .. • Whether functional foods and food supplements with a lipid-
.
populationarescarce. .. loweringeffectcansafelyreducetheriskofCVD.
.
.
.
Erectiledysfunction .. Bloodpressure
.
.
.
• ThebenefitofroutinescreeningforEDandthemosteffective .. • Whatisthe incrementalbenefit,overCVD riskcalculators,of
.
tooltoassessitarestillunclear. .. measuresofHMODinreclassifyingtheCVriskofpatientswith
.
• Thebenefitofassessmentofsubclinicalvasculardiseaseinmen .. hypertension?
.
withEDandlow-to-intermediateCVDriskisunclear. .. • Direct empirical evidence for the stepwise approach to treat-
.
.. mentintensificationfromRCTs.
.
Riskfactorsandinterventionsattheindividuallevel . • WhatarethebenefitsofBPtreatmentforpatientswithBPinthe
.
.
Physicalactivityandexercise . high-normalrange? .
.
. • More dataonthebenefitsofBPtreatmentin very old people
• Knowledgeoftherelativeimportanceofthevariouscharacteris- .. . andtheinfluenceoffrailty.
ticsofaerobicPAandresistanceexercise,ortheircombination, ..
. • Effectofsingle-pillvs.multidrugtreatmentstrategiesonadher-
onall-causemortality,CVincidence,andmortality. ..
. encetotreatment,BPcontrol,andclinicaloutcomes.
• Understandinghowsex,age,weight,race/ethnicity,occupation, ..
. • Effectivenessofantihypertensivetreatmentinpreventingcogni-
andsocioeconomicstatusmaymodifyassociationsbetweenPA ..
. tivedysfunctionordementia.
andhealthoutcomes. ...
• Efficacyandcost-effectivenessofinvasiveproceduresanddevi-
• Implementationofstrategiestoachievelong-termadherenceto ..
. cesforthetreatmentofhypertension.
PA. ...
• Sex-specificBPtreatmentthresholdsformenandwomen.
• EvaluationoftheeffectsofeHealthtoolsinpromotingPA. ..
.
.. Diabetesmellitus
Nutrition ..
.
.. • MoreworkisneededtodevelopriskscoresforbothMACEand
• Effectivestrategiestoencouragepeopletochangetheirdietand .
.. HFintype2DM.
toenjoyandmaintainahealthydiet. .
. • WhethercombinedSGLT2inhibitorandGLP-1RAtreatments
.
.
. lower MACE or other outcomes beyond either drug alone
Bodyweight .
.
.. requirestesting.
• Knowledge and implementation of effective lifestyle and .. • Longer-termsafetyofnewerclassesofdrugisrequired.
.
.
medication-assistedstrategiestoachieveweightlossandmain- .
.
tainalong-termhealthyweight. .. Antithrombotictherapy
.
.
.. • The role of antithrombotic therapy in primary prevention in
Mentalhealthcareandpsychosocialinterventions . .
. (very)high-riskindividualsremainstobeestablished.
. • The effectiveness of mental healthcare for the prevention of ..
.
majorCVDevents. .. Cardiacrehabilitationandpreventionprogrammes
.
• HowtoimplementeffectiveCVDpreventionmeasuresinthis ...
• TheeffectandtheoptimaldeliveryofEBCRinwomen,older/
high-riskpopulationofpatientswithmentaldisorders. ...
frail patients, patients with cardiacimplantable electronic devi-
.
Smokingintervention
... ces, after heart transplantation or valve replacement, and in
.. patients with AF, stroke, HFpEF, LEAD, or multiple
. • Abetterunderstandingofhowtoincorporateeffectivesmoking .. comorbidities.
.
cessationintoclinicalpractice. .. • Alternativeandcost-effectivemodelsofCRneedtoensurepar-
.
.. ticipationglobally,includinglow-andmiddle-incomecountries.
Lipids ...
• Large RCTs investigating the long-term effects of home-based
.
• Direct empirical evidence for the stepwise approach to treat- .. telerehabilitationandmHealthareneeded.
.
.
ment intensification from RCTs. The feasibility and effects of .
.. Environment,airpollution,andclimatechange
reaching LDL-C levels <1.4 mmol/L (55 mg/dL) needs further .
.
.
investigation,especiallyinprimarycare. . • Individual-level exposure studies are needed to better specify
.
.
• Particularlyamongpeopleatlow-to-moderateCVDrisk,older .. theeffectofmitigatingmeasures.
.
people, and for newer interventions, more evidence of the .
.
effects of lipid-modifying treatments on overall mortality is .. Riskmanagementofdisease-specificcardiovasculardisease
.
neededintheformoflong-termpost-trialfollow-upinRCTs. .. Coronaryarterydisease
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 79 ---
ESCGuidelines 3305
.
• Theefficacyandsafetyofaspirinorotherantithromboticther- .. Lowerextremityarterydisease
.
apyinpatientswithoutclinicalmanifestationsofCAD—butwith ..
.. • The optimal type and potency of antithrombotic therapy in
atherosclerotic disease identified on imaging, suchasCCTA— .
.. patientswithdifferentmanifestationsofsymptomaticorasymp-
requiresfurtherassessment. .
• Theoptimallong-termantithrombotictherapyinpatientsathigh
... tomaticLEADarepartlyunclear.
.
riskofischaemiceventsisuncertain. ...
Chronickidneydisease
• ClinicalstudiescomparingtheefficacyandsafetyofP2Y 12inhibi- ...
tors vs.low-dose rivaroxabanorother factorXainhibitors, in .. • FewCVDtrialshaveafocusonpatientswithCKD,particularly
.
combination with aspirin, are warranted to determine which .. thosewithadvancedCKD.
.
subgroupswillderivegreaterclinicalbenefitwitheachstrategy. .. • Additionalprospectivestudiesfocusingondiagnosis,prevention,
.
. andtreatmentofCADandCVDareneededinCKD.
.
.
Heartfailure .
.
. Atrialfibrillation
.
• ForpatientswithHFpEF,nospecificpharmacotherapyordevice ..
.
implantation has been shown to modify the risk of any CV .. • TheeffectsofvariousCVriskfactorsandcomorbiditiesinAF.
outcome.
... • OptimaltreatmentofOSAanditseffectonAFprogressionand
• LowerdosageofHFtreatmentsinwomenwithHFrEFneedsto ... symptoms.
.
beaddressed,sincewomenwereunderrepresentedinmanyHF ..
. Multimorbidity
trials. ..
.
.. • TheeffectofdifferentclustersorcombinationsofCVandnon-
Cerebrovasculardisease ...
CVcomorbiditiesonCVoutcomes.
.
• TheoptimalselectionofpatientforashortcourseofDAPT.
.. • Optimal,pragmatictreatmentstrategiesinpatientswithCVand
.
• TheoptimalantihypertensiveregimenandtargetBP. .. non-CV comorbidities, with particular focus on treatment
.
• TheoptimaltargetlevelofLDL-C. .. adherenceandtherapeuticcompetition.
.
• Optimal treatment for patients with silent cerebrovascular ..
.
disease. .
9. ‘What to do’ and ‘what not to do’ messages from the guidelines
Recommendations Classa Levelb
Recommendationsforcardiovasculardiseaseriskassessment
SystematicglobalCVDriskassessmentisrecommendedinindividualswithanymajorvascularriskfactor(i.e.familyhistoryof
prematureCVD,FH,CVDriskfactorssuchassmoking,arterialhypertension,DM,raisedlipidlevel,obesity,orcomorbidities I C
increasingCVDrisk).
SystematicCVDriskassessmentinmen<40yearsofageandwomen<50yearsofagewithnoknownCVriskfactorsisnot III C
recommended.
Recommendationsforcardiovasculardiseaseriskestimation
Inapparentlyhealthypeople<70yearsofagewithoutestablishedASCVD,DM,CKD,genetic/rarerlipidorBPdisorders,estima-
I B
tionof10-yearfatalandnon-fatalCVDriskwithSCORE2isrecommended.
Inapparentlyhealthypeople>_70yearsofagewithoutestablishedASCVD,DM,CKD,genetic/rarerlipidorBPdisorder,estima-
I B
tionof10-yearfatalandnonfatalCVDriskwithSCORE2-OPisrecommended.
PatientswithestablishedCVDand/orDMand/ormoderate-to-severerenaldiseaseand/orgenetic/rarerlipidorBPdisordersare
I A
tobeconsideredathighorveryhighCVDrisk.
Astepwisetreatment-intensificationapproachaimingatintensiveriskfactortreatmentisrecommendedforapparentlyhealthy
peopleathighorveryhighCVDrisk,aswellaspatientswithestablishedASCVDand/orDM,withconsiderationofCVDrisk, I B
treatmentbenefitofriskfactors,riskmodifiers,comorbidities,andpatientpreferences.
TreatmentofASCVDriskfactorsisrecommendedinapparentlyhealthypeoplewithoutDM,CKD,genetic/rarerlipidorBPdis-
orderswhoareatveryhighrisk(SCORE2>_7.5%forageunder50;SCORE2>_10%forage50(cid:2)69;SCORE2-OP>_15%forage I C
>_70years).
Recommendationforcardiovasculardiseaseriskcommunication
AninformeddiscussionaboutCVDriskandtreatmentbenefitstailoredtotheneedsofapatientisrecommended. I C
Recommendationsforriskmodifiers
Theroutinecollectionofotherpotentialmodifiers,suchasgeneticriskscores,circulatingorurinarybiomarkers,orvasculartests
III B
orimagingmethods(otherthanCACscoringorcarotidultrasoundforplaquedetermination),isnotrecommended.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 80 ---
3306 ESCGuidelines
Recommendationsforcardiovasculardiseaseriskassessmentinspecificclinicalconditions
InallCKDpatients,withorwithoutDM,appropriatescreeningforASCVDandkidneydiseaseprogression,includingmonitoring
I C
changesinalbuminuriaisrecommended.
Itisrecommendedtomonitorcardiacdysfunctionusingimagingtechniquesandcirculatingbiomarkersbefore,periodicallyduring,
I B
andaftercancertreatment.
ScreeningforCVriskfactorsandoptimizationoftheCVriskprofileisrecommendedinpatientsontreatmentforcancer. I C
ItisrecommendedthatallCOPDpatientsbeinvestigatedforASCVDandASCVDriskfactors. I C
InpatientswithCVD,obesity,andhypertension,regularscreeningfornon-restorativesleepisindicated(e.g.bythequestion:
I C
‘howoftenhaveyoubeenbotheredbytroublefallingorstayingasleep,orsleepingtoomuch?’).
Iftherearesignificantsleepproblems,whicharenotrespondingwithin4weekstosleephygiene,referraltoaspecialistis
I C
recommended.
Itisrecommendedthatmentaldisorderswitheithersignificantfunctionalimpairmentordecreaseduseofhealthcaresystemsbe
I C
consideredasinfluencingtotalCVDrisk.
Itisrecommendedforadultsofallagestostriveforatleast150(cid:2)300minaweekofmoderate-intensityor75(cid:2)150minaweek
ofvigorous-intensityaerobicPA,oranequivalentcombinationthereof,toreduceall-causemortality,CVmortality,and I A
morbidity.
Itisrecommendedthatadultswhocannotperform150minofmoderate-intensityPAaweekshouldstayasactiveastheirabil-
I B
itiesandhealthconditionallow.
Itisrecommendedtoreducesedentarytimetoengageinatleastlightactivitythroughoutthedaytoreduceall-causeandCV
I B
mortalityandmorbidity.
Performingresistanceexercise,inadditiontoaerobicactivity,isrecommendedon2ormoredaysperweektoreduceall-cause
I B
mortality.
Recommendationsfornutritionandalcohol
AhealthydietisrecommendedasacornerstoneofCVDpreventioninallindividuals. I A
ItisrecommendedtoadoptaMediterraneanorsimilardiettolowerriskofCVD. I A
ItisrecommendedtoreplacesaturatedwithunsaturatedfatstolowertheriskofCVD. I A
ItisrecommendedtoreducesaltintaketolowerBPandriskofCVD. I A
Itisrecommendedtochooseamoreplant-basedfoodpattern,richinfibre,thatincludeswholegrains,fruits,vegetables,pulses,
I B
andnuts.
Itisrecommendedtorestrictalcoholconsumptiontoamaximumof100gperweek. I B
Itisrecommendedtoeatfish,preferablyfatty,atleastonceaweekandrestrict(processed)meat. I B
Itisrecommendedtorestrictfreesugarconsumption,inparticularsugar-sweetenedbeverages,toamaximumof10%ofenergy
I B
intake.
Recommendationsforbodyweight
ItisrecommendedthatoverweightandobesepeopleaimforareductioninweighttoreduceBP,dyslipidaemia,andriskoftype2
I A
DM,andthusimprovetheirCVDriskprofile.
Whilearangeofdietsareeffectiveforweightloss,itisrecommendedthatahealthydietinregardtoCVDriskismaintained
I A
overtime.
Recommendationsformentalhealthcareandpsychosocialinterventionsattheindividuallevel
Patientswithmentaldisordersneedintensifiedattentionandsupporttoimproveadherencetolifestylechangesanddrug
I C
treatment.
InASCVDpatientswithmentaldisorders,evidence-basedmentalhealthcareandinterdisciplinarycooperationare
I B
recommended.
InpatientswithHFandmajordepression,SSRIs,SNRIs,andtricyclicantidepressantsarenotrecommended. III B
Recommendationsforsmokinginterventionstrategies
Allsmokingoftobaccoshouldbestopped,astobaccouseisstronglyandindependentlycausalofASCVD. I A
Smokingcessationisrecommendedregardlessofweightgain,asweightgaindoesnotlessentheASCVDbenefitsofcessation. I B
Recommendationsonlow-densitylipoproteincholesterolgoals
Astepwisetreatment-intensificationapproachisrecommendedforapparentlyhealthypeopleathighorveryhighCVDrisk,as
wellaspatientswithestablishedASCVDand/orDMwithconsiderationofCVDrisk,treatmentbenefit,riskmodifiers,comorbid- I C
ities,andpatientpreferences.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 81 ---
ESCGuidelines 3307
Recommendationsforpharmacologicallow-densitylipoproteincholesterolloweringforthose<70yearsofage
Itisrecommendedthatahigh-intensitystatinisprescribeduptothehighesttolerateddosetoreachtheLDL-Cgoalssetforthe
I A
specificriskgroup.
InpatientswithestablishedASCVD,lipid-loweringtreatmentwithanultimateLDL-Cgoalof<1.4mmol/L(55mg/dL)anda
I A
>_50%reductioninLDL-Cvs.baselineisrecommended.
Ifthegoalsarenotachievedwiththemaximumtolerateddoseofastatin,combinationwithezetimibeisrecommended. I B
Forsecondarypreventionpatientsnotachievingtheirgoalsonamaximumtolerateddoseofastatinandezetimibe,combination
I A
therapyincludingaPCSK9inhibitorisrecommended.
Forvery-high-riskFHpatients(thatis,withASCVDorwithanothermajorriskfactor)whodonotachievetheirgoalsonamaxi-
I C
mumtolerateddoseofastatinandezetimibe,combinationtherapyincludingaPCSK9inhibitorisrecommended.
Statintherapyisnotrecommendedinpremenopausalfemalepatientswhoareconsideringpregnancyorarenotusingadequate
III C
contraception.
Recommendationfordrugtreatmentsofpatientswithhypertriglyceridaemia
StatintreatmentisrecommendedasthefirstdrugofchoiceforreducingCVDriskinhigh-riskindividualswithhypertriglyceridae-
I A
mia[triglycerides>2.3mmol/L(200mg/dL)].
Recommendationsforthetreatmentofdyslipidaemiasinolderpeople((cid:3)70years)
TreatmentwithstatinsisrecommendedforolderpeoplewithASCVDinthesamewayasforyoungerpatients. I A
Itisrecommendedthatthestatinisstartedatalowdoseifthereissignificantrenalimpairmentand/orthepotentialfordrug
I C
interactions.
Recommendationforthetreatmentofdyslipidaemiasindiabetesmellitus
Inpatientswithtype2DMatveryhighrisk(e.g.withestablishedASCVDand/orsevereTOD)intensivelipid-loweringtherapy,
I A
ultimatelyaimingat>_50%LDL-CreductionandanLDL-Cof<1.4mmol/L(55mg/dL)isrecommended.
Inpatientswithtype2DM>40yearsathighrisk,lipid-loweringtreatmentwithanultimateLDL-Cgoalof>_50%LDL-Creduction
I A
andanLDL-Cof<1.8mmol/L(70mg/dL)isrecommended.
Recommendationsforlipidmanagementinpatientswithmoderate-to-severechronickidneydisease(KidneyDiseaseOutcomes
QualityInitiativestages3(cid:2)5)
Theuseofstatinsorstatin/ezetimibecombinationisrecommendedinpatientswithnon-dialysis-dependent,stage3(cid:2)5CKD. I A
Inpatientswithdialysis-dependentCKDwhoarefreeofASCVD,commencingstatintherapyisnotrecommended. III A
Recommendationsfortheclinicalmanagementofhypertension
ClassificationofBP
ItisrecommendedthatBPshouldbeclassifiedasoptimal,normal,high-normal,orgrades1(cid:2)3hypertension,accordingtooffice
I C
BP.
Diagnosisofhypertension
Itisrecommendedtobasethediagnosisofhypertensionon:
• RepeatedofficeBPmeasurements,onmorethanonevisit,exceptwhenhypertensionissevere(e.g.grade3andespeciallyin I C
high-riskpatients)or
• Out-of-officeBPmeasurementwithABPMand/orHBPMwhenfeasible. I C
AssessmentofHMOD
ToevaluateforthepresenceofHMOD,measurementofserumcreatinine,eGFR,electrolytes,andACRisrecommendedforall
patients.A12-leadECGisrecommendedforallpatients,andechocardiographyisrecommendedforthosewithECGabnormal-
I B
itiesorsigns/symptomsofLVdysfunction.Fundoscopyorretinalimagingisrecommendedforpatientswithgrades2or3hyper-
tensionandallhypertensivepatientswithDM.
Thresholdsforinitiationofdrugtreatmentofhypertension
Forgrade1hypertension,treatmentinitiationbasedonabsoluteCVDrisk,estimatedlifetimebenefit,andthepresenceof
I C
HMODisrecommended.
Forpatientswithgrade2hypertensionorhigher,drugtreatmentisrecommended. I A
OfficeBPtreatmenttargets
ItisrecommendedthatthefirstobjectiveoftreatmentistolowerBPto<140/90mmHginallpatients,andthatsubsequentBP
I A
targetsaretailoredtoageandspecificcomorbidities.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 82 ---
3308 ESCGuidelines
Intreatedpatientsaged18(cid:2)69years,itisrecommendedthatSBPshouldultimatelybeloweredtoatargetrangeof120(cid:2)130
I A
mmHginmostpatients.
Intreatedpatientsaged>_70years,itisrecommendedthatSBPshouldgenerallybetargetedto<140anddownto130mmHgif
I A
tolerated.
Inalltreatedpatients,DBPisrecommendedtobeloweredto<80mmHg. I A
Treatmentofhypertension:lifestyleinterventions
Lifestyleinterventionsarerecommendedforpeoplewithhigh-normalBPorhigher. I A
Treatmentofhypertension:drugtreatment
Itisrecommendedtoinitiateantihypertensivetreatmentwithatwo-drugcombinationinmostpatients,preferablyasasingle-pill
I B
combination.Exceptionsarefrailolderpatientsandthosewithlow-risk,grade1hypertension(particularlyifSBP<150mmHg).
ItisrecommendedthatthepreferredcombinationsincludeaRASblocker(i.e.anACEinhibitororARB)withaCCBordiuretic,
butothercombinationsofthefivemajorclassescanbeused(ACEinhibitor,ARB,beta-blocker,CCB,thiazide/thiazide-like I A
diuretic).
Itisrecommended,ifBPremainsuncontrolledwithatwo-drugcombination,thattreatmentbeincreasedtoathree-drugcombi-
I A
nation,usuallyaRASblockerwithaCCBandadiuretic,preferablyasasingle-pillcombination.
Itisrecommended,ifBPisnotcontrolledbyathree-drugcombination,thattreatmentshouldbeincreasedbytheadditionofspi-
ronolactone,orifnottolerated,otherdiureticssuchasamilorideorhigherdosesofotherdiuretics,analpha-blockerorbeta- I B
blocker,orclonidine.
ThecombinationoftwoRASblockersisnotrecommended. III A
Recommendationsforthetreatmentofpatientswithdiabetesmellitus
Lifestyle
Lifestylechangesincludingsmokingcessation,alowsaturatedfat,high-fibrediet,aerobicPA,andstrengthtrainingare
I A
recommended.
Reductioninenergyintakeisrecommendedtopatients,tohelpachievelowerbodyweightorpreventorslowweightgain. I A
Glycaemiatarget
AtargetHbA1cforthereductionofCVDriskandmicrovascularcomplicationsofDMof<7.0%(53mmol/mol)isrecommended
I A
forthemajorityofadultswitheithertype1ortype2DM.
TreatmentofhyperglycaemiaandASCVD/cardiorenalrisks
Metforminisrecommendedasfirst-linetherapy,followingevaluationofrenalfunction,inthemajorityofpatientswithoutpre-
I B
viousASCVD,CKD,orHF.
Inpersonswithtype2DMandASCVD,theuseofaGLP-1RAorSGLT2inhibitorwithprovenoutcomebenefitsisrecom-
I A
mendedtoreduceCVand/orcardiorenaloutcomes.
Inpatientswithtype2DMandCKD,theuseofanSGLT2inhibitorisrecommendedtoimproveCVDand/orcardiorenal
I A
outcomes.
Inpatientswithtype2DMandHFrEF,useofanSGLT2inhibitorwithprovenoutcomebenefitsisrecommendedtolessenHF
I A
hospitalizationsandCVdeath.
Recommendationsforantithrombotictherapy
Aspirin75(cid:2)100mgdailyisrecommendedforsecondarypreventionofCVD. I A
Clopidogrel75mgdailyisrecommendedasanalternativetoaspirininsecondarypreventionincaseofaspirinintolerance. I B
Concomitantuseofaprotonpumpinhibitorisrecommendedinpatientsreceivingantiplatelettherapywhoareathighriskofgas-
I B
trointestinalbleeding.
Antiplatelettherapyisnotrecommendedinindividualswithlow/moderateCVriskduetotheincreasedriskofmajorbleeding. III A
Recommendationsforcardiacrehabilitation
Participationinamedicallysupervised,structured,comprehensive,multidisciplinaryEBCRandpreventionprogrammeforpatients
afterASCVDeventsand/orrevascularization,andforpatientswithHF(mainlyHFrEF),isrecommendedtoimprovepatient I A
outcomes.
Recommendationforpolicyinterventionsatthepopulationlevel
Puttinginplacemeasurestoreduceairpollution,includingreducingPMemissionandgaseouspollutants,reducingtheuseoffossil
I C
fuels,andlimitingcarbondioxideemissions,arerecommended,toreduceCVDmortalityandmorbidity.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 83 ---
ESCGuidelines 3309
Recommendationsforpatientswithcoronaryarterydisease
Aspirin75(cid:2)100mgdailyisrecommendedforpatientswithapreviousmyocardialinfarctionorrevascularization. I A
InACS,DAPTwithaP2Y inhibitorinadditiontoaspirinisrecommendedfor12months,unlesstherearecontraindications
12 I A
suchasexcessiveriskofbleeding.
InpatientswithCCS,clopidogrel75mgdailyisrecommended,inadditiontoaspirin,for6monthsfollowingcoronarystenting,
irrespectiveofstenttype,unlessashorterduration(1(cid:2)3months)isindicatedduetoriskortheoccurrenceoflife-threatening I A
bleeding.
ACEinhibitors(orARB)arerecommendedifapatienthasotherconditions(e.g.HF,hypertension,orDM). I A
Beta-blockersarerecommendedinpatientswithLVdysfunctionorsystolicHF. I A
InpatientswithestablishedASCVD,orallipid-loweringtreatmentwithanultimateLDL-Cgoalof<1.4mmol/L(55mg/dL)anda
I A
>_50%reductioninLDL-Cvs.baselineisrecommended.
Recommendationsregardingpharmacologicalandnonpharmacologicalinterventionsforpatientswithsymptomatic(NewYorkHeart
AssociationclassII-IV)heartfailurewithreducedejectionfraction(leftventricularejectionfraction<40%)withprovenbenefitsonclin-
icaloutcomes,includingcardiovascularmorbidityandmortality
ItisrecommendedthatpatientswithHFareenrolledinacomprehensiveCRprogrammetoreducetheriskofHFhospitalization
I A
anddeath.
EBCRisrecommendedinstablesymptomaticpatientswithHFrEFtoreducetheriskofHFhospitalization. I A
ItisrecommendedtoscreenpatientswithHFforbothCVandnon-CVcomorbidities,which,ifpresent,shouldbetreated,pro-
I A
videdsafeandeffectiveinterventionsexist,notonlytoalleviatesymptomsbutalsotoimproveprognosis.
AnACEinhibitorisrecommended,inadditiontoabeta-blockerandanMRA,forpatientswithsymptomaticHFrEFtoreducethe
I A
riskofHFhospitalizationanddeath.
Abeta-blockerisrecommended,inadditiontoanACEinhibitor(oranARNI)andanMRA,forpatientswithstable,symptomatic
I A
HFrEFtoreducetheriskofHFhospitalizationanddeath.
AnMRAisrecommendedforpatientswithHFrEFalreadytreatedwithanACEinhibitor(oranARNI)andabeta-blocker,to
I A
reducetheriskofHFhospitalizationanddeath.
Sacubitril/valsartanisrecommendedasareplacementforanACEinhibitortoreducetheriskofHFhospitalizationanddeathin
I B
patientswithHFrEF.
AnARBisrecommendedtoreducetheriskofHFhospitalizationorCVdeathinsymptomaticpatientswithHFrEFwhoare
I B
unabletotolerateanACEinhibitorand/orARNI(patientsshouldalsoreceiveabeta-blockerandanMRA).
Dapagliflozinorempagliflozinarerecommended,inadditiontooptimaltreatmentofanACEinhibitor(orARNI),abeta-blocker,
I A
andanMRA,forpatientswithHFrEFtoreducetheriskofHFhospitalizationanddeath.
DiureticsarerecommendedinpatientswithHFrEFwithsignsand/orsymptomsofcongestiontoreducetheriskofHF
I C
hospitalization.
Recommendationsforpatientswithcerebrovasculardisease
Inpatientswithacerebrovascularevent,improvementoflifestylefactorsinadditiontoappropriatepharmacologicalmanagement
I A
isrecommended.
InpatientswithischaemicstrokeorTIA,preventionwithantithromboticsisrecommended;choiceofantithromboticdependson
themechanismofevent.Useofanantiplateletisrecommendedforpatientswithnon-cardioembolicischaemicstrokeorTIA, I A
anduseofananticoagulantisrecommendedinpatientswithcardioembolicischaemicstrokeorTIA.
Inpatientswithnon-cardioembolicischaemicstrokeorTIA,preventionwithaspirinonly,ordipyridamoleplusaspirin,orclopi-
I A
dogrelaloneisrecommended.
InpatientswithstrokeorTIAwhohaveBPof140/90mmHgorhigher,BPloweringisrecommended. I A
Recommendationsforpatientswithlowerextremityarterydisease:bestmedicaltherapy
SmokingcessationisrecommendedinallpatientswithLEAD. I B
HealthydietandPAarerecommendedforallpatientswithLEAD. I C
Inpatientswithintermittentclaudication:
I A
• Supervisedexercisetrainingisrecommended
• Non-supervisedexercisetrainingisrecommendedwhensupervisedexercisetrainingisnotfeasibleoravailable. I C
AntiplatelettherapyisrecommendedinpatientswithsymptomaticLEAD. I C
InpatientswithLEADandhypertension,itisrecommendedtocontrolBPat<140/90mmHg. I A
InpatientswithLEADandDM,strictglycaemiccontrolisrecommended. I A
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 84 ---
3310 ESCGuidelines
Recommendationsinpatientswithchronickidneydisease:bestmedicaltherapy
TreatmentwithanACEinhibitororanARBisrecommendedinpatientswithDM,hypertension,andalbuminuria.Thesemedica-
I B
tionsshouldbetitratedtothehighestapproveddosethatistolerated.
CombinationtreatmentwithACEinhibitorsandARBsisnotrecommended. III C
Recommendationsforlifestyleinterventionsandmanagementofriskfactorsandconcomitantdiseasesinpatientswithatrial
fibrillation
Identificationandmanagementofriskfactorsandconcomitantdiseasesarerecommendedtobeconsideredanintegralpartof
I B
treatment.
ModificationofunhealthylifestyleandtargetedtherapyofintercurrentconditionsisrecommendedtoreduceAFburdenand
I B
symptomseverity.
AttentiontogoodBPcontrolisrecommendedinAFpatientswithhypertensiontoreduceAFrecurrencesandriskofstrokeand
I B
bleeding.
ABPM=ambulatorybloodpressuremonitoring;ACE=angiotensin-convertingenzyme;ACR=albumin-to-creatinineratio;ACS=acutecoronarysyndromes;AF=atrialfibril-
lation;ARB=angiotensinreceptorblocker;ARNI=angiotensinreceptorneprilysininhibitor;ASCVD=atheroscleroticcardiovasculardisease;BP=bloodpressure;CAC=
coronaryarterycalcium;CCB=calciumchannelblocker;CCS=chroniccoronarysyndromes;CKD=chronickidneydisease;COPD=chronicobstructivepulmonarydisease;
CR=cardiacrehabilitation;CV=cardiovascular;CVD=cardiovasculardisease;DAPT=dualantiplatelettherapy;DBP=diastolicbloodpressure;DM=diabetesmellitus;
EBCR=exercise-basedcardiacrehabilitation;ECG=electrocardiogram;eGRF=estimatedglomerularfiltrationrate;FH=familialhypercholesterolaemia;GLP-1RA=gluca-
gon-likepeptide-1receptoragonist;HbA1c=glycatedhaemoglobin;HBPM=homebloodpressuremonitoring;HF=heartfailure;HFrEF=heartfailurewithreducedejection
fraction;HMOD=hypertension-mediatedorgandamage;LDL-C=low-densitylipoproteincholesterol;LEAD=lowerextremityarterydisease;LV=leftventricular;MRA=
mineralocorticoidreceptorantagonist;PA=physicalactivity;PCSK9=proproteinconvertasesubtilisin/kexintype9;PM=particulatematter;RAS=renin-angiotensinsystem;
SBP=systolicbloodpressure;SCORE2=SystematicCoronaryRiskEstimation2;SCORE2-OP=SystematicCoronaryRiskEstimation2-OlderPersons;SGLT2=sodium-glu-
cosecotransporter2;SNRI=serotonin-noradrenalinereuptakeinhibitor;SSRI=selectiveserotoninreuptakeinhibitor;TIA=transientischaemicattack;TOD=targetorgan
damage.
.
10. Quality indicators .. 11 Supplementary data
.
.
.
.
.
Qualityindicators(QIs)aretoolsthatmaybeusedtoevaluatecare . Supplementary data with additional Supplementary Figures, Tables,
.
quality,includingthatofprocessesofcareandclinicaloutcomes.730 .. andtextcomplementingthefulltextareavailableontheEuropean
.
.
They may also serve as a mechanism for enhancing adherence to . HeartJournalwebsiteandviatheESCwebsiteathttps://www.escar
.
.
guideline recommendations, through quality assurance endeavours . dio.org/guidelines.
.
andbenchmarkingofcareproviders.831Assuch,theroleofQIsin ..
.
.
driving quality improvement is increasingly recognized and attracts .
.
.
interest from healthcare authorities, professional organizations, .. 12. Author information
payers,andthepublic.832 ..
.
.
The ESC recognizes the need for measuring and reporting the .. Author/TaskForceMemberAffiliations:YvoM.Smulders,
.
qualityandoutcomesofCVcare.Oneaspectofthisisthedevelop- .. Internal Medicine, Amsterdam University Medical Center,
.
ment and implementation of QIs for CVD. The methodology by .. Amsterdam, Netherlands; David Carballo, Cardiology, Geneva
.
whichtheESCQIsaredevelopedhasbeenpublished832and,todate, ..
University Hospitals, Geneva, Switzerland; Konstantinos C. .
asuiteofQIsforaninitialtrancheofCVconditionshasbeenpro- .. Koskinas, Cardiology, Bern University Hospital (cid:2) INSELSPITAL,
.
duced.833,834Tofacilitatequalityimprovementinitiatives,thedisease- .. Bern,Switzerland;MariaBa€ck,UnitofPhysiotherapy,Department
.
specificESCQIsareincludedincorrespondingESCClinicalPractice .. of Health, Medicine and Caring Sciences, Linko¨ping University,
.
Guidelines.215,680Thisisfurtherenhancedbywayoftheirintegration .. Linko¨ping, Sweden, and Department of Molecular and Clinical
.
into the EORP (EURObservational Research Programme) and the .. Medicine,InstituteofMedicine,SahlgrenskaAcademy,Universityof
.
EuroHeart (European Unified RegistriesOnHeart CareEvaluation .. Gothenburg, and Sahlgrenska University Hospital, Gothenburg,
. andRandomizedTrials)project.835 ..
Sweden; Athanase Benetos, Geriatric Department CHRU de
.
ForCVDprevention,QIsareavailableforspecificconditions,such .. Nancy and ISERM DCAC, Universite´ de Lorraine, Nancy, France;
.
asthemanagementofhighBP836andsecondarylipidprevention.837 ..
AlessandroBiffi,Cardiology,FIMSandEFSMA,Rome,Italy;Jose´-
.
However,acomprehensivesetofQIsthatencompassesthedepth ... ManuelBoavida,APDP (cid:2) DiabetesPortugal,IDF-EInternational
.
andbreadthofCVDpreventionislacking.Suchasetmayevaluate .. Diabetes Federation (cid:2) Europe, Lisbon, Portugal; Davide
.
theadoptionof,andadherenceto,theguidelinerecommendations .. Capodanno, Cardiothoracic, Vascular and Transplants, Policlinico
.
provided in this document, and may be applied retrospectively to .. “G. Rodolico-San Marco”, University of Catania, Catania, Italy;
.
assess the delivery of evidence-based care. Thus, and in line with .. Bernard Cosyns, Cardiology, Centrum voor Hart en vaatziekte
.
otherESCClinicalPracticeGuidelines,theprocessofdevelopingand .. (CHVZ)UniversitairZiekenhuisBrussel,Brussels,Belgium;Carolyn
.
definingQIsforCVDpreventionhasbeeninitiatedduringthewriting .. A. Crawford, (Northern Ireland), ESC Patient Forum, Sophia
.
of this guideline and the results will be published in a separate .. Antipolis, France; Constantinos H. Davos, Cardiovascular
.
document. . ResearchLaboratory,BiomedicalResearchFoundation,Academyof
1202
CSE
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 85 ---
ESCGuidelines 3311
.
.
Athens, Athens, Greece; Ileana Desormais, INSERM, Univ. . (Switzerland), John William McEvoy (Ireland), Paul McGreavy
.
.
Limoges, CHU Limoges, IRD, U1094 TropicalNeuroepidemiology, . (United Kingdom), Bela Merkely (Hungary), Lis Neubeck (United
.
.
GEIST, Limoges, France; Emanuele Di Angelantonio, . Kingdom), Jens Cosedis Nielsen (Denmark), Joep Perk (Sweden),
.
.
Department of Public Health and Primary Care, University of . Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy),
.
.
Cambridge, Cambridge, UK; Oscar H. Franco Duran, ISPM . Massimo Piepoli (Italy), Nana Goar Pogosova (Russia), Eva Irene
.
.
InstituteofSocialandPreventiveMedicine,UniversityofBern,Bern, . Bossano Prescott (Denmark), Kausik K. Ray (United Kingdom),
.
.
Switzerland; Sigrun Halvorsen, Department ofCardiology, Oslo . Zeljko Reiner (Croatia), Dimitrios J. Richter (Greece), Lars Ryde´n
.
.
UniversityHospitalUllevaal,Oslo,Norway;F.D.RichardHobbs, . (Sweden), Evgeny Shlyakhto (Russia), Marta Sitges (Spain), Miguel
.
.
NDPCHS,UniversityofOxford,Oxford,UK;MonikaHollander, .. Sousa-Uva (Portugal), Isabella Sudano (Switzerland), Monica Tiberi
.
JuliusCenterforHealthSciencesandPrimaryCare,UMCUtrecht, .. (Italy), Rhian M. Touyz (United Kingdom), Andrea Ungar (Italy),
.
Utrecht University, Utrecht, Netherlands; Ewa A. Jankowska, .. W.M.MoniqueVerschuren(Netherlands),OlovWiklund(Sweden),
.
Department of Heart Diseases, Wroclaw Medical University, .. DavidWood(UnitedKingdom/Ireland),JoseLuisZamorano(Spain).
.
Wroclaw,Poland;MatthiasMichal,DepartmentofPsychosomatic ..
.
Medicine and Psychotherapy, University Medical Center Mainz, .. ESCNationalCardiacSocietiesactivelyinvolvedinthereview
.
Mainz, Germany; Simona Sacco, Department of Applied Clinical .. processofthe2021ESCGuidelinesoncardiovasculardiseasepre-
.
andBiotechnologicalSciences,UniversityofL’Aquila,L’Aquila,Italy; .. ventioninclinicalpractice:
.
Naveed Sattar, Institute of Cardiovascular and Medical Sciences, ..
.
University of Glasgow, Glasgow, UK; Lale Tokgozoglu, .. Algeria: Algerian Society of Cardiology, Naima Hammoudi;
.
Cardiology, Hacettepe University, Ankara, Turkey; Serena .. Armenia:ArmenianCardiologistsAssociation,ParounakZelveian;
. Tonstad, Preventive Cardiology, Oslo University Hospital, Oslo, .. Austria: Austrian Society of Cardiology, Peter Siostrzonek;
.
.
Norway;KonstantinosP.Tsioufis,FirstCardiologyClinic,Medical . Azerbaijan: Azerbaijan Society of Cardiology, Elman Alakbarov;
.
.
School,NationalandKapodistrianUniversity,HippokrationHospital, . Belarus: Belorussian Scientific Society of Cardiologists, Olga
.
.
Athens, Greece; Ineke van Dis, European Heart Network, . Pavlova;Belgium:BelgianSocietyofCardiology,JohanDeSutter;
.
.
Brussels,Belgium;IsabelleC.vanGelder,Cardiology,University . BosniaandHerzegovina:AssociationofCardiologistsofBosnia
.
.
of Groningen, University Medical Center Groningen; Groningen, . and Herzegovina, Mirza Dili(cid:3)c; Bulgaria: Bulgarian Society of
.
.
Netherlands; Christoph Wanner, Department of Nephrology, . Cardiology, Nina Gotcheva; Croatia: Croatian Cardiac Society,
.
.
University Wu¨rzburg, Germany; Bryan Williams, Institute of . Bosko Skoric; Cyprus: Cyprus Society of Cardiology, Hera
.
.
CardiovascularScience,UniversityCollegeLondon,London,UK . Heracleous Moustra; Czech Republic: Czech Society of
.
.
. Cardiology, Renata Cifkova; Denmark: Danish Society of
.
.
. Cardiology, Ann Bovin; Egypt: Egyptian Society of Cardiology,
.
.
13. Appendix . Bassem Zarif; Estonia: Estonian Society of Cardiology, Margus
.
.
.. Viigimaa; Finland: Finnish Cardiac Society, Anna-Mari Hekkala;
.
ESCScientificDocumentGroup .. France:FrenchSocietyofCardiology,SergeKownator;Georgia:
.
IncludesDocumentReviewersandESCNationalCardiacSocieties. .. GeorgianSocietyofCardiology,ZurabPagava;Germany:German
.
.. Cardiac Society, Ulf Landmesser; Greece: Hellenic Society of
.
Document Reviewers: Guy De Backer (CPG Review .. Cardiology, Harry Grassos; Hungary: Hungarian Society of
.
Coordinator) (Belgium), Vera Regitz-Zagrosek (CPG Review .. Cardiology, Eszter Szabados; Iceland: Icelandic Society of
.
Coordinator) (Germany), Anne Hege Aamodt (Norway), Magdy .. Cardiology, Karl Andersen; Ireland: Irish Cardiac Society, John
.
Abdelhamid (Egypt), Victor Aboyans (France), Christian Albus .. William McEvoy; Israel: Israel Heart Society, Barak Zafrir; Italy: .
(Germany), Riccardo Asteggiano (Italy), Magnus B€ack (Sweden), .. Italian Federation of Cardiology, Francesco Barill(cid:4)a; Kosovo
.
Michael A. Borger (Germany), Carlos Brotons (Spain), Jelena .. (Republic of): Kosovo Society of Cardiology, Pranvera Ibrahimi;
.
C(cid:2)elutkiene_ (Lithuania),RenataCifkova(CzechRepublic),MajaCikes .. Kyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov;
.
. (Croatia),FrancescoCosentino(Italy),NikolaosDagres(Germany), . Latvia: Latvian Society of Cardiology, Iveta Mintale; Lebanon:
.
.
Tine De Backer (Belgium), Dirk De Bacquer (Belgium), Victoria . Lebanese Society of Cardiology, Samir Arnaout; Lithuania:
.
Delgado (Netherlands), Hester Den Ruijter (Netherlands), Paul
.. LithuanianSocietyofCardiology,Rimvydas(cid:2)Slapikas;Luxembourg:
. .
Dendale(Belgium),HeinzDrexel(Austria),VolkmarFalk(Germany), . LuxembourgSocietyofCardiology,CristianaBanu;Malta:Maltese
.
LaurentFauchier(France),BrianA.Ference1(UnitedKingdom),Jean .. Cardiac Society, Mark Abela; Moldova (Republic of): Moldavian
.
Ferrie`res (France), Marc Ferrini (France), Miles Fisher2 (United .. Society of Cardiology, Victor Rudi; Montenegro: Montenegro
.
.
Kingdom),DaniloFliser(Germany),ZlatkoFras(Slovenia),DanGaita . SocietyofCardiology,AnetaBoskovic;Morocco:MoroccanSociety
.
.
(Romania),SimonaGiampaoli(Italy),StephanGielen(Germany),Ian .. ofCardiology,MohamedAlami;Netherlands:NetherlandsSociety
.
Graham (Ireland), Catriona Jennings (Ireland), Torben Jorgensen .. of Cardiology, Hareld M.C. Kemps; North Macedonia: North
.
(Denmark), Alexandra Kautzky-Willer (Austria), Maryam Kavousi .. Macedonian Society of Cardiology, Marijan Bosevski; Norway:
.
(Netherlands), Wolfgang Koenig (Germany), Aleksandra Konradi .. NorwegianSocietyofCardiology,ErikEkkerSolberg;Poland:Polish
.
(Russia), Dipak Kotecha (United Kingdom), Ulf Landmesser .. CardiacSociety,TomaszZdrojewski;Portugal:PortugueseSociety
.
(Germany), Madalena Lettino (Italy), Basil S. Lewis (Israel), Ale(cid:2)s .. of Cardiology, Carlos Rabac¸al; Romania: Romanian Society of
.
Linhart(CzechRepublic),Maja-LisaLøchen(Norway),Konstantinos .. Cardiology, Dan Gaita; Russian Federation: Russian Society of
.
Makrilakis (Greece), Giuseppe Mancia (Italy), Pedro Marques-Vidal . Cardiology, Yury Belenkov; San Marino: San Marino Society of
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 86 ---
3312 ESCGuidelines
.
.
Cardiology, Luca Bertelli; Serbia: Cardiology Society of Serbia, . 5. CosentinoF,GrantPJ,AboyansV,BaileyCJ,CerielloA,DelgadoV,FedericiM,
.
VojislavGiga;Slovakia:SlovakSocietyofCardiology,DanielPella; .. FilippatosG,GrobbeeDE,HansenTB,HuikuriHV,JohanssonI,JuniP,LettinoM,
.. MarxN,MellbinLG,OstgrenCJ,RoccaB,RoffiM,SattarN,SeferovicPM,Sousa-
Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain: .. Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group. 2019 ESC
.
Spanish Society of Cardiology, Regina Dalmau; Sweden: Swedish . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in
.
SocietyofCardiology,AnnaKiessling;Switzerland:SwissSocietyof .. collaborationwiththeEASD.EurHeartJ2020;41:255(cid:2)323.
.. 6. Jorgensen T, Jacobsen RK, Toft U, Aadahl M, Glumer C, Pisinger C. Effect of
Cardiology, Otmar Pfister; Syrian Arab Republic: Syrian .. screeningandlifestylecounsellingonincidenceofischaemicheartdiseaseingen-
.
Cardiovascular Association, Yassin Bani Marjeh; Tunisia: Tunisian . eralpopulation:Inter99randomisedtrial.BMJ2014;348:g3617.
.
Society of Cardiology and Cardio-Vascular Surgery, Salem
.. 7. EbrahimS,TaylorF,WardK,BeswickA,BurkeM,DaveySmithG.Multiplerisk
.. factorinterventionsforprimarypreventionofcoronaryheartdisease.Cochrane
Abdessalem;Turkey:TurkishSocietyofCardiology,OnerOzdogan; .. DatabaseSystRev2011:CD001561.
.
Ukraine: Ukrainian Association of Cardiology, Elena Nesukay; .. 8. KennedyO,SuF,PearsR,WalmsleyE,RoderickP.Evaluatingtheeffectivenessof
United Kingdom of Great Britain and Northern Ireland:
... the NHS Health Check programmein South England: aquasi-randomised con-
. trolledtrial.BMJOpen2019;9:e029420.
BritishCardiovascularSociety,RiyazPatel;Uzbekistan:Association .. 9. Krogsboll LT, Jorgensen KJ, Gotzsche PC. General health checks in adults for
.
ofCardiologistsofUzbekistan,GuzalMullabayeva. .. reducing morbidity and mortality from disease. Cochrane Database Syst Rev
ESC Clinical Practice Guidelines Committee (CPG):
... 2019;1:CD009009.
. 10. Si S, Moss JR, Sullivan TR, Newton SS, Stocks NP. Effectiveness of general
ColinBaigent(Chairperson)(UnitedKingdom),MagdyAbdelhamid .. practice-based health checks: a systematic review and meta-analysis. Br J Gen
.
(Egypt), Victor Aboyans (France), Sotiris Antoniou (United .. Pract2014;64:e47-53.
Kingdom),ElenaArbelo(Spain),RiccardoAsteggiano(Italy),Andreas
... 11. PatelR,BarnardS,ThompsonK,LagordC,CleggE,WorrallR,EvansT,Carter
. S,FlowersJ,RobertsD,NuttallM,SamaniNJ,RobsonJ,KearneyM,DeanfieldJ,
Baumbach(United Kingdom),Michael A.Borger (Germany),Jelena ... WaterallJ.EvaluationoftheuptakeanddeliveryoftheNHSHealthCheckpro-
C(cid:2)elutkiene_ (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet .. gramme in England, using primary care data from 9.5 million people: a cross-
. (France),VolkmarFalk(Germany),LaurentFauchier(France),Chris .. sectionalstudy.BMJOpen2020;10:e042963.
.. 12. MehtaS,WellsS,GreyC,RiddellT,KerrA,MarshallR,AmeratungaS,Harrison
P.Gale(UnitedKingdom),SigrunHalvorsen(Norway),BernardIung .. J, Kenealy T, Bramley D, Chan WC, Thornley S, Sundborn G, Jackson R.
.
(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia), . Initiationandmaintenanceofcardiovascularmedicationsfollowingcardiovascular
.
Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United .. risk assessment in a large primary care cohort: PREDICT CVD-16. Eur J Prev
.. Cardiol2014;21:192(cid:2)202.
Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ale(cid:2)s .
. 13. ChamnanP,SimmonsRK,KhawKT,WarehamNJ,GriffinSJ.Estimatingthepop-
.
Linhart(CzechRepublic),Maja-LisaLøchen(Norway),JensCosedis .. ulationimpactofscreeningstrategiesforidentifyingandtreatingpeopleathigh
Nielsen(Denmark),SteffenE.Petersen(UnitedKingdom),EvaIrene .. riskofcardiovasculardisease:modellingstudy.BMJ2010;340:c1693.
.
. 14. Lindholt JS, Sogaard R. Population screening and intervention for vascular
BossanoPrescott(Denmark),AminaRakisheva(Kazakhstan),Marta .
.. disease in Danish men (VIVA): a randomised controlled trial. Lancet
Sitges(Spain),RhianM.Touyz(UnitedKingdom) .. 2017;390:2256(cid:2)2265.
.
. 15. ChristensenB,EngbergM,LauritzenT.Nolong-termpsychologicalreactionto
.
.. informationaboutincreasedriskofcoronaryheartdiseaseingeneralpractice.
.. EurJCardiovascPrevRehabil2004;11:239(cid:2)243.
.
.. 16. NielsenAD,VidebechP,GerkeO,PetersenH,JensenJM,SandNP,EgstrupK,
14. References .. Larsen ML, Mickley H, Diederichsen AC. Population screening for coronary
.
. arterycalcificationdoesnotincreasementaldistressandtheuseofpsychoactive
.
. medication.JThoracImaging2012;27:202(cid:2)206.
.
1. KotsevaK,DeBackerG,DeBacquerD,RydenL,HoesA,GrobbeeD,Maggioni .. 17. LokkegaardT,AndersenJS,JacobsenRK,BadsbergJH,JorgensenT,PisingerC.
A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, .. Psychologicalconsequencesofscreeningforcardiovascularriskfactorsinanun-
CifkovaR,DavletovK,DilicM,DolzhenkoM,GaitaD,GotchevaN,Hasan-AliH, .. selected general population: results from the Inter99 randomised intervention
.
JankowskiP,LionisC,MancasS,MilicicD,MirrakhimovE,OganovR,PogosovaN, . study.ScandJPublicHealth2015;43:102(cid:2)110.
.
ReinerZ,VulicD,WoodD.Primarypreventioneffortsarepoorlydevelopedin .. 18.Jorgensen T,Ladelund S, Borch-Johnsen K, Pisinger C, Schrader AM, Thomsen T,
people at high cardiovascular risk: A report from the European Society of .. GlumerC,IbsenH,MortensenEL.Screeningforriskofcardiovasculardiseaseisnot
CardiologyEURObservationalResearchProgrammeEUROASPIREVsurveyin16 .. associatedwithmentaldistress:theInter99study.PrevMed2009;48:242(cid:2)246.
. Europeancountries.EurJPrevCardiol2020:2047487320908698. .. 19. PiperMA,EvansCV,BurdaBU,MargolisKL,O’ConnorE,SmithN,WebberE,
2. PiepoliMF,HoesAW,AgewallS,AlbusC,BrotonsC,CatapanoAL,CooneyMT, .. PerdueLA,BiglerKD,WhitlockEP.ScreeningforHighBloodPressureinAdults:A
Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, .. Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville
.
Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, . (MD);2014. .
SmuldersY,TiberiM,vanderWorpHB,vanDisI,VerschurenWMM,BinnoS, .. 20. FerenceBA,GinsbergHN,GrahamI,RayKK,PackardCJ,BruckertE,Hegele
ESCScientificDocumentGroup.2016EuropeanGuidelinesoncardiovasculardis- .. RA,KraussRM,RaalFJ,SchunkertH,WattsGF,BorenJ,FazioS,HortonJD,
.
easepreventioninclinicalpractice:TheSixthJointTaskForceoftheEuropean . Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR,
.
SocietyofCardiologyandOtherSocietiesonCardiovascularDiseasePrevention . Tokgozoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ,
.
inClinicalPractice(constitutedbyrepresentativesof10societiesandbyinvited .. CatapanoAL.Low-densitylipoproteinscauseatheroscleroticcardiovasculardis-
experts)DevelopedwiththespecialcontributionoftheEuropeanAssociationfor .. ease.1.Evidencefromgenetic,epidemiologic,andclinicalstudies.Aconsensus
.
Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J . statement from the European Atherosclerosis Society Consensus Panel. Eur
.
2016;37:2315(cid:2)2381. .. HeartJ2017;38:2459(cid:2)2472.
3. MachF,BaigentC,CatapanoAL,KoskinasKC,CasulaM,BadimonL,Chapman .. 21. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L,
MJ,DeBackerGG,DelgadoV,FerenceBA,GrahamIM,HallidayA,Landmesser .. EmbersonJ,HollandLE,ReithC,BhalaN,PetoR,BarnesEH,KeechA,SimesJ,
.
U,MihaylovaB,PedersenTR,RiccardiG,RichterDJ,SabatineMS,TaskinenMR, . CollinsR.EfficacyandsafetyofmoreintensiveloweringofLDLcholesterol:a
.
Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS .. meta-analysisofdatafrom170,000participantsin26randomisedtrials.Lancet
Guidelinesforthemanagementofdyslipidaemias:lipidmodificationtoreducecar- .. 2010;376:1670(cid:2)1681.
.
diovascularrisk.EurHeartJ2020;41:111(cid:2)188. . 22. CholesterolTreatmentTrialists’(CTT)Collaborators,MihaylovaB,EmbersonJ,
.
4. WilliamsB,ManciaG,SpieringW,AgabitiRoseiE,AziziM,BurnierM,Clement .. BlackwellL,KeechA,SimesJ,BarnesEH,VoyseyM,GrayA,CollinsR,Baigent
DL,CocaA,deSimoneG,DominiczakA,KahanT,MahfoudF,RedonJ,Ruilope .. C.TheeffectsofloweringLDLcholesterolwithstatintherapyinpeopleatlow
L,ZanchettiA,KerinsM,KjeldsenSE,KreutzR,LaurentS,LipGYH,McManusR, .. riskofvasculardisease:meta-analysisofindividualdatafrom27randomisedtri-
.
NarkiewiczK,Ruschitzka F,SchmiederRE,ShlyakhtoE,TsioufisC,AboyansV, . als.Lancet2012;380:581(cid:2)590.
.
DesormaisI,ESCScientificDocumentGroup.2018ESC/ESHGuidelinesforthe .. 23. Pencina KM, Thanassoulis G, Wilkins JT, Vasan RS, Navar AM, Peterson ED,
managementofarterialhypertension.EurHeartJ2018;39:3021(cid:2)3104. .. Pencina MJ, Sniderman AD. Trajectories of Non-HDL Cholesterol Across
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 87 ---
ESCGuidelines 3313
.
.
Midlife: Implications for Cardiovascular Prevention. J Am Coll Cardiol . Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R,
.
2019;74:70(cid:2)79. . WeissmanMM,WhiteRA,WhitefordH,WiersmaST,WilkinsonJD,Williams
.
24. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, .. HC,WilliamsW,WilsonN,WoolfAD,YipP,ZielinskiJM,LopezAD,Murray
KaptogeS,RayKK,ThompsonA,WoodAM,LewingtonS,SattarN,PackardCJ, .. CJ,EzzatiM,AlMazroaMA,MemishZA.Acomparativeriskassessmentofbur-
.
CollinsR,ThompsonSG,DaneshJ.Majorlipids,apolipoproteins,andriskofvas- . denofdiseaseandinjuryattributableto67riskfactorsandriskfactorclustersin
.
culardisease.JAMA2009;302:1993(cid:2)2000. .. 21regions,1990-2010:asystematicanalysisfortheGlobalBurdenofDisease
25. HolmesMV,AsselbergsFW,PalmerTM,DrenosF,LanktreeMB,NelsonCP, .. Study2010.Lancet2012;380:2224(cid:2)2260.
.
Dale CE, Padmanabhan S, Finan C, Swerdlow DI, Tragante V, van Iperen EP, . 30. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies
.
Sivapalaratnam S, Shah S, Elbers CC, Shah T, Engmann J, Giambartolomei C, . Collaboration.Age-specificrelevanceofusualbloodpressuretovascularmortal-
.
WhiteJ,ZabanehD,SofatR,McLachlanS,UCLEBconsortium,DoevendansPA, .. ity: a meta-analysis of individual data for one million adults in 61 prospective
Balmforth AJ, Hall AS, North KE, Almoguera B, Hoogeveen RC, Cushman M, .. studies.Lancet2002;360:1903(cid:2)1913.
.
FornageM,PatelSR,RedlineS,Siscovick DS,TsaiMY,KarczewskiKJ,Hofker . 31. WheltonSP,McEvoyJW,ShawL,PsatyBM,LimaJAC,BudoffM,NasirK,Szklo
.
MH,VerschurenWM,BotsML,vanderSchouwYT,MelanderO,Dominiczak .. M, Blumenthal RS, Blaha MJ. Association of Normal Systolic Blood Pressure
AF,MorrisR,Ben-ShlomoY,PriceJ,KumariM,BaumertJ,PetersA,ThorandB, .. LevelWithCardiovascularDiseaseintheAbsenceofRiskFactors.JAMACardiol
.
KoenigW,GauntTR,HumphriesSE,ClarkeR,WatkinsH,FarrallM,WilsonJG, . 2020;5:1011(cid:2)1018.
.
RichSS,deBakkerPI,LangeLA,DaveySmithG,ReinerAP,TalmudPJ,Kivimaki . 32. WillsAK,LawlorDA,MatthewsFE,SayerAA,BakraE,Ben-ShlomoY,Benzeval
.
M, Lawlor DA, Dudbridge F, Samani NJ, Keating BJ, Hingorani AD, Casas JP. .. M,BrunnerE,CooperR,KivimakiM,KuhD,Muniz-TerreraG,HardyR.Life
Mendelianrandomizationofbloodlipidsforcoronaryheartdisease.EurHeartJ .. coursetrajectoriesofsystolicbloodpressureusinglongitudinaldatafromeight
.
2015;36:539(cid:2)550. . UKcohorts.PLoSMed2011;8:e1000440.
.
26. VoightBF,PelosoGM,Orho-MelanderM,Frikke-SchmidtR,BarbalicM,Jensen . 33. JiH,NiiranenTJ,RaderF,HenglinM,KimA,EbingerJE,ClaggettB,MerzCNB,
.
MK,HindyG,HolmH,DingEL,JohnsonT,SchunkertH,SamaniNJ,ClarkeR, .. ChengS.SexDifferencesinBloodPressureAssociationsWithCardiovascular
HopewellJC,ThompsonJF,LiM,ThorleifssonG,Newton-ChehC,MusunuruK, .. Outcomes.Circulation2021;143:761(cid:2)763.
.
PirruccelloJP,SaleheenD,ChenL,StewartA,SchillertA,ThorsteinsdottirU, . 34. JiH,KimA,EbingerJE,NiiranenTJ,ClaggettBL,BaireyMerzCN,ChengS.Sex
. Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, .. DifferencesinBloodPressureTrajectoriesOvertheLifeCourse.JAMACardiol
Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, .. 2020;5:19(cid:2)26.
. BurnettMS,MooserV,RipattiS,SurakkaI,NieminenMS,SinisaloJ,LokkiML, . 35. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50
.
PerolaM,HavulinnaA,deFaireU,GiganteB,IngelssonE,ZellerT,WildP,de . years’observationsonmaleBritishdoctors.BMJ2004;328:1519.
.
BakkerPI,KlungelOH,Maitland-vanderZeeAH,PetersBJ,deBoerA,Grobbee .. 36. PrescottE,HippeM,SchnohrP,HeinHO,VestboJ.Smokingandriskofmyocar-
DE,KamphuisenPW,DeneerVH,ElbersCC,Onland-MoretNC,HofkerMH, .. dial infarction in women and men: longitudinal population study. BMJ
.
Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, . 1998;316:1043(cid:2)1047.
.
FrossardP,DemissieS,WillerC,DoR,OrdovasJM,AbecasisGR,BoehnkeM, . 37. HuxleyRR,WoodwardM.Cigarettesmokingasariskfactorforcoronaryheart
.
Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, .. diseaseinwomencomparedwithmen:asystematicreviewandmeta-analysisof
.
GabrielS,MarrugatJ,PedenJ,ErdmannJ,DiemertP,WillenborgC,KonigIR, . prospectivecohortstudies.Lancet2011;378:1297(cid:2)1305.
.
Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de . 38.GBD2017RiskFactorCollaborators.Global,regional,andnationalcomparativerisk
.
WerfF,FoxKA,ElMokhtariNE,RubinD,SchrezenmeirJ,SchreiberS,Schafer .. assessmentof84behavioural,environmentalandoccupational,andmetabolicrisksor
A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, .. clustersofrisksfor195countriesandterritories,1990-2017:asystematicanalysisfor
.
OvervadK,RimmE,BoerwinkleE,Tybjaerg-HansenA,CupplesLA,ReillyMP, . theGlobalBurdenofDiseaseStudy2017.Lancet2018;392:1923(cid:2)1994.
.
Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, . 39. LvX,SunJ,BiY,XuM,LuJ,ZhaoL,XuY.Riskofall-causemortalityandcardio-
.
O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, .. vascular disease associated with secondhand smoke exposure: a systematic
KathiresanS.PlasmaHDLcholesterolandriskofmyocardialinfarction:amende- .. reviewandmeta-analysis.IntJCardiol2015;199:106(cid:2)115.
.
lianrandomisationstudy.Lancet2012;380:572(cid:2)580. . 40. GuptaR,GuptaS,SharmaS,SinhaDN,MehrotraR.RiskofCoronaryHeart
.
27. Frikke-SchmidtR,NordestgaardBG,SteneMC,SethiAA,RemaleyAT,Schnohr .. Disease Among Smokeless Tobacco Users: Results of Systematic Review and
P,GrandeP,Tybjaerg-HansenA.Associationofloss-of-functionmutationsinthe .. Meta-AnalysisofGlobalData.NicotineTobRes2019;21:25(cid:2)31.
.
ABCA1genewithhigh-densitylipoproteincholesterollevelsandriskofischemic . 41. EmergingRiskFactorsCollaboration,SarwarN,GaoP,SeshasaiSR,GobinR,
.
heartdisease.JAMA2008;299:2524(cid:2)2532. . Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M,
.
28. HPS3/TIMI55(cid:2)REVEALCollaborativeGroup,BowmanL,HopewellJC,ChenF, .. StehouwerCD,LewingtonS,PennellsL,ThompsonA,SattarN,WhiteIR,Ray
Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, .. KK,DaneshJ.Diabetesmellitus,fastingbloodglucoseconcentration,andriskof
.
SammonsE,LandrayMJ.EffectsofAnacetrapibinPatientswithAtherosclerotic . vasculardisease:acollaborativemeta-analysisof102prospectivestudies.Lancet
.
VascularDisease.NEnglJMed2017;377:1217(cid:2)1227. . 2010;375:2215(cid:2)2222.
.
29. LimSS,VosT,FlaxmanAD,DanaeiG,ShibuyaK,Adair-RohaniH,AmannM, .. 42. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in
Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, .. women compared with men: a systematic review and meta-analysis of 64
.
BalakrishnanK,BalmesJ,Barker-ColloS,BaxterA,BellML,BloreJD,BlythF, . cohorts, including 775,385 individuals and 12,539 strokes. Lancet .
BonnerC,BorgesG,BourneR,BoussinesqM,BrauerM,BrooksP,BruceNG, .. 2014;383:1973(cid:2)1980.
BrunekreefB,Bryan-HancockC,BucelloC,BuchbinderR,BullF,BurnettRT, .. 43. NCDRiskFactorCollaboration(NCD-RisC).Worldwidetrendsinbody-mass
.
Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, . index,underweight,overweight,andobesityfrom1975to2016:apooledanaly-
.
ChenJS,ChengAT,ChildJC,CohenA,ColsonKE,CowieBC,DarbyS,Darling . sisof2416population-basedmeasurementstudiesin128.9millionchildren,ado-
.
S,DavisA,DegenhardtL,DentenerF,DesJarlaisDC,DevriesK,DheraniM, .. lescents,andadults.Lancet2017;390:2627(cid:2)2642.
DingEL,DorseyER,DriscollT,EdmondK,AliSE,EngellRE,ErwinPJ,FahimiS, .. 44. SunYQ,BurgessS,StaleyJR,WoodAM,BellS,KaptogeSK,GuoQ,BoltonTR,
.
FalderG,FarzadfarF,FerrariA,FinucaneMM,FlaxmanS,FowkesFG,Freedman . MasonAM,ButterworthAS,DiAngelantonioE,VieGA,BjorngaardJH,Kinge
.
G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, . JM,ChenY,MaiXM.BodymassindexandallcausemortalityinHUNTandUK
. GraingerR,GrantB,GunnellD,GutierrezHR,HallW,HoekHW,HoganA, .. Biobank studies: linear and non-linear mendelian randomisation analyses. BMJ
.
HosgoodHD,3rd,HoyD,HuH,HubbellBJ,HutchingsSJ,IbeanusiSE,Jacklyn . 2019;364:l1042.
.
GL,JasrasariaR,JonasJB,KanH,KanisJA,KassebaumN,KawakamiN,Khang . 45. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N,
.
YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, .. WormserD,GaoP,KaptogeS,BerringtondeGonzalezA,CairnsBJ,HuxleyR,
LeasherJL,LeighJ,LiY,LinJK,LipshultzSE,LondonS,LozanoR,LuY,MakJ, .. JacksonChL,JoshyG,LewingtonS,MansonJE,MurphyN,PatelAV,SametJM,
.
MalekzadehR,MallingerL,MarcenesW,MarchL,MarksR,MartinR,McGaleP, . WoodwardM,ZhengW,ZhouM,BansalN,BarricarteA,CarterB,CerhanJR,
.
McGrathJ,MehtaS,MensahGA,MerrimanTR,MichaR,MichaudC,MishraV, . SmithGD,FangX,FrancoOH,GreenJ,HalseyJ,HildebrandJS,JungKJ,Korda
.
MohdHanafiahK,MokdadAA,MorawskaL,MozaffarianD,MurphyT,Naghavi .. RJ, McLerran DF, Moore SC, O’Keeffe LM, Paige E, Ramond A, Reeves GK,
M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, .. RollandB,SacerdoteC,SattarN,SofianopoulouE,StevensJ,ThunM,Ueshima
.
OsborneR,OstroB,PageA,PandeyKD,ParryCD,PassmoreE,PatraJ,Pearce . H,YangL,YunYD,WilleitP,BanksE,BeralV,ChenZ,GapsturSM,GunterMJ,
.
N,PelizzariPM,PetzoldM,PhillipsMR,PopeD,PopeCA,3rd,PowlesJ,RaoM, .. Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG,
Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, .. DaneshJ,HuFB.Body-massindexandall-causemortality:individual-participant-
.
Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, . data meta-analysis of 239 prospective studies in four continents. Lancet
.
SalomonJA,SampsonU,Sanchez-RieraL,SanmanE,SapkotaA,SeedatS,ShiP, . 2016;388:776(cid:2)786.
.
Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, .. 46. AuneD,SenA,PrasadM,NoratT,JanszkyI,TonstadS,RomundstadP,Vatten
SteenlandK,StocklH,StovnerLJ,StraifK,StraneyL,ThurstonGD,TranJH,Van . LJ.BMIandallcausemortality:systematicreviewandnon-lineardose-response
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 88 ---
3314 ESCGuidelines
.
.
meta-analysisof230cohortstudieswith3.74milliondeathsamong30.3million . 66. CersosimoE,JohnsonEL,ChovanesC,SkolnikN.Initiatingtherapyinpatients
.
participants.BMJ2016;353:i2156. . newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise
.
47. EmergingRiskFactorsCollaboration,WormserD,KaptogeS,DiAngelantonio .. approach.DiabetesObesMetab2018;20:497(cid:2)507.
E, Wood AM, Pennells L, Thompson A, Sarwar N, Kizer JR, Lawlor DA, .. 67. RodbardHW,ViscoVE,AndersenH,HiortLC,ShuDH.Treatmentintensifica-
.
Nordestgaard BG, Ridker P, Salomaa V, Stevens J, Woodward M, Sattar N, . tionwithstepwiseadditionofprandialinsulinaspartbolusescomparedwithfull
.
CollinsR,ThompsonSG,WhitlockG,DaneshJ.Separateandcombinedassocia- .. basal-bolustherapy(FullSTEPStudy):arandomised,treat-to-targetclinicaltrial.
tionsofbody-massindexandabdominal adipositywithcardiovasculardisease: .. LancetDiabetesEndocrinol2014;2:30(cid:2)37.
.
collaborativeanalysisof58prospectivestudies.Lancet2011;377:1085(cid:2)1095. . 68. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2
.
48. World Health Organization. Gender and health. https://www.who.int/health- . riskpredictionalgorithms:newmodelstoestimate10-yearriskofcardiovascular
.
topics/gender#tab=tab_1(4June2021). .. diseaseinEurope.EurHeartJ2021;42:2439(cid:2)2454.
49. GlobalHealth50/50.Genderandglobalhealth.https://globalhealth5050.org/gen .. 69. Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr
.
der-and-global-health(4June2021). . Cardiol2002;11:101(cid:2)107.
.
50. Mauvais-JarvisF,BaireyMerzN,BarnesPJ,BrintonRD,CarreroJJ,DeMeoDL, . 70. WolbersM,KollerMT,WittemanJC,SteyerbergEW.Prognosticmodelswith
.
De Vries GJ, Epperson CN, Govindan R, Klein SL, Lonardo A, Maki PM, .. competing risks: methods and application to coronary risk prediction.
.
McCullough LD, Regitz-Zagrosek V, Regensteiner JG, Rubin JB, Sandberg K, . Epidemiology2009;20:555(cid:2)561.
.
Suzuki A. Sex and gender: modifiers of health, disease, and medicine. Lancet . 71. BerrySD,NgoL,SamelsonEJ,KielDP.Competingriskofdeath:animportant
.
2020;396:565(cid:2)582. .. considerationinstudiesofolderadults.JAmGeriatrSoc2010;58:783(cid:2)787.
51. PetersSAE,MuntnerP,WoodwardM.SexDifferencesinthePrevalenceof,and .. 72. SCORE2-OP working group and ESC Cardiovascular risk collaboration.
.
Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United . SCORE2-OPriskpredictionalgorithms:estimatingincidentcardiovascularevent
.
States,2001to2016.Circulation2019;139:1025(cid:2)1035. . risk in older persons in four geographical risk regions. Eur Heart J
.
52. Lee CMY, Mnatzaganian G, Woodward M, Chow CK, Sitas F, Robinson S, .. 2021;42:2455(cid:2)2467.
HuxleyRR.Sexdisparitiesinthemanagementofcoronaryheartdiseaseingen- .. 73. WorldHealthOrganization.Diseaseburdenandmortalityestimates.www.who.
.
eralpracticesinAustralia.Heart2019;105:1898(cid:2)1904. . int/healthinfo/global_burden_disease/estimates/en(4June2021).
. 53. CushmanM,ShayCM,HowardVJ,JimenezMC,LeweyJ,McSweeneyJC,Newby .. 74. PennellsL,KaptogeS,WoodA,SweetingM,ZhaoX,WhiteI,BurgessS,Willeit
LK, PoudelR,Reynolds HR,Rexrode KM,Sims M,MoscaLJ, American Heart .. P,BoltonT,MoonsKGM,vanderSchouwYT,SelmerR,KhawKT,GudnasonV,
. Association.Ten-YearDifferencesinWomen’sAwarenessRelatedtoCoronary . Assmann G, Amouyel P, Salomaa V, Kivimaki M, Nordestgaard BG, Blaha MJ,
.
HeartDisease:Resultsofthe2019AmericanHeartAssociationNationalSurvey: . KullerLH,BrennerH,GillumRF,MeisingerC,FordI,KnuimanMW,Rosengren
.
A Special Report From the American Heart Association. Circulation .. A, Lawlor DA, Volzke H, Cooper C, Marin Ibanez A, Casiglia E, Kauhanen J,
2021;143:e239(cid:2)e248. .. CooperJA,RodriguezB,SundstromJ,Barrett-ConnorE,DanknerR,NietertPJ,
.
54. PelletierR,KhanNA,CoxJ,DaskalopoulouSS,EisenbergMJ,BaconSL,Lavoie . Davidson KW, Wallace RB, Blazer DG, Bjorkelund C, Donfrancesco C,
.
KL,DaskuptaK,RabiD,HumphriesKH,NorrisCM,ThanassoulisG,BehlouliH, . Krumholz HM, Nissinen A, Davis BR, Coady S, Whincup PH, Jorgensen T,
.
Pilote L, GENESIS-PRAXY Investigators. Sex Versus Gender-Related .. Ducimetiere P, Trevisan M, Engstrom G, Crespo CJ, Meade TW, Visser M,
.
Characteristics: Which Predicts OutcomeAfter Acute Coronary Syndrome in . KromhoutD,KiechlS,Daimon M,Price JF,GomezdelaCamara A,Wouter
.
theYoung?JAmCollCardiol2016;67:127(cid:2)135. . JukemaJ,LamarcheB,OnatA,SimonsLA,KavousiM,Ben-ShlomoY,Gallacher
.
55. Bots SH, Groepenhoff F, Eikendal ALM, Tannenbaum C, Rochon PA, Regitz- .. J,DekkerJM,ArimaH,SharaN,TippingRW,RousselR,BrunnerEJ,KoenigW,
ZagrosekV,MillerVM,DayD,AsselbergsFW,denRuijterHM.AdverseDrug .. SakuraiM,PavlovicJ,GansevoortRT,NagelD,GoldbourtU,BarrELM,Palmieri
.
Reactions to Guideline-Recommended Heart Failure Drugs in Women: A . L,NjolstadI,SatoS,MoniqueVerschurenWM,VargheseCV,GrahamI,Onuma
.
SystematicReviewoftheLiterature.JACCHeartFail2019;7:258(cid:2)266. . O,GreenlandP,WoodwardM,EzzatiM,PsatyBM,SattarN,JacksonR,Ridker
.
56. Regitz-ZagrosekV,SeelandU.Sexandgenderdifferencesinclinicalmedicine. .. PM, Cook NR, D’Agostino RB, Thompson SG, Danesh J, Di Angelantonio E,
HandbExpPharmacol2012:3(cid:2)22. .. Emerging Risk Factors Collaboration. Equalization of four cardiovascular risk
.
57. WehnerGJ,JingL,HaggertyCM,SueverJD,LeaderJB,HartzelDN,Kirchner . algorithms after systematic recalibration: individual-participant meta-analysis of
.
HL,ManusJNA,JamesN,AyarZ,GladdingP,GoodCW,ClelandJGF,Fornwalt .. 86prospectivestudies.EurHeartJ2019;40:621(cid:2)631.
BK.Routinelyreportedejectionfractionandmortalityinclinicalpractice:where .. 75. Berkelmans GFN, Gudbjornsdottir S, Visseren FLJ, Wild SH, Franzen S,
.
doesthenadirofrisklie?EurHeartJ2020;41:1249(cid:2)1257. . ChalmersJ,DavisBR,Poulter NR,Spijkerman AM,WoodwardM,Pressel SL,
.
58. ChungAK,DasSR,LeonardD,PeshockRM,KaziF,AbdullahSM,CanhamRM, . Gupta AK, van der Schouw YT, Svensson AM, van der Graaf Y, Read SH,
.
LevineBD,DraznerMH.Womenhavehigherleftventricularejectionfractions .. EliassonB,DorresteijnJAN.Predictionofindividuallife-yearsgainedwithoutcar-
thanmenindependentofdifferencesinleftventricularvolume:theDallasHeart .. diovascular events from lipid, blood pressure, glucose, and aspirin treatment
.
Study.Circulation2006;113:1597(cid:2)1604. . basedondataofmorethan500000patientswithType2diabetesmellitus.Eur
.
59. MaasA,RosanoG,CifkovaR,ChieffoA,vanDijkenD,HamodaH,KunadianV, . HeartJ2019;40:2899(cid:2)2906.
.
LaanE,LambrinoudakiI,MaclaranK,PanayN,StevensonJC,vanTrotsenburgM, .. 76. JaspersNEM,BlahaMJ,MatsushitaK,vanderSchouwYT,WarehamNJ,Khaw
CollinsP.Cardiovascularhealthaftermenopausetransition,pregnancydisorders, .. KT,GeiselMH,LehmannN,ErbelR,JockelKH,vanderGraafY,Verschuren
.
andothergynaecologicconditions:aconsensusdocumentfromEuropeancardi- . WMM,BoerJMA,NambiV,VisserenFLJ,DorresteijnJAN.Predictionofindivid- .
ologists,gynaecologists,andendocrinologists.EurHeartJ2021;42:967(cid:2)984. .. ualized lifetime benefit from cholesterol lowering, blood pressure lowering,
60. GlasziouPP,IrwigLM.Anevidencebasedapproachtoindividualisingtreatment. .. antithrombotictherapy,andsmokingcessationinapparentlyhealthypeople.Eur
.
BMJ1995;311:1356(cid:2)1359. . HeartJ2020;41:1190(cid:2)1199.
.
61. Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg . 77. Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D’Agostino RB, Sr.,
.
EW, van der Graaf Y, Cook NR. Estimating treatment effects for .. MassaroJM,vanderGraafY,CramerMJM,KappelleLJ,deBorstGJ,StegPG,
individual patients based on the results of randomised clinical trials. BMJ .. Visseren FLJ. Estimated Life Expectancy Without Recurrent Cardiovascular
.
2011;343:d5888. . Events in Patients With Vascular Disease: The SMART-REACH Model. J Am
.
62. FoxCS,MatsushitaK,WoodwardM,BiloHJ,ChalmersJ,HeerspinkHJ,LeeBJ, . HeartAssoc2018;7:e009217.
. PerkinsRM,RossingP,SairenchiT,TonelliM,VassalottiJA,YamagishiK,Coresh .. 78. RosselloX,DorresteijnJA,JanssenA,LambrinouE,ScherrenbergM,Bonnefoy-
.
J, de Jong PE, Wen CP, Nelson RG, Chronic Kidney Disease Prognosis . CudrazE,CobainM,PiepoliMF,VisserenFL,DendaleP.Riskpredictiontoolsin
.
Consortium. Associations of kidney disease measures with mortality and end- . cardiovasculardiseaseprevention:AreportfromtheESCPreventionofCVD
.
stage renal disease in individuals with and without diabetes: a meta-analysis. .. ProgrammeledbytheEuropeanAssociationofPreventiveCardiology(EAPC)in
Lancet2012;380:1662(cid:2)1673. .. collaborationwiththeAcuteCardiovascularCareAssociation(ACCA)andthe
.
63. RobbinsJM,StraussG,AronD,LongJ,KubaJ,KaplanY.Mortalityratesanddia- . Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J
.
beticfootulcers:isittimetocommunicatemortalityrisktopatientswithdia- . CardiovascNurs2019;18:534(cid:2)544.
.
beticfootulceration?JAmPodiatrMedAssoc2008;98:489(cid:2)493. .. 79. BenetosA,PetrovicM,StrandbergT.HypertensionManagementinOlderand
64. BrownriggJR,HughesCO,BurleighD,KarthikesalingamA,PattersonBO,Holt .. FrailOlderPatients.CircRes2019;124:1045(cid:2)1060.
.
PJ,ThompsonMM,deLusignanS,RayKK,HinchliffeRJ.Microvasculardisease . 80. FerenceBA,BhattDL,CatapanoAL,PackardCJ,GrahamI,KaptogeS,Ference
.
and risk of cardiovascular events among individuals with type 2 diabetes: a .. TB,GuoQ,LaufsU,RuffCT,CupidoA,HovinghGK,DaneshJ,HolmesMV,
population-levelcohortstudy.LancetDiabetesEndocrinol2016;4:588(cid:2)597. .. Smith GD, Ray KK, Nicholls SJ, Sabatine MS. Association of Genetic Variants
.
65. InternationalSocietyofNephrology.KDIGO2020ClinicalPracticeGuidelinefor . RelatedtoCombinedExposuretoLowerLow-DensityLipoproteinsandLower
.
Diabetes Management in Chronic Kidney Disease. https://kdigo.org/wp-content/ . Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA
.
uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf(4June2021). .. 2019;322:1381(cid:2)1391.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 89 ---
ESCGuidelines 3315
.
.
81. KaasenbroodL,BoekholdtSM,vanderGraafY,RayKK,PetersRJ,KasteleinJJ, . 96. KarmaliKN,PersellSD,PerelP,Lloyd-JonesDM,BerendsenMA,HuffmanMD.
.
Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, . Risk scoring for the primary prevention of cardiovascular disease. Cochrane
.
VisserenFL.DistributionofEstimated10-YearRiskofRecurrentVascularEvents .. DatabaseSystRev2017;3:CD006887.
and Residual Risk in a Secondary Prevention Population. Circulation .. 97. Damman OC, Vonk SI, van den Haak MJ, van Hooijdonk CMJ, Timmermans
.
2016;134:1419(cid:2)1429. . DRM.Theeffectsofinfographicsandseveralquantitativeversusqualitativefor-
.
82. DeBacquerD,UedaP,ReinerZ,DeSutterJ,DeSmedtD,LovicD,Gotcheva .. matsforcardiovasculardiseaserisk,includingheartage,onpeople’sriskunder-
N,FrasZ,PogosovaN,MirrakhimovE,LehtoS,JernbergT,KotsevaK,RydenL, .. standing.PatientEducCouns2018;101:1410(cid:2)1418.
.
WoodD,EUROASPIREIVandVNationalCoordinators.Predictionofrecurrent . 98. CooneyMT,VartiainenE,LaatikainenT,DeBacquerD,McGorrianC,Dudina
.
eventinpatientswithcoronaryheartdisease:theEUROASPIRERiskModel.Eur . A, Graham I, SCORE and FINRISK investigators. Cardiovascular risk age: con-
.
JPrevCardiol2020:[Onlineaheadofprint]. .. ceptsandpracticalities.Heart2012;98:941(cid:2)946.
83. Eikelboom JW,Connolly SJ,BoschJ, Dagenais GR, Hart RG, ShestakovskaO, .. 99. CuendeJI,CuendeN,Calaveras-LagartosJ.Howtocalculatevascularagewith
.
DiazR,AlingsM,LonnEM,AnandSS,WidimskyP,HoriM,AvezumA,Piegas . theSCOREprojectscales:anewmethodofcardiovascularriskevaluation.Eur
.
LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez- .. HeartJ2010;31:2351(cid:2)2358.
JaramilloP,O’DonnellM,KakkarAK,FoxKAA,ParkhomenkoAN,ErtlG,Stork .. 100.AlbusC,WallerC,FritzscheK,GunoldH,HaassM,HamannB,KindermannI,
.
S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp- . KollnerV,LeithauserB,MarxN,MeesmannM,MichalM,RonelJ,SchererM,
.
PedersenC,GuzikTJ,VerhammePB,VinereanuD,KimJH,TonkinAM,Lewis . SchraderV,SchwaabB,WeberCS,Herrmann-LingenC.Significanceofpsycho-
.
BS,FelixC,YusoffK,StegPG,MetsarinneKP,CookBrunsN,MisselwitzF,Chen .. social factors in cardiology: update 2018 : Position paper of the German
E, Leong D, Yusuf S, COMPASS Investigators. Rivaroxaban with or without .. CardiacSociety.ClinResCardiol2019;108:1175(cid:2)1196.
.
AspirininStableCardiovascularDisease.NEnglJMed2017;377:1319(cid:2)1330. . 101.Schnohr P, Marott JL, Kristensen TS, Gyntelberg F, Gronbaek M, Lange P,
.
84. BhattDL,StegPG,MillerM,BrintonEA,JacobsonTA,KetchumSB,DoyleRT, . JensenMT,JensenGB,PrescottE.Rankingofpsychosocialandtraditionalrisk
.
Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT .. factorsbyimportanceforcoronaryheartdisease:theCopenhagenCityHeart
Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for .. Study.EurHeartJ2015;36:1385(cid:2)1393.
.
Hypertriglyceridemia.NEnglJMed2019;380:11(cid:2)22. . 102.KimJM,StewartR,KangHJ,KimSY,KimJW,LeeHJ,LeeJY,KimSW,ShinIS,
. 85. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The .. KimMC,ShinHY,HongYJ,AhnY,JeongMH,YoonJS.Long-termcardiacout-
SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, .. comesofdepressionscreening,diagnosisandtreatmentinpatientswithacute
. NieropP,WhelanA,HendriksR,SwartH,SchaapJ,KuijperAFM,vanHessen . coronarysyndrome:theDEPACSstudy.PsycholMed2020:1(cid:2)11.
.
MWJ,SaklaniP,TanI,ThompsonAG,MortonA,JudkinsC,BaxWA,DirksenM, . 103.LinJS,EvansCV,JohnsonE,RedmondN,CoppolaEL,SmithN.Nontraditional
.
Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL, .. Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence
LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary .. ReportandSystematicReviewfortheUSPreventiveServicesTaskForce.JAMA
.
Disease.NEnglJMed2020;383:1838(cid:2)1847. . 2018;320:281(cid:2)297.
.
86. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, . 104.PetersSA,denRuijterHM,BotsML,MoonsKG.Improvementsinriskstratifi-
.
IbrahimR,GamraH,KiwanGS,BerryC,Lopez-SendonJ,OstadalP,KoenigW, .. cationfortheoccurrenceofcardiovasculardiseasebyimagingsubclinicalathe-
.
AngoulvantD, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, . rosclerosis:asystematicreview.Heart2012;98:177(cid:2)184.
.
BlondeauL,OrfanosA,L’AllierPL,GuertinMC,RoubilleF.EfficacyandSafetyof . 105.Hippisley-CoxJ,CouplandC,BrindleP.DevelopmentandvalidationofQRISK3
.
Low-Dose Colchicine after Myocardial Infarction. N Engl J Med .. riskpredictionalgorithmstoestimatefutureriskofcardiovasculardisease:pro-
2019;381:2497(cid:2)2505. .. spectivecohortstudy.BMJ2017;357:j2099.
.
87. Sattar N, Rawshani A, Franzen S, Rawshani A, Svensson AM, Rosengren A, . 106.Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of
.
McGuireDK,EliassonB,GudbjornsdottirS.AgeatDiagnosisofType2Diabetes . emerging biomarkers with cardiovascular disease. JAMA Intern Med
.
Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation .. 2013;173:664(cid:2)671.
2019;139:2228(cid:2)2237. .. 107.Kooter AJ, Kostense PJ, Groenewold J, Thijs A, Sattar N, Smulders YM.
.
88. KaasenbroodL,PoulterNR,SeverPS,ColhounHM,LivingstoneSJ,Boekholdt . Integratinginformationfromnovelriskfactorswithcalculatedrisks:thecritical
.
SM,PresselSL,DavisBR,vanderGraafY,VisserenFL,CARDS,ALLHAT,and .. impactofriskfactorprevalence.Circulation2011;124:741(cid:2)745.
ASCOT Investigators. Development and Validation of a Model to Predict .. 108.KivimakiM,SteptoeA.Effectsofstressonthedevelopmentandprogressionof
.
Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in . cardiovasculardisease.NatRevCardiol2018;15:215(cid:2)229.
.
Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian . 109.RozanskiA.Behavioralcardiology:currentadvancesandfuturedirections.JAm
.
Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to .. CollCardiol2014;64:100(cid:2)110.
PreventHeartAttackTrial,andCollaborativeAtorvastatinDiabetesStudy.Circ .. 110.CrawshawJ,AuyeungV,NortonS,WeinmanJ.Identifyingpsychosocialpredic-
.
CardiovascQualOutcomes2016;9:213(cid:2)221. . torsofmedicationnon-adherencefollowingacutecoronarysyndrome:Asys-
.
89. Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, Chalmers J, . tematicreviewandmeta-analysis.JPsychosomRes2016;90:10(cid:2)32.
.
ColagiuriS,GrobbeeDE,HametP,HellerS,NealB,WoodwardM,ADVANCE .. 111.SteinbergML,WilliamsJM,LiY.PoorMentalHealthandReducedDeclinein
CollaborativeGroup.Contemporarymodelforcardiovascularriskpredictionin .. SmokingPrevalence.AmJPrevMed2015;49:362(cid:2)369.
.
peoplewithtype2diabetes.EurJCardiovascPrevRehabil2011;18:393(cid:2)398. . 112.Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, .
90. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective .. Blackett KN, Sitthi-amorn C, Sato H, Yusuf S, INTERHEART investigators.
DiabetesStudy(UKPDS)Group.TheUKPDSriskengine:amodelfortheriskof .. Associationofpsychosocialriskfactorswithriskofacutemyocardialinfarction
.
coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) . in 11119 cases and 13648 controls from 52 countries (the INTERHEART
.
2001;101:671(cid:2)679. . study):case-controlstudy.Lancet2004;364:953(cid:2)962.
.
91. Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM, .. 113.Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M,
Eliasson B, Gudbjornsdottir S. Excess mortality and cardiovascular disease in .. DunckerDJ,KollerA,ManfriniO,MilicicD,PadroT,PriesAR,QuyyumiAA,
.
young adults with type 1 diabetes in relation to age at onset: a nationwide, . TousoulisD,TrifunovicD,VasiljevicZ,deWitC,BugiardiniR,ESCScientific
.
register-basedcohortstudy.Lancet2018;392:477(cid:2)486. .. Document Group Reviewers. Depression and coronary heart disease: 2018
92. RawshaniA,RawshaniA,SattarN,FranzenS,McGuireDK,EliassonB,Svensson .. position paper of the ESC working group on coronary pathophysiology and
.
AM, Zethelius B, Miftaraj M, Rosengren A, Gudbjornsdottir S. Relative . microcirculation.EurHeartJ2020;41:1687(cid:2)1696.
.
Prognostic Importance and Optimal Levels of Risk Factors for Mortality and . 114.AlbusC,BarkhausenJ,FleckE,HaasenritterJ,LindnerO,SilberS.TheDiagnosis
.
Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation .. ofChronicCoronaryHeartDisease.DtschArzteblInt2017;114:712(cid:2)719.
2019;139:1900(cid:2)1912. .. 115.JhaMK,QamarA,VaduganathanM,CharneyDS,MurroughJW.Screeningand
.
93. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, . Management of Depression in Patients With Cardiovascular Disease: JACC
.
ClelandS,LeeseGP,McKnightJ,MorrisAD,PearsonDW,PedenNR,PetrieJR, . State-of-the-ArtReview.JAmCollCardiol2019;73:1827(cid:2)1845.
.
Philip S, Sattar N, Sullivan F, Colhoun HM. Risk of cardiovascular disease and .. 116.SpitzerRL,KroenkeK,WilliamsJB.Validationandutilityofaself-reportversion
totalmortalityinadultswithtype1diabetes:Scottishregistrylinkagestudy.PLoS .. ofPRIME-MD:thePHQprimarycarestudy.PrimaryCareEvaluationofMental
.
Med2012;9:e1001321. . Disorders.PatientHealthQuestionnaire.JAMA1999;282:1737(cid:2)1744.
.
94. Spiegelhalter D, Pearson M, Short I. Visualizing uncertainty about the future. .. 117.CelanoCM,SuarezL,MastromauroC,JanuzziJL,HuffmanJC.Feasibilityand
Science2011;333:1393(cid:2)1400. .. utilityofscreeningfordepressionandanxietydisordersinpatientswithcardio-
.
95. ZipkinDA,UmscheidCA,KeatingNL,AllenE,AungK,BeythR,KaatzS,Mann . vasculardisease.CircCardiovascQualOutcomes2013;6:498(cid:2)504.
.
DM, Sussman JB, Korenstein D, Schardt C, Nagi A, Sloane R, Feldstein DA. . 118.MacGregorKL,FunderburkJS,PigeonW,MaistoSA.EvaluationofthePHQ-9
.
Evidence-based risk communication: a systematic review. Ann Intern Med .. Item 3 as a screen for sleep disturbance in primary care. J Gen Intern Med
2014;161:270(cid:2)280. . 2012;27:339(cid:2)344.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 90 ---
3316 ESCGuidelines
.
.
119. HadamitzkyM,FreissmuthB,MeyerT,HeinF,KastratiA,MartinoffS,Schomig . SalomaaV,PeltonenL,KathiresanS.Amultilocusgeneticriskscoreforcoro-
.
A,HausleiterJ.Prognosticvalueofcoronarycomputedtomographicangiogra- . nary heart disease: case-control and prospective cohort analyses. Lancet
.
phyforpredictionofcardiaceventsinpatientswithsuspectedcoronaryartery .. 2010;376:1393(cid:2)1400.
disease.JACCCardiovascImaging2009;2:404(cid:2)411. .. 136.SivapalaratnamS,BoekholdtSM,TripMD,SandhuMS,Luben R,Kastelein JJ,
.
120. SCOT-HEART Investigators, Newby DE, Adamson PD, Berry C, Boon NA, . Wareham NJ, Khaw KT. Family history of premature coronary heart disease
.
Dweck MR, Flather M, Forbes J, Hunter A, Lewis S, MacLean S, Mills NL, .. and risk prediction in the EPIC-Norfolk prospective population study. Heart
Norrie J, Roditi G, Shah ASV, Timmis AD, van Beek EJR, Williams MC. .. 2010;96:1985(cid:2)1989.
.
CoronaryCTAngiographyand5-YearRiskofMyocardialInfarction.NEnglJ . 137.Veronesi G, Gianfagna F, Giampaoli S, Chambless LE, Mancia G, Cesana G,
.
Med2018;379:924(cid:2)933. . FerrarioMM.Improvinglong-termpredictionoffirstcardiovascularevent:the
.
121. DenRuijterHM,PetersSA,AndersonTJ,BrittonAR,DekkerJM,EijkemansMJ, .. contributionoffamilyhistoryofcoronaryheartdiseaseandsocialstatus.Prev
Engstrom G, Evans GW, de Graaf J, Grobbee DE, Hedblad B, Hofman A, .. Med2014;64:75(cid:2)80.
.
HolewijnS,IkedaA,KavousiM,KitagawaK,KitamuraA,KoffijbergH,LonnEM, . 138.YeboahJ,McClellandRL,PolonskyTS,BurkeGL,SibleyCT,O’LearyD,CarrJJ,
.
LorenzMW,MathiesenEB,NijpelsG,OkazakiS,O’LearyDH,PolakJF,Price . GoffDC,GreenlandP,HerringtonDM.Comparisonofnovelriskmarkersfor
.
JF, Robertson C, Rembold CM, Rosvall M, Rundek T, Salonen JT, Sitzer M, .. improvementincardiovascularriskassessmentinintermediate-riskindividuals.
.
StehouwerCD,WittemanJC,MoonsKG,BotsML.Commoncarotidintima- . JAMA2012;308:788(cid:2)795.
.
mediathicknessmeasurementsincardiovascularriskprediction:ameta-analysis. . 139.Antiochos P, Marques-Vidal P, McDaid A, Waeber G, Vollenweider P.
.
JAMA2012;308:796(cid:2)803. .. Associationbetweenparentalhistoryandgeneticriskscoresforcoronaryheart
122. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, .. disease prediction: The population-based CoLaus study. Atherosclerosis
.
RemboldCM,PostWS,AmericanSocietyofEchocardiographyCarotidIntima- . 2016;244:59(cid:2)65.
.
MediaThicknessTaskForce.Useofcarotidultrasoundtoidentifysubclinical . 140.vanDisI,GeleijnseJM,KromhoutD,BoerJ,BoshuizenH,VerschurenWM.Do
.
vasculardiseaseandevaluatecardiovasculardiseaserisk:aconsensusstatement .. obesity and parental history of myocardial infarction improve cardiovascular
from the American Society of Echocardiography Carotid Intima-Media .. riskprediction?EurJPrevCardiol2013;20:793(cid:2)799.
.
ThicknessTaskForce.EndorsedbytheSocietyforVascularMedicine.JAmSoc . 141.Merry AH, Boer JM, Schouten LJ, Ambergen T, Steyerberg EW, Feskens EJ,
. Echocardiogr2008;21:93(cid:2)111;quiz189-190. .. VerschurenWM,GorgelsAP,vandenBrandtPA.Riskpredictionofincident
123. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular .. coronaryheartdiseaseinTheNetherlands:re-estimationandimprovementof
. events and all-cause mortality with arterial stiffness: a systematic review and . theSCOREriskfunction.EurJPrevCardiol2012;19:840(cid:2)848.
.
meta-analysis.JAmCollCardiol2010;55:1318(cid:2)1327. . 142.MusunuruK,KathiresanS.GeneticsofCommon,ComplexCoronaryArtery
.
124. McDermottMM,GreenlandP,LiuK,GuralnikJM,CelicL,CriquiMH,ChanC, .. Disease.Cell2019;177:132(cid:2)145.
Martin GJ, Schneider J, Pearce WH, Taylor LM, Clark E. The ankle brachial .. 143.TorkamaniA,WineingerNE,TopolEJ.Thepersonalandclinicalutilityofpoly-
.
indexisassociatedwithlegfunctionandphysicalactivity:theWalkingandLeg . genicriskscores.NatRevGenet2018;19:581(cid:2)590.
.
CirculationStudy.AnnInternMed2002;136:873(cid:2)883. . 144.LambertSA,GilL,JuppS,RitchieSC,XuY,BunielloA,McMahonA,Abraham
.
125. AnkleBrachialIndexCollaboration,FowkesFG,MurrayGD,ButcherI,Heald .. G, Chapman M, Parkinson H, Danesh J, MacArthur JAL, Inouye M. The
.
CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBackerG, . PolygenicScoreCatalogasanopendatabaseforreproducibilityandsystematic
.
Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, . evaluation.NatGenet2021;53:420(cid:2)425.
.
FowkesFG,LeeAJ,PriceJF,d’AgostinoRB,MurabitoJM,NormanPE,Jamrozik .. 145.WandH,LambertSA,TamburroC,IacoccaMA,O’SullivanJW,SillariC,Kullo
K,CurbJD,MasakiKH,RodriguezBL,DekkerJM,BouterLM,HeineRJ,Nijpels .. IJ, Rowley R, Dron JS, Brockman D, Venner E, McCarthy MI, Antoniou AC,
.
G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, . EastonDF, HegeleRA, Khera AV, Chatterjee N, Kooperberg C,EdwardsK,
.
KnottnerusJA,OgrenM,HedbladB,WittemanJC,BretelerMM,HuninkMG, . Vlessis K, Kinnear K, Danesh JN, Parkinson H, Ramos EM, Roberts MC,
.
HofmanA,CriquiMH,LangerRD,FronekA,HiattWR,HammanR,Resnick .. Ormond KE, Khoury MJ, Janssens A, Goddard KAB, Kraft P, MacArthur JAL,
HE, Guralnik J, McDermott MM. Ankle brachial index combined with .. InouyeM, Wojcik GL. Improvingreporting standardsfor polygenic scoresin
.
FraminghamRiskScoretopredictcardiovasculareventsandmortality:ameta- . riskpredictionstudies.Nature2021;591:211(cid:2)219.
.
analysis.JAMA2008;300:197(cid:2)208. .. 146.Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk
126. Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Popma JJ, .. scores.HumMolGenet2019;28:R133(cid:2)R142.
.
FerrucciL,FormanDE.Frailtyassessmentinthecardiovascularcareofolder . 147.InouyeM,AbrahamG,NelsonCP,WoodAM,SweetingMJ,DudbridgeF,Lai
.
adults.JAmCollCardiol2014;63:747(cid:2)762. . FY,KaptogeS,BrozynskaM,WangT,YeS,WebbTR,RutterMK,TzoulakiI,
.
127. SinghM,StewartR,WhiteH.Importanceoffrailtyinpatientswithcardiovascu- .. Patel RS, Loos RJF, Keavney B, Hemingway H, Thompson J, Watkins H,
lardisease.EurHeartJ2014;35:1726(cid:2)1731. .. Deloukas P, Di Angelantonio E, Butterworth AS, Danesh J, Samani NJ, UK
.
128. TamuraY,IshikawaJ,FujiwaraY,TanakaM,KanazawaN,ChibaY,IizukaA, . Biobank CardioMetabolic Consortium CHD Working Group. Genomic Risk
.
Kaito S, Tanaka J, Sugie M, Nishimura T, Kanemaru A, Shimoji K, Hirano H, . Prediction of Coronary Artery Disease in 480,000 Adults: Implications for
.
Furuta K, Kitamura A, Seino S, Shinkai S, Harada K, Kyo S, Ito H, Araki A. .. PrimaryPrevention.JAmCollCardiol2018;72:1883(cid:2)1893.
Prevalenceoffrailty,cognitiveimpairment,andsarcopeniainoutpatientswith .. 148.KheraAV,ChaffinM,AragamKG,HaasME,RoselliC,ChoiSH,NatarajanP,
.
cardiometabolicdiseaseinafrailtyclinic.BMCGeriatr2018;18:264. . LanderES,LubitzSA,EllinorPT,KathiresanS.Genome-widepolygenicscores .
129. ChainaniV,ShaharyarS,DaveK,ChoksiV,RavindranathanS,HannoR,Jamal .. for common diseases identify individuals with risk equivalent to monogenic
O, AbdoA, AbiRafehN. Objective measuresof the frailtysyndrome(hand .. mutations.NatGenet2018;50:1219(cid:2)1224.
.
gripstrengthandgaitspeed)andcardiovascularmortality:Asystematicreview. . 149.SunL,PennellsL,KaptogeS,NelsonCP,RitchieSC,AbrahamG,ArnoldM,
.
IntJCardiol2016;215:487(cid:2)493. . BellS,BoltonT,BurgessS,DudbridgeF,GuoQ,SofianopoulouE,StevensD,
.
130. Higueras-Fresnillo S, Cabanas-Sanchez V, Lopez-Garcia E, Esteban-Cornejo I, .. ThompsonJR,ButterworthAS,WoodA,DaneshJ,SamaniNJ,InouyeM,Di
BanegasJR,SadaranganiKP,Rodriguez-ArtalejoF,Martinez-GomezD.Physical .. AngelantonioE.Polygenicriskscoresincardiovascularriskprediction:Acohort
.
Activity and Association Between Frailty and All-Cause and Cardiovascular . studyandmodellinganalyses.PLoSMed2021;18:e1003498.
.
Mortality in Older Adults: Population-Based Prospective Cohort Study. J Am . 150.Elliott J,BodinierB,Bond TA,Chadeau-Hyam M,Evangelou E,Moons KGM,
. GeriatrSoc2018;66:2097(cid:2)2103. .. DehghanA,MullerDC,ElliottP,TzoulakiI.PredictiveAccuracyofaPolygenic
.
131. Vaes B, Depoortere D, Van Pottelbergh G, Mathei C, Neto J, Degryse J. . RiskScore-EnhancedPredictionModelvsaClinicalRiskScoreforCoronary
.
Associationbetweentraditionalcardiovascularriskfactorsandmortalityinthe . ArteryDisease.JAMA2020;323:636(cid:2)645.
.
oldestold:untanglingtheroleoffrailty.BMCGeriatr2017;17:234. .. 151.MosleyJD,GuptaDK,TanJ,YaoJ,WellsQS,ShafferCM,KunduS,Robinson-
132. VigoritoC,AbreuA,AmbrosettiM,BelardinelliR,CorraU,CupplesM,Davos .. CohenC,PsatyBM,RichSS,PostWS,GuoX,RotterJI,RodenDM,Gerszten
.
CH,HoeferS,IliouMC,SchmidJP,VoellerH,DohertyP.Frailtyandcardiac . RE,WangTJ.PredictiveAccuracyofaPolygenicRiskScoreComparedWitha
.
rehabilitation:AcalltoactionfromtheEAPCCardiacRehabilitationSection. . Clinical Risk Score for Incident Coronary Heart Disease. JAMA
.
EurJPrevCardiol2017;24:577(cid:2)590. .. 2020;323:627(cid:2)635.
133. Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD.Association between .. 152.Levin MG, Rader DJ. Polygenic Risk Scores and Coronary Artery Disease:
.
familyhistoryandcoronaryheartdiseasedeathacrosslong-termfollow-upin . ReadyforPrimeTime?Circulation2020;141:637(cid:2)640.
.
men:theCooperCenterLongitudinalStudy.Circulation2012;125:3092(cid:2)3098. .. 153.SchultzWM,KelliHM,LiskoJC,VargheseT,ShenJ,SandesaraP,QuyyumiAA,
134. TikkanenE,HavulinnaAS,PalotieA,SalomaaV,RipattiS.Geneticriskpredic- .. TaylorHA,GulatiM,HaroldJG,MieresJH,FerdinandKC,MensahGA,Sperling
.
tionanda2-stageriskscreeningstrategyforcoronaryheartdisease.Arterioscler . LS. Socioeconomic Status and Cardiovascular Outcomes: Challenges and
.
ThrombVascBiol2013;33:2261(cid:2)2266. . Interventions.Circulation2018;137:2166(cid:2)2178.
.
135. RipattiS,TikkanenE,Orho-MelanderM,HavulinnaAS,SilanderK,SharmaA, .. 154.deMestralC,StringhiniS.SocioeconomicStatusandCardiovascularDisease:
GuiducciC,PerolaM,JulaA,SinisaloJ,LokkiML,NieminenMS,MelanderO, . anUpdate.CurrCardiolRep2017;19:115.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 91 ---
ESCGuidelines 3317
.
.
155. KhaingW,VallibhakaraSA,AttiaJ,McEvoyM,ThakkinstianA.Effectsofeduca- . graft? A systematic review and network meta-analysis. Obes Rev
.
tionandincomeoncardiovascularoutcomes:Asystematicreviewandmeta- . 2018;19:1236(cid:2)1247.
.
analysis.EurJPrevCardiol2017;24:1032(cid:2)1042. .. 169.Mahajan R, Stokes M, Elliott A, Munawar DA, Khokhar KB, Thiyagarajah A,
156. Kivimaki M, Pentti J, Ferrie JE, Batty GD, Nyberg ST, Jokela M, Virtanen M, .. HendriksJ,LinzD,GallagherC,KayeD,LauD,SandersP.Complexinteraction
.
AlfredssonL,DraganoN,FranssonEI,GoldbergM,KnutssonA,KoskenvuoM, . of obesity, intentional weight loss and heart failure: a systematic review and
.
Koskinen A, Kouvonen A, Luukkonen R, Oksanen T, Rugulies R, Siegrist J, .. meta-analysis.Heart2020;106:58(cid:2)68.
Singh-ManouxA,SuominenS,TheorellT,VaananenA,VahteraJ,Westerholm .. 170.BellJA,HamerM,SabiaS,Singh-ManouxA,BattyGD,KivimakiM.Thenatural
.
PJM,WesterlundH,ZinsM,StrandbergT,SteptoeA,DeanfieldJ,IPD-Work . courseofhealthyobesityover20years.JAmCollCardiol2015;65:101(cid:2)102.
.
consortium.Workstressandriskofdeathinmenandwomenwithandwith- . 171.ChangAR,GramsME,BallewSH,BiloH,CorreaA,EvansM,GutierrezOM,
.
out cardiometabolic disease: a multicohort study. Lancet Diabetes Endocrinol .. HosseinpanahF,IsekiK,KenealyT,KleinB,KronenbergF,LeeBJ,LiY,MiuraK,
2018;6:705(cid:2)713. .. Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L,
.
157. Burroughs Pena MS, Rollins A. Environmental Exposures and Cardiovascular . Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M,
.
Disease:AChallengeforHealthandDevelopmentinLow-andMiddle-Income . CKDPrognosisConsortium(CKD-PC).Adiposityandriskofdeclineinglomer-
.
Countries.CardiolClin2017;35:71(cid:2)86. .. ularfiltrationrate:meta-analysisofindividualparticipantdatainaglobalconsor-
.
158. Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K, . tium.BMJ2019;364:k5301.
.
Forastiere F, Franchini M, Franco OH, Graham I, Hoek G, Hoffmann B, . 172.GBDChronicKidneyDiseaseCollaboration.Global,regional,andnationalbur-
.
HoylaertsMF,KunzliN,MillsN,PekkanenJ,PetersA,PiepoliMF,Rajagopalan .. denofchronickidneydisease,1990-2017:asystematicanalysisfortheGlobal
S,StoreyRF,ESCWorkingGrouponThrombosis,EuropeanAssociationfor .. BurdenofDiseaseStudy2017.Lancet2020;395:709(cid:2)733.
.
Cardiovascular Prevention and Rehabilitation, ESC Heart Failure Association. . 173.Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P,
.
Expertpositionpaperonairpollutionandcardiovasculardisease.EurHeartJ . Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S,
.
2015;36:83(cid:2)93b. .. BarberisV,FlachskampfFA,CeponieneI,Haegler-LaubeE,SuterT,Lapinskas
159. LelieveldJ,PozzerA,PoschlU,FnaisM,HainesA,MunzelT.Lossoflifeexpect- .. T,PrasadS,deBoerRA,WechalekarK,AnkerMS,IakobishviliZ,Bucciarelli-
.
ancyfromairpollutioncomparedtootherriskfactors:aworldwideperspec- . Ducci C, Schulz-Menger J, Cosyns B, Gaemperli O, Belenkov Y, Hulot JS,
. tive.CardiovascRes2020;116:1910(cid:2)1917. .. GalderisiM,LancellottiP,BaxJ,MarwickTH,ChioncelO,JaarsmaT,Mullens
160. LiuC,ChenR,SeraF,Vicedo-CabreraAM,GuoY,TongS,CoelhoM,Saldiva .. W, Piepoli M, Thum T, Heymans S, Mueller C, Moura B, Ruschitzka F,
. PHN,LavigneE,MatusP,ValdesOrtegaN,OsorioGarciaS,PascalM,Stafoggia . ZamoranoJL,RosanoG,CoatsAJS, AsteggianoR,Seferovic P,Edvardsen T,
.
M,ScortichiniM,HashizumeM,HondaY,Hurtado-DiazM,CruzJ,NunesB, . LyonAR.Roleofcardiovascularimagingincancerpatientsreceivingcardiotoxic
.
Teixeira JP, Kim H,TobiasA,Iniguez C, ForsbergB, Astrom C, Ragettli MS, .. therapies: a position statement on behalf of the Heart Failure Association
GuoYL,ChenBY,BellML,WrightCY,ScovronickN,GarlandRM,MilojevicA, .. (HFA),theEuropeanAssociation ofCardiovascularImaging(EACVI)andthe
.
KyselyJ,UrbanA,OrruH,IndermitteE,JaakkolaJJK,RytiNRI,KatsouyanniK, . Cardio-OncologyCounciloftheEuropeanSocietyofCardiology(ESC).EurJ
.
AnalitisA,ZanobettiA,SchwartzJ,ChenJ,WuT,CohenA,GasparriniA,Kan . HeartFail2020;22:1504(cid:2)1524.
.
H.AmbientParticulateAirPollutionandDailyMortalityin652Cities.NEnglJ .. 174.Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM,
.
Med2019;381:705(cid:2)715. . Morales-RuizM,PereaRJ,MonzoM,EsteveJ.Enalaprilandcarvedilolforpre-
.
161. Argacha JF, Mizukami T, Bourdrel T, Bind MA. Ecology of the cardiovascular . venting chemotherapy-induced left ventricular systolic dysfunction in patients
.
system:PartII-Afocusonnon-airrelatedpollutants.TrendsCardiovascMed .. with malignant hemopathies: the OVERCOME trial (preventiOn of left
2019;29:274(cid:2)282. .. VentriculardysfunctionwithEnalaprilandcaRvedilolinpatientssubmittedto
.
162. Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most . intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am
.
popular blood biomarkers of cardiovascular disease. Circ Res . CollCardiol2013;61:2355(cid:2)2362.
.
2012;110:658(cid:2)662. .. 175.KalamK,MarwickTH.Roleofcardioprotectivetherapyforpreventionofcardi-
163. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, .. otoxicity with chemotherapy: a systematic review and meta-analysis. Eur J
.
KaptogeS,CaslakeM,ThompsonA,ButterworthAS,SarwarN,WormserD, . Cancer2013;49:2900(cid:2)2909.
.
SaleheenD,BallantyneCM,PsatyBM,SundstromJ,RidkerPM,NagelD,Gillum .. 176.AgcaR,HeslingaSC,RollefstadS,HeslingaM,McInnesIB,PetersMJ,KvienTK,
RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, .. DougadosM,RadnerH,AtzeniF,PrimdahlJ,SodergrenA,WallbergJonssonS,
.
D’AgostinoRB,Sr.,DagenaisGR,Cooper JA,KromhoutD,OnatA,Tipping . vanRompayJ,ZabalanC,PedersenTR,JacobssonL,deVlamK,Gonzalez-Gay
.
RW,Gomez-de-la-CamaraA,RosengrenA,SutherlandSE,GallacherJ,Fowkes . MA,SembAG,KitasGD,SmuldersYM,SzekaneczZ,SattarN,SymmonsDP,
.
FG,CasigliaE,HofmanA,SalomaaV,Barrett-ConnorE,ClarkeR,BrunnerE, .. Nurmohamed MT. EULAR recommendations for cardiovascular disease risk
Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, .. managementinpatientswithrheumatoidarthritisandotherformsofinflamma-
.
Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, . toryjointdisorders:2015/2016update.AnnRheumDis2017;76:17(cid:2)28.
.
Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related . 177.OgdieA,YuY,HaynesK,LoveTJ,MalihaS,JiangY,TroxelAB,HennessyS,
.
markersandcardiovasculardiseaseprediction.JAMA2012;307:2499(cid:2)2506. .. KimmelSE,MargolisDJ,ChoiH,MehtaNN,GelfandJM.Riskofmajorcardio-
164. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) .. vascular events in patients with psoriatic arthritis, psoriasis and rheumatoid
.
levels and improved cardiovascular risk prediction. J Am Coll Cardiol . arthritis:apopulation-basedcohortstudy.AnnRheumDis2015;74:326(cid:2)332. .
2013;61:1146(cid:2)1156. .. 178.Hung YM, Chang WP, Wei JC, Chou P, Wang PY. Midlife Ankylosing
165. Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S, Welsh P, .. Spondylitis Increases the Risk of Cardiovascular Diseases in Males 5 Years
.
Butterworth AS, Chowdhury R, Spackman SA, PennellsL, Gao P,Burgess S, . Later:ANationalPopulation-BasedStudy.Medicine(Baltimore)2016;95:e3596.
.
FreitagDF,SweetingM,WoodAM,CookNR,JuddS,TrompetS,NambiV, . 179.Adelborg K, Szepligeti SK, Holland-Bill L, Ehrenstein V, Horvath-Puho E,
.
Olsen MH, Everett BM, Kee F, Arnlov J, Salomaa V, Levy D, Kauhanen J, .. Henderson VW, Sorensen HT. Migraine and risk of cardiovascular diseases:
Laukkanen JA, Kavousi M, Ninomiya T, Casas JP, Daniels LB, Lind L, Kistorp .. Danishpopulationbasedmatchedcohortstudy.BMJ2018;360:k96.
.
CN, Rosenberg J, Mueller T, Rubattu S, Panagiotakos DB, Franco OH, de . 180.MahmoudAN,MentiasA,ElgendyAY,QaziA,BarakatAF,SaadM,MohsenA,
.
LemosJA,LuchnerA,KizerJR,KiechlS,SalonenJT,GoyaWannametheeS,de . AbuzaidA,MansoorH,MojadidiMK,ElgendyIY.Migraineandtheriskofcardi-
. BoerRA,NordestgaardBG,AnderssonJ,JorgensenT,MelanderO,Ballantyne .. ovascular and cerebrovascular events: a meta-analysis of 16 cohort studies
.
ChM,DeFilippiC,RidkerPM, CushmanM,RosamondWD,ThompsonSG, . including1152407subjects.BMJOpen2018;8:e020498.
.
GudnasonV,SattarN,DaneshJ,DiAngelantonioE.Natriureticpeptidesand . 181.SaccoS,OrnelloR,RipaP,TiseoC,DeganD,PistoiaF,CaroleiA.Migraine
.
integratedriskassessmentforcardiovasculardisease:anindividual-participant- .. and riskof ischaemic heartdisease:a systematic review andmeta-analysisof
datameta-analysis.LancetDiabetesEndocrinol2016;4:840(cid:2)849. .. observationalstudies.EurJNeurol2015;22:1001(cid:2)1011.
.
166. WilleitP,WelshP,EvansJDW,TschidererL,BoachieC,JukemaJW,FordI, . 182.ChangCL,DonaghyM,PoulterN.Migraineandstrokeinyoungwomen:case-
.
TrompetS,StottDJ,KearneyPM,MooijaartSP,KiechlS,DiAngelantonioE, . control study. The World Health Organisation Collaborative Study of
.
Sattar N. High-Sensitivity Cardiac Troponin Concentration and Risk of First- .. Cardiovascular Disease and Steroid Hormone Contraception. BMJ
Ever Cardiovascular Outcomes in 154,052 Participants. J Am Coll Cardiol .. 1999;318:13(cid:2)18.
.
2017;70:558(cid:2)568. . 183.Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK,
.
167. LamelasPM,MaheerK,SchwalmJD.Bodymassindexandmortalityafteracute .. MarchbanksPA,JamiesonDJ.Useofcombinedhormonalcontraceptivesamong
coronary syndromes: a systematic review and meta-analysis. Acta Cardiol .. women with migraines and risk of ischemic stroke. Am J Obstet Gynecol
.
2017;72:655(cid:2)661. . 2017;216:489e481(cid:2)489e487.
.
168. MaWQ,SunXJ,WangY,HanXQ,ZhuY,LiuNF.Doesbodymassindextruly . 184.EngelandA,BjorgeT,DaltveitAK,SkurtveitS,VangenS,VollsetSE,FuruK.
.
affectmortalityandcardiovascularoutcomesinpatientsaftercoronaryrevascu- .. Risk of diabetes aftergestational diabetes andpreeclampsia.Aregistry-based
larizationwithpercutaneouscoronaryinterventionorcoronaryarterybypass . studyof230,000womeninNorway.EurJEpidemiol2011;26:157(cid:2)163.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 92 ---
3318 ESCGuidelines
.
.
185. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. . 207.Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal Trends in
.
Hypertensive pregnancy disorders and subsequent cardiovascular morbidity . Incidence,Prevalence,andMortalityofAtrialFibrillationinPrimaryCare.JAm
.
andtype2diabetesmellitusinthemother.Hypertension2009;53:944(cid:2)951. .. HeartAssoc2017;6:e005155.
186. SkjaervenR,WilcoxAJ,KlungsoyrK,IrgensLM,VikseBE,VattenLJ,LieRT. .. 208.Ko D, Rahman F,SchnabelRB, Yin X,BenjaminEJ,Christophersen IE.Atrial
.
Cardiovascularmortalityafterpre-eclampsiainonechildmothers:prospective, . fibrillationinwomen:epidemiology,pathophysiology,presentation,andprogno-
.
populationbasedcohortstudy.BMJ2012;345:e7677. .. sis.NatRevCardiol2016;13:321(cid:2)332.
187. WilsonBJ,WatsonMS,PrescottGJ,SunderlandS,CampbellDM,HannafordP, .. 209.Mou L, Norby FL, Chen LY, O’Neal WT, Lewis TT, Loehr LR, Soliman EZ,
.
SmithWC.Hypertensivediseasesofpregnancyandriskofhypertensionand . AlonsoA.LifetimeRiskofAtrialFibrillationbyRaceandSocioeconomicStatus:
.
strokeinlaterlife:resultsfromcohortstudy.BMJ2003;326:845. . ARICStudy(AtherosclerosisRiskinCommunities).CircArrhythmElectrophysiol
.
188. BellamyL,CasasJP,HingoraniAD,WilliamsD.Type2diabetesmellitusafter .. 2018;11:e006350.
gestational diabetes: a systematic review and meta-analysis. Lancet .. 210.MagnussenC,NiiranenTJ,OjedaFM,GianfagnaF,BlankenbergS,NjolstadI,
.
2009;373:1773(cid:2)1779. . Vartiainen E, Sans S, Pasterkamp G, Hughes M, Costanzo S, Donati MB,
.
189. MoranLJ,MissoML,WildRA,NormanRJ.Impairedglucosetolerance,type2 . JousilahtiP,LinnebergA,PalosaariT,deGaetanoG,BobakM,denRuijterHM,
.
diabetes andmetabolic syndrome inpolycystic ovarysyndrome: asystematic .. Mathiesen E, Jorgensen T, Soderberg S, Kuulasmaa K, Zeller T, Iacoviello L,
.
reviewandmeta-analysis.HumReprodUpdate2010;16:347(cid:2)363. . Salomaa V, Schnabel RB, BiomarCaRE Consortium. Sex Differences and
.
190. Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse out- . Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality
.
comeinyoungwomenwithpolycysticovarysyndromeversusmatched,refer- .. in Community Cohorts: Results From the BiomarCaRE Consortium
ence controls: a retrospective, observational study. J Clin Endocrinol Metab .. (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation
.
2012;97:3251(cid:2)3260. . 2017;136:1588(cid:2)1597.
.
191. VenkataramanH,SattarN,SaravananP.Postnataltestingfollowinggestational . 211.WyseDG,VanGelderIC,EllinorPT,GoAS,KalmanJM,NarayanSM,NattelS,
.
diabetes: time to replace the oral glucose tolerance test? Lancet Diabetes .. SchottenU,RienstraM.Loneatrialfibrillation:doesitexist?JAmCollCardiol
Endocrinol2015;3:754(cid:2)756. .. 2014;63:1715(cid:2)1723.
.
192. BonamyAK,ParikhNI,CnattingiusS,LudvigssonJF,IngelssonE.Birthcharac- . 212.Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, Perel P,
. teristicsandsubsequentrisksofmaternalcardiovasculardisease:effectsofges- .. MorleyK,BanerjeeA,HemingwayH.Arecardiovascularriskfactorsalsoasso-
tationalageandfetalgrowth.Circulation2011;124:2839(cid:2)2846. .. ciatedwiththeincidenceofatrialfibrillation?Asystematicreviewandfieldsyn-
. 193. Lykke JA, Paidas MJ, Damm P, Triche EW, Kuczynski E, Langhoff-Roos J. . opsisof23factorsin32population-basedcohortsof20millionparticipants.
.
Preterm delivery and risk of subsequent cardiovascular morbidity and type-II . ThrombHaemost2017;117:837(cid:2)850.
.
diabetesinthemother.BJOG2010;117:274(cid:2)281. .. 213.Feghaly J, Zakka P, London B, MacRae CA, Refaat MM. Genetics of Atrial
194. JagerKJ,KovesdyC,LanghamR,RosenbergM,JhaV,ZoccaliC.Asinglenum- .. Fibrillation.JAmHeartAssoc2018;7:e009884.
.
berforadvocacyandcommunication-worldwidemorethan850millionindivid- . 214.StaerkL,WangB,PreisSR,LarsonMG,LubitzSA,EllinorPT,McManusDD,
.
ualshavekidneydiseases.NephrolDialTransplant2019;34:1803(cid:2)1805. . KoD,WengLC,LunettaKL,FrostL,BenjaminEJ,TrinquartL.Lifetimeriskof
.
195. GBD2016CausesofDeathCollaborators.Global,regional,andnationalage- .. atrialfibrillationaccordingtooptimal,borderline,orelevatedlevelsofriskfac-
.
sexspecificmortalityfor264causesofdeath,1980-2016:asystematicanalysis . tors: cohort study based on longitudinal data from the Framingham Heart
.
fortheGlobalBurdenofDiseaseStudy2016.Lancet2017;390:1151(cid:2)1210. . Study.BMJ2018;361:k1453.
.
196. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, .. 215.HindricksG,PotparaT,DagresN,ArbeloE,BaxJJ,Blomstrom-LundqvistC,
MannJF,MatsushitaK,WenCP.Chronickidneydiseaseandcardiovascularrisk: .. BorianiG,CastellaM,DanGA,DilaverisPE,FauchierL,FilippatosG,Kalman
.
epidemiology,mechanisms,andprevention.Lancet2013;382:339(cid:2)352. . JM,LaMeirM,LaneDA,LebeauJP,LettinoM,LipGYH,PintoFJ,ThomasGN,
.
197. ChronicKidneyDiseasePrognosisConsortium,MatsushitaK,vanderVeldeM, . Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific
.
Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. .. DocumentGroup.2020ESCGuidelinesforthediagnosisandmanagementof
Association of estimated glomerular filtration rate and albuminuria with all- .. atrialfibrillationdevelopedincollaborationwiththeEuropeanAssociationfor
.
causeandcardiovascularmortalityingeneralpopulationcohorts:acollabora- . Cardio-ThoracicSurgery(EACTS):TheTaskForceforthediagnosisandman-
.
tivemeta-analysis.Lancet2010;375:2073(cid:2)2081. .. agement of atrial fibrillation of the European Society of Cardiology (ESC)
198. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, .. Developed with the special contribution of the European Heart Rhythm
.
CoreshJ,LeveyAS,SarnakMJ.Levelofkidneyfunctionasariskfactorforathe- . Association(EHRA)oftheESC.EurHeartJ2021;42:373(cid:2)498.
.
rosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol . 216.Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J,
.
2003;41:47(cid:2)55. .. GeelhoedB,TielemanRG,HillegeHL,TukkieR,VanVeldhuisenDJ,CrijnsH,
199. DzayeO,DudumR,Reiter-BrennanC,KianoushS,Tota-MaharajR,Cainzos- .. VanGelderIC,RACE3Investigators.Targetedtherapyofunderlyingconditions
.
AchiricaM,BlahaMJ.Coronaryarterycalciumscoringforindividualizedcardio- . improvessinusrhythmmaintenanceinpatientswithpersistentatrialfibrillation:
.
vascular risk estimation in important patient subpopulations after the 2019 . resultsoftheRACE3trial.EurHeartJ2018;39:2987(cid:2)2996.
.
AHA/ACC primary prevention guidelines. Prog Cardiovasc Dis .. 217.ParkashR,WellsGA,SappJL,HealeyJS,TardifJC,GreissI,RivardL,RouxJF,
2019;62:423(cid:2)430. .. GulaL,NaultI,NovakP,BirnieD,HaA,WiltonSB,MangatI,GrayC,Gardner
.
200. ChenJ,BudoffMJ,ReillyMP,YangW,RosasSE,RahmanM,ZhangX,RoyJA, . M,TangASL.EffectofAggressiveBloodPressureControlontheRecurrence .
LustigovaE,NesselL,FordV,RajD,Porter AC,Soliman EZ,WrightJT,Jr., .. of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label
WolfM, HeJ,CRIC Investigators.Coronary Artery CalcificationandRisk of .. Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood
.
Cardiovascular Disease and Death Among Patients With Chronic Kidney . PressureControl]).Circulation2017;135:1788(cid:2)1798.
.
Disease.JAMACardiol2017;2:635(cid:2)643. . 218.LinHJ,WolfPA,Kelly-HayesM,BeiserAS,KaseCS,BenjaminEJ,D’Agostino
.
201. Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, Peralta CA, .. RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke
WoodwardM,KramerHJ,JacobsDR,SarnakMJ,CoreshJ.Subclinicalathero- .. 1996;27:1760(cid:2)1764.
.
sclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol . 219.KalantarianS,SternTA,MansourM,RuskinJN.Cognitiveimpairmentassoci-
.
2015;26:439(cid:2)447. .. atedwithatrialfibrillation:ameta-analysis.AnnInternMed2013;158:338(cid:2)346.
202. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between .. 220.Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM,
.
chronickidneydiseaseandcoronaryarterycalcification:theDallasHeartStudy. . EdvardssonN,PociD.All-causemortalityin272,186patientshospitalizedwith
.
JAmSocNephrol2005;16:507(cid:2)513. . incidentatrialfibrillation1995-2008:aSwedishnationwidelong-termcase-con-
.
203. BudoffMJ,RaderDJ,ReillyMP,MohlerER,3rd,LashJ,YangW,RosenL,Glenn .. trolstudy.EurHeartJ2013;34:1061(cid:2)1067.
M, Teal V, Feldman HI, CRIC Study Investigators. Relationship of estimated .. 221.AnY,OgawaH,YamashitaY,IshiiM,IguchiM,MasunagaN,EsatoM,TsujiH,
.
GFRandcoronaryarterycalcificationintheCRIC(ChronicRenalInsufficiency . WadaH,HasegawaK,AbeM,LipGYH,AkaoM.CausesofdeathinJapanese
.
Cohort)Study.AmJKidneyDis2011;58:519(cid:2)526. . patientswithatrialfibrillation:TheFushimiAtrialFibrillationRegistry.EurHeart
.
204. WannerC,AmannK,ShojiT.Theheartandvascularsystemindialysis.Lancet .. JQualCareClinOutcomes2019;5:35(cid:2)42.
2016;388:276(cid:2)284. .. 222.BozkurtB,CoatsAJS,TsutsuiH,AbdelhamidCM,AdamopoulosS,AlbertN,
.
205. OdutayoA,WongCX,HsiaoAJ,HopewellS,AltmanDG,EmdinCA.Atrial . Anker SD, Atherton J, Bohm M, Butler J, Drazner MH, Michael Felker G,
.
fibrillationandrisksofcardiovasculardisease,renaldisease,anddeath:system- .. FilippatosG,FiuzatM,FonarowGC,Gomez-MesaJE,HeidenreichP,Imamura
aticreviewandmeta-analysis.BMJ2016;354:i4482. .. T,JankowskaEA,JanuzziJ,KhazanieP,KinugawaK,LamCSP,MatsueY,Metra
.
206. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, . M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y,
.
Odutayo AA. Atrial fibrillation as risk factor for cardiovascular disease and . SeferovicP,StarlingRC,TeerlinkJR,VardenyO,YamamotoK,YancyC,Zhang
.
deathinwomencomparedwithmen:systematicreviewandmeta-analysisof .. J,ZierothS.Universaldefinitionandclassificationofheartfailure:areportof
cohortstudies.BMJ2016;532:h7013. . the Heart Failure Society of America, Heart Failure Association of the
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 93 ---
ESCGuidelines 3319
.
.
European Society of Cardiology, Japanese Heart Failure Society and Writing . 238.ChenW,ThomasJ,SadatsafaviM,FitzGeraldJM.Riskofcardiovascularcomor-
.
Committee of the Universal Definition of Heart Failure: Endorsed by the . bidity in patients with chronic obstructive pulmonary disease: a systematic
.
Canadian Heart Failure Society, Heart Failure Association of India, Cardiac .. reviewandmeta-analysis.LancetRespirMed2015;3:631(cid:2)639.
SocietyofAustraliaandNewZealand,andChineseHeartFailureAssociation. .. 239.VanfleterenLEGW,SpruitMA,WoutersEFM,FranssenFME.Managementof
.
EurJHeartFail2021;23:352(cid:2)380. . chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med
.
223. ChewDS,HeikkiH,SchmidtG,KavanaghKM,DommaschM,BlochThomsen .. 2016;4:911(cid:2)924.
PE,SinneckerD,RaatikainenP,ExnerDV.ChangeinLeftVentricularEjection .. 240.BrekkePH,OmlandT,SmithP,SoysethV.Underdiagnosisofmyocardialinfarc-
.
Fraction Following First Myocardial Infarction and Outcome. JACC Clin . tioninCOPD-CardiacInfarctionInjuryScore(CIIS)inpatientshospitalised
.
Electrophysiol2018;4:672(cid:2)682. . forCOPDexacerbation.RespirMed2008;102:1243(cid:2)1247.
.
224. DoyleJJ,NeugutAI,JacobsonJS,GrannVR,HershmanDL.Chemotherapyand .. 241.SinDD,ManSF.Chronicobstructivepulmonarydiseaseasariskfactorforcar-
cardiotoxicityinolderbreastcancerpatients:apopulation-basedstudy.JClin .. diovascularmorbidityandmortality.ProcAmThoracSoc2005;2:8(cid:2)11.
.
Oncol2005;23:8597(cid:2)8605. . 242.KunisakiKM,DransfieldMT,AndersonJA,BrookRD,CalverleyPMA,CelliBR,
.
225. PatnaikJL,ByersT,DiGuiseppiC,DabeleaD,DenbergTD.Cardiovasculardis- . CrimC,HartleyBF,MartinezFJ,NewbyDE,PragmanAA,VestboJ,YatesJC,
.
ease competes with breast cancer as the leading cause of death for older .. NiewoehnerDE,SUMMITInvestigators.ExacerbationsofChronicObstructive
.
females diagnosed with breast cancer: a retrospective cohort study. Breast . PulmonaryDiseaseandCardiacEvents.APostHocCohortAnalysisfromthe
.
CancerRes2011;13:R64. . SUMMITRandomizedClinicalTrial.AmJRespirCritCareMed2018;198:51(cid:2)57.
.
226. DarbyS,McGaleP,PetoR,GranathF,HallP,EkbomA.Mortalityfromcardio- .. 243.RothnieKJ,ConnellO,MullerovaH,SmeethL,PearceN,DouglasI,QuintJK.
vascular disease more than 10 years after radiotherapy for breast cancer: .. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic
.
nationwidecohortstudyof90000Swedishwomen.BMJ2003;326:256(cid:2)257. . ObstructivePulmonaryDisease.AnnAmThoracSoc2018;15:935(cid:2)946.
.
227. DarbySC,EwertzM,McGaleP,BennetAM,Blom-GoldmanU,BronnumD, . 244.HuiartL,ErnstP,SuissaS.CardiovascularmorbidityandmortalityinCOPD.
.
Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, .. Chest2005;128:2640(cid:2)2646.
RahimiK,TaylorC,HallP.Riskofischemicheartdiseaseinwomenafterradio- .. 245.CebronLipovecN,BeijersRJ,vandenBorstB,DoehnerW,LainscakM,Schols
.
therapyforbreastcancer.NEnglJMed2013;368:987(cid:2)998. . AM.ThePrevalenceofMetabolicSyndromeInChronicObstructivePulmonary
. 228. DahlenT,EdgrenG,LambeM,HoglundM,BjorkholmM,SandinF,SjalanderA, .. Disease:ASystematicReview.COPD2016;13:399(cid:2)406.
Richter J, Olsson-Stromberg U, Ohm L, Back M, Stenke L, Swedish CML .. 246.WangLY,ZhuYN,CuiJJ,YinKQ,LiuSX,GaoYH.Subclinicalatherosclerosis
. Group,SwedishCMLRegisterGroup.CardiovascularEventsAssociatedWith . riskmarkersinpatientswithchronicobstructivepulmonarydisease:Asystem-
.
UseofTyrosineKinaseInhibitorsinChronicMyeloidLeukemia:APopulation- . aticreviewandmeta-analysis.RespirMed2017;123:18(cid:2)27.
.
BasedCohortStudy.AnnInternMed2016;165:161(cid:2)166. .. 247.AgustiA,EdwardsLD,RennardSI,MacNeeW,Tal-SingerR,MillerBE,Vestbo
229. PudilR,MuellerC,CelutkieneJ,HenriksenPA,LenihanD,DentS,BaracA, .. J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK,
.
StanwayS,MoslehiJ,SuterTM,KyB,SterbaM,CardinaleD,Cohen-SolalA, . CoxsonHO,BakkeP,MayerRJ,CelliB,EvaluationofCOPDLongitudinallyto
.
TocchettiCG,FarmakisD,Bergler-KleinJ,AnkerMS,VonHaehlingS,Belenkov . IdentifyPredictiveSurrogateEndpoints(ECLIPSE)Investigators.Persistentsys-
.
Y,IakobishviliZ,MaackC,CiardielloF,RuschitzkaF,CoatsAJS,SeferovicP, .. temicinflammationisassociatedwithpoorclinicaloutcomesinCOPD:anovel
.
LainscakM,PiepoliMF,ChioncelO,BaxJ,HulotJS,SkouriH,Hagler-LaubeES, . phenotype.PLoSOne2012;7:e37483.
.
AsteggianoR,FernandezTL,deBoerRA,LyonAR.Roleofserumbiomarkers . 248.MacDonaldMI,ShafuddinE,KingPT,ChangCL,BardinPG,HancoxRJ.Cardiac
.
incancerpatientsreceivingcardiotoxiccancertherapies:apositionstatement .. dysfunction during exacerbations of chronic obstructive pulmonary disease.
fromtheCardio-OncologyStudyGroupoftheHeartFailureAssociationand .. LancetRespirMed2016;4:138(cid:2)148.
.
the Cardio-Oncology Council of the European Society of Cardiology. Eur J . 249.Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD,
.
HeartFail2020;22:1966(cid:2)1983. . Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in
.
230. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, .. acuteexacerbationsofCOPD.Thorax2011;66:764(cid:2)768.
GravdehaugB,vonKnobelsdorff-BrenkenhoffF,BratlandA,StorasTH,Hagve .. 250.MaclayJD,McAllisterDA,JohnstonS,RaftisJ,McGuinnesC,DeansA,Newby
.
TA,RosjoH,SteineK,GeislerJ,OmlandT.Preventionofcardiacdysfunction . DE,MillsNL,MacNeeW.Increasedplateletactivationinpatientswithstable
.
duringadjuvantbreastcancertherapy(PRADA):a2x2factorial,randomized, .. andacuteexacerbationofCOPD.Thorax2011;66:769(cid:2)774.
placebo-controlled, double-blind clinical trial of candesartan and metoprolol. .. 251.LahousseL,TiemeierH,IkramMA,BrusselleGG.Chronicobstructivepulmo-
.
EurHeartJ2016;37:1671(cid:2)1680. . narydiseaseandcerebrovasculardisease:Acomprehensivereview.RespirMed
.
231. NarayanHK,FrenchB,KhanAM,PlappertT,HymanD,BajulaiyeA,Domchek . 2015;109:1371(cid:2)1380.
.
S, DeMichele A, Clark A, Matro J, Bradbury A, Fox K, Carver JR, Ky B. .. 252.Houben-WilkeS,JorresRA,BalsR,FranssenFM,GlaserS,HolleR,KarchA,
Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential .. Koch A,MagnussenH,ObstA,Schulz H,SpruitMA, WackerME,WelteT,
.
Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. JACC . WoutersEF,VogelmeierC,WatzH.PeripheralArteryDiseaseandItsClinical
.
CardiovascImaging2016;9:1131(cid:2)1141. . Relevance in Patients with Chronic Obstructive Pulmonary Disease in the
.
232. ThavendiranathanP,PoulinF,LimKD,PlanaJC,WooA,MarwickTH.Useof .. COPDandSystemicConsequences-ComorbiditiesNetworkStudy.AmJRespir
myocardialstrainimagingbyechocardiographyfortheearlydetectionofcardi- .. CritCareMed2017;195:189(cid:2)197.
.
otoxicityinpatientsduringandaftercancerchemotherapy:asystematicreview. . 253.TerzikhanN,LahousseL,VerhammeKMC,FrancoOH,IkramAM,StrickerBH, .
JAmCollCardiol2014;63:2751(cid:2)2768. .. BrusselleGG.COPDisassociatedwithanincreasedriskofperipheralartery
233. YuAF,KyB.Roadmapforbiomarkersofcancertherapycardiotoxicity.Heart .. diseaseandmortality.ERJOpenRes2018;4:[eCollection].
.
2016;102:425(cid:2)430. . 254.AmbrosinoP,LupoliR,CafaroG,IervolinoS,CaroneM,PapponeN,DiMinno
.
234. BoekhoutAH,GietemaJA,MilojkovicKerklaanB,vanWerkhovenED,Altena . MND.Subclinicalcarotidatherosclerosisinpatientswithchronicobstructivepulmo-
.
R,HonkoopA,LosM,SmitWM,NieboerP,SmorenburgCH,MandigersCM, .. narydisease:ameta-analysisofliteraturestudies.AnnMed2017;49:513(cid:2)524.
vanderWouwAJ,KesselsL,vanderVeldenAW,OttevangerPB,SmildeT,de .. 255.XiongJ,WuZ,ChenC,GuoW.Chronicobstructivepulmonarydiseaseeffect
.
BoerJ,vanVeldhuisenDJ,KemaIP,deVriesEG,SchellensJH.AngiotensinII- . ontheprevalenceandpostoperativeoutcomeofabdominalaorticaneurysms:
.
Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related . Ameta-analysis.SciRep2016;6:25003.
. Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized .. 256.Goudis CA, Konstantinidis AK, Ntalas IV, Korantzopoulos P.
.
ClinicalTrial.JAMAOncol2016;2:1030(cid:2)1037. . Electrocardiographicabnormalitiesandcardiacarrhythmiasinchronicobstruc-
.
235. PituskinE,MackeyJR,KoshmanS,JassalD,PitzM,HaykowskyMJ,PaganoJJ, . tivepulmonarydisease.IntJCardiol2015;199:264(cid:2)273.
.
ChowK,ThompsonRB,VosLJ,GhoshS,OuditGY,EzekowitzJA,Paterson .. 257.BuchP,FribergJ,ScharlingH,LangeP,PrescottE.Reducedlungfunctionand
DI. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology .. risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J
.
Research(MANTICORE101-Breast):ARandomizedTrialforthePrevention . 2003;21:1012(cid:2)1016.
.
ofTrastuzumab-AssociatedCardiotoxicity.JClinOncol2017;35:870(cid:2)877. . 258.Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An
.
236. JonesLW,HabelLA,WeltzienE,CastilloA,GuptaD,KroenkeCH,KwanML, .. unknownrelationship.JCardiol2017;69:699(cid:2)705.
QuesenberryCP,Jr.,ScottJ,SternfeldB,YuA,KushiLH,CaanBJ.Exerciseand .. 259.Konecny T, Somers KR, Park JY, John A, Orban M, Doshi R, Scanlon PD,
.
RiskofCardiovascularEventsinWomenWithNonmetastaticBreastCancer.J . AsirvathamSJ,RihalCS,BradyPA.Chronicobstructivepulmonarydiseaseasa
.
ClinOncol2016;34:2743(cid:2)2749. .. riskfactorforventriculararrhythmiasindependentofleftventricularfunction.
237. ArmenianSH,XuL,KyB,SunC,FarolLT,PalSK,DouglasPS,BhatiaS,Chao .. HeartRhythm2018;15:832(cid:2)838.
.
C. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A . 260.vandenBergME,StrickerBH,BrusselleGG,LahousseL.Chronicobstructive
.
Community-Based Retrospective Cohort Study. J Clin Oncol . pulmonary disease and sudden cardiac death: A systematic review. Trends
.
2016;34:1122(cid:2)1130. .. CardiovascMed2016;26:606(cid:2)613.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 94 ---
3320 ESCGuidelines
.
.
261. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, . C,HoenB,HoffmanH,HotezPJ,HoyD,HuangJJ,IbeanusiSE,JacobsenKH,
.
ArakakiD,LaffayeN,FuselliJJ,MassolinHP,GambarteJ,RomeroM,Tognoni . JamesSL,JarvisD,JasrasariaR,JayaramanS,JohnsN,JonasJB,KarthikeyanG,
.
G.UnrecognisedventriculardysfunctioninCOPD.EurRespirJ2012;39:51(cid:2)58. .. Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM,
262. CurkendallSM,DeLuiseC,JonesJK,LanesS,StangMR,GoehringE,Jr.,SheD. .. KobusingyeO,KorantengA,KrishnamurthiR,LallooR,LaslettLL,LathleanT,
.
Cardiovasculardiseaseinpatientswithchronicobstructivepulmonarydisease, . LeasherJL,LeeYY,LeighJ,LimSS,LimbE,LinJK,LipnickM,LipshultzSE,Liu
.
SaskatchewanCanadacardiovasculardiseaseinCOPDpatients.AnnEpidemiol .. W,LoaneM,OhnoSL,LyonsR,MaJ,MabweijanoJ,MacIntyreMF,Malekzadeh
2006;16:63(cid:2)70. .. R,MallingerL,ManivannanS,MarcenesW,MarchL,MargolisDJ,MarksGB,
.
263. ManninoDM,ThornD,SwensenA,HolguinF.Prevalenceandoutcomesofdia- . MarksR,MatsumoriA,MatzopoulosR,MayosiBM,McAnultyJH,McDermott
.
betes, hypertension and cardiovascular disease in COPD. Eur Respir J . MM,McGillN,McGrathJ,Medina-MoraME,MeltzerM,MensahGA,Merriman
.
2008;32:962(cid:2)969. .. TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO,
264. LiC,ChengW,GuoJ,GuanW.Relationshipofinhaledlong-actingbronchodi- .. Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A,
.
lators with cardiovascular outcomes among patients with stable COPD: a . MorawskaL,MoriR,MurdochME,MwanikiMK,NaidooK,NairMN,NaldiL,
.
meta-analysisandsystematicreviewof43randomizedtrials.IntJChronObstruct . Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S,
.
PulmonDis2019;14:799(cid:2)808. .. NormanP,NormanR,O’DonnellM,O’HanlonS,OlivesC,OmerSB,Ortblad
.
265.SinghS,SinghH,LoftusEV,Jr.,PardiDS.Riskofcerebrovascularaccidentsandische- . K,OsborneR,OzgedizD,PageA,PahariB,PandianJD,RiveroAP,PattenSB,
.
micheartdiseaseinpatientswithinflammatoryboweldisease:asystematicreview . PearceN, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips
.
andmeta-analysis.ClinGastroenterolHepatol2014;12:382(cid:2)393e381:quize322. .. MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA, 3rd, Popova S,
266. HsuePY,WatersDD.HIVinfectionandcoronaryheartdisease:mechanisms .. Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D,
.
andmanagement.NatRevCardiol2019;16:745(cid:2)759. . RazaviH,ReganM,RehmJT,ReinDB,RemuzziG,RichardsonK,RivaraFP,
.
267. SinhaA,FeinsteinMJ.CoronaryArteryDiseaseManifestationsinHIV:What, . Roberts T, Robinson C, De Leon FR, Ronfani L, Room R, Rosenfeld LC,
.
How,andWhy.CanJCardiol2019;35:270(cid:2)279. .. RushtonL,SaccoRL,SahaS,SampsonU,Sanchez-RieraL,SanmanE,Schwebel
268. BeckmanJA,DuncanMS,AlcornCW,So-ArmahK,ButtAA,GoetzMB,Tindle .. DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R,
.
HA, Sico JJ, Tracy RP, Justice AC, Freiberg MS. Association of Human . SinghD,SinghGM,SinghJA,SingletonJ,SleetDA,SliwaK,SmithE,SmithJL,
. Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease. .. Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S,
Circulation2018;138:255(cid:2)265. .. Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B,
. 269. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of . ThomsonWM,ThurstonGD,TleyjehIM,TonelliM,TowbinJA,TruelsenT,
.
myocardialinfarctionandstrokeafteracuteinfectionorvaccination.NEnglJ . TsilimbarisMK,UbedaC,UndurragaEA,vanderWerfMJ,vanOsJ,Vavilala
.
Med2004;351:2611(cid:2)2618. .. MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ,
270. UdellJA,ZawiR,BhattDL,Keshtkar-JahromiM,GaughranF,PhrommintikulA, .. Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA,
.
Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association . WhitefordH,WiersmaST,WilkinsonJD,WilliamsHC,WilliamsSR,WittE,
.
between influenza vaccination and cardiovascular outcomes in high-risk . WolfeF,WoolfAD,WulfS,YehPH,ZaidiAK,ZhengZJ,ZoniesD,Lopez
.
patients:ameta-analysis.JAMA2013;310:1711(cid:2)1720. .. AD,MurrayCJ,AlMazroaMA,MemishZA.Yearslivedwithdisability(YLDs)
.
271. DietrichT,JimenezM,KrallKayeEA,VokonasPS,GarciaRI.Age-dependent . for1160sequelaeof289diseasesandinjuries1990-2010:asystematicanalysis
.
associations between chronic periodontitis/edentulism and risk of coronary . fortheGlobalBurdenofDiseaseStudy2010.Lancet2012;380:2163(cid:2)2196.
.
heartdisease.Circulation2008;117:1668(cid:2)1674. .. 279.KurthT,WinterAC,EliassenAH,DushkesR,MukamalKJ,RimmEB,Willett
272. Carrizales-Sepulveda EF, Ordaz-Farias A, Vera-Pineda R, Flores-Ramirez R. .. WC, Manson JE, Rexrode KM. Migraine and risk of cardiovascular disease in
.
Periodontal Disease, Systemic Inflammation and the Risk of Cardiovascular . women:prospectivecohortstudy.BMJ2016;353:i2610.
.
Disease.HeartLungCirc2018;27:1327(cid:2)1334. . 280.Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and
.
273. RydenL,BuhlinK,EkstrandE,deFaireU,GustafssonA,HolmerJ,KjellstromB, .. cardiovascular disease: systematic review and meta-analysis. BMJ
LindahlB,NorhammarA,NygrenA,NasmanP,RathnayakeN,SvenungssonE, .. 2009;339:b3914.
.
Klinge B. Periodontitis Increases the Risk of a First Myocardial Infarction: A . 281.SaccoS,KurthT.Migraineandtheriskforstrokeandcardiovasculardisease.
.
ReportFromthePAROKRANKStudy.Circulation2016;133:576(cid:2)583. .. CurrCardiolRep2014;16:524.
274. Qi J, Zihang Z, Zhang J, Park YM, Shrestha D, Jianling B, Merchant AT. .. 282.Sacco S, Merki-Feld GS, KL AE, Bitzer J Canonico M, Kurth T, Lampl C,
.
PeriodontalAntibodiesandAll-CauseandCardiovascularDiseaseMortality.J . Lidegaard O, Anne MacGregor E, MaassenVanDenBrink A, Mitsikostas DD,
.
DentRes2020;99:51(cid:2)59. . NappiRE,NtaiosG,SandsetPM,Martellettip,EuropeanHeadacheFederation
.
275. LeeYL,HuHY,ChouP,ChuD.Dentalprophylaxisdecreasestheriskofacute .. (EHF) and the European Society of Contraception and Reproductive Health
myocardialinfarction:anationwidepopulation-basedstudyinTaiwan.ClinInterv .. (ESC). Hormonal contraceptives and risk of ischemic stroke in women with
.
Aging2015;10:175(cid:2)182. . migraine: a consensus statement from the European Headache Federation
.
276. HolmlundA,LampaE,LindL.PoorResponsetoPeriodontalTreatmentMay . (EHF) and the European Society of Contraception and Reproductive Health
.
PredictFutureCardiovascularDisease.JDentRes2017;96:768(cid:2)773. .. (ESC).JHeadachePain2017;18:108.
277. Park SY, Kim SH, Kang SH, Yoon CH, Lee HJ, Yun PY, Youn TJ, Chae IH. .. 283.Ornello R, Canonico M, Merki-Feld GS, Kurth T, Lidegaard O, MacGregor EA,
.
Improvedoralhygienecareattenuatesthecardiovascularriskoforalhealthdis- . LamplC,NappiRE,MartellettiP,SaccoS.Migraine,low-dosecombinedhormonal .
ease:apopulation-basedstudyfromKorea.EurHeartJ2019;40:1138(cid:2)1145. .. contraceptives,andischemicstrokeinyoungwomen:asystematicreviewandsug-
278. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, .. gestionsforfutureresearch.ExpertRevNeurother2020;20:313(cid:2)317.
.
SalomonJA,AbdallaS,AboyansV,AbrahamJ,AckermanI,AggarwalR,Ahn . 284.Badran M, Yassin BA, Fox N, Laher I, Ayas N. Epidemiology of Sleep
.
SY,AliMK,AlvaradoM,AndersonHR,AndersonLM,AndrewsKG,Atkinson . Disturbances and Cardiovascular Consequences. Can J Cardiol
.
C,BaddourLM,BahalimAN,Barker-ColloS,BarreroLH,BartelsDH,Basanez .. 2015;31:873(cid:2)879.
MG,BaxterA,BellML,BenjaminEJ,BennettD,BernabeE,BhallaK,Bhandari .. 285.SofiF,CesariF,CasiniA,MacchiC,AbbateR,GensiniGF.Insomniaandriskof
.
B,BikbovB,BinAbdulhakA,BirbeckG,BlackJA,BlencoweH,BloreJD,Blyth . cardiovasculardisease:ameta-analysis.EurJPrevCardiol2014;21:57(cid:2)64.
.
F,BolligerI,BonaventureA,BoufousS,BourneR,BoussinesqM,BraithwaiteT, . 286.GeL,GuyattG,TianJ,PanB,ChangY,ChenY,LiH,ZhangJ,LiY,LingJ,Yang
. Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, .. K.Insomniaandriskofmortalityfromall-cause,cardiovasculardisease,andcan-
.
BucelloC,BuchbinderR,BuckleG,BudkeCM,BurchM,BurneyP,BursteinR, . cer:Systematicreviewandmeta-analysisofprospectivecohortstudies.Sleep
.
CalabriaB,CampbellB,CanterCE,CarabinH,CarapetisJ,CarmonaL,Cella . MedRev2019;48:101215.
.
C,CharlsonF,ChenH,ChengAT,ChouD,ChughSS,CoffengLE,ColanSD, .. 287.YinJ,JinX,ShanZ,LiS,HuangH,LiP,PengX,PengZ,YuK,BaoW,YangW,
Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, .. ChenX,LiuL.Relationship of SleepDurationWithAll-CauseMortalityand
.
Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, . CardiovascularEvents:ASystematicReviewandDose-ResponseMeta-Analysis
.
DabhadkarKC,DahiyaM,DahodwalaN,Damsere-DerryJ,DanaeiG,DavisA, . ofProspectiveCohortStudies.JAmHeartAssoc2017;6:e005947.
.
DeLeoD,DegenhardtL,DellavalleR,DelossantosA,DenenbergJ,DerrettS, .. 288.Kerkhof GA. Epidemiology of sleep and sleep disorders in The Netherlands.
DesJarlaisDC,DharmaratneSD,DheraniM,Diaz-TorneC,DolkH,Dorsey .. SleepMed2017;30:229(cid:2)239.
.
ER,DriscollT,DuberH,EbelB,EdmondK,ElbazA,AliSE,ErskineH,ErwinPJ, . 289.RemiJ,PollmacherT,SpiegelhalderK,TrenkwalderC,YoungP.Sleep-Related
.
EspindolaP,EwoigbokhanSE,FarzadfarF,FeiginV,FelsonDT,FerrariA,Ferri .. DisordersinNeurologyandPsychiatry.DtschArzteblInt2019;116:681(cid:2)688.
CP,FevreEM,FinucaneMM,FlaxmanS,FloodL,ForemanK,ForouzanfarMH, .. 290.KalmbachDA,Cuamatzi-CastelanAS,TonnuCV,TranKM,AndersonJR,Roth
.
FowkesFG,FranklinR,FransenM,FreemanMK,GabbeBJ,GabrielSE,Gakidou . T, Drake CL. Hyperarousal and sleep reactivity in insomnia: current insights.
.
E,GanatraHA,GarciaB,GaspariF,GillumRF,GmelG,GosselinR,GraingerR, . NatSciSleep2018;10:193(cid:2)201.
.
GroegerJ,GuilleminF,GunnellD,GuptaR,HaagsmaJ,HaganH,HalasaYA, .. 291.Tietjens JR, Claman D, Kezirian EJ, De Marco T, Mirzayan A, Sadroonri B,
HallW,HaringD,HaroJM,HarrisonJE,HavmoellerR,HayRJ,HigashiH,Hill . Goldberg AN, Long C, Gerstenfeld EP, Yeghiazarians, Y. Obstructive Sleep
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 95 ---
ESCGuidelines 3321
.
.
Apnea in Cardiovascular Disease: A Review of the Literature and Proposed . SattarN.Non-alcoholicfattyliverdiseaseandriskofincidentacutemyocardial
.
Multidisciplinary Clinical Management Strategy. J Am Heart Assoc . infarction and stroke: findings from matched cohort study of 18 million
.
2019;8:e010440. .. Europeanadults.BMJ2019;367:l5367.
292. McEvoyRD,AnticNA,HeeleyE,LuoY,OuQ,ZhangX,MedianoO,ChenR, .. 314.Young L, Cho L. Unique cardiovascular risk factors in women. Heart
.
DragerLF,LiuZ,ChenG,DuB,McArdleN,MukherjeeS,TripathiM,BillotL, . 2019;105:1656(cid:2)1660.
.
LiQ,Lorenzi-FilhoG,BarbeF,RedlineS,WangJ,ArimaH,NealB,WhiteDP, .. 315.DamV,Onland-MoretNC,VerschurenWMM,BoerJMA,BenschopL,Franx
GrunsteinRR,ZhongN,AndersonCS,SAVEInvestigatorsandCoordinators. .. A, Moons KGM, Boersma E, van der Schouw YT, CREW-consortium.
.
CPAPforPreventionofCardiovascularEventsinObstructiveSleepApnea.N . Cardiovascularriskmodelperformanceinwomenwithandwithouthyperten-
.
EnglJMed2016;375:919(cid:2)931. . sivedisordersofpregnancy.Heart2019;105:330(cid:2)336.
.
293. CollenJ,LettieriC,WickwireE,HolleyA.Obstructivesleepapneaandcardio- .. 316.GrandiSM,FilionKB,YoonS,AyeleHT,DoyleCM,HutcheonJA,SmithGN,
vasculardisease,astoryofconfounders!SleepBreath2020;24:1299(cid:2)1313. .. Gore GC, Ray JG, Nerenberg K, Platt RW. Cardiovascular Disease-Related
.
294. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S, INCOSACT . Morbidity and Mortality in Women With a History of Pregnancy
.
Initiative(InternationalCollaborationofSleepApneaCardiovascularTrialists). .. Complications.Circulation2019;139:1069(cid:2)1079.
Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and .. 317.Riise HKR, Sulo G, Tell GS, Igland J, Nygard O, Iversen AC, Daltveit AK.
.
NeedforTeamScience.Circulation2017;136:1840(cid:2)1850. . Association Between Gestational Hypertension and Risk of Cardiovascular
.
295. KasiakogiasA,TsioufisC,ThomopoulosC,TousoulisD.Effectsofcontinuous . Disease Among 617 589 Norwegian Women. J Am Heart Assoc
.
positive airway pressure on blood pressure in hypertensive patients with .. 2018;7:e008337.
obstructivesleepapnoea.JHypertens2014;32:2279(cid:2)2280. .. 318.Grandi SM,ReynierP,PlattRW,BassoO, FilionKB.Thetiming ofonsetof
.
296. WittchenHU,JacobiF,RehmJ,GustavssonA,SvenssonM,JonssonB,Olesen . hypertensivedisordersinpregnancyandtheriskofincidenthypertensionand
.
J,AllgulanderC,AlonsoJ,FaravelliC,FratiglioniL,JennumP,LiebR,Maercker . cardiovasculardisease.IntJCardiol2018;270:273(cid:2)275.
.
A,vanOsJ,PreisigM,Salvador-CarullaL,SimonR,SteinhausenHC.Thesize .. 319.Timpka S, Markovitz A, Schyman T, Mogren I, Fraser A, Franks PW, Rich-
and burden of mental disorders and other disorders of the brain in Europe .. Edwards JW. Midlife development of type 2 diabetes and hypertension in
.
2010.EurNeuropsychopharmacol2011;21:655(cid:2)679. . womenbyhistoryofhypertensivedisordersofpregnancy.CardiovascDiabetol
. 297. KrupchankaD,MladaK,WinklerP,KhazaalY,AlbaneseE.Mortalityinpeople .. 2018;17:124.
with mental disorders in the Czech Republic: a nationwide, register-based .. 320.KramerCK,CampbellS,RetnakaranR.Gestationaldiabetesandtheriskofcar-
. cohortstudy.LancetPublicHealth2018;3:e289(cid:2)e295. . diovascular disease in women: a systematic review and meta-analysis.
.
298. StaraceF,MungaiF,BaccariF,GaleazziGM.Excessmortalityinpeoplewith . Diabetologia2019;62:905(cid:2)914.
.
mental illness: findings from a Northern Italy psychiatric case register. Soc .. 321.ClaessonR,IgnellC,ShaatN,BerntorpK.HbA1casapredictorofdiabetes
PsychiatryPsychiatrEpidemiol2018;53:249(cid:2)257. .. aftergestationaldiabetesmellitus.PrimCareDiabetes2017;11:46(cid:2)51.
.
299. John U, Rumpf HJ, Hanke M, Meyer C. Mental disorders and total mortality . 322.DingT,HardimanPJ,PetersenI,WangFF,QuF,BaioG.Theprevalenceofpol-
.
after20yearsinanadultgeneralpopulationsample.EurPsychiatry2020;63:e30. . ycystic ovary syndrome in reproductive-aged women of different ethnicity: a
.
300. LawrenceD,HancockKJ,KiselyS.Thegapinlifeexpectancyfrompreventable .. systematicreviewandmeta-analysis.Oncotarget2017;8:96351(cid:2)96358.
.
physicalillnessinpsychiatricpatientsinWesternAustralia:retrospectiveanaly- . 323.LiuJ,WuQ,HaoY,JiaoM,WangX,JiangS,HanL.Measuringtheglobaldis-
.
sisofpopulationbasedregisters.BMJ2013;346:f2539. . easeburdenofpolycysticovarysyndromein194countries:GlobalBurdenof
.
301. ScottKM,deJongeP,AlonsoJ,VianaMC,LiuZ,O’NeillS,Aguilar-GaxiolaS, .. DiseaseStudy2017.HumReprod2021;36:1108(cid:2)1119.
BruffaertsR,Caldas-de-AlmeidaJM,SteinDJ,deGirolamoG,FlorescuSE,Hu .. 324.Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD,
.
C,TaibNI,LepineJP,LevinsonD,MatschingerH,Medina-MoraME,PiazzaM, . Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE,
.
Posada-Villa JA, Uda H, Wojtyniak BJ, Lim CC, Kessler RC. Associations . BittnerV,HodgsonTK,RogersW,PepineCJ.Postmenopausalwomenwitha
.
betweenDSM-IVmentaldisordersandsubsequentheartdiseaseonset:beyond .. historyofirregularmensesandelevatedandrogenmeasurementsathighrisk
depression.IntJCardiol2013;168:5293(cid:2)5299. .. for worsening cardiovascular event-free survival: results from the National
.
302. HarterM,BaumeisterH,ReuterK,JacobiF,HoflerM,BengelJ,WittchenHU. . Institutes of Health–National Heart, Lung, and Blood Institute sponsored
.
Increased 12-month prevalence rates of mental disorders in patients with .. Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab
chronicsomaticdiseases.PsychotherPsychosom2007;76:354(cid:2)360. .. 2008;93:1276(cid:2)1284.
.
303.DarT,RadfarA,AbohashemS,PitmanRK,TawakolA,OsborneMT.Psychosocial . 325.MukaT, Oliver-Williams C, KunutsorS,Laven JS, Fauser BC,Chowdhury R,
.
StressandCardiovascularDisease.CurrTreatOptionsCardiovascMed2019;21:23. . KavousiM,FrancoOH.AssociationofAgeatOnsetofMenopauseandTime
.
304. ZhangWY,NanN,SongXT,TianJF,YangXY.Impactofdepressiononclinical .. Since Onset of Menopause With Cardiovascular Outcomes, Intermediate
outcomes following percutaneouscoronary intervention: a systematic review .. VascularTraits,andAll-CauseMortality:ASystematicReviewandMeta-analy-
.
andmeta-analysis.BMJOpen2019;9:e026445. . sis.JAMACardiol2016;1:767(cid:2)776.
.
305. PetersenBD,StenagerE,MogensenCB,ErlangsenA.Theassociationbetween . 326.Ding DC, Tsai IJ, Wang JH, Lin SZ, Sung FC. Coronary artery disease
.
heart diseases and suicide: a nationwide cohort study. J Intern Med .. risk in young women with polycystic ovary syndrome. Oncotarget
2020;287:558(cid:2)568. .. 2018;9:8756(cid:2)8764.
.
306. Duflou J. Psychostimulant use disorder and the heart. Addiction . 327.HongJS,YiSW,KangHC,JeeSH,KangHG,Bayasgalan G,OhrrH.Ageat .
2020;115:175(cid:2)183. .. menopause and cause-specific mortality in South Korean women: Kangwha
307. SchnyderN,PanczakR,GrothN,Schultze-LutterF.Associationbetweenmen- .. CohortStudy.Maturitas2007;56:411(cid:2)419.
.
talhealth-relatedstigmaandactivehelp-seeking:systematicreviewandmeta- . 328.ZhaoL,ZhuZ,LouH,ZhuG,HuangW,ZhangS,LiuF.Polycysticovarysyn-
.
analysis.BrJPsychiatry2017;210:261(cid:2)268. . drome(PCOS)andtheriskofcoronaryheartdisease(CHD):ameta-analysis.
.
308. KnaakS,MantlerE,SzetoA.Mentalillness-relatedstigmainhealthcare:Barriers .. Oncotarget2016;7:33715(cid:2)33721.
to access and care and evidence-based solutions. Healthc Manage Forum .. 329.Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early meno-
.
2017;30:111(cid:2)116. . pausepredictsfuturecoronaryheartdiseaseandstroke:theMulti-EthnicStudy
.
309. HendersonC,NoblettJ,ParkeH,ClementS,CaffreyA,Gale-GrantO,Schulze .. ofAtherosclerosis.Menopause2012;19:1081(cid:2)1087.
B,DrussB,ThornicroftG.Mentalhealth-relatedstigmainhealthcareandmen- .. 330.DeLayKJ,HaneyN,HellstromWJ.ModifyingRiskFactorsintheManagement
.
talhealth-caresettings.LancetPsychiatry2014;1:467(cid:2)482. . ofErectileDysfunction:AReview.WorldJMensHealth2016;34:89(cid:2)100.
.
310. ThornicroftG.Physicalhealthdisparitiesandmentalillness:thescandalofpre- . 331.Kessler A, Sollie S, Challacombe B, Briggs K, Van Hemelrijck M. The global
.
maturemortality.BrJPsychiatry2011;199:441(cid:2)442. .. prevalence of erectile dysfunction: a review. BJU Int 2019:[Online ahead of
311. Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R. .. print].
.
Predictionofcardiovasculardiseaseriskamongpeoplewithseverementalill- . 332.Ibrahim A, Ali M, Kiernan TJ, Stack AG. Erectile Dysfunction and Ischaemic
.
ness:Acohortstudy.PLoSOne2019;14:e0221521. . HeartDisease.EurCardiol2018;13:98(cid:2)103.
.
312. PiepoliMF,AbreuA,AlbusC,AmbrosettiM,BrotonsC,CatapanoAL,Corra .. 333.MinerM,NehraA,JacksonG,BhasinS,BillupsK,BurnettAL,BuvatJ,Carson
U,CosynsB,DeatonC,GrahamI,HoesA,LochenML,MatroneB,RedonJ, .. C,CunninghamG,GanzP,GoldsteinI,GuayA,HackettG,KlonerRA,Kostis
.
SattarN,SmuldersY,TiberiM.Updateoncardiovascularpreventioninclinical . JB, LaFlamme KE, Montorsi P, Ramsey M, Rosen R, Sadovsky R, Seftel A,
.
practice: A position paper of the European Association of Preventive .. ShabsighR,VlachopoulosC,WuF.Allmenwithvasculogenicerectiledysfunc-
Cardiology of the European Society of Cardiology. Eur J Prev Cardiol .. tionrequireacardiovascularworkup.AmJMed2014;127:174(cid:2)182.
.
2020;27:181(cid:2)205. . 334.MontorsiP,RavagnaniPM,GalliS,SaloniaA,BrigantiA,WerbaJP,MontorsiF.
.
313. AlexanderM,LoomisAK,vanderLeiJ,Duarte-SallesT,Prieto-AlhambraD, . Associationbetweenerectiledysfunctionandcoronaryarterydisease:Matching
.
Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, .. the right target with the right test in the right patient. Eur Urol
Dhalwani NN, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W, . 2006;50:721(cid:2)731.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 96 ---
3322 ESCGuidelines
.
.
335. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, . 358.AmbrosettiM,AbreuA,CorraU,DavosCH,HansenD,FrederixI,IliouMC,
.
StefanadisCI.Predictionofcardiovasculareventsandall-causemortalitywith . PedrettiRF,SchmidJP,VigoritoC,VollerH,WilhelmM,PiepoliMF,Bjarnason-
.
erectile dysfunction: asystematic review andmeta-analysis of cohort studies. .. WehrensB,BergerT,Cohen-SolalA,CornelissenV,DendaleP,DoehnerW,
CircCardiovascQualOutcomes2013;6:99(cid:2)109. .. GaitaD,GevaertAB,KempsH,KraenkelN,LaukkanenJ,MendesM,Niebauer
.
336. ZhaoB,ZhangW.Doeserectiledysfunctionindependentlypredictcardiovas- . J, Simonenko M, Zwisler AO. Secondary prevention through comprehensive
.
cular events? It’s time to act on the evidence. Eur J Prev Cardiol .. cardiovascularrehabilitation:Fromknowledgetoimplementation.2020update.
2018;25:1307(cid:2)1311. .. ApositionpaperfromtheSecondaryPreventionandRehabilitationSectionof
.
337. Chrysant SG. Antihypertensive therapy causes erectile dysfunction. Curr Opin . the European Association of Preventive Cardiology. Eur J Prev Cardiol
.
Cardiol2015;30:383(cid:2)390. . 2020:2047487320913379.
.
338. FanY,HuB,ManC,CuiF.Erectiledysfunctionandriskofcardiovascularand .. 359.NaderiSH,BestwickJP,WaldDS.Adherencetodrugsthatpreventcardiovas-
all-causemortalityinthegeneralpopulation:ameta-analysisofcohortstudies. .. culardisease:meta-analysison376,162patients.AmJMed2012;125:882(cid:2)887
.
WorldJUrol2018;36:1681(cid:2)1689. . e881.
.
339. ImprialosKP,StavropoulosK,DoumasM,TziomalosK,KaragiannisA,Athyros . 360.Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication
.
VG.SexualDysfunction,CardiovascularRiskandEffectsofPharmacotherapy. .. Adherence:TruthandConsequences.AmJMedSci2016;351:387(cid:2)399.
.
CurrVascPharmacol2018;16:130(cid:2)142. . 361.ChowdhuryR,KhanH,HeydonE,ShroufiA,FahimiS,MooreC,StrickerB,
.
340. OsonduCU,VoB,OniET,BlahaMJ,VeledarE,FeldmanT,AgatstonAS,Nasir . MendisS,HofmanA,MantJ,FrancoOH.Adherencetocardiovasculartherapy:
.
K,AneniEC.Therelationshipoferectiledysfunctionandsubclinicalcardiovas- .. a meta-analysis of prevalence and clinical consequences. Eur Heart J
culardisease:Asystematicreviewandmeta-analysis.VascMed2018;23:9(cid:2)20. .. 2013;34:2940(cid:2)2948.
.
341. Raheem OA, Su JJ, Wilson JR, Hsieh TC. The Association of Erectile . 362.Arlt AD, Nestoriuc Y, Rief W. Why current drug adherence programs fail:
.
Dysfunction and Cardiovascular Disease: A Systematic Critical Review. Am J . addressing psychological risk factors of nonadherence. Curr Opin Psychiatry
.
MensHealth2017;11:552(cid:2)563. .. 2017;30:326(cid:2)333.
342. GowaniZ,UddinSMI,MirboloukM,AyyazD,BillupsKL,MinerM,FeldmanDI, .. 363.Easthall C, Taylor N, Bhattacharya D. Barriers to medication adherence in
.
BlahaMJ.VascularErectileDysfunctionandSubclinicalCardiovascularDisease. . patients prescribed medicines for the prevention of cardiovascular disease: a
. CurrSexHealthRep2017;9:305(cid:2)312. .. conceptualframework.IntJPharmPract2019;27:223(cid:2)231.
343. ShahNP,Cainzos-AchiricaM,FeldmanDI,BlumenthalRS,NasirK,MinerMM, .. 364.SeaburySA,DoughertyJS,SullivanJ.Medicationadherenceasameasureofthe
. BillupsKL,BlahaMJ.CardiovascularDiseasePreventioninMenwithVascular . qualityofcareprovidedbyphysicians.AmJManagCare2019;25:78(cid:2)83.
.
Erectile Dysfunction: The View of the Preventive Cardiologist. Am J Med . 365.Schneider APH, Gaedke MA, Garcez A, Barcellos NT, Paniz VMV. Effect of
.
2016;129:251(cid:2)259. .. characteristicsofpharmacotherapyonnon-adherenceinchroniccardiovascular
344. GerbildH,LarsenCM,GraugaardC,AreskougJosefssonK.PhysicalActivityto .. disease:Asystematicreviewandmeta-analysisofobservationalstudies.IntJClin
.
Improve Erectile Function: A Systematic Review of Intervention Studies. Sex . Pract2018;72:[Epub].
.
Med2018;6:75(cid:2)89. . 366.AlbarqouniL,DoustJ,GlasziouP.Patientpreferencesforcardiovascularpre-
.
345. Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in .. ventivemedication:asystematicreview.Heart2017;103:1578(cid:2)1586.
.
thecardiovascularpatient.EurHeartJ2013;34:2034(cid:2)2046. . 367.HenneinR,HwangSJ,AuR,LevyD,MuntnerP,FoxCS,MaJ.Barrierstomedi-
.
346. Rachamin Y, Grischott T, Rosemann T, Meyer MR. Inferior control of low- . cation adherence and links to cardiovascular disease risk factor control: the
.
densitylipoproteincholesterolinwomenistheprimarysexdifferenceinmodi- .. FraminghamHeartStudy.InternMedJ2018;48:414(cid:2)421.
fiable cardiovascular risk: Alarge-scale, cross-sectionalstudyin primary care. .. 368.Goldstein CM, Gathright EC, Garcia S. Relationship between depression and
.
Atherosclerosis2021;324:141(cid:2)147. . medicationadherenceincardiovasculardisease:theperfectchallengeforthe
.
347. VictorBM,TealV,AhedorL,KaralisDG.Genderdifferencesinachievingopti- . integratedcareteam.PatientPreferAdherence2017;11:547(cid:2)559.
.
mal lipid goals in patients with coronary artery disease. Am J Cardiol .. 369.Palmer MJ, Barnard S, Perel P, Free C. Mobile phone-based interventions
2014;113:1611(cid:2)1615. .. forimprovingadherencetomedicationprescribedfortheprimaryprevention
.
348. ViraniSS,WoodardLD,RamseyDJ,UrechTH,AkeroydJM,ShahT,DeswalA, . of cardiovascular disease in adults. Cochrane Database Syst Rev
.
BozkurtB,BallantyneCM,PetersenLA.Genderdisparitiesinevidence-based .. 2018;6:CD012675.
statin therapy in patients with cardiovascular disease. Am J Cardiol .. 370.GuerrieroC,CairnsJ,RobertsI,RodgersA,WhittakerR,FreeC.Thecost-
.
2015;115:21(cid:2)26. . effectiveness of smoking cessation support delivered by mobile phone text
.
349. XiaS,DuX,GuoL,DuJ,ArnottC,LamCSP,HuffmanMD,ArimaH,YuanY, . messaging:Txt2stop.EurJHealthEcon2013;14:789(cid:2)797.
.
ZhengY,WuS,GuangX,ZhouX,LinH,ChengX,AndersonCS,DongJ,Ma .. 371.KrausWE,PowellKE,HaskellWL,JanzKF,CampbellWW,JakicicJM,Troiano
C. Sex Differences in Primary and Secondary Prevention of Cardiovascular .. RP,SprowK,TorresA,PiercyKL,2018PhysicalActivityGuidelinesAdvisory
.
DiseaseinChina.Circulation2020;141:530(cid:2)539. . Committee. Physical Activity, All-Cause and Cardiovascular Mortality, and
.
350. Hyun KK, Redfern J, Patel A, Peiris D, Brieger D, Sullivan D, Harris M, . CardiovascularDisease.MedSciSportsExerc2019;51:1270(cid:2)1281.
.
UsherwoodT,MacMahonS,LyfordM,WoodwardM.Genderinequalitiesin .. 372.Powell KE, King AC, Buchner DM, Campbell WW, DiPietro L, Erickson KI,
cardiovascular risk factor assessment and management in primaryhealthcare. .. HillmanCH,JakicicJM,JanzKF,KatzmarzykPT,KrausWE,MackoRF,Marquez
.
Heart2017;103:492(cid:2)498. . DX, McTiernan A, Pate RR, Pescatello LS, Whitt-Glover MC. The Scientific .
351. MoscaL,Barrett-ConnorE,WengerNK.Sex/genderdifferencesincardiovas- .. Foundation for the Physical Activity Guidelines for Americans, 2nd Edition. J
cular disease prevention: what a difference a decade makes. Circulation .. PhysActHealth2018:1(cid:2)11.
.
2011;124:2145(cid:2)2154. . 373.Sattelmair J, Pertman J, Ding EL, Kohl HW, 3rd, Haskell W, Lee IM. Dose
.
352. WandellPE,deWaardAM,HolzmannMJ,GornitzkiC,LionisC,deWitN, . responsebetweenphysicalactivityandriskofcoronaryheartdisease:ameta-
.
Sondergaard J, Sonderlund AL, Kral N, Seifert B, Korevaar JC, Schellevis FG, .. analysis.Circulation2011;124:789(cid:2)795.
Carlsson AC. Barriers and facilitators among health professionals in primary .. 374.HupinD,RocheF,GremeauxV,ChatardJC,OriolM,GaspozJM,Barthelemy
.
caretopreventionofcardiometabolicdiseases:Asystematicreview.FamPract . JC, Edouard P. Even a low-dose of moderate-to-vigorous physical activity
.
2018;35:383(cid:2)398. .. reducesmortalityby22%inadultsaged>/=60years:asystematicreviewand
353. AstinF,LucockM,JenningsCS.Heartandmind:behaviouralcardiologydemys- .. meta-analysis.BrJSportsMed2015;49:1262(cid:2)1267.
.
tifiedfortheclinician.Heart2019;105:881(cid:2)888. . 375.EkelundU,TarpJ,Steene-JohannessenJ,HansenBH,JefferisB,FagerlandMW,
.
354. LeeWW,ChoiKC,YumRW,YuDS,ChairSY.Effectivenessofmotivational . Whincup P, Diaz KM, Hooker SP, Chernofsky A, Larson MG, Spartano N,
.
interviewingonlifestylemodificationandhealthoutcomesofclientsatriskor .. Vasan RS, Dohrn IM, Hagstromer M, Edwardson C, Yates T, Shiroma E,
diagnosed with cardiovascular diseases: A systematic review. Int J Nurs Stud .. Anderssen SA, Lee IM. Dose-response associations between accelerometry
.
2016;53:331(cid:2)341. . measuredphysicalactivityandsedentarytimeandallcausemortality:system-
.
355. ZulmanDM,HaverfieldMC,ShawJG,Brown-JohnsonCG,SchwartzR,Tierney . aticreviewandharmonisedmeta-analysis.BMJ2019;366:l4570.
.
AA,ZiontsDL,SafaeiniliN,FischerM,ThadaneyIsraniS,AschSM,VergheseA. .. 376.PattersonR,McNamaraE,TainioM,deSaTH,SmithAD,SharpSJ,EdwardsP,
Practices to Foster Physician Presence and Connection With Patients in the .. WoodcockJ,BrageS,WijndaeleK.Sedentarybehaviourandriskofall-cause,
.
ClinicalEncounter.JAMA2020;323:70(cid:2)81. . cardiovascularandcancermortality,andincidenttype2diabetes:asystematic
.
356. MillerWR,RoseGS.Towardatheoryofmotivationalinterviewing.AmPsychol .. reviewanddoseresponsemeta-analysis.EurJEpidemiol2018;33:811(cid:2)829.
2009;64:527(cid:2)537. .. 377.Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA.
.
357. MichieS,vanStralenMM,WestR.Thebehaviourchangewheel:anewmethod . Sedentarytimeanditsassociationwithriskfordiseaseincidence,mortality,and
.
forcharacterisinganddesigningbehaviourchangeinterventions.ImplementSci . hospitalizationinadults:asystematicreviewandmeta-analysis.AnnInternMed
.
2011;6:42. .. 2015;162:123(cid:2)132.
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 97 ---
ESCGuidelines 3323
.
.
378. LiuY,LeeDC,LiY,ZhuW,ZhangR,SuiX,LavieCJ,BlairSN.Associationsof . 396.ChastinSFM,DeCraemerM,DeCockerK,PowellL,VanCauwenbergJ,Dall
.
ResistanceExercisewithCardiovascularDiseaseMorbidityandMortality.Med . P,HamerM,StamatakisE.Howdoeslight-intensityphysicalactivityassociate
.
SciSportsExerc2019;51:499(cid:2)508. .. withadultcardiometabolichealthandmortality?Systematicreviewwithmeta-
379. SaeidifardF,Medina-InojosaJR,WestCP,OlsonTP,SomersVK,Bonikowske .. analysis of experimental and observational studies. Br J Sports Med
.
AR,ProkopLJ,VinciguerraM,Lopez-JimenezF.Theassociationofresistance . 2019;53:370(cid:2)376.
.
trainingwithmortality:Asystematicreviewandmeta-analysis.EurJPrevCardiol .. 397.LeeIM,ShiromaEJ,LobeloF,PuskaP,BlairSN,KatzmarzykPT,LancetPhysical
2019;26:1647(cid:2)1665. .. Activity Series Working Group. Effect of physical inactivity on major non-
.
380. Cradock KA, OL G, Finucane FM, Gainforth HL, Quinlan LR, Ginis KA. . communicable diseases worldwide: an analysis of burden of disease and life
.
Behaviourchangetechniquestargetingbothdietandphysicalactivityintype2 . expectancy.Lancet2012;380:219(cid:2)229.
.
diabetes: A systematic review and meta-analysis. Int J Behav Nutr Phys Act .. 398.KatzmarzykPT,PowellKE,JakicicJM,TroianoRP,PiercyK,TennantB,2018
2017;14:18. .. Physical Activity Guidelines Advisory Committee. Sedentary Behavior and
.
381. HowlettN,TrivediD,TroopNA,ChaterAM.Arephysicalactivityinterven- . Health: Update from the 2018 Physical Activity Guidelines Advisory
.
tions for healthy inactive adults effective in promoting behavior change and .. Committee.MedSciSportsExerc2019;51:1227(cid:2)1241.
maintenance,andwhichbehaviorchangetechniquesareeffective?Asystematic .. 399.Young DR, Hivert MF, Alhassan S, Camhi SM, Ferguson JF, Katzmarzyk PT,
.
reviewandmeta-analysis.TranslBehavMed2019;9:147(cid:2)157. . Lewis CE, Owen N, Perry CK, Siddique J, Yong CM, Physical Activity
.
382. BrickwoodKJ,WatsonG,O’BrienJ,WilliamsAD.Consumer-BasedWearable . CommitteeoftheCouncilonLifestyleandCardiometabolicHealth,Councilon
.
ActivityTrackersIncreasePhysicalActivityParticipation:SystematicReviewand .. Clinical Cardiology, Council on Epidemiology and Prevention, Council on
Meta-Analysis.JMIRMhealthUhealth2019;7:e11819. .. FunctionalGenomicsandTranslationalBiology,andStrokeCouncil.Sedentary
.
383. KyuHH,BachmanVF,AlexanderLT,MumfordJE,AfshinA,EstepK,Veerman . BehaviorandCardiovascularMorbidityandMortality:AScienceAdvisoryFrom
.
JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJ, . theAmericanHeartAssociation.Circulation2016;134:e262-279.
.
ForouzanfarMH.Physicalactivityandriskofbreastcancer,coloncancer,diabe- .. 400.YatesT,EdwardsonCL,Celis-MoralesC,BiddleSJH,BodicoatD,DaviesMJ,
tes,ischemicheartdisease,andischemicstrokeevents:systematicreviewand .. Esliger D, Henson J, Kazi A, Khunti K, Sattar N, Sinclair AJ, Rowlands A,
.
dose-responsemeta-analysisfortheGlobalBurdenofDiseaseStudy2013.BMJ . Velayudhan L, Zaccardi F, Gill JMR. Metabolic Effects of Breaking Prolonged
. 2016;354:i3857. .. Sitting With Standing or Light Walking in Older South Asians and White
384. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, .. Europeans: A Randomized Acute Study. J Gerontol A Biol Sci Med Sci
. Friedemann Smith C, Wilkins E, Rayner M, Roberts N, Scarborough P. . 2020;75:139(cid:2)146.
.
Quantifying the Association Between Physical Activity and Cardiovascular . 401.Eilat-AdarS,SinaiT,YosefyC,HenkinY.Nutritionalrecommendationsforcar-
.
DiseaseandDiabetes:ASystematicReviewandMeta-Analysis.JAmHeartAssoc .. diovasculardiseaseprevention.Nutrients2013;5:3646(cid:2)3683.
2016;5:e002495. .. 402.EuropeanHeartNetwork.TransformingEuropeanfoodanddrinkpoliciesforcardi-
.
385. MooreSC,PatelAV,MatthewsCE,BerringtondeGonzalezA,ParkY,Katki . ovascular health. http://www.ehnheart.org/publications-and-papers/publications/
.
HA,LinetMS,WeiderpassE,VisvanathanK,HelzlsouerKJ,ThunM,Gapstur . 1093:transforming-european-food-and-drinks-policies-for-cardiovascular-health.
.
SM,HartgeP,LeeIM.Leisuretimephysicalactivityofmoderatetovigorous .. html(21July2020).
.
intensity and mortality: a large pooled cohort analysis. PLoS Med . 403.SofiF,AbbateR,GensiniGF,CasiniA.Accruingevidenceonbenefitsofadher-
.
2012;9:e1001335. . encetotheMediterraneandietonhealth:anupdatedsystematicreviewand
.
386. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, .. meta-analysis.AmJClinNutr2010;92:1189(cid:2)1196.
KeadleSK,AremH,BerringtondeGonzalezA,HartgeP,AdamiHO,BlairCK, .. 404.EstruchR,RosE,Salas-SalvadoJ,CovasMI,CorellaD,ArosF,Gomez-Gracia
.
BorchKB,BoydE,CheckDP,FournierA,FreedmanND,GunterM,Johannson . E,Ruiz-GutierrezV,FiolM,LapetraJ,Lamuela-RaventosRM,Serra-MajemL,
.
M,KhawKT,LinetMS,OrsiniN,ParkY,RiboliE,RobienK,SchairerC,Sesso . PintoX,BasoraJ,MunozMA,SorliJV,MartinezJA,FitoM,GeaA,HernanMA,
.
H,SpriggsM,VanDusenR,WolkA,MatthewsCE,PatelAV.Associationof .. Martinez-GonzalezMA,PREDIMEDStudyInvestigators.PrimaryPreventionof
Leisure-TimePhysicalActivityWithRiskof26TypesofCancerin1.44Million .. CardiovascularDiseasewithaMediterraneanDietSupplementedwithExtra-
.
Adults.JAMAInternMed2016;176:816(cid:2)825. . VirginOliveOilorNuts.NEnglJMed2018;378:e34.
.
387. AremH,MooreSC,PatelA,HartgeP,BerringtondeGonzalezA,Visvanathan .. 405.MensinkRP.Effectsofsaturatedfattyacidsonserumlipidsandlipoproteins:asys-
K, Campbell PT, Freedman M, Weiderpass E, Adami HO, Linet MS, Lee IM, .. tematic review and regression analysis https://apps.who.int/iris/bitstream/handle/
.
Matthews CE. Leisure time physical activity and mortality: a detailed pooled . 10665/246104/9789241565349-eng.pdf?sequence=1(21July2020).
.
analysisofthedose-responserelationship.JAMAInternMed2015;175:959(cid:2)967. . 406.Guasch-FerreM,SatijaA,BlondinSA,JaniszewskiM,EmlenE,O’ConnorLE,
.
388. PellicciaA,SharmaS,GatiS,BackM,BorjessonM,CaselliS,ColletJP,Corrado .. Campbell WW, Hu FB, Willett WC, Stampfer MJ. Meta-Analysis of
D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, .. RandomizedControlledTrialsofRedMeatConsumptioninComparisonWith
.
Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, . Various Comparison Diets on Cardiovascular Risk Factors. Circulation
.
Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific . 2019;139:1828(cid:2)1845.
.
DocumentGroup.2020ESCGuidelinesonsportscardiologyandexercisein .. 407.ChenM,LiY,SunQ,PanA,MansonJE,RexrodeKM,WillettWC,RimmEB,
patientswithcardiovasculardisease.EurHeartJ2021;42:17(cid:2)96. .. HuFB.Dairyfatandriskofcardiovasculardiseasein3cohortsofUSadults.
.
389. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, . AmJClinNutr2016;104:1209(cid:2)1217. .
Nieman DC, Swain DP, American College of Sports Medicine. American .. 408.Li Y, Hruby A, Bernstein AM, Ley SH, Wang DD, Chiuve SE, Sampson L,
CollegeofSportsMedicinepositionstand.Quantityandqualityofexercisefor .. RexrodeKM,RimmEB,WillettWC,HuFB.SaturatedFatsComparedWith
.
developingandmaintainingcardiorespiratory,musculoskeletal,andneuromotor . Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of
.
fitnessinapparentlyhealthyadults:guidanceforprescribingexercise.MedSci . Coronary Heart Disease: A Prospective Cohort Study. J Am Coll Cardiol
.
SportsExerc2011;43:1334(cid:2)1359. .. 2015;66:1538(cid:2)1548.
390. JakicicJM,KrausWE,PowellKE,CampbellWW,JanzKF,TroianoRP,SprowK, .. 409.SacksFM,LichtensteinAH,WuJHY,AppelLJ,CreagerMA,Kris-EthertonPM,
.
Torres A, Piercy KL, 2018 Physical Activity Guidelines Advisory Committee. . MillerM,RimmEB,RudelLL,RobinsonJG,StoneNJ,VanHornLV,American
.
AssociationbetweenBoutDurationofPhysicalActivityandHealth:Systematic . Heart Association. Dietary Fats and Cardiovascular Disease: A Presidential
. Review.MedSciSportsExerc2019;51:1213(cid:2)1219. .. AdvisoryFromtheAmericanHeartAssociation.Circulation2017;136:e1(cid:2)e23.
.
391. AinsworthBE,HaskellWL,HerrmannSD,MeckesN,BassettDR,Jr.,Tudor- . 410.HeFJ,TanM,MaY,MacGregorGA.SaltReductiontoPreventHypertension
.
LockeC,GreerJL,VezinaJ,Whitt-GloverMC,LeonAS.2011Compendiumof . and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol
.
PhysicalActivities: asecondupdateofcodesandMETvalues.MedSciSports .. 2020;75:632(cid:2)647.
Exerc2011;43:1575(cid:2)1581. .. 411.WillettW,RockstromJ,LokenB,SpringmannM,LangT,VermeulenS,Garnett
.
392. HowleyET.Typeofactivity:resistance,aerobicandleisureversusoccupational . T, Tilman D, DeClerck F, Wood A, Jonell M, Clark M, Gordon LJ, Fanzo J,
.
physicalactivity.MedSciSportsExerc2001;33:S364(cid:2)369;discussionS419-320. . Hawkes C, Zurayk R, Rivera JA, De Vries W, Majele Sibanda L, Afshin A,
.
393. OrtegaFB,SilventoinenK,TyneliusP,RasmussenF.Muscularstrengthinmale .. ChaudharyA,HerreroM,AgustinaR,BrancaF,LarteyA,FanS,CronaB,Fox
adolescentsandprematuredeath:cohortstudyofonemillionparticipants.BMJ .. E,BignetV,TroellM,LindahlT,SinghS,CornellSE,SrinathReddyK,NarainS,
.
2012;345:e7279. . Nishtar S, Murray CJL. Food in the Anthropocene: the EAT-Lancet
.
394. RuizJR,SuiX,LobeloF,MorrowJR,Jr.,JacksonAW,SjostromM,BlairSN. .. Commission on healthy diets from sustainable food systems. Lancet
Association between muscular strength and mortality in men: prospective .. 2019;393:447(cid:2)492.
.
cohortstudy.BMJ2008;337:a439. . 412.WorldHealthOrganization.Ahealthydietsustainablyproduced.https://apps.
.
395. VolaklisKA,HalleM,MeisingerC.Muscularstrengthasastrongpredictorof . who.int/iris/bitstream/handle/10665/278948/WHO-NMH-NHD-18.12-eng.pdf?
.
mortality:Anarrativereview.EurJInternMed2015;26:303(cid:2)310. .. ua=1(21July2020).
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 98 ---
3324 ESCGuidelines
.
.
413. WoodAM,KaptogeS,ButterworthAS,WilleitP,WarnakulaS,BoltonT,Paige . GuelpenB,HolgerssonPL,TsilidisKK,HeathAK,MullerD,RiboliE,Gunter
.
E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, . MJ,MurphyN.AssociationBetweenSoftDrinkConsumptionandMortalityin
.
SelmerRM,VerschurenWMM,SatoS,NjolstadI,WoodwardM,SalomaaV, .. 10EuropeanCountries.JAMAInternMed2019;179:1479(cid:2)1490.
Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B, .. 420.World Health Organization. Guideline: sugars intake for adults and children.
.
MarmotM,KoenigW,CasigliaE,CooperC,ArndtV,FrancoOH,Wennberg . https://www.who.int/publications/i/item/9789241549028(21July2020).
.
P,GallacherJ,delaCamaraAG,VolzkeH,DahmCC,DaleCE,BergmannMM, .. 421.SundforTM,SvendsenM,HeggenE,DushanovS,KlemsdalTO,TonstadS.BMI
CrespoCJ,vanderSchouwYT,KaaksR,SimonsLA,LagiouP,SchoufourJD, .. modifies the effect of dietary fat on atherogenic lipids: a randomized clinical
.
Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO, . trial.AmJClinNutr2019;110:832(cid:2)841.
.
SacerdoteC,WallaceRB,QuirosJR,TuminoR,BlazerDG,2nd,LinnebergA, . 422.Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty
.
DaimonM,PanicoS,HowardB,SkeieG,StrandbergT,WeiderpassE,Nietert .. acidsandcardiovasculardisease.NEnglJMed2006;354:1601(cid:2)1613.
PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM, .. 423.SacksFM,SvetkeyLP,VollmerWM,AppelLJ,BrayGA,HarshaD,ObarzanekE,
.
GrioniS,PalliD,HuertaJM,PriceJ,SundstromJ,ArriolaL,ArimaH,TravisRC, . ConlinPR,MillerER,3rd,Simons-MortonDG,KaranjaN,LinPH,DASH-Sodium
.
Panagiotakos DB, Karakatsani A, Trichopoulou A, Kuhn T, Grobbee DE, . CollaborativeResearchGroup.Effectsonbloodpressureofreduceddietarysodium
.
Barrett-ConnorE,vanSchoorN,BoeingH,OvervadK,KauhanenJ,Wareham .. and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium
.
N,LangenbergC,ForouhiN,WennbergM,DespresJP,CushmanM,Cooper . CollaborativeResearchGroup.NEnglJMed2001;344:3(cid:2)10.
.
JA,RodriguezCJ,SakuraiM,ShawJE,KnuimanM,VoortmanT,MeisingerC, . 424.MenteA,O’DonnellM,RangarajanS,DagenaisG,LearS,McQueenM,DiazR,
.
TjonnelandA,BrennerH,PalmieriL,DallongevilleJ,BrunnerEJ,AssmannG, .. AvezumA,Lopez-JaramilloP,LanasF,LiW,LuY,YiS,RenshengL,IqbalR,
TrevisanM,GillumRF,FordI,SattarN,LazoM,ThompsonSG,FerrariP,Leon .. MonyP,YusufR,YusoffK,SzubaA,OguzA,RosengrenA,BahonarA,Yusufali
.
DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J, . A, Schutte AE, Chifamba J, Mann JF, Anand SS, Teo K, Yusuf S, PURE,
.
Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study . EPIDREAMandONTARGET/TRANSCENDInvestigators.Associationsofuri-
.
Group. Risk thresholds for alcohol consumption: combined analysis of .. narysodiumexcretionwithcardiovasculareventsinindividualswithandwith-
individual-participantdatafor599912currentdrinkersin83prospectivestud- .. out hypertension: a pooled analysis of data from four studies. Lancet
.
ies.Lancet2018;391:1513(cid:2)1523. . 2016;388:465(cid:2)475.
. 414. MillwoodIY,WaltersRG,MeiXW,GuoY,YangL,BianZ,BennettDA,Chen .. 425.CappuccioFP,CampbellNR.PopulationDietarySaltReductionandtheRiskof
Y,DongC,HuR,ZhouG,YuB,JiaW,ParishS,ClarkeR,DaveySmithG, .. Cardiovascular Disease:ACommentary onRecent Evidence. J Clin Hypertens
. Collins R, Holmes MV, Li L, Peto R, Chen Z, China Kadoorie Biobank . (Greenwich)2017;19:4(cid:2)5.
.
CollaborativeGroup.Conventionalandgeneticevidenceonalcoholandvascu- . 426.He FJ, Ma Y, Campbell NRC, MacGregor GA, Cogswell ME, Cook NR.
.
lardiseaseaetiology:aprospectivestudyof500000menandwomeninChina. .. FormulastoEstimateDietarySodiumIntakeFromSpotUrineAlterSodium-
Lancet2019;393:1831(cid:2)1842. .. MortalityRelationship.Hypertension2019;74:572(cid:2)580.
.
415. HolmesMV,DaleCE,ZuccoloL,SilverwoodRJ,GuoY,YeZ,Prieto-Merino . 427.AburtoNJ,HansonS,GutierrezH,HooperL,ElliottP,CappuccioFP.Effectof
.
D,DehghanA,TrompetS,WongA,CavadinoA,DroganD,PadmanabhanS, . increasedpotassiumintakeoncardiovascularriskfactorsanddisease:system-
.
LiS,YesupriyaA,LeusinkM,SundstromJ,HubacekJA,PikhartH,Swerdlow .. aticreviewandmeta-analyses.BMJ2013;346:f1378.
.
DI,PanayiotouAG,BorinskayaSA,FinanC,ShahS,KuchenbaeckerKB,ShahT, . 428.Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H,
.
Engmann J, Folkersen L, Eriksson P, Ricceri F, Melander O, Sacerdote C, . Gordon D, Copeland T, D’Agostino D, Friedenberg G, Ridge C, Bubes V,
.
GambleDM,RayaproluS,RossOA,McLachlanS,VikhirevaO,SluijsI,Scott .. Giovannucci EL, Willett WC, Buring JE, VITAL Research Group. Vitamin D
RA,AdamkovaV,FlickerL,BockxmeerFM,PowerC,Marques-VidalP,Meade .. Supplements and Prevention of Cancer and Cardiovascular Disease. NEngl J
.
T,MarmotMG,FerroJM,Paulos-PinheiroS,HumphriesSE,TalmudPJ,Mateo . Med2019;380:33(cid:2)44.
.
LeachI,VerweijN,LinnebergA,SkaabyT,DoevendansPA,CramerMJ,van . 429.HuangT,AfzalS,YuC,GuoY,BianZ,YangL,MillwoodIY,WaltersRG,Chen
.
derHarstP,KlungelOH,DowlingNF,DominiczakAF,KumariM,Nicolaides .. Y,ChenN,GaoR,ChenJ,ClarkeR,ChenZ,EllervikC,NordestgaardBG,Lv
AN,WeikertC,BoeingH,EbrahimS,GauntTR,PriceJF,LannfeltL,PeaseyA, .. J, Li L, China Kadoorie Biobank Collaborative Group. Vitamin D and cause-
.
KubinovaR,PajakA,MalyutinaS,VoevodaMI,TamosiunasA,Maitland-vander . specificvasculardiseaseandmortality:aMendelianrandomisationstudyinvolv-
.
Zee AH, Norman PE, Hankey GJ, Bergmann MM, Hofman A, Franco OH, .. ing99,012Chineseand106,911Europeanadults.BMCMed2019;17:160.
CooperJ,PalmenJ,SpieringW,deJongPA,KuhD,HardyR,UitterlindenAG, .. 430.Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C,
.
IkramMA,FordI,HypponenE,AlmeidaOP,WarehamNJ,KhawKT,Hamsten . WoodheadC,CadeJE,GaleCP,BurleyVJ.Dietaryfibreintakeandriskofcar-
.
A,HusemoenLL,TjonnelandA,TolstrupJS,RimmE,BeulensJW,Verschuren . diovasculardisease:systematicreviewandmeta-analysis.BMJ2013;347:f6879.
.
WM,Onland-MoretNC,HofkerMH,WannametheeSG,WhincupPH,Morris .. 431.ZhangZ,XuG,LiuD,ZhuW,FanX,LiuX.Dietaryfiberconsumptionand
R,VicenteAM,WatkinsH,FarrallM,JukemaJW,MeschiaJ,CupplesLA,Sharp .. riskofstroke.EurJEpidemiol2013;28:119(cid:2)130.
.
SJ,FornageM,KooperbergC,LaCroixAZ,DaiJY,LanktreeMB,SiscovickDS, . 432.YaoB,FangH,XuW,YanY,XuH,LiuY,MoM,ZhangH,ZhaoY.Dietary
.
JorgensonE,SpringB,CoreshJ,LiYR,BuxbaumSG,SchreinerPJ,EllisonRC, . fiberintakeandriskoftype2diabetes:adose-responseanalysisofprospective
.
Tsai MY, Patel SR, Redline S, Johnson AD, Hoogeveen RC, Hakonarson H, .. studies.EurJEpidemiol2014;29:79(cid:2)88.
Rotter JI, Boerwinkle E, de Bakker PI, Kivimaki M, Asselbergs FW, Sattar N, .. 433.Giacco R, Costabile G, Della Pepa G, Anniballi G, Griffo E, Mangione A,
.
Lawlor DA, Whittaker J, Davey Smith G, Mukamal K, Psaty BM, Wilson JG, . Cipriano P, Viscovo D, Clemente G, Landberg R, Pacini G, Rivellese AA, .
LangeLA,HamidovicA,HingoraniAD,NordestgaardBG,BobakM,LeonDA, .. RiccardiG.Awhole-graincereal-baseddietlowerspostprandialplasmainsulin
Langenberg C, Palmer TM, Reiner AP, Keating BJ, Dudbridge F, Casas JP, .. and triglyceride levels in individuals with metabolic syndrome. Nutr Metab
.
InterActConsortium.Associationbetweenalcoholandcardiovasculardisease: . CardiovascDis2014;24:837(cid:2)844.
.
Mendelian randomisation analysis based on individual participant data. BMJ . 434.WangX,OuyangY,LiuJ,ZhuM,ZhaoG,BaoW,HuFB.Fruitandvegetable
.
2014;349:g4164. .. consumptionandmortalityfromallcauses,cardiovasculardisease,andcancer:
416. ZeraatkarD,JohnstonBC,BartoszkoJ,CheungK,BalaMM,ValliC,RabassaM, .. systematicreviewanddose-responsemeta-analysisofprospectivecohortstud-
.
Sit D, Milio K, Sadeghirad B, Agarwal A, Zea AM, Lee Y,Han MA, Vernooij . ies.BMJ2014;349:g4490.
.
RWM,Alonso-CoelloP,GuyattGH,ElDibR.EffectofLowerVersusHigher . 435.He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and
. Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic .. stroke:meta-analysisofcohortstudies.Lancet2006;367:320(cid:2)326.
.
ReviewofRandomizedTrials.AnnInternMed2019;171:721(cid:2)731. . 436.Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable con-
.
417. Zhong VW, Van Horn L, Greenland P, Carnethon MR, Ning H, Wilkins JT, . sumptionandriskofcoronaryheartdisease:ameta-analysisofcohortstudies.J
.
Lloyd-JonesDM,AllenNB.AssociationsofProcessedMeat,UnprocessedRed .. Nutr2006;136:2588(cid:2)2593.
Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and All- .. 437.LuoC,ZhangY,DingY,ShanZ,ChenS,YuM,HuFB,LiuL.Nutconsumption
.
CauseMortality.JAMAInternMed2020;180:503(cid:2)512. . andriskoftype2diabetes,cardiovasculardisease,andall-causemortality:asys-
.
418. ZhengJ,HuangT,YuY,HuX,YangB,LiD.FishconsumptionandCHDmor- . tematicreviewandmeta-analysis.AmJClinNutr2014;100:256(cid:2)269.
.
tality:anupdatedmeta-analysisofseventeencohortstudies.PublicHealthNutr .. 438.Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and
2012;15:725(cid:2)737. .. legumesandriskofincidentischemicheartdisease,stroke,anddiabetes:asys-
.
419. MulleeA,RomagueraD,Pearson-StuttardJ,ViallonV,StepienM,FreislingH, . tematicreviewandmeta-analysis.AmJClinNutr2014;100:278(cid:2)288.
.
Fagherazzi G, Mancini FR, Boutron-Ruault MC, Kuhn T, Kaaks R, Boeing H, .. 439.World CancerResearch Fund, American Institute for Cancer Research. Diet,
AleksandrovaK,TjonnelandA,HalkjaerJ,OvervadK,WeiderpassE,SkeieG, .. Nutrition,PhysicalActivityandCancer:aGlobalPerspective,2018.https://www.wcrf.
.
Parr CL, Quiros JR, Agudo A, Sanchez MJ, Amiano P, Cirera L, Ardanaz E, . org/dietandcancer/recommendations/limit-red-processed-meat(21July2020).
.
KhawKT,TongTYN,SchmidtJA,TrichopoulouA,MartimianakiG,Karakatsani . 440.Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S,
.
A,PalliD,AgnoliC,TuminoR,SacerdoteC,PanicoS,Bueno-de-MesquitaB, .. Kiefte-de-JongJC,KhanH,BaenaCP,PrabhakaranD,HoshenMB,FeldmanBS,
Verschuren WMM, Boer JMA, Vermeulen R, Ramne S, Sonestedt E, van . PanA,JohnsonL,CroweF,HuFB,FrancoOH.VitaminDandriskofcause
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 99 ---
ESCGuidelines 3325
.
.
specificdeath:systematicreviewandmeta-analysisofobservationalcohortand . 460.Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L.
.
randomisedinterventionstudies.BMJ2014;348:g1903. . Carbohydrate quality and human health: a series of systematic reviews and
.
441. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between .. meta-analyses.Lancet2019;393:434(cid:2)445.
omega-3 fatty acid supplementation and risk of major cardiovascular disease .. 461.Kirkpatrick CF, Bolick JP, Kris-Etherton PM, Sikand G, Aspry KE, Soffer DE,
.
events:asystematicreviewandmeta-analysis.JAMA2012;308:1024(cid:2)1033. . WillardKE,MakiKC.Reviewofcurrentevidenceandclinicalrecommendations
.
442. AbdelhamidAS,BrownTJ,BrainardJS,BiswasP,ThorpeGC,MooreHJ,Deane .. ontheeffectsoflow-carbohydrateandvery-low-carbohydrate(includingketo-
KH,AlAbdulghafoorFK,SummerbellCD,WorthingtonHV,SongF,HooperL. .. genic)dietsforthemanagementofbodyweightandothercardiometabolicrisk
.
Omega-3fattyacidsfortheprimaryandsecondarypreventionofcardiovascu- . factors: A scientific statement from the National Lipid Association Nutrition
.
lardisease.CochraneDatabaseSystRev2018;7:CD003177. . andLifestyleTaskForce.JClinLipidol2019;13:689(cid:2)711e681.
.
443. AungT,HalseyJ,KromhoutD,GersteinHC,MarchioliR,TavazziL,GeleijnseJM, .. 462.SeidelmannSB,Claggett B,ChengS,Henglin M,ShahA, SteffenLM,Folsom
RauchB,NessA,GalanP,ChewEY,BoschJ,CollinsR,LewingtonS,ArmitageJ, .. AR,RimmEB,WillettWC,SolomonSD.Dietarycarbohydrateintakeandmor-
.
ClarkeR,Omega-3TreatmentTrialists’Collaboration.AssociationsofOmega-3 . tality: a prospective cohort study and meta-analysis. Lancet Public Health
.
FattyAcidSupplementUseWithCardiovascularDiseaseRisks:Meta-analysisof .. 2018;3:e419(cid:2)e428.
10TrialsInvolving77917Individuals.JAMACardiol2018;3:225(cid:2)234. .. 463.Rynders CA, Thomas EA, Zaman A, Pan Z, Catenacci VA, Melanson EL.
.
444. HuY,HuFB,MansonJE.MarineOmega-3SupplementationandCardiovascular . EffectivenessofIntermittentFastingandTime-RestrictedFeedingComparedto
.
Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials . ContinuousEnergyRestrictionforWeightLoss.Nutrients2019;11:2442.
.
Involving127477Participants.JAmHeartAssoc2019;8:e013543. .. 464.Kane JA, Mehmood T, Munir I, Kamran H, Kariyanna PT, Zhyvotovska A,
445. NichollsSJ,LincoffAM,GarciaM,BashD,BallantyneCM,BarterPJ,Davidson .. Yusupov D, Suleman UJ, Gustafson DR, McFarlane SI. Cardiovascular Risk
.
MH,KasteleinJJP,KoenigW,McGuireDK,MozaffarianD,RidkerPM,RayKK, . ReductionAssociatedwithPharmacologicalWeightLoss:AMeta-Analysis.IntJ
.
KatonaBG, HimmelmannA,LossLE,RensfeldtM,LundstromT, AgrawalR, . ClinResTrials2019;4:131.
.
MenonV,WolskiK,NissenSE.EffectofHigh-DoseOmega-3FattyAcidsvs .. 465.BarberS,ThornicroftG.ReducingtheMortality GapinPeopleWithSevere
Corn Oil on Major Adverse Cardiovascular Events in Patients at High .. Mental Disorders: The Role of Lifestyle Psychosocial Interventions. Front
.
Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA . Psychiatry2018;9:463.
. 2020;324:2268(cid:2)2280. .. 466.RichardsSH,AndersonL,JenkinsonCE,WhalleyB,ReesK,DaviesP,Bennett
446. TverdalA,SelmerR,CohenJM,ThelleDS.Coffeeconsumptionandmortality .. P, Liu Z, West R, Thompson DR, Taylor RS. Psychological interventions for
. from cardiovascular diseases and total mortality: Does the brewing method . coronaryheartdisease.CochraneDatabaseSystRev2017;4:CD002902.
.
matter?EurJPrevCardiol2020;27:1986(cid:2)1993. . 467.GullikssonM,BurellG,VessbyB,LundinL,TossH,SvardsuddK.Randomized
.
447. PooleR,KennedyOJ,RoderickP,FallowfieldJA,HayesPC,ParkesJ.Coffee .. controlledtrialofcognitivebehavioraltherapyvsstandardtreatmenttopre-
consumptionandhealth: umbrellareview ofmeta-analysesofmultiplehealth .. ventrecurrentcardiovascular events in patients with coronaryheartdisease:
.
outcomes.BMJ2017;359:j5024. . SecondaryPreventioninUppsalaPrimaryHealthCareproject(SUPRIM).Arch
.
448. RasRT,GeleijnseJM,TrautweinEA.LDL-cholesterol-loweringeffectofplant . InternMed2011;171:134(cid:2)140.
.
sterolsandstanolsacrossdifferentdoseranges:ameta-analysisofrandomised .. 468.Orth-GomerK,SchneidermanN,WangHX,WalldinC,BlomM,JernbergT.
.
controlledstudies.BrJNutr2014;112:214(cid:2)219. . Stressreductionprolongslifeinwomenwithcoronarydisease:theStockholm
.
449. Peng D, Fong A, Pelt AV. Original Research: The Effects of Red Yeast . Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ
.
Rice Supplementation on Cholesterol Levels in Adults. Am J Nurs .. CardiovascQualOutcomes2009;2:25(cid:2)32.
2017;117:46(cid:2)54. .. 469.BlumenthalJA,SherwoodA,SmithPJ,WatkinsL,MabeS,KrausWE,IngleK,
.
450. ZomerE,GurusamyK,LeachR,TrimmerC,LobsteinT,MorrisS,JamesWP, . Miller P, Hinderliter A. Enhancing Cardiac Rehabilitation With Stress
.
FinerN.Interventionsthatcauseweightlossandtheimpactoncardiovascular . Management Training: A Randomized, Clinical Efficacy Trial. Circulation
.
risk factors: a systematic review and meta-analysis. Obes Rev .. 2016;133:1341(cid:2)1350.
2016;17:1001(cid:2)1011. .. 470.PizziC,RutjesAW,CostaGM,FontanaF,MezzettiA,ManzoliL.Meta-analysis
.
451. WingRR,EspelandMA,ClarkJM,HazudaHP,KnowlerWC,PownallHJ,Unick . ofselectiveserotoninreuptakeinhibitorsinpatientswithdepressionandcoro-
.
J,WaddenT,WagenknechtL,ActionforHealthinDiabetes(LookAHEAD) .. naryheartdisease.AmJCardiol2011;107:972(cid:2)979.
StudyGroup.AssociationofWeightLossMaintenanceandWeightRegainon .. 471.KimJM,StewartR,LeeYS,LeeHJ,KimMC,KimJW,KangHJ,BaeKY,Kim
.
4-YearChangesinCVDRiskFactors:theActionforHealthinDiabetes(Look . SW,ShinIS,HongYJ,KimJH,AhnY,JeongMH,YoonJS.EffectofEscitalopram
.
AHEAD)ClinicalTrial.DiabetesCare2016;39:1345(cid:2)1355. . vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in
.
452. Howell S, Kones R. "Calories in, calories out" and macronutrient intake: the .. PatientsWithAcuteCoronarySyndrome:ARandomizedClinicalTrial.JAMA
hope, hype, and science of calories. Am J Physiol Endocrinol Metab .. 2018;320:350(cid:2)358.
.
2017;313:E608(cid:2)E612. . 472.HeW,ZhouY,MaJ,WeiB,FuY.Effectofantidepressantsondeathinpatients
.
453. Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL, Svendrovski A, . with heart failure: a systematic review and meta-analysis. Heart Fail Rev
.
KiflenR,QuadriK,KwonHY,KaramouzianM,Adams-WebberT,AhmedW, .. 2020;25:919(cid:2)926.
DamanhouryS,Zeraatkar D,NikolakopoulouA,TsuyukiRT,TianJ,YangK, .. 473.Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R,
.
GuyattGH,JohnstonBC.Comparisonofdietarymacronutrientpatternsof14 . Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, .
popularnameddietaryprogrammesforweight andcardiovascularriskfactor .. PrettinC,GottwikM,BohmM,FallerH,DeckertJ,ErtlG,MOOD-HFStudy
reductioninadults:systematicreviewandnetworkmeta-analysisofrandomised .. Investigators and Committee Members. Effect of Escitalopram on All-Cause
.
trials.BMJ2020;369:m696. . Mortality and Hospitalization in Patients With Heart Failure and Depression:
.
454. TobiasDK,ChenM,MansonJE,LudwigDS,WillettW,HuFB.Effectoflow-fat . TheMOOD-HFRandomizedClinicalTrial.JAMA2016;315:2683(cid:2)2693.
.
dietinterventionsversusotherdietinterventionsonlong-termweightchange .. 474.Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P.
in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol .. Changeinmentalhealthaftersmokingcessation:systematicreviewandmeta-
.
2015;3:968(cid:2)979. . analysis.BMJ2014;348:g1151.
.
455. CardosoL,RodriguesD,GomesL,CarrilhoF.Short-andlong-termmortality . 475.ProchaskaJJ,HallSE,DelucchiK,HallSM.Efficacyofinitiatingtobaccodepend-
. after bariatric surgery: A systematic review and meta-analysis. Diabetes Obes .. encetreatmentininpatientpsychiatry:arandomizedcontrolledtrial.AmJPublic
.
Metab2017;19:1223(cid:2)1232. . Health2014;104:1557(cid:2)1565.
.
456. Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, Sharma P, . 476.CooneyGM,DwanK,GreigCA,LawlorDA,RimerJ,WaughFR,McMurdoM,
.
FraserC,MacLennanG.Effectsofweightlossinterventionsforadultswhoare .. MeadGE.Exercisefordepression.CochraneDatabaseSystRev2013:CD004366.
obeseonmortality,cardiovasculardisease,andcancer:systematicreviewand .. 477.OpieRS,ItsiopoulosC,ParlettaN,Sanchez-VillegasA,AkbaralyTN,Ruusunen
.
meta-analysis.BMJ2017;359:j4849. . A,JackaFN.Dietaryrecommendationsforthepreventionofdepression.Nutr
.
457. Mancini JG, Filion KB, Atallah R, Eisenberg MJ. Systematic Review of the . Neurosci2017;20:161(cid:2)171.
.
MediterraneanDietforLong-TermWeightLoss.AmJMed2016;129:407(cid:2)415 .. 478.PalmerVJ,LewisM,StylianopolousV,FurlerJ.Primarycarepreventionofthe
e404. .. cardiovascular health crisis for people with severe mental illnesses: The ele-
.
458.SofiF,DinuM,PagliaiG,CesariF,GoriAM,SereniA,BecattiM,FiorilloC,Marcucci . phantintheroom.AustJGenPract2018;47:846(cid:2)850.
.
R,CasiniA.Low-CalorieVegetarianVersusMediterraneanDietsforReducingBody .. 479.Druss BG, von Esenwein SA, Compton MT, Rask KJ, Zhao L, Parker RM. A
Weight and Improving Cardiovascular Risk Profile: CARDIVEG Study .. randomizedtrialofmedicalcaremanagementforcommunitymentalhealthset-
.
(CardiovascularPreventionWithVegetarianDiet).Circulation2018;137:1103(cid:2)1113. . tings:thePrimaryCareAccess,Referral,andEvaluation(PCARE)study.AmJ
.
459. Huang RY, Huang CC, Hu FB, Chavarro JE. Vegetarian Diets and Weight . Psychiatry2010;167:151(cid:2)159.
.
Reduction:aMeta-AnalysisofRandomizedControlledTrials.JGenInternMed .. 480.Osborn D, Burton A, Walters K, Atkins L, Barnes T, Blackburn R, Craig T,
2016;31:109(cid:2)116. . GilbertH,GrayB,HardoonS,HeinkelS,HoltR,HunterR,JohnstonC,King
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 100 ---
3326 ESCGuidelines
.
.
M,LeibowitzJ,MarstonL,MichieS,MorrisR,MorrisS,NazarethI,OmarR, . Varenicline for Smoking Cessation in Hospitalized Patients With Acute
.
PetersenI,PevelerR,PinfoldV,StevensonF,ZomerE.Primarycaremanagement . CoronarySyndrome.Circulation2016;133:21(cid:2)30.
.
ofcardiovascularriskforpeoplewithseverementalillnesses:thePrimroseresearch .. 501.Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D,
programmeincludingclusterRCT.Southampton(UK);2019. .. AscherJ,RussC,KrishenA,EvinsAE.Neuropsychiatricsafetyandefficacyof
.
481. SeldenrijkA,VogelzangsN,BatelaanNM,WiemanI,vanSchaikDJ,PenninxBJ. . varenicline,bupropion,andnicotinepatchinsmokerswithandwithoutpsychi-
.
Depression,anxietyand6-yearriskofcardiovasculardisease.JPsychosomRes .. atricdisorders(EAGLES):adouble-blind,randomised,placebo-controlledclini-
2015;78:123(cid:2)129. .. caltrial.Lancet2016;387:2507(cid:2)2520.
.
482. Gilsanz P,KubzanskyLD, TchetgenTchetgenEJ, WangQ, KawachiI,Patton . 502.BenowitzNL,PipeA,WestR,HaysJT,TonstadS,McRaeT,LawrenceD,St
.
KK, Fitzpatrick AL, Kop WJ, Longstreth WT, Jr., Glymour MM. Changes in . AubinL,AnthenelliRM.CardiovascularSafetyofVarenicline,Bupropion,and
.
Depressive Symptoms and Subsequent Risk of Stroke in the Cardiovascular .. Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med
HealthStudy.Stroke2017;48:43(cid:2)48. .. 2018;178:622(cid:2)631.
.
483. SmolderenKG,BuchananDM,GoschK,WhooleyM,ChanPS,VaccarinoV, . 503.Hartmann-BoyceJ,McRobbieH,LindsonN,BullenC,BeghR,TheodoulouA,
.
Parashar S, Shah AJ, Ho PM, Spertus JA. Depression Treatment and 1-Year . NotleyC,RigottiNA,TurnerT,ButlerAR,HajekP.Electroniccigarettesfor
.
Mortality After Acute Myocardial Infarction: Insights From the TRIUMPH .. smokingcessation.CochraneDatabaseSystRev2020;10:CD010216.
.
Registry (Translational Research Investigating Underlying Disparities in Acute . 504.Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, Li J,
.
MyocardialInfarctionPatients’HealthStatus).Circulation2017;135:1681(cid:2)1689. . ParrottS,SasieniP,DawkinsL,RossL,GoniewiczM,WuQ,McRobbieHJ.A
.
484. SmolderenKG,SpertusJA,GoschK,DreyerRP,D’OnofrioG,LichtmanJH, .. Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N
GedaM,BeltrameJ,SafdarB,BuenoH,KrumholzHM.DepressionTreatment .. EnglJMed2019;380:629(cid:2)637.
.
and Health Status Outcomes in Young Patients With Acute Myocardial . 505.LiJ,HajekP,PesolaF,WuQ,Phillips-WallerA,PrzuljD,MyersSmithK,Bisal
.
Infarction: Insights From the VIRGO Study (Variation in Recovery: Role of . N,SasieniP,DawkinsL,RossL,GoniewiczML,McRobbieH,ParrottS.Cost-
.
Gender on Outcomes of Young AMI Patients). Circulation .. effectiveness of e-cigarettes compared with nicotine replacement therapy in
2017;135:1762(cid:2)1764. .. stopsmokingservices inEngland(TECstudy):arandomized controlled trial.
.
485. TullyPJ,BaumeisterH.Collaborativecareforcomorbiddepressionandcoro- . Addiction2020;115:507(cid:2)517.
. naryheartdisease:asystematicreviewandmeta-analysisofrandomisedcon- .. 506.KavousiM,PisingerC,BarthelemyJC,SmedtD,KoskinasK,Marques-VidalP,
trolledtrials.BMJOpen2015;5:e009128. .. PanagiotakosD,PrescottEB,TiberiM,VassiliouVS,LochenML.Electronicciga-
. 486. Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M, . rettesandhealthwithspecialfocusoncardiovasculareffects:positionpaperof
.
KortelainenML,HuikuriHV.Psychotropicmedicationsandtheriskofsudden . theEuropeanAssociationofPreventiveCardiology(EAPC).EurJPrevCardiol
.
cardiacdeathduringanacutecoronaryevent.EurHeartJ2012;33:745(cid:2)751. .. 2020:2047487320941993.
487. CritchleyJA,CapewellS.Mortalityriskreductionassociatedwithsmokingces- .. 507.EuropeanHeartNetwork.Electroniccigarettesandcardiovasculardisease (cid:2)
.
sation in patients with coronary heart disease: a systematic review. JAMA . an update from the European Heart Network http://www.ehnheart.org/compo
.
2003;290:86(cid:2)97. . nent/attachments/attachments.html?task=attachment&id=3093(21July2020).
.
488.AnthonisenNR,SkeansMA,WiseRA,ManfredaJ,KannerRE,ConnettJE,Lung .. 508.AmarencoP,KimJS,LabreucheJ,CharlesH,AbtanJ,BejotY,CabrejoL,Cha
.
HealthStudyResearchGroup.Theeffectsofasmokingcessationinterventionon . JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B,
.
14.5-yearmortality:arandomizedclinicaltrial.AnnInternMed2005;142:233(cid:2)239. . LavalleePC,LeeBC,LeeKB,LeysD,MahagneMH,MeseguerE,Nighoghossian
.
489. Hartmann-BoyceJ,ChepkinSC,YeW,BullenC,LancasterT.Nicotinereplace- .. N,PicoF,SamsonY,SibonI,StegPG,SungSM,TouboulPJ,TouzeE,Varenne
menttherapyversuscontrolforsmokingcessation.CochraneDatabaseSystRev .. O, Vicaut E, Yelles N, Bruckert E, Treat Stroke to Target Investigators. A
.
2018;5:CD000146. . ComparisonofTwoLDLCholesterolTargetsafterIschemicStroke.NEnglJ
.
490. HughesJR, Stead LF, Lancaster T. Antidepressants for smoking cessation. . Med2020;382:9.
.
CochraneDatabaseSystRev2007:CD000031. .. 509.ChapmanMJ,GinsbergHN,AmarencoP,AndreottiF,BorenJ,CatapanoAL,
491. CahillK,Lindson-HawleyN,ThomasKH,FanshaweTR,LancasterT.Nicotine .. Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L,
.
receptor partial agonists for smoking cessation. Cochrane Database Syst Rev . Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-
.
2016:CD006103. .. Hansen A, Watts GF, European Atherosclerosis Society Consensus Panel.
492. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. .. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in
.
Differentdoses,durationsandmodesofdeliveryofnicotinereplacementther- . patientsathighriskofcardiovasculardisease:evidenceandguidanceforman-
.
apyforsmokingcessation.CochraneDatabaseSystRev2019;4:CD013308. . agement.EurHeartJ2011;32:1345(cid:2)1361.
.
493. WoolfKJ,ZabadMN,PostJM,McNittS,WilliamsGC,BisognanoJD.Effectof .. 510.Cartier LJ, Collins C, Lagace M, Douville P. Comparison of fasting and non-
nicotinereplacementtherapyoncardiovascularoutcomesafteracutecoronary .. fastinglipidprofilesinalargecohortofpatientspresentingatacommunityhos-
.
syndromes.AmJCardiol2012;110:968(cid:2)970. . pital.ClinBiochem2018;52:61(cid:2)66.
.
494. Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, Joseph L, . 511.SampsonM,LingC,SunQ,HarbR,AshmaigM,WarnickR,SethiA,Fleming
.
ReynierPM,FilionKB.EfficacyandSafetyofSmokingCessationInterventionsin .. JK, Otvos JD, Meeusen JW, Delaney SR, Jaffe AS, Shamburek R, Amar M,
Patients With Cardiovascular Disease: A Network Meta-Analysis of .. Remaley AT. A New Equation for Calculation of Low-Density Lipoprotein
.
RandomizedControlledTrials.CircCardiovascQualOutcomes2017;10:e002458. . Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. .
495. HuY,ZongG,LiuG,WangM,RosnerB,PanA,WillettWC,MansonJE,Hu .. JAMACardiol2020;5:540(cid:2)548.
FB,SunQ.SmokingCessation,WeightChange,Type2Diabetes,andMortality. .. 512.PensonP,MartinSS,HenneyNC,BanachM.ComparisonofLDL-Ccalculation
.
NEnglJMed2018;379:623(cid:2)632. . by friedewald and martin/hopkins methods in 12,243 adults from the United
.
496.MonsU,MuezzinlerA,GellertC,SchottkerB,AbnetCC,BobakM,deGrootL, . StatesofAmerica[abstract].EurHeartJ2020;41(Suppl2):2932.
.
Freedman ND, Jansen E, Kee F, Kromhout D, Kuulasmaa K, Laatikainen T, .. 513.BoekholdtSM,ArsenaultBJ,MoraS,PedersenTR,LaRosaJC,NestelPJ,Simes
O’DohertyMG,Bueno-de-MesquitaB,OrfanosP,PetersA,vanderSchouwYT, .. RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH,
.
Wilsgaard T, Wolk A, Trichopoulou A, Boffetta P, Brenner H, CHANCES . ClearfieldMB,DownsJR,TonkinAM,ColhounHM,GottoAM,Jr.,RidkerPM,
.
Consortium.Impactofsmokingandsmokingcessationoncardiovasculareventsand . KasteleinJJ.AssociationofLDLcholesterol,non-HDLcholesterol,andapolipo-
. mortalityamongolderadults:meta-analysisofindividualparticipantdatafrompro- .. proteinBlevelswithriskofcardiovasculareventsamongpatientstreatedwith
.
spectivecohortstudiesoftheCHANCESconsortium.BMJ2015;350:h1551. . statins:ameta-analysis.JAMA2012;307:1302(cid:2)1309.
.
497. Gellert C, Schottker B, Brenner H. Smoking and all-cause mortality in older . 514.WelshC,Celis-MoralesCA,BrownR,MackayDF,LewseyJ,MarkPB,GraySR,
.
people: systematic review and meta-analysis. Arch Intern Med .. Ferguson LD, Anderson JJ, Lyall DM, Cleland JG, Jhund PS, Gill JMR, Pell JP,
2012;172:837(cid:2)844. .. Sattar N, Welsh P. Comparison of Conventional Lipoprotein Tests and
.
498. PruggerC,WellmannJ,HeidrichJ,DeBacquerD,DeBackerG,PerierMC, . Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation
.
Empana JP, Reiner Z, Fras Z, Jennings C, Kotseva K, Wood D, Keil U, . 2019;140:542(cid:2)552.
.
EUROASPIREStudyGroup.Readinessforsmokingcessationincoronaryheart .. 515.CannonCP,BlazingMA,GiuglianoRP,McCaggA,WhiteJA,TherouxP,Darius
diseasepatientsacrossEurope:ResultsfromtheEUROASPIREIIIsurvey.EurJ .. H,LewisBS,OphuisTO,JukemaJW,DeFerrariGM,RuzylloW,DeLuccaP,Im
.
PrevCardiol2015;22:1212(cid:2)1219. . K,BohulaEA,ReistC,WiviottSD,TershakovecAM,MuslinerTA,BraunwaldE,
.
499. Hartmann-BoyceJ,SteadLF,CahillK,LancasterT.Efficacyofinterventionsto .. Califf RM, IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after
combat tobacco addiction: Cochrane update of 2013 reviews. Addiction .. AcuteCoronarySyndromes.NEnglJMed2015;372:2387(cid:2)2397.
.
2014;109:1414(cid:2)1425. . 516.SabatineMS,GiuglianoRP,KeechAC,HonarpourN,WiviottSD,MurphySA,
.
500. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A, . KuderJF,WangH,LiuT,WassermanSM,SeverPS,PedersenTR,FOURIER
.
LauzonC,SrivastavaN,ClarkeA,CassavarD,DionD,HaughtH,MehtaSR, .. SteeringCommittee andInvestigators.EvolocumabandClinical Outcomesin
BarilJF,LambertC,MadanM,AbramsonBL,DehghaniP,EVITAInvestigators. . PatientswithCardiovascularDisease.NEnglJMed2017;376:1713(cid:2)1722.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 101 ---
ESCGuidelines 3327
.
.
517. SchwartzGG,StegPG,SzarekM,BhattDL,BittnerVA,DiazR,EdelbergJM, . 530.Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA,
.
Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey . RichardsonT,JarosM,WijngaardPLJ,KasteleinJJP,ORION-10andORION-11
.
KW,MoryusefA,PordyR,QuinteroK,RoeMT,SasielaWJ,TambyJF,Tricoci .. Investigators. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL
P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and .. Cholesterol.NEnglJMed2020;382:1507(cid:2)1519.
.
Investigators.AlirocumabandCardiovascularOutcomesafterAcuteCoronary . 531.Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors
.
Syndrome.NEnglJMed2018;379:2097(cid:2)2107. .. Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di
518. RidkerPM,RoseLM,KasteleinJJP,SantosRD,WeiC,RevkinJ,YunisC,Tardif .. AngelantonioE,BoekholdtSM,OuwehandW,WatkinsH,SamaniNJ,Saleheen
.
JC,ShearCL,StudiesofPCSK9InhibitionandtheReductionofvascularEvents . D,LawlorD,ReillyMP,HingoraniAD,TalmudPJ,DaneshJ.Triglyceride-medi-
.
(SPIRE) Investigators. Cardiovascular event reduction with PCSK9 inhibition . ated pathways and coronary disease: collaborative analysis of 101 studies.
.
among1578patientswithfamilialhypercholesterolemia:ResultsfromtheSPIRE .. Lancet2010;375:1634(cid:2)1639.
randomizedtrialsofbococizumab.JClinLipidol2018;12:958(cid:2)965. .. 532.CiceroAFG,CollettiA,BajraktariG,DescampsO,DjuricDM,EzhovM,Fras
.
519. MozaffarianD.Naturaltransfat,dairyfat,partiallyhydrogenatedoils,andcardi- . Z,KatsikiN,LangloisM,LatkovskisG,PanagiotakosDB,ParaghG,Mikhailidis
.
ometabolichealth:theLudwigshafenRiskandCardiovascularHealthStudy.Eur . DP,MitchenkoO,PaulweberB,PellaD,PitsavosC,ReinerZ,RayKK,Rizzo
.
HeartJ2016;37:1079(cid:2)1081. .. M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablik M,
.
520. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de . WongND,BanachM.Lipid-loweringnutraceuticalsinclinicalpractice:posi-
.
Craen AJ, Knopp RH,NakamuraH,RidkerP,van DomburgR, Deckers JW. . tion paper from an International Lipid Expert Panel. Nutr Rev
.
Thebenefitsofstatinsinpeoplewithoutestablishedcardiovasculardiseasebut .. 2017;75:731(cid:2)767.
withcardiovascularriskfactors:meta-analysisofrandomisedcontrolledtrials. .. 533.Vallejo-VazAJ,FayyadR,BoekholdtSM,HovinghGK,KasteleinJJ,MelamedS,
.
BMJ2009;338:b2376. . BarterP,WatersDD,RayKK.Triglyceride-RichLipoproteinCholesteroland
.
521. MillsEJ,RachlisB,WuP,DevereauxPJ,AroraP,PerriD.Primarypreventionof . RiskofCardiovascularEventsAmongPatientsReceivingStatinTherapyinthe
.
cardiovascular mortality and events with statin treatments: a network meta- .. TNTTrial.Circulation2018;138:770(cid:2)781.
analysis involving more than 65,000 patients. J Am Coll Cardiol .. 534.ChapmanMJ,RedfernJS,McGovernME,GiralP.Niacinandfibratesinathero-
.
2008;52:1769(cid:2)1781. . genic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol
. 522. CholesterolTreatmentTrialists’(CTT)Collaboration,FulcherJ,O’ConnellR, .. Ther2010;126:314(cid:2)345.
VoyseyM,EmbersonJ,BlackwellL,MihaylovaB,SimesJ,CollinsR,KirbyA, .. 535.ACCORDStudyGroup,GinsbergHN,ElamMB,LovatoLC,CrouseJR,3rd,
. ColhounH,BraunwaldE,LaRosaJ,PedersenTR,TonkinA,DavisB,SleightP, . LeiterLA,LinzP,FriedewaldWT,BuseJB,GersteinHC,ProbstfieldJ,Grimm
.
FranzosiMG,BaigentC,KeechA.EfficacyandsafetyofLDL-loweringtherapy . RH,Ismail-BeigiF,BiggerJT,GoffDC,Jr.,CushmanWC,Simons-MortonDG,
.
amongmenandwomen:meta-analysisofindividualdatafrom174,000partici- .. ByingtonRP.Effectsofcombinationlipidtherapyintype2diabetesmellitus.N
pantsin27randomisedtrials.Lancet2015;385:1397(cid:2)1405. .. EnglJMed2010;362:1563(cid:2)1574.
.
523. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, . 536.KeechA,SimesRJ,BarterP,BestJ,ScottR,TaskinenMR,ForderP,PillaiA,
.
BruckertE,JacobsonTA,KopeckySL,Baccara-DinetMT,DuY,PordyR,Gipe . Davis T, Glasziou P,DruryP, Kesaniemi YA, Sullivan D, Hunt D, Colman P,
.
DA,ODYSSEYALTERNATIVEInvestigators.Efficacyandsafetyofalirocumab .. d’Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators.
.
vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The . Effectsoflong-termfenofibratetherapyoncardiovasculareventsin9795peo-
.
ODYSSEYALTERNATIVErandomizedtrial.JClinLipidol2015;9:758(cid:2)769. . plewithtype2diabetesmellitus(theFIELDstudy):randomisedcontrolledtrial.
.
524. NissenSE,StroesE,Dent-AcostaRE,RosensonRS,LehmanSJ,SattarN,Preiss .. Lancet2005;366:1849(cid:2)1861.
D,BruckertE,CeskaR,LeporN,BallantyneCM,Gouni-BertholdI,ElliottM, .. 537.MortensenMB,NordestgaardBG.ElevatedLDLcholesterolandincreasedrisk
.
Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, GAUSS-3 . ofmyocardialinfarctionandatheroscleroticcardiovasculardiseaseinindividuals
.
Investigators.EfficacyandTolerabilityofEvolocumabvsEzetimibeinPatients . aged 70-100 years: a contemporary primary prevention cohort. Lancet
.
With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical .. 2020;396:1644(cid:2)1652.
Trial.JAMA2016;315:1580(cid:2)1590. .. 538.Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin
.
525. BaigentC,LandrayMJ,ReithC,EmbersonJ,WheelerDC,TomsonC,Wanner . therapyinolderpeople:ameta-analysisofindividualparticipantdatafrom28
.
C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, .. randomisedcontrolledtrials.Lancet2019;393:407(cid:2)415.
GazianoM,KasiskeB,WalkerR,MassyZA,Feldt-RasmussenB,KrairittichaiU, .. 539.Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E,
.
OphascharoensukV,FellstromB,HoldaasH,TesarV,WiecekA,GrobbeeD, . GiuglianoRP,SabatineMS.EfficacyandsafetyofloweringLDLcholesterolin
.
de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, . olderpatients:asystematicreviewandmeta-analysisofrandomisedcontrolled
.
Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, .. trials.Lancet2020;396:1637(cid:2)1643.
Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, .. 540.CholesterolTreatmentTrialists’(CTT)Collaborators,KearneyPM,BlackwellL,
.
SimpsonD,SleightP,YoungA,CollinsR,SHARPInvestigators.Theeffectsof . Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of
.
lowering LDL cholesterol with simvastatin plus ezetimibe in patients with . cholesterol-loweringtherapyin18,686peoplewithdiabetesin14randomised
.
chronic kidney disease (Study of Heart and Renal Protection): a randomised .. trialsofstatins:ameta-analysis.Lancet2008;371:117(cid:2)125.
placebo-controlledtrial.Lancet2011;377:2181(cid:2)2192. .. 541.EmergingRiskFactorsCollaboration,DiAngelantonioE,KaptogeS,Wormser
.
526. SchremlJ,Gouni-BertholdI.RoleofAnti-PCSK9AntibodiesintheTreatment . D, Willeit P, Butterworth AS, Bansal N, O’Keeffe LM, Gao P, Wood AM, .
ofPatientswithStatinIntolerance.CurrMedChem2018;25:1538(cid:2)1548. .. BurgessS,FreitagDF,PennellsL,PetersSA,HartCL,HaheimLL,GillumRF,
527. CollinsR,ReithC,EmbersonJ,ArmitageJ,BaigentC,BlackwellL,Blumenthal .. NordestgaardBG,PsatyBM,YeapBB,KnuimanMW,NietertPJ,KauhanenJ,
.
R,DaneshJ,Smith GD,DeMets D,Evans S,Law M,MacMahon S,Martin S, . Salonen JT, Kuller LH, Simons LA, van der Schouw YT, Barrett-Connor E,
.
Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, . SelmerR,CrespoCJ,RodriguezB,VerschurenWM,SalomaaV,SvardsuddK,
.
SchulzK,SeverP,SimesJ,SmeethL,WaldN,YusufS,PetoR.Interpretationof .. van der Harst P, Bjorkelund C, Wilhelmsen L, Wallace RB, Brenner H,
the evidence for the efficacy and safety of statin therapy. Lancet .. AmouyelP,BarrEL,IsoH,OnatA,TrevisanM,D’AgostinoRB,Sr.,CooperC,
.
2016;388:2532(cid:2)2561. . Kavousi M, Welin L, Roussel R, Hu FB, Sato S, Davidson KW, Howard BV,
.
528. Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won . LeeningMJ,LeeningM,RosengrenA,DorrM,DeegDJ,KiechlS,Stehouwer
. HH,MorrisonAC,PelosoGM,DoR,LangeLA,FontanillasP,GuptaN,Duga .. CD,NissinenA,GiampaoliS,DonfrancescoC,KromhoutD,PriceJF,PetersA,
.
S, Goel A, Farrall M, Saleheen D, Ferrario P, Konig I, Asselta R, Merlini PA, . MeadeTW,CasigliaE,LawlorDA,GallacherJ,NagelD,FrancoOH,Assmann
.
Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, . G,DagenaisGR,JukemaJW,SundstromJ,WoodwardM,BrunnerEJ,KhawKT,
.
WilenskyR,RaderDJ,HovinghGK,MeitingerT,KesslerT,KastratiA,Laugwitz .. Wareham NJ, Whitsel EA, Njolstad I, Hedblad B, Wassertheil-Smoller S,
KL,SiscovickD,RotterJI,HazenSL,TracyR,CresciS,SpertusJ,JacksonR, .. Engstrom G, Rosamond WD, Selvin E, Sattar N, Thompson SG, Danesh J.
.
SchwartzSM,NatarajanP,CrosbyJ,MuznyD,BallantyneC,RichSS,O’Donnell . Association of Cardiometabolic Multimorbidity With Mortality. JAMA
.
CJ,AbecasisG,SunaevS,NickersonDA,BuringJE,RidkerPM,ChasmanDI, . 2015;314:52(cid:2)60.
.
AustinE,KulloIJ,WeekePE,ShafferCM,BastaracheLA,DennyJC,RodenDM, .. 542.GiuglianoRP,CannonCP,BlazingMA,NicolauJC,CorbalanR,SpinarJ,Park
PalmerC,DeloukasP,LinDY,TangZZ,ErdmannJ,SchunkertH,DaneshJ, .. JG,WhiteJA,BohulaEA,BraunwaldE,IMPROVE-IT(ImprovedReductionof
.
MarrugatJ,ElosuaR,ArdissinoD,McPhersonR,WatkinsH,ReinerAP,Wilson . Outcomes:VytorinEfficacyInternationalTrial)Investigators.BenefitofAdding
.
JG,AltshulerD,GibbsRA,LanderES,BoerwinkleE,GabrielS,KathiresanS. .. EzetimibetoStatinTherapyonCardiovascularOutcomesandSafetyinPatients
InactivatingmutationsinNPC1L1andprotectionfromcoronaryheartdisease. .. WithVersusWithoutDiabetesMellitus:ResultsFromIMPROVE-IT(Improved
.
NEnglJMed2014;371:2072(cid:2)2082. . Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation
.
529. ChoL,RoccoM,ColquhounD,SullivanD,RosensonRS,DentR,XueA,Scott . 2018;137:1571(cid:2)1582.
.
R,WassermanSM,StroesE.ClinicalProfileofStatinIntoleranceinthePhase3 .. 543.Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid
GAUSS-2Study.CardiovascDrugsTher2016;30:297(cid:2)304. . Guideline Development Work Group Members. KDIGO Clinical Practice
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 102 ---
3328 ESCGuidelines
.
.
GuidelineforLipidManagementinCKD:summaryofrecommendationstate- . 558.ThomopoulosC,ParatiG,ZanchettiA.Effectsofbloodpressureloweringon
.
mentsandclinicalapproachtothepatient.KidneyInt2014;85:1303(cid:2)1309. . outcomeincidenceinhypertension:7.Effectsofmorevs.lessintensiveblood
.
544. Cholesterol Treatment Trialists’ (CTT) Collaboration, Herrington WG, .. pressureloweringanddifferentachievedbloodpressurelevels-updatedover-
EmbersonJ,MihaylovaB,BlackwellL,ReithC,SolbuMD,MarkPB,FellstromB, .. viewandmeta-analysesofrandomizedtrials.JHypertens2016;34:613(cid:2)622.
.
JardineAG,WannerC,HoldaasH,FulcherJ,HaynesR,LandrayMJ,KeechA, . 559.ACCORDStudyGroup,CushmanWC,EvansGW,ByingtonRP,GoffDC,Jr.,
.
SimesJ,CollinsR,BaigentC.ImpactofrenalfunctionontheeffectsofLDL .. Grimm RH, Jr., Cutler JA, Simons-Morton DG, Basile JN, Corson MA,
cholesterol lowering with statin-based regimens: a meta-analysis of individual .. Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT,
.
participant data from 28 randomised trials. Lancet Diabetes Endocrinol . GersteinHC,Ismail-BeigiF.Effectsofintensiveblood-pressurecontrolintype
.
2016;4:829(cid:2)839. . 2diabetesmellitus.NEnglJMed2010;362:1575(cid:2)1585.
.
545. BarylskiM,NikfarS,MikhailidisDP,TothPP,SalariP,RayKK,PencinaMJ,Rizzo .. 560.WaldDS,LawM,MorrisJK,BestwickJP,WaldNJ.Combinationtherapyversus
M,RyszJ,AbdollahiM,NichollsSJ,BanachM,LipidandBloodPressureMeta- .. monotherapyinreducingbloodpressure:meta-analysison11,000participants
.
AnalysisCollaborationGroup.Statinsdecreaseall-causemortalityonlyinCKD . from42trials.AmJMed2009;122:290(cid:2)300.
.
patientsnotrequiringdialysistherapy–ameta-analysisof11randomizedcon- . 561.Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg
.
trolledtrialsinvolving21,295participants.PharmacolRes2013;72:35(cid:2)44. .. KS.Initialmonotherapyandcombinationtherapyandhypertensioncontrolthe
.
546. WannerC,KraneV,MarzW,OlschewskiM,MannJF,RufG,RitzE,German . firstyear.Hypertension2012;59:1124(cid:2)1131.
.
DiabetesandDialysisStudyInvestigators.Atorvastatininpatientswithtype2 . 562.ReaF,CorraoG,MerlinoL,ManciaG.Earlycardiovascularprotectionbyinitial
.
diabetesmellitusundergoinghemodialysis.NEnglJMed2005;353:238(cid:2)248. .. two-drugfixed-dosecombinationtreatmentvs.monotherapyinhypertension.
547. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, .. EurHeartJ2018;39:3654(cid:2)3661.
.
Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, . 563.SalamA,KanukulaR,AtkinsE,WangX,IslamS,KishoreSP,JaffeMG,PatelA,
.
MayerG,McMahonAW,ParvingHH,RemuzziG,SamuelssonO,SonkodiS, . RodgersA.Efficacyandsafetyofdualcombinationtherapyofbloodpressure-
.
SciD,SuleymanlarG,TsakirisD,TesarV,TodorovV,WiecekA,WuthrichRP, .. loweringdrugs as initialtreatment forhypertension:asystematicreview and
GottlowM,JohnssonE,ZannadF,AURORAStudyGroup.Rosuvastatinand .. meta-analysisofrandomizedcontrolledtrials.JHypertens2019;37:1768(cid:2)1774.
.
cardiovascular events in patients undergoing hemodialysis. N Engl J Med . 564.GuptaP,PatelP,StrauchB,LaiFY,AkbarovA,GulsinGS,BeechA,Maresova
. 2009;360:1395(cid:2)1407. .. V,TophamPS,StanleyA,ThurstonH,SmithPR,HorneR,WidimskyJ,Keavney
548. OkinPM,DevereuxRB,JernS,KjeldsenSE,JuliusS,NieminenMS,SnapinnS, .. B,HeagertyA,SamaniNJ,WilliamsB,TomaszewskiM.BiochemicalScreening
. HarrisKE,AurupP,EdelmanJM,WedelH,LindholmLH,DahlofB,LIFEStudy . for Nonadherence Is Associated With Blood Pressure Reduction and
.
Investigators. Regression of electrocardiographic left ventricular hypertrophy . ImprovementinAdherence.Hypertension2017;70:1042(cid:2)1048.
.
duringantihypertensive treatmentandthepredictionof majorcardiovascular .. 565.MacDonaldTM,WilliamsB,WebbDJ,MorantS,CaulfieldM,CruickshankJK,
events.JAMA2004;292:2343(cid:2)2349. .. FordI,SeverP,MackenzieIS,PadmanabhanS,McCannGP,SalsburyJ,McInnes
.
549. SehestedtT,JeppesenJ,HansenTW,WachtellK,IbsenH,Torp-PedersenC, . G, Brown MJ, British Hypertension Society Programme of Prevention And
.
Hildebrandt P, Olsen MH. Risk prediction is improved by adding markers of . Treatment of Hypertension With Algorithm-based Therapy (PATHWAY).
.
subclinicalorgandamagetoSCORE.EurHeartJ2010;31:883(cid:2)891. .. Combination Therapy Is Superior to Sequential Monotherapy for the Initial
.
550. Perrone-FilardiP,CocaA,GalderisiM,PaolilloS,AlpenduradaF,deSimoneG, . Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. J
.
DonalE,KahanT,ManciaG,RedonJ,SchmiederR,WilliamsB,Agabiti-RoseiE. . AmHeartAssoc2017;6:e006986.
.
Non-invasivecardiovascularimagingforevaluatingsubclinicaltargetorgandam- .. 566.DahlofB,SeverPS,PoulterNR,WedelH,BeeversDG,CaulfieldM,CollinsR,
ageinhypertensivepatients:AconsensuspaperfromtheEuropeanAssociation .. Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E,
.
of Cardiovascular Imaging (EACVI), the European Society of Cardiology . OstergrenJ,ASCOTInvestigators.Preventionofcardiovasculareventswithan
.
Council on Hypertension, and the European Society of Hypertension (ESH). . antihypertensiveregimenofamlodipineaddingperindoprilasrequiredversus
.
EurHeartJCardiovascImaging2017;18:945(cid:2)960. .. atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian
551. NinomiyaT,PerkovicV,deGalanBE,ZoungasS,PillaiA,JardineM,PatelA, .. CardiacOutcomesTrial-BloodPressureLoweringArm(ASCOT-BPLA):amul-
.
CassA, NealB, Poulter N, MogensenCE,CooperM,MarreM,WilliamsB, . ticentrerandomisedcontrolledtrial.Lancet2005;366:895(cid:2)906.
.
Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE .. 567.JamersonK,WeberMA,BakrisGL,DahlofB,PittB,ShiV,HesterA,GupteJ,
Collaborative Group. Albuminuria and kidney function independently predict .. GatlinM,VelazquezEJ,ACCOMPLISHTrialInvestigators.Benazeprilplusamlo-
.
cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol . dipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J
.
2009;20:1813(cid:2)1821. . Med2008;359:2417(cid:2)2428.
.
552. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, .. 568.YusufS,LonnE,PaisP,BoschJ,Lopez-JaramilloP,ZhuJ,XavierD,AvezumA,
ChalmersJ,RodgersA,RahimiK.Bloodpressureloweringforpreventionof .. LeiterLA,PiegasLS,ParkhomenkoA,KeltaiM,KeltaiK,SliwaK,ChazovaI,
.
cardiovasculardiseaseanddeath:asystematicreviewandmeta-analysis.Lancet . PetersRJ,HeldC,YusoffK,LewisBS,JanskyP,KhuntiK,ToffWD,ReidCM,
.
2016;387:957(cid:2)967. . Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A,
.
553. SundstromJ,ArimaH,JacksonR,TurnbullF,RahimiK,ChalmersJ,Woodward .. DagenaisG,HOPE-3Investigators.Blood-PressureandCholesterolLowering
M,NealB,BloodPressureLoweringTreatmentTrialists’Collaboration.Effects .. inPersonswithoutCardiovascularDisease.NEnglJMed2016;374:2032(cid:2)2043.
.
of blood pressure reduction in mild hypertension: a systematic review and . 569.MatsuzakiM,OgiharaT,UmemotoS,RakugiH,MatsuokaH,ShimadaK,Abe .
meta-analysis.AnnInternMed2015;162:184(cid:2)191. .. K,SuzukiN,EtoT,HigakiJ,ItoS,KamiyaA,KikuchiK,SuzukiH,TeiC,Ohashi
554. ThomopoulosC,ParatiG,ZanchettiA.Effectsofbloodpressureloweringon .. Y,SarutaT,CombinationTherapyofHypertensiontoPreventCardiovascular
.
outcome incidence in hypertension. 1. Overview, meta-analyses, and meta- . EventsTrialGroup.Preventionofcardiovasculareventswithcalciumchannel
.
regressionanalysesofrandomizedtrials.JHypertens2014;32:2285(cid:2)2295. . blocker-basedcombinationtherapiesinpatientswithhypertension:arandom-
.
555. SPRINTResearchGroup,WrightJT,Jr.,WilliamsonJD,WheltonPK,SnyderJK, .. izedcontrolledtrial.JHypertens2011;29:1649(cid:2)1659.
SinkKM,RoccoMV,ReboussinDM,RahmanM,OparilS,LewisCE,Kimmel .. 570.Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ, 3rd, Graff A, Shojaee A,
.
PL,JohnsonKC,GoffDC,Jr.,FineLJ,CutlerJA,CushmanWC,CheungAK, . WaverczakWF,QianC,JonesCJ,NeutelJM.Atitrate-to-goalstudyofswitch-
.
Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood- . ingpatientsuncontrolledonantihypertensivemonotherapytofixed-dosecom-
. PressureControl.NEnglJMed2015;373:2103(cid:2)2116. .. binationsofamlodipineandolmesartanmedoxomilþ/-hydrochlorothiazide.J
.
556. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, . ClinHypertens(Greenwich)2011;13:404(cid:2)412.
.
WoodwardM,BillotL,HarrapS,PoulterN,MarreM,CooperM,GlasziouP, . 571.VolpeM,ChristianRumpL,AmmentorpB,LaeisP.Efficacyandsafetyoftriple
.
Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, .. antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide
RodgersA,WilliamsB.Effectsofafixedcombinationofperindoprilandindapa- .. combination.ClinDrugInvestig2012;32:649(cid:2)664.
.
mideonmacrovascularandmicrovascularoutcomesinpatientswithtype2dia- . 572.WilliamsB,MacDonaldTM,MorantSV,WebbDJ,SeverP,McInnesGT,FordI,
.
betes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet . CruickshankJK,CaulfieldMJ,PadmanabhanS,MackenzieIS,SalsburyJ,Brown
.
2007;370:829(cid:2)840. .. MJ,BritishHypertensionSocietyprogrammeofPreventionAndTreatmentof
557. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, .. Hypertension With Algorithm based Therapy (PATHWAY) Study Group.
.
ChertowGM,FineLJ,HaleyWE,HawfieldAT,IxJH,KitzmanDW,KostisJB, . Endocrine and haemodynamic changes in resistant hypertension, and blood
.
Krousel-WoodMA,LaunerLJ,OparilS,RodriguezCJ,RoumieCL,ShorrRI, .. pressureresponsestospironolactoneoramiloride:thePATHWAY-2mecha-
Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT, Jr., .. nismssubstudies.LancetDiabetesEndocrinol2018;6:464(cid:2)475.
.
PajewskiNM,SPRINTResearchGroup.IntensivevsStandardBloodPressure . 573.AgarwalR,RossignolP,RomeroA,GarzaD,MayoMR,WarrenS,MaJ,White
.
ControlandCardiovascularDiseaseOutcomesinAdultsAged>/=75Years:A . WB, Williams B. Patiromer versus placebo to enable spironolactone use in
.
RandomizedClinicalTrial.JAMA2016;315:2673(cid:2)2682. .. patients with resistant hypertension and chronic kidney disease (AMBER): a
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 103 ---
ESCGuidelines 3329
.
.
phase 2, randomised, double-blind, placebo-controlled trial. Lancet . risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet
.
2019;394:1540(cid:2)1550. . 1998;352:837(cid:2)853.
.
574. KriegerEM,DragerLF,GiorgiDMA,PereiraAC,Barreto-FilhoJAS,Nogueira .. 588.ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B,
AR,MillJG,LotufoPA,AmodeoC,BatistaMC,BodaneseLC,CarvalhoACC, .. BillotL,WoodwardM,MarreM,CooperM,GlasziouP,GrobbeeD,HametP,
.
CastroI,ChavesH,CostaEAS,FeitosaGS,FrancoRJS,FuchsFD,Guimaraes . HarrapS,HellerS,LiuL,ManciaG,MogensenCE,PanC,PoulterN,Rodgers
.
AC, Jardim PC, Machado CA, Magalhaes ME, Mion D, Jr., Nascimento RM, .. A,WilliamsB,BompointS,deGalanBE,JoshiR,TravertF.Intensivebloodglu-
Nobre F, Nobrega AC, Ribeiro ALP, Rodrigues-Sobrinho CR, Sanjuliani AF, .. cosecontrolandvascularoutcomesinpatientswithtype2diabetes.NEnglJ
.
TeixeiraM,KriegerJE,ReHOTInvestigators.SpironolactoneVersusClonidine . Med2008;358:2560(cid:2)2572.
.
as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT . 589.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-
.
RandomizedStudy(Resistant HypertensionOptimal Treatment). Hypertension .. glucosecontrolwithmetforminoncomplicationsinoverweightpatientswith
2018;71:681(cid:2)690. .. type2diabetes(UKPDS34).Lancet1998;352:854(cid:2)865.
.
575. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, . 590.ZelnikerTA,WiviottSD,RazI,ImK,GoodrichEL,BonacaMP,MosenzonO,
.
Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or . KatoET,CahnA,Furtado RHM,BhattDL,Leiter LA,McGuireDK,Wilding
.
both in patients at high risk for vascular events. N Engl J Med .. JPH,SabatineMS.SGLT2inhibitorsforprimaryandsecondarypreventionof
.
2008;358:1547(cid:2)1559. . cardiovascularandrenaloutcomesintype2diabetes:asystematicreviewand
.
576. ParvingHH,BrennerBM,McMurrayJJ,deZeeuwD,HaffnerSM,SolomonSD, . meta-analysisofcardiovascularoutcometrials.Lancet2019;393:31(cid:2)39.
.
ChaturvediN,PerssonF,DesaiAS,NicolaidesM,RichardA,XiangZ,BrunelP, .. 591.KristensenSL,RorthR,JhundPS,DochertyKF,SattarN,PreissD,KoberL,
PfefferMA,ALTITUDEInvestigators.Cardiorenalendpointsinatrialofaliski- .. PetrieMC,McMurrayJJV.Cardiovascular,mortality,andkidneyoutcomeswith
.
renfortype2diabetes.NEnglJMed2012;367:2204(cid:2)2213. . GLP-1receptoragonistsinpatientswithtype2diabetes:asystematicreview
.
577. ForouzanfarMH,LiuP,RothGA,NgM,BiryukovS,MarczakL,AlexanderL, . and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol
.
EstepK,HassenAbateK,AkinyemijuTF,AliR,Alvis-GuzmanN,AzzopardiP, .. 2019;7:776(cid:2)785.
BanerjeeA,BarnighausenT,BasuA,BekeleT,BennettDA,BiadgilignS,Catala- .. 592.BuseJB,WexlerDJ,TsapasA,RossingP,MingroneG,MathieuC,D’Alessio
.
Lopez F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, . DA,DaviesMJ.2019updateto:Managementofhyperglycaemiaintype2diabe-
. Hankey GJ, Jonas JB, Judd SE, Khang YH, Khosravi A, Kim YJ, Kimokoti RW, .. tes,2018.AconsensusreportbytheAmericanDiabetesAssociation(ADA)
KokuboY,KolteD,LopezA,LotufoPA,MalekzadehR,MelakuYA,Mensah .. andtheEuropeanAssociationfortheStudyofDiabetes(EASD).Diabetologia
. GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, . 2020;63:221(cid:2)228.
.
OhkuboT,PourmalekF,RafayA,RaiRK,Rojas-RuedaD,SampsonUK,Santos . 593.DuckworthW,AbrairaC,MoritzT,RedaD,EmanueleN,ReavenPD,Zieve
.
IS,SawhneyM,SchutteAE,SepanlouSG,ShifaGT,ShiueI,TedlaBA,Thrift .. FJ,MarksJ,DavisSN,HaywardR,WarrenSR,GoldmanS,McCarrenM,Vitek
AG,TonelliM,TruelsenT,TsilimparisN,UkwajaKN,UthmanOA,Vasankari .. ME,HendersonWG,HuangGD,VADTInvestigators.Glucosecontrolandvas-
.
T,VenketasubramanianN,VlassovVV,VosT,WestermanR,YanLL,YanoY, . cular complications in veterans with type 2 diabetes. N Engl J Med
.
YonemotoN,ZakiME,MurrayCJ.GlobalBurdenofHypertensionandSystolic . 2009;360:129(cid:2)139.
.
Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA .. 594.Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr., Granger CB,
.
2017;317:165(cid:2)182. . JonesNP,LeiterLA,RosenbergAE,SigmonKN,SomervilleMC,ThorpeKM,
.
578. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, . McMurrayJJV,DelPratoS,HarmonyOutcomescommitteesandinvestigators.
.
ChifambaJ,DagenaisG,DiazR,KazmiK,LanasF,WeiL,Lopez-Jaramillo P, .. Albiglutideandcardiovascularoutcomesinpatientswithtype2diabetesand
Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, .. cardiovascular disease (Harmony Outcomes): a double-blind, randomised
.
Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S, PURE . placebo-controlledtrial.Lancet2018;392:1519(cid:2)1529.
.
(ProspectiveUrbanRuralEpidemiology)Studyinvestigators.Prevalence,aware- . 595.Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L,
.
ness,treatment,andcontrolofhypertensioninruralandurbancommunitiesin .. LakshmananM,MellbinL,ProbstfieldJ,RiddleMC,ShawJE,AvezumA,Basile
high-,middle-,andlow-incomecountries.JAMA2013;310:959(cid:2)968. .. JN,CushmanWC,JanskyP,KeltaiM,LanasF,LeiterLA,Lopez-JaramilloP,Pais
.
579. SiuAL,USPreventiveServicesTaskForce.Screeningforhighbloodpressurein . P,PiragsV,PogosovaN,RaubenheimerPJ,SheuWH,RydenL.Similarcardio-
.
adults: U.S. Preventive Services Task Force recommendation statement. Ann .. vascularoutcomesinpatientswithdiabetesandestablishedorhighriskforcor-
InternMed2015;163:778(cid:2)786. .. onary vascular disease treated with dulaglutide with and without baseline
.
580. Huang CJ, Chiang CE, Williams B, Kario K, Sung SH, Chen CH, Wang TD, . metformin.EurHeartJ2020:[Onlineaheadofprint].
.
Cheng HM. Effect Modification by Age on the Benefit or Harm of . 596.CrowleyMJ,McGuireDK,AlexopoulosAS,JensenTJ,RasmussenS,Saevereid
.
Antihypertensive Treatment for Elderly Hypertensives: A Systematic Review .. HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in
andMeta-analysis.AmJHypertens2019;32:163(cid:2)174. .. Type2DiabetesPatientsWithandWithoutBaselineMetforminUse:PostHoc
.
581. VermaAA,KhuuW,TadrousM,GomesT,MamdaniMM.Fixed-dosecombina- . AnalysesoftheLEADERTrial.DiabetesCare2020;43:e108(cid:2)e110.
.
tion antihypertensive medications, adherence, and clinical outcomes: A . 597.NeuenBL,ArnottC,PerkovicV,FigtreeG,deZeeuwD,FulcherG,JunM,
.
population-basedretrospectivecohortstudy.PLoSMed2018;15:e1002584. .. Jardine MJ, Zoungas S, Pollock C, Mahaffey KW, Neal B, Heerspink HJL.
582. ThomopoulosC,ParatiG,ZanchettiA.Effectsofbloodpressureloweringon .. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A
.
outcomeincidenceinhypertension:4.Effectsofvariousclassesofantihyperten- . meta-analysisofcardiovascular,kidneyandmortalityoutcomes.DiabetesObes .
sivedrugs-overviewandmeta-analyses.JHypertens2015;33:195(cid:2)211. .. Metab2021;23:382(cid:2)390.
583. SattarN,Preiss D.HbA1c intype 2diabetes diagnostic criteria:addressing .. 598.Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM,
.
the right questions to move the field forwards. Diabetologia . EdwardsR,AgarwalR,BakrisG,BullS,CannonCP,CapuanoG,ChuPL,de
.
2012;55:1564(cid:2)1567. . Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H,
.
584. TheTaskForceondiabetes,pre-diabetes,andcardiovasculardiseasesofthe .. Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial
EuropeanSocietyofCardiology(ESC)anddevelopedincollaborationwiththe .. Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and
.
European Association for the Study of Diabetes (EASD). ESC Guidelines on . Nephropathy.NEnglJMed2019;380:2295(cid:2)2306.
.
diabetes,pre-diabetes,andcardiovasculardiseasesdevelopedincollaboration . 599.HeerspinkHJL,StefanssonBV,Correa-RotterR,ChertowGM,GreeneT,Hou
. withtheEASD.EurHeartJ2013;34:3035(cid:2)3087. .. FF,MannJFE,McMurrayJJV,LindbergM,RossingP,SjostromCD,TotoRD,
.
585. LeanMEJ,LeslieWS,BarnesAC,BrosnahanN,ThomG,McCombieL,Peters . LangkildeAM,WheelerDC,DAPA-CKDTrialCommitteesandInvestigators.
.
C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med
.
RehackovaL,AdamsonAJ,SniehottaFF,MathersJC,RossHM,McIlvennaY, .. 2020;383:1436(cid:2)1446.
Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R. .. 600.McMurrayJJV,SolomonSD,InzucchiSE,KoberL,KosiborodMN,MartinezFA,
.
Durabilityofaprimarycare-ledweight-managementinterventionforremission . Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE,
.
oftype2diabetes:2-yearresultsoftheDiRECTopen-label,cluster-randomised . ChopraVK,deBoerRA,DesaiAS,DiezM,DrozdzJ,DukatA,GeJ,Howlett
.
trial.LancetDiabetesEndocrinol2019;7:344(cid:2)355. .. JG,KatovaT,KitakazeM,LjungmanCEA,MerkelyB,NicolauJC,O’MearaE,
586. TaheriS,ZaghloulH,ChagouryO,ElhadadS,AhmedSH,ElKhatibN,Amona .. PetrieMC,VinhPN,SchouM,TereshchenkoS,VermaS,HeldC,DeMetsDL,
.
RA,ElNahasK,SuleimanN,AlnaamaA,Al-HamaqA,CharlsonM,WellsMT, . Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, LangkildeAM, DAPA-HF
.
Al-Abdulla S, Abou-Samra AB. Effect of intensive lifestyle intervention on .. TrialCommitteesandInvestigators.DapagliflozininPatientswithHeartFailure
bodyweightandglycaemiainearlytype2diabetes(DIADEM-I):anopen-label, .. andReducedEjectionFraction.NEnglJMed2019;381:1995(cid:2)2008.
.
parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol . 601.Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J,
.
2020;8:477(cid:2)489. . Verma S,TsutsuiH,BrueckmannM,JamalW,KimuraK,SchneeJ,Zeller C,
.
587. UKProspectiveDiabetesStudy(UKPDS)Group.Intensiveblood-glucosecon- .. CottonD,BocchiE,BohmM,ChoiDJ,ChopraV,ChuquiureE,GiannettiN,
trolwithsulphonylureasorinsulincomparedwithconventionaltreatmentand . Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP,
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 104 ---
3330 ESCGuidelines
.
.
Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, . 616.Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, Buse JB.
.
Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR- . Guidelinerecommendationsandthepositioningofnewerdrugsintype2diabe-
.
Reduced Trial Investigators. Cardiovascular and Renal Outcomes with .. tescare.LancetDiabetesEndocrinol2021;9:46(cid:2)52.
EmpagliflozininHeartFailure.NEnglJMed2020;383:1413(cid:2)1424. .. 617.WritingGroupfortheDCCT/EDICResearchGroup,OrchardTJ,NathanDM,
.
602. SattarN,McMurrayJJ,ChengAY.Cardiorenalriskreductionguidanceindiabe- . ZinmanB,ClearyP,BrillonD,BacklundJY,LachinJM.Associationbetween7
.
tes:canwereachconsensus?LancetDiabetesEndocrinol2020;8:357(cid:2)360. .. yearsofintensivetreatmentoftype1diabetesandlong-termmortality.JAMA
603. GongQ,ZhangP,WangJ,MaJ,AnY,ChenY,ZhangB,FengX,LiH,ChenX, .. 2015;313:45(cid:2)53.
.
ChengYJ,GreggEW,HuY,BennettPH,LiG,DaQingDiabetesPrevention . 618.PetrieJR,ChaturvediN,FordI,BrouwersM,GreenlawN,TillinT,HramiakI,
.
Study Group. Morbidity and mortality after lifestyle intervention for people . Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer
.
with impaired glucose tolerance: 30-year results of the Da Qing Diabetes .. CDA, Sattar N, Colhoun HM, REMOVAL Study Group. Cardiovascular and
PreventionOutcomeStudy.LancetDiabetesEndocrinol2019;7:452(cid:2)461. .. metaboliceffectsofmetformininpatientswithtype1diabetes(REMOVAL):a
.
604. Celis-Morales CA, Petermann F, Hui L, Lyall DM, Iliodromiti S, McLaren J, . double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol
.
Anderson J, Welsh P, Mackay DF, Pell JP, Sattar N, Gill JMR, Gray SR. .. 2017;5:597(cid:2)609.
AssociationsBetweenDiabetesandBothCardiovascularDiseaseandAll-Cause .. 619.AntithromboticTrialists’(ATT)Collaboration,BaigentC,BlackwellL,Collins
.
Mortality Are Modified by Grip Strength: Evidence From UK Biobank, a . R,EmbersonJ,GodwinJ,PetoR,BuringJ,HennekensC,KearneyP,MeadeT,
.
Prospective Population-Based Cohort Study. Diabetes Care . PatronoC,RoncaglioniMC,ZanchettiA.Aspirinintheprimaryandsecondary
.
2017;40:1710(cid:2)1718. .. preventionofvasculardisease:collaborativemeta-analysisofindividualpartici-
605. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, .. pantdatafromrandomisedtrials.Lancet2009;373:1849(cid:2)1860.
.
ErqouS,SattarN.Effectofintensivecontrolofglucoseoncardiovascularout- . 620.CAPRIESteeringCommittee.Arandomised,blinded,trialofclopidogrelversus
.
comesanddeathinpatientswithdiabetesmellitus:ameta-analysisofrando- . aspirin in patients at risk of ischaemic events (CAPRIE). Lancet
.
misedcontrolledtrials.Lancet2009;373:1765(cid:2)1772. .. 1996;348:1329(cid:2)1339.
606. ControlGroup,TurnbullFM,AbrairaC,AndersonRJ,ByingtonRP,Chalmers .. 621.ChiaritoM,Sanz-SanchezJ,CannataF,CaoD,SturlaM,PanicoC,GodinoC,
.
JP,DuckworthWC,EvansGW,GersteinHC,HolmanRR,MoritzTE,NealBC, . Regazzoli D, Reimers B, De Caterina R, Condorelli G, Ferrante G, Stefanini
. NinomiyaT,PatelAA,PaulSK,TravertF,WoodwardM.Intensiveglucosecon- .. GG.MonotherapywithaP2Y12inhibitororaspirinforsecondaryprevention
trol and macrovascular outcomes in type 2 diabetes. Diabetologia .. inpatientswithestablishedatherosclerosis:asystematicreviewandmeta-analy-
. 2009;52:2288(cid:2)2298. . sis.Lancet2020;395:1487(cid:2)1495.
.
607. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, . 622.Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C,
.
KaufmanKD,KoglinJ,KornS,LachinJM,McGuireDK,PencinaMJ,StandlE, .. PrescottE,StoreyRF,DeatonC,CuissetT,AgewallS,DicksteinK,Edvardsen
Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS .. T,EscanedJ,GershBJ,SvitilP,GilardM,HasdaiD,HatalaR,MahfoudF,Masip
.
Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 . J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ, ESC Scientific Document
.
Diabetes.NEnglJMed2015;373:232(cid:2)242. . Group.2019ESCGuidelinesforthediagnosisandmanagementofchroniccor-
.
608. SciricaBM,BhattDL,BraunwaldE,StegPG,DavidsonJ,HirshbergB,OhmanP, .. onarysyndromes.EurHeartJ2020;41:407(cid:2)477.
.
Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, . 623.ValgimigliM,BuenoH,ByrneRA,ColletJP,CostaF,JeppssonA,JuniP,Kastrati
.
MosenzonO,McGuireDK,RayKK,LeiterLA,RazI,SAVOR-TIMI53Steering . A,KolhP,MauriL,MontalescotG,NeumannFJ,PetricevicM,RoffiM,StegPG,
.
Committee and Investigators. Saxagliptin and cardiovascular outcomes in .. WindeckerS,ZamoranoJL,LevineGN,ESCScientificDocumentGroup.2017
patientswithtype2diabetesmellitus.NEnglJMed2013;369:1317(cid:2)1326. .. ESC focused update on dual antiplatelet therapy in coronary artery disease
.
609. WhiteWB,CannonCP,HellerSR,NissenSE,BergenstalRM,BakrisGL,Perez . developedincollaborationwithEACTS.EurJCardiothoracSurg2018;53:34(cid:2)78.
.
AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, . 624.ASCENDStudyCollaborativeGroup,BowmanL,MafhamM,WallendszusK,
.
EXAMINEInvestigators.Alogliptinafteracute coronarysyndromeinpatients .. StevensW,BuckG,BartonJ,MurphyK,AungT,HaynesR,CoxJ,Murawska
withtype2diabetes.NEnglJMed2013;369:1327(cid:2)1335. .. A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J,
.
610. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, . Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R,
.
AlexanderJH,PencinaM,TotoRD,WannerC,ZinmanB,WoerleHJ,Baanstra .. ParishS,ArmitageJ.EffectsofAspirinforPrimaryPreventioninPersonswith
D,PfarrE,SchnaidtS,MeinickeT,GeorgeJT,vonEynattenM,McGuireDK, .. DiabetesMellitus.NEnglJMed2018;379:1529(cid:2)1539.
.
CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major . 625.SeiduS,KunutsorSK,SessoHD,GazianoJM,BuringJE,RoncaglioniMC,Khunti
.
CardiovascularEventsinAdultsWithType2DiabetesandHighCardiovascular . K.Aspirinhaspotentialbenefitsforprimarypreventionofcardiovascularout-
.
and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA .. comes in diabetes: updated literature-based and individual participant data
2019;321:69(cid:2)79. .. meta-analysesofrandomizedcontrolledtrials.CardiovascDiabetol2019;18:70.
.
611. ZinmanB,WannerC,LachinJM,FitchettD,BluhmkiE,HantelS,MattheusM, . 626.McNeilJJ,WolfeR,WoodsRL,TonkinAM,DonnanGA,NelsonMR,ReidCM,
.
Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG . LockeryJE,Kirpach B,StoreyE,ShahRC,WilliamsonJD,MargolisKL,Ernst
.
OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and .. ME,AbhayaratnaWP,StocksN,FitzgeraldSM,OrchardSG,TrevaksRE,Beilin
MortalityinType2Diabetes.NEnglJMed2015;373:2117(cid:2)2128. .. LJ,JohnstonCI,RyanJ,RadziszewskaB,JelinekM,MalikM,EatonCB,BrauerD,
.
612. NealB,PerkovicV,MahaffeyKW,deZeeuwD,FulcherG,EronduN,Shaw . CloudG,WoodEM,MahadySE,SatterfieldS,GrimmR,MurrayAM,ASPREE .
W,LawG,DesaiM,MatthewsDR,CANVASProgramCollaborativeGroup. .. InvestigatorGroup.EffectofAspirinonCardiovascularEventsandBleedingin
CanagliflozinandCardiovascularandRenalEventsinType2Diabetes.NEnglJ .. theHealthyElderly.NEnglJMed2018;379:1509(cid:2)1518.
.
Med2017;377:644(cid:2)657. . 627.Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB,
.
613. WiviottSD,RazI,BonacaMP,MosenzonO,KatoET,CahnA,SilvermanMG, . Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G,
.
ZelnikerTA,KuderJF,MurphySA,BhattDL,LeiterLA,McGuireDK,Wilding .. ARRIVEExecutiveCommittee.Useofaspirintoreduceriskofinitialvascular
JPH,RuffCT,Gause-NilssonIAM,FredrikssonM,JohanssonPA,LangkildeAM, .. eventsinpatientsatmoderateriskofcardiovasculardisease(ARRIVE):arando-
.
Sabatine MS, DECLARE(cid:2)TIMI 58 Investigators. Dapagliflozin and . mised,double-blind,placebo-controlledtrial.Lancet2018;392:1036(cid:2)1046.
.
Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med . 628.AbdelazizHK,SaadM,PothineniNVK,MegalyM,PotluriR,SalehM,KonDLC,
. 2019;380:347(cid:2)357. .. RobertsDH,BhattDL,AronowHD,AbbottJD,MehtaJL.AspirinforPrimary
.
614. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, . PreventionofCardiovascularEvents.JAmCollCardiol2019;73:2915(cid:2)2929.
.
CharbonnelB,FrederichR,GalloS,CosentinoF,ShihWJ,GantzI,TerraSG, . 629.ZhengSL,RoddickAJ.AssociationofAspirinUseforPrimaryPreventionWith
.
Cherney DZI, McGuire DK, VERTIS CV Investigators. Cardiovascular .. CardiovascularEventsandBleedingEvents:ASystematicReviewandMeta-anal-
Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med .. ysis.JAMA2019;321:277(cid:2)287.
.
2020;383:1425(cid:2)1435. . 630.MahmoudAN,GadMM,ElgendyAY,ElgendyIY,BavryAA.Efficacyandsafety
.
615. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, . ofaspirinforprimarypreventionofcardiovascularevents:ameta-analysisand
.
ProbstfieldJ,RiesmeyerJS,RiddleMC,RydenL,XavierD,AtissoCM,DyalL, .. trial sequential analysis of randomized controlled trials. Eur Heart J
Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, .. 2019;40:607(cid:2)617.
.
Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, . 631.Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL.
.
LanasF,LeiterLA,Lopez-JaramilloP,CardonaMunozEG,PiragsV,Pogosova .. Aspirinfortheprimarypreventionofcardiovasculareventsinwomenandmen:
N,RaubenheimerPJ,ShawJE,SheuWH,Temelkova-KurktschievT,REWIND .. a sex-specific meta-analysis of randomized controlled trials. JAMA
.
Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes . 2006;295:306(cid:2)313.
.
(REWIND): a double-blind, randomised placebo-controlled trial. Lancet . 632.HalvorsenS,AndreottiF,tenBergJM,CattaneoM,CoccheriS,MarchioliR,
.
2019;394:121(cid:2)130. .. Morais J, Verheugt FW, De Caterina R. Aspirin therapy in primary
.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 105 ---
ESCGuidelines 3331
.
.
cardiovasculardiseaseprevention:apositionpaperoftheEuropeanSocietyof . patients with ischemic heart disease: A systematic review. J Psychosom Res
.
Cardiologyworkinggrouponthrombosis.JAmCollCardiol2014;64:319(cid:2)327. . 2018;105:80(cid:2)91.
.
633. YusufS,JosephP,DansA,GaoP,TeoK,XavierD,Lopez-JaramilloP,YusoffK, .. 650.TaylorRS,WalkerS,SmartNA,PiepoliMF,WarrenFC,CianiO,WhellanD,
Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, .. O’ConnorC,KeteyianSJ,CoatsA,DavosCH,DalalHM,DracupK,Evangelista
.
Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P, International . LS, Jolly K, Myers J, Nilsson BB, Passino C, Witham MD, Yeh GY,
.
PolycapStudy3Investigators.PolypillwithorwithoutAspirininPersonswith- .. ExTraMATCHIICollaboration.ImpactofExerciseRehabilitationonExercise
outCardiovascularDisease.NEnglJMed2021;384:216(cid:2)228. .. Capacity and Quality-of-Life in Heart Failure: Individual Participant Meta-
.
634. ScallyB,EmbersonJR,SpataE,ReithC,DaviesK,HallsH,HollandL,WilsonK, . Analysis.JAmCollCardiol2019;73:1430(cid:2)1443.
.
BhalaN,HawkeyC,HochbergM,HuntR,LaineL,LanasA,PatronoC,Baigent . 651.ShieldsGE,WellsA,DohertyP,HeagertyA,BuckD,DaviesLM.Cost-effec-
.
C.Effectsofgastroprotectantdrugsforthepreventionandtreatmentofpeptic .. tiveness of cardiac rehabilitation: a systematic review. Heart
ulcerdiseaseanditscomplications:ameta-analysisofrandomisedtrials.Lancet .. 2018;104:1403(cid:2)1410.
.
GastroenterolHepatol2018;3:231(cid:2)241. . 652.Bjarnason-WehrensB,McGeeH,ZwislerAD,PiepoliMF,BenzerW,Schmid
.
635. AgewallS,CattaneoM,ColletJP,AndreottiF,LipGY,VerheugtFW,HuberK, . JP, Dendale P, Pogosova NG, Zdrenghea D, Niebauer J, Mendes M, Cardiac
.
Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, .. RehabilitationSectionEuropeanAssociationofCardiovascularPreventionand
.
KjeldsenK,StoreyRF,ESCWorkingGrouponCardiovascularPharmacology . Rehabilitation. Cardiac rehabilitation in Europe: results from the European
.
andDrugTherapyandESCWorkingGrouponThrombosis.Expertposition . Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prev Rehabil
.
paperontheuseofprotonpumpinhibitorsinpatientswithcardiovasculardis- .. 2010;17:410(cid:2)418.
ease and antithrombotic therapy. Eur Heart J 2013;34:1708(cid:2)1713, 1713a- .. 653.BenzerW,RauchB,SchmidJP,ZwislerAD,DendaleP,DavosCH,KouidiE,
.
1713b. . Simon A, Abreu A, Pogosova N, Gaita D, Miletic B, Bonner G, Ouarrak T,
.
636. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, . McGee H, EuroCaReD study group. Exercise-based cardiac rehabilitation in
.
FonsecaF,NicolauJ,KoenigW,AnkerSD,KasteleinJJP,CornelJH,PaisP,Pella .. twelveEuropeancountriesresultsoftheEuropeancardiacrehabilitationregis-
D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, .. try.IntJCardiol2017;228:58(cid:2)67.
.
Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, . 654.Kabboul NN, Tomlinson G, Francis TA, Grace SL, Chaves G, Rac V, Daou-
. Libby P, Glynn RJ, CANTOS Trial Group. Antiinflammatory Therapy with .. KabboulT,BieleckiJM,AlterDA,KrahnM.ComparativeEffectivenessofthe
CanakinumabforAtheroscleroticDisease.NEnglJMed2017;377:1119(cid:2)1131. .. Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A
. 637. RidkerPM,EverettBM,PradhanA,MacFadyenJG,SolomonDH,ZaharrisE, . SystematicReviewandNetworkMeta-Analysis.JClinMed2018;7:514.
.
Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, . 655.AndersonL,BrownJP,ClarkAM,DalalH,RossauHK,BridgesC,TaylorRS.
.
ClearfieldM,LibbyP,GoldhaberSZ,SeagleR,OforiC,SaklayenM,ButmanS, .. Patient education in the management of coronary heart disease. Cochrane
Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ, CIRT .. DatabaseSystRev2017;6:CD008895.
.
Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic . 656.Borjesson M, Dellborg M, Niebauer J, LaGerche A, Schmied C, Solberg EE,
.
Events.NEnglJMed2019;380:752(cid:2)762. . HalleM,AdamiE,BiffiA,CarreF,CaselliS,PapadakisM,PresslerA,Rasmusen
.
638. AndersonL,ThompsonDR,OldridgeN,ZwislerAD,ReesK,MartinN,Taylor .. H,SerratosaL,SharmaS,vanBuurenF,PellicciaA.Recommendationsforpar-
.
RS.Exercise-basedcardiacrehabilitationforcoronaryheartdisease.Cochrane . ticipationinleisuretimeorcompetitivesportsinathletes-patientswithcoro-
.
DatabaseSystRev2016:CD001800. . naryarterydisease:apositionstatementfromtheSportsCardiologySectionof
.
639. LongL,MordiIR,BridgesC,SagarVA,DaviesEJ,CoatsAJ,DalalH,ReesK, .. the European Association of Preventive Cardiology (EAPC). Eur Heart J
SinghSJ,TaylorRS.Exercise-basedcardiacrehabilitationforadultswithheart .. 2019;40:13(cid:2)18.
.
failure.CochraneDatabaseSystRev2019;1:CD003331. . 657.AbreuA,Frederix I,DendaleP,JanssenA, DohertyP,PiepoliMF,VollerH,
.
640. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch M, . SecondaryPreventionandRehabilitationSectionofEAPC.Standardizationand
.
VollerH,SchmidJP,DavosCH.Effectivenessofcomprehensivecardiacrehabil- .. qualityimprovementofsecondarypreventionthroughcardiovascularrehabilita-
itationincoronaryarterydiseasepatientstreatedaccordingtocontemporary .. tion programmes in Europe: The avenue towards EAPC accreditation pro-
.
evidencebasedmedicine:UpdateoftheCardiacRehabilitationOutcomeStudy . gramme:ApositionstatementoftheSecondaryPreventionandRehabilitation
.
(CROS-II).EurJPrevCardiol2020;27:1756(cid:2)1774. .. Section of the European Association of Preventive Cardiology (EAPC). Eur J
641. SantiagodeAraujoPioC,MarzoliniS,PakoshM,GraceSL.EffectofCardiac .. PrevCardiol2020:2047487320924912.
.
Rehabilitation Dose on Mortality and Morbidity: A Systematic Review and . 658.HansenD,RoveloRuizG,DohertyP,IliouMC,VromenT,HintonS,Frederix
.
Meta-regressionAnalysis.MayoClinProc2017;92:1644(cid:2)1659. . I,WilhelmM,SchmidJP,AbreuA,AmbrosettiM,Garcia-PorreroE,ConinxK,
.
642. van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. .. DendaleP,EAPCEXPERTworkinggroup.Docliniciansprescribeexercisesimi-
Lessonsfromcontemporarytrialsofcardiovascularpreventionandrehabilita- .. larlyinpatientswithdifferentcardiovasculardiseases?FindingsfromtheEAPC
.
tion:Asystematicreviewandmeta-analysis.IntJCardiol2017;232:294(cid:2)303. . EXPERTworkinggroupsurvey.EurJPrevCardiol2018;25:682(cid:2)691.
.
643. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. . 659.Hansen D, Dendale P, Coninx K, Vanhees L, Piepoli MF, Niebauer J,
.
Interventionstopromotepatientutilisationofcardiacrehabilitation.Cochrane .. CornelissenV,PedrettiR,GeurtsE,RuizGR,CorraU,SchmidJP,GrecoE,
DatabaseSystRev2019;2:CD007131. .. DavosCH,EdelmannF,AbreuA,RauchB,AmbrosettiM,BragaSS,BarnaO,
.
644. JorstadHT,vonBirgelenC,AlingsAM,LiemA,vanDantzigJM,JaarsmaW,Lok . Beckers P, Bussotti M, Fagard R, Faggiano P, Garcia-Porrero E, Kouidi E, .
DJ,KragtenHJ,deVriesK,deMillianoPA,WithagenAJ,ScholteOpReimer .. LamotteM,NeunhausererD,ReibisR,SpruitMA,StettlerC,TakkenT,Tonoli
WJ,TijssenJG,PetersRJ.Effectofanurse-coordinatedpreventionprogramme .. C,VigoritoC,VollerH,DohertyP.TheEuropeanAssociationofPreventive
.
oncardiovascularriskafteranacutecoronarysyndrome:mainresultsofthe . Cardiology Exercise Prescription in Everyday Practice and Rehabilitative
.
RESPONSErandomisedtrial.Heart2013;99:1421(cid:2)1430. . Training(EXPERT)tool:Adigitaltraininganddecisionsupportsystemforopti-
.
645. JenningsC,KotsevaK,DeBacquerD,HoesA,deVelascoJ,BrusaferroS,Mead .. mizedexerciseprescriptionincardiovasculardisease.Concept,definitionsand
A, Jones J, Tonstad S, Wood D, EUROACTION PLUS Study Group. .. constructionmethodology.EurJPrevCardiol2017;24:1017(cid:2)1031.
.
EffectivenessofapreventivecardiologyprogrammeforhighCVDriskpersis- . 660.Abell B, Glasziou P, Hoffmann T. The Contribution of Individual Exercise
.
tent smokers: the EUROACTION PLUS varenicline trial. Eur Heart J . TrainingComponentstoClinicalOutcomesinRandomisedControlledTrialsof
. 2014;35:1411(cid:2)1420. .. Cardiac Rehabilitation: ASystematic Review andMeta-regression. Sports Med
.
646. WoodDA,KotsevaK,ConnollyS,JenningsC,MeadA,JonesJ,HoldenA,De . Open2017;3:19.
.
Bacquer D, Collier T, De Backer G, Faergeman O, EUROACTION Study . 661.KotsevaK,DeBackerG,DeBacquerD,RydenL,HoesA,GrobbeeD,Maggioni
.
Group.Nurse-coordinatedmultidisciplinary,family-basedcardiovasculardisease .. A,Marques-VidalP,JenningsC,AbreuA,AguiarC,BadarieneJ,BruthansJ,Castro
preventionprogramme(EUROACTION)forpatientswithcoronaryheartdis- .. CondeA,CifkovaR,CrowleyJ,DavletovK,DeckersJ,DeSmedtD,DeSutterJ,
.
ease and asymptomatic individuals at high risk of cardiovascular disease: a . Dilic M, Dolzhenko M, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N,
.
paired,cluster-randomisedcontrolledtrial.Lancet2008;371:1999(cid:2)2012. . HeuschmannP,Hasan-AliH,JankowskiP,LalicN,LehtoS,LovicD,MancasS,
.
647. Anderson L, Sharp GA, Norton RJ, Dalal H, Dean SG, Jolly K, Cowie A, .. MellbinL,MilicicD,MirrakhimovE,OganovR,PogosovaN,ReinerZ,StoerkS,
ZawadaA,TaylorRS.Home-basedversuscentre-basedcardiacrehabilitation. .. TokgozogluL,TsioufisC,VulicD,WoodD,EUROASPIREInvestigators.Lifestyle
.
CochraneDatabaseSystRev2017;6:CD007130. . andimpactoncardiovascularriskfactorcontrolincoronarypatientsacross27
.
648. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B, Briffa T, .. countries: Results from the European Society of Cardiology ESC-EORP
BaumanA,RedfernJ,NeubeckL.Telehealthinterventionsforthesecondary .. EUROASPIREVregistry.EurJPrevCardiol2019;26:824(cid:2)835.
.
preventionofcoronaryheartdisease:Asystematicreviewandmeta-analysis. . 662.ResurreccionDM,Moreno-PeralP,Gomez-HerranzM,Rubio-ValeraM,Pastor
.
EurJCardiovascNurs2019;18:260(cid:2)271. . L,CaldasdeAlmeidaJM,MotricoE.Factorsassociatedwithnon-participation
.
649. VerschuerenS,EskesAM,MaaskantJM,RoestAM,LatourCHM,OpReimer .. inanddropoutfromcardiacrehabilitationprogrammes:asystematicreviewof
WS. The effect of exercise therapy on depressive and anxious symptoms in . prospectivecohortstudies.EurJCardiovascNurs2019;18:38(cid:2)47.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 106 ---
3332 ESCGuidelines
.
.
663. HamiltonSJ,MillsB,BirchEM,ThompsonSC.Smartphonesinthesecondary . Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS
.
preventionofcardiovasculardisease:asystematicreview.BMCCardiovascDisord . Guidelinesonmyocardialrevascularization.EurHeartJ2019;40:87(cid:2)165.
.
2018;18:25. .. 680.ColletJP,ThieleH,BarbatoE,BarthelemyO,BauersachsJ,BhattDL,Dendale
664. Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, .. P,DorobantuM,EdvardsenT,FolliguetT,GaleCP,GilardM,JobsA,JuniP,
.
ChieffoC,GattoneM,GriffoR,SchweigerC,TavazziL,UrbinatiS,ValagussaF, . Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M,
.
VanuzzoD,GOSPELInvestigators.Globalsecondarypreventionstrategiesto .. RuttenFH,SibbingD,SiontisGCM,ESCScientificDocumentGroup.2020ESC
limiteventrecurrenceaftermyocardialinfarction:resultsoftheGOSPELstudy, .. Guidelinesforthemanagementofacutecoronarysyndromesinpatientspre-
.
a multicenter, randomized controlled trial from the Italian Cardiac . senting without persistent ST-segment elevation. Eur Heart J
.
RehabilitationNetwork.ArchInternMed2008;168:2194(cid:2)2204. . 2021;42:1289(cid:2)1367.
.
665. RoseG.Sickindividualsandsickpopulations.IntJEpidemiol1985;14:32(cid:2)38. .. 681.YusufS,ZhaoF,MehtaSR,ChrolaviciusS,TognoniG,FoxKK,Clopidogrelin
666. RoseG.Strategyofprevention:lessonsfromcardiovasculardisease.BrMedJ .. UnstableAnginatoPreventRecurrentEventsTrialInvestigators.Effectsofclo-
.
(ClinResEd)1981;282:1847(cid:2)1851. . pidogrelinadditiontoaspirininpatientswithacutecoronarysyndromeswith-
.
667. Sniderman AD, Thanassoulis G, Wilkins JT, Furberg CD, Pencina M. Sick .. outST-segmentelevation.NEnglJMed2001;345:494(cid:2)502.
IndividualsandSickPopulationsbyGeoffreyRose:CardiovascularPrevention .. 682.WiviottSD,BraunwaldE,McCabeCH,MontalescotG,RuzylloW,GottliebS,
.
Updated.JAmHeartAssoc2018;7:e010049. . NeumannFJ,ArdissinoD,DeServiS,MurphySA,RiesmeyerJ,WeerakkodyG,
.
668. DoyleYG,FureyA,FlowersJ.Sickindividualsandsickpopulations:20years . GibsonCM,AntmanEM,TRITON-TIMI38Investigators.Prasugrelversusclopi-
.
later.JEpidemiolCommunityHealth2006;60:396(cid:2)398. .. dogrel in patients with acute coronary syndromes. N Engl J Med
669. Sorensen K, Pelikan JM, Rothlin F, Ganahl K, Slonska Z, Doyle G, Fullam J, .. 2007;357:2001(cid:2)2015.
.
KondilisB,AgrafiotisD,UitersE,FalconM,MensingM,TchamovK,vanden . 683.WallentinL,BeckerRC,BudajA,CannonCP,EmanuelssonH,HeldC,Horrow
.
BrouckeS,BrandH,HLS-EUConsortium.HealthliteracyinEurope:compara- . J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG,
.
tiveresultsoftheEuropeanhealthliteracysurvey(HLS-EU).EurJPublicHealth .. Storey RF, Harrington RA, PLATO Investigators. Ticagrelor versus
2015;25:1053(cid:2)1058. .. clopidogrel in patients with acute coronary syndromes. N Engl J Med
.
670. MagnaniJW,MujahidMS,AronowHD,CeneCW,DicksonVV,HavranekE, . 2009;361:1045(cid:2)1057.
. Morgenstern LB, Paasche-Orlow MK, Pollak A, Willey JZ, American Heart .. 684.Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J,
Association Council on Epidemiology and Prevention, Council on .. RichardtG,LiebetrauC,WitzenbichlerB,AntoniucciD,AkinI,Bott-FlugelL,
. Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke . Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M,
.
Nursing,CouncilonPeripheralVascularDisease,CouncilonQualityofCare . Boncompagni D, Hilz R,RottbauerW, Okrojek R, Mollmann H,Hochholzer
.
and Outcomes Research, Council S. Health Literacy and Cardiovascular .. W,MiglioriniA,CasseseS,MolloP,XhepaE,KufnerS,StrehleA,LeggewieS,
Disease: Fundamental Relevance to Primary and Secondary Prevention: A .. AllaliA,NdrepepaG,SchuhlenH,AngiolilloDJ,HammCW,HapfelmeierA,
.
Scientific Statement From the American Heart Association. Circulation . TolgR,TrenkD,SchunkertH,LaugwitzKL,KastratiA,ISAR-REACT5Trial
.
2018;138:e48(cid:2)e74. . Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary
.
671. Jorgensen T, Capewell S, Prescott E, Allender S, Sans S, Zdrojewski T, De .. Syndromes.NEnglJMed2019;381:1524(cid:2)1534.
.
BacquerD,deSutterJ,FrancoOH,LogstrupS,VolpeM,MalyutinaS,Marques- . 685.Navarese EP, Khan SU, Kolodziejczak M, Kubica J, Buccheri S, Cannon CP,
.
VidalP,ReinerZ,TellGS,VerschurenWM,VanuzzoD,PEPsectionofEACPR. . Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM,
.
Population-level changes to promote cardiovascular health. Eur J Prev Cardiol .. WallentinL,RoeMT,JamesS.ComparativeEfficacyandSafetyofOralP2Y12
2013;20:409(cid:2)421. .. Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816
.
672. MozaffarianD,AfshinA,BenowitzNL,BittnerV,DanielsSR,FranchHA,Jacobs . PatientsFrom12RandomizedTrials.Circulation2020;142:150(cid:2)160.
.
DR, Jr., Kraus WE, Kris-Etherton PM, Krummel DA, Popkin BM, Whitsel LP, . 686.HahnJY,SongYB,OhJH,ChoDK,LeeJB,DohJH,KimSH,JeongJO,BaeJH,
.
Zakai NA, American Heart Association Council on Epidemiology and .. KimBO,ChoJH,SuhIW,KimDI,ParkHK,ParkJS,ChoiWG,LeeWS,KimJ,
Prevention,CouncilonNutrition,PhysicalActivityandMetabolism,Councilon .. ChoiKH,ParkTK,LeeJM,YangJH,ChoiJH,ChoiSH,GwonHC,SMART-
.
ClinicalCardiology,CouncilonCardiovascularDiseaseintheYoung,Council . DATEinvestigators.6-monthversus12-monthorlongerdualantiplateletther-
.
on the Kidney in Cardiovascular Disease, Council on Peripheral Vascular .. apyafterpercutaneouscoronaryinterventioninpatientswithacutecoronary
Disease,theAmericanHeartAssociationAdvocacyCoordinatingCommittee. .. syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
.
Populationapproachestoimprovediet,physicalactivity,andsmokinghabits:a . Lancet2018;391:1274(cid:2)1284.
.
scientific statement from the American Heart Association. Circulation . 687.Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG,
.
2012;126:1514(cid:2)1563. .. Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff
673. ShahAS,LangrishJP,NairH,McAllisterDA,HunterAL,DonaldsonK,Newby .. MW,HermillerJ,DauermanHL,SimonDI,KandzariDE,GarrattKN,LeeDP,
.
DE,MillsNL.Globalassociationofairpollutionandheartfailure:asystematic . PowTK,VerLeeP,RinaldiMJ,MassaroJM,DAPTStudyInvestigators.Twelve
.
reviewandmeta-analysis.Lancet2013;382:1039(cid:2)1048. . or30monthsofdualantiplatelettherapyafterdrug-elutingstents.NEnglJMed
.
674. ShahAS,LeeKK,McAllisterDA,HunterA,NairH,WhiteleyW,LangrishJP, .. 2014;371:2155(cid:2)2166.
NewbyDE,MillsNL.Shorttermexposuretoairpollutionandstroke:system- .. 688.BonacaMP,BraunwaldE,SabatineMS.Long-TermUseofTicagrelorinPatients
.
aticreviewandmeta-analysis.BMJ2015;350:h1295. . withPriorMyocardialInfarction.NEnglJMed2015;373:1274(cid:2)1275. .
675. Al-KindiSG,BrookRD,BiswalS,RajagopalanS.Environmentaldeterminantsof .. 689.Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C,
cardiovascular disease: lessons learned from air pollution. Nat Rev Cardiol .. AnderssonM,HimmelmannA,RidderstraleW,Leonsson-ZachrissonM,LiuY,
.
2020;17:656(cid:2)672. . Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalan R, Cornel JH,
.
676. HainesA,EbiK.TheImperativeforClimateActiontoProtectHealth.NEnglJ . Widimsky P, Leiter LA, THEMIS Steering Committee and Investigators.
.
Med2019;380:263(cid:2)273. .. TicagrelorinPatientswithStableCoronaryDiseaseandDiabetes.NEnglJMed
677. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, .. 2019;381:1309(cid:2)1320.
.
Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, . 690.McDonaghT,MetraM,AdamoM,GardnerR,BaumbachA,Bo¨hmM,BurriH,
LancellottiP,LandmesserU,MehilliJ,MukherjeeD,StoreyRF,WindeckerS, .. ButlerJ,C(cid:2)elutkiene_ J,ChioncelO,ClelandJGF,CoatsAJS,Crespo-LeiroMG,
. ESCScientificDocumentGroup.2015ESCGuidelinesforthemanagementof .. Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EW,
.
acute coronary syndromes in patients presenting without persistent ST- . Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R,
.
segment elevation: Task Force for the Management of Acute Coronary . MunerettoC,PiepoliMF,PriceS,RosanoGMC,RuschitzkaF,SkibelundAK,
.
SyndromesinPatientsPresentingwithoutPersistentST-SegmentElevationof .. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and
theEuropeanSocietyofCardiology(ESC).EurHeartJ2016;37:267(cid:2)315. .. treatment of acute andchronic heart failure. Eur Heart J2021;doi: 10.1093/
.
678. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, . eurheartj/ehab368.
.
Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, . 691.Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR.
.
Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, .. Comprehensivedischargeplanningwithpostdischargesupportforolderpatients
Widimsky P, ESC Scientific Document Group. 2017 ESC Guidelines for the .. withcongestiveheartfailure:ameta-analysis.JAMA2004;291:1358(cid:2)1367.
.
management of acute myocardial infarction in patients presenting with ST- . 692.Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial
.
segment elevation: The Task Force for the management of acute myocardial .. effectsofahome-basedinterventiononunplannedreadmissionsandmortality
infarction in patients presenting with ST-segment elevation of the European .. among patients with congestive heart failure. Arch Intern Med
.
SocietyofCardiology(ESC).EurHeartJ2018;39:119(cid:2)177. . 1999;159:257(cid:2)261.
.
679. Neumann FJ,Sousa-Uva M,AhlssonA, AlfonsoF, Banning AP,BenedettoU, . 693.McAlisterFA,StewartS,FerruaS,McMurrayJJ.Multidisciplinarystrategiesfor
.
ByrneRA,ColletJP,FalkV,HeadSJ,JuniP,KastratiA,KollerA,KristensenSD, .. themanagementofheartfailurepatientsathighriskforadmission:asystematic
NiebauerJ, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, . reviewofrandomizedtrials.JAmCollCardiol2004;44:810(cid:2)819.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 107 ---
ESCGuidelines 3333
.
694. FeltnerC,JonesCD,CeneCW, ZhengZJ,SuetaCA,Coker-SchwimmerEJ, .. congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA
ArvanitisM,LohrKN,MiddletonJC,JonasDE.Transitionalcareinterventions .. 2000;283:1295(cid:2)1302.
.
topreventreadmissionsforpersonswithheartfailure:asystematicreviewand . 712.Packer M, Coats AJ, Fowler MB,KatusHA, KrumH,Mohacsi P,Rouleau JL,
.
meta-analysis.AnnInternMed2014;160:774(cid:2)784. . Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol
.
695. HorwichTB,HamiltonMA,MaclellanWR,FonarowGC.Lowserumtotalcho- .. ProspectiveRandomizedCumulativeSurvivalStudyGroup.Effectofcarvedilol
lesterolisassociatedwithmarkedincreaseinmortalityinadvancedheartfail- .. onsurvivalinseverechronicheartfailure.NEnglJMed2001;344:1651(cid:2)1658.
.
ure.JCardFail2002;8:216(cid:2)224. . 713.Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM,
.
696. Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, . ShustermanNH.Theeffectofcarvedilolonmorbidityandmortalityinpatients
.
NodariS,SubaciusHP,FonarowGC,BonowRO,GheorghiadeM,EVEREST .. withchronicheartfailure.U.S.CarvedilolHeartFailureStudyGroup.NEnglJ
TrialInvestigators.Prognosticsignificanceofserumtotalcholesterolandtrigly- .. Med1996;334:1349(cid:2)1355.
.
ceridelevelsinpatientshospitalizedforheartfailurewithreducedejectionfrac- . 714.MERIT-HFStudyGroup.EffectofmetoprololCR/XLinchronicheartfailure:
.
tion(fromtheEVERESTTrial).AmJCardiol2013;111:574(cid:2)581. .. MetoprololCR/XLRandomisedInterventionTrialinCongestiveHeartFailure
697. Sharma A, Lavie CJ, Borer JS, Vallakati A, Goel S, Lopez-Jimenez F, Arbab- .. (MERIT-HF).Lancet1999;353:2001(cid:2)2007.
.
ZadehA,MukherjeeD,LazarJM.Meta-analysisoftherelationofbodymass . 715.PackerM,FowlerMB,RoeckerEB,CoatsAJ,KatusHA,KrumH,MohacsiP,
.
indexto all-cause and cardiovascular mortality andhospitalization inpatients . Rouleau JL,TenderaM,StaigerC,HolcslawTL,Amann-ZalanI,DeMetsDL,
.
withchronicheartfailure.AmJCardiol2015;115:1428(cid:2)1434. .. CarvedilolProspectiveRandomizedCumulativeSurvivalStudyGroup.Effectof
698. GuptaPP,FonarowGC,HorwichTB.Obesityandtheobesityparadoxinheart .. carvedilolonthemorbidityofpatientswithseverechronicheartfailure:results
.
failure.CanJCardiol2015;31:195(cid:2)202. . ofthecarvedilolprospectiverandomizedcumulativesurvival(COPERNICUS)
.
699. PandeyA,ParasharA,KumbhaniD,AgarwalS,GargJ,KitzmanD,LevineB, .. study.Circulation2002;106:2194(cid:2)2199.
DraznerM,BerryJ.Exercisetraininginpatientswithheartfailureandpreserved .. 716.CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol
.
ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail . StudyII(CIBIS-II):arandomisedtrial.Lancet1999;353:9(cid:2)13.
.
2015;8:33(cid:2)40. . 717.Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A,
.
700. O’ConnorCM,WhellanDJ,LeeKL,KeteyianSJ,CooperLS,EllisSJ,LeiferES, .. Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J,
Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, .. TavazziL,SpinarovaL,TomanJ,BohmM,AnkerSD,ThompsonSG,Poole-
.
Schulman KA, McKelvie RS, Zannad F, Pina IL, HF-ACTION Investigators. . WilsonPA,SENIORSInvestigators.Randomizedtrialtodeterminetheeffectof
. Efficacyandsafetyofexercisetraininginpatientswithchronicheartfailure:HF- . nebivololonmortalityandcardiovascularhospitaladmissioninelderlypatients
.
ACTIONrandomizedcontrolledtrial.JAMA2009;301:1439(cid:2)1450. .. withheartfailure(SENIORS).EurHeartJ2005;26:215(cid:2)225.
701. TaylorRS,SagarVA,DaviesEJ,BriscoeS,CoatsAJ,DalalH,LoughF,ReesK, .. 718.PittB,ZannadF,RemmeWJ,CodyR,CastaigneA,PerezA,PalenskyJ,Wittes
.
SinghS.Exercise-basedrehabilitationforheartfailure.CochraneDatabaseSyst . J. The effect of spironolactone on morbidity and mortality in patients with
.
Rev2014:CD003331. .. severeheart failure. Randomized Aldactone Evaluation StudyInvestigators. N
702. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe .. EnglJMed1999;341:709(cid:2)717.
.
congestive heart failure. Results of the Cooperative North Scandinavian . 719.ZannadF,McMurrayJJ,KrumH,vanVeldhuisenDJ,SwedbergK,ShiH,Vincent
.
EnalaprilSurvivalStudy(CONSENSUS).NEnglJMed1987;316:1429(cid:2)1435. . J,PocockSJ,PittB,EMPHASIS-HFStudyGroup.Eplerenoneinpatientswith
.
703. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting .. systolicheartfailureandmildsymptoms.NEnglJMed2011;364:11(cid:2)21.
enzyme inhibitors on mortality and morbidity in patients with heart failure. .. 720.McMurrayJJV,JacksonAM,LamCSP,RedfieldMM,AnandIS,GeJ,Lefkowitz
.
CollaborativeGrouponACEInhibitorTrials.JAMA1995;273:1450(cid:2)1456. . MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR,
.
704. PackerM,Poole-WilsonPA,ArmstrongPW,ClelandJG,HorowitzJD,Massie . SabarwalSV,ShahAM,ShahSJ,ShiVC,vanVeldhuisenDJ,ZannadF,ZileMR,
.
BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high .. Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N,
doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity .. VardenyO,Claggett B,JhundPS,SolomonSD.EffectsofSacubitril-Valsartan
.
and mortality in chronic heart failure. ATLAS Study Group. Circulation . Versus Valsartan in Women Compared With Men With Heart Failure and
.
1999;100:2312(cid:2)2318. .. Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation
705. SOLVDInvestigators,YusufS,PittB,DavisCE,HoodWB,CohnJN.Effectof .. 2020;141:338(cid:2)351.
.
enalaprilonsurvivalinpatientswithreducedleftventricularejectionfractions . 721.SantemaBT,OuwerkerkW,TrompJ,SamaIE,RaveraA,Regitz-ZagrosekV,
.
andcongestiveheartfailure.NEnglJMed1991;325:293(cid:2)302. . HillegeH,SamaniNJ,ZannadF,DicksteinK,LangCC,ClelandJG,TerMaaten
.
706. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, .. JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van
OstergrenJ,PfefferMA,SwedbergK,CHARMInvestigatorsandCommittees. .. Veldhuisen DJ, Meyer S, Lam CSP, ASIAN-HF investigators, Voors AA.
.
Effectsofcandesartaninpatientswithchronicheartfailureandreducedleft- . Identifying optimal doses of heart failure medications in men compared with
.
ventricularsystolicfunctionintoleranttoangiotensin-converting-enzymeinhibi- .. women: a prospective, observational, cohort study. Lancet
tors:theCHARM-Alternativetrial.Lancet2003;362:772(cid:2)776. .. 2019;394:1254(cid:2)1263.
.
707. McMurrayJJ,PackerM,DesaiAS,GongJ,LefkowitzMP,RizkalaAR,RouleauJL, . 722.ArmstrongPW,PieskeB,AnstromKJ,EzekowitzJ,HernandezAF,ButlerJ,Lam
.
ShiVC,SolomonSD,SwedbergK,ZileMR,PARADIGM-HFInvestigatorsand . CSP,PonikowskiP,VoorsAA,JiaG,McNultySE,PatelMJ,RoessigL,KoglinJ,
.
Committees.Angiotensin-neprilysininhibitionversusenalaprilinheartfailure.N .. O’Connor CM, VICTORIA Study Group. Vericiguat in Patients with Heart
EnglJMed2014;371:993(cid:2)1004. .. FailureandReducedEjectionFraction.NEnglJMed2020;382:1883(cid:2)1893.
.
708. VelazquezEJ,MorrowDA,DeVoreAD,DuffyCI,AmbrosyAP,McCagueK, . 723.FarisRF,FlatherM,PurcellH,Poole-WilsonPA,CoatsAJ.Diureticsforheart
. Rocha R, Braunwald E, PIONEER-HF Investigators. Angiotensin-Neprilysin . failure.CochraneDatabaseSystRev2012:CD003838.
.
Inhibition in Acute Decompensated Heart Failure. N Engl J Med .. 724.FarisR,FlatherM,PurcellH,HeneinM,Poole-WilsonP,CoatsA.Currentevi-
2019;380:539(cid:2)548. .. dencesupportingtheroleofdiureticsinheartfailure:ametaanalysisofrando-
.
709. DeVoreAD,BraunwaldE,MorrowDA,DuffyCI,AmbrosyAP,Chakraborty . misedcontrolledtrials.IntJCardiol2002;82:149(cid:2)158.
.
H,McCagueK,RochaR,VelazquezEJ,PIONEER-HFInvestigators.Initiationof .. 725.Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A,
Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: .. Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in
.
Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. . chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet
.
JAMACardiol2020;5:202(cid:2)207. . 2010;376:875(cid:2)885.
.
710.WachterR,SenniM,BelohlavekJ,Straburzynska-MigajE,WitteKK,KobalavaZ, .. 726.Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I,
Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bohmer E, .. SHIFTInvestigators.Effectsonoutcomesofheartratereductionbyivabradine
.
PouleurAC,MuellerC,TribouilloyC,LonnE,ALBJ,GniotJ,MozheikoM,Lelonek . inpatientswithcongestiveheartfailure:isthereaninfluenceofbeta-blocker
.
M, Noe A, Schwende H, Bao W, Butylin D, Pascual-Figal D, TRANSITION . dose?: findings fromtheSHIFT(Systolic Heartfailure treatment with theI(f)
.
Investigators.Initiationofsacubitril/valsartaninhaemodynamicallystabilisedheartfail- .. inhibitorivabradineTrial)study.JAmCollCardiol2012;59:1938(cid:2)1945.
urepatientsinhospitalorearlyafterdischarge:primaryresultsoftherandomised .. 727.Cin(cid:4)aCS,DevereauxPJ,McFallsEO,wardHB,MoritzTE,GoldmanS,Krupski
.
TRANSITIONstudy.EurJHeartFail2019;21:998(cid:2)1007. . WC,LittooyF,PierpontG,SantilliS,RappJ,HattlerB,ShunkK,JaenickeC,
.
711. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, .. ThottapurathuL,EllisN,RedaDJ,HendersonWG.Coronary-arteryrevascula-
WikstrandJ,ElAllafD,VitovecJ,AldershvileJ,HalinenM,DietzR,Neuhaus .. rizationbeforeelectivemajorvascularsurgery.NEnglJMed.2004;351:2795-
.
KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, . 804.VascMed2006;11:61-63.
.
RickenbacherP,BallS,GottliebS,DeedwaniaP.Effectsofcontrolled-release . 728.Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE,
.
metoprololontotalmortality,hospitalizations,andwell-beinginpatientswith .. DunkmanWB,JacobsW,FrancisGS,Flohr KH,Goldman S,CobbFR,Shah
heart failure: the Metoprolol CR/XL Randomized Intervention Trial in . PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 108 ---
3334 ESCGuidelines
.
.
vasodilatortherapyonmortalityinchroniccongestiveheartfailure.Resultsofa . 745.SaccoRL,DienerHC,YusufS,CottonD,OunpuuS,LawtonWA,PaleschY,
.
Veterans Administration Cooperative Study. N Engl J Med . Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L,
.
1986;314:1547(cid:2)1552. .. DahlofB,DeKeyserJ,DonnanGA,EstolC,GorelickP,GuV,HermanssonK,
729. DigitalisInvestigationGroup.Theeffectofdigoxinonmortalityandmorbidity .. HilbrichL,KasteM,LuC,MachnigT,PaisP,RobertsR,SkvortsovaV,TealP,
.
inpatientswithheartfailure.NEnglJMed1997;336:525(cid:2)533. . Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW, PRoFESS Study
.
730. MinchinM,RolandM,RichardsonJ,RowarkS,GuthrieB.QualityofCareinthe .. Group. Aspirin and extended-release dipyridamole versus clopidogrel for
United Kingdom after Removal of Financial Incentives. N Engl J Med .. recurrentstroke.NEnglJMed2008;359:1238(cid:2)1251.
.
2018;379:948(cid:2)957. . 746.JohnstonSC,AmarencoP,AlbersGW,DenisonH,EastonJD,EvansSR,Held
.
731. TaylorAL,ZiescheS,YancyC,CarsonP,D’AgostinoR,Jr.,FerdinandK,Taylor . P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS, SOCRATES
.
M,AdamsK,SabolinskiM,WorcelM,CohnJN,African-AmericanHeartFailure .. Steering Committee and Investigators. Ticagrelor versus Aspirin in Acute
TrialInvestigators.Combinationofisosorbidedinitrateandhydralazineinblacks .. StrokeorTransientIschemicAttack.NEnglJMed2016;375:35(cid:2)43.
.
withheartfailure.NEnglJMed2004;351:2049(cid:2)2057. . 747.SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM,
.
732. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz . CoffeyCS,PearceLA.Effectsofclopidogreladdedtoaspirininpatientswith
.
MD,FangMC,FisherM,FurieKL,HeckDV,JohnstonSC,KasnerSE,KittnerSJ, .. recentlacunarstroke.NEnglJMed2012;367:817(cid:2)825.
.
Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA, American . 748.Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P,
.
Heart Association Stroke Council, Council on Cardiovascular and Stroke . Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW,
.
Nursing, Council on Clinical Cardiology, Council on Peripheral Vascular .. Hankey GJ,JohnstonSC,Mak KH,MasJL, Montalescot G,PearsonTA, Steg
Disease. Guidelines for the prevention of stroke in patients with stroke and .. PG,SteinhublSR,WeberMA,BrennanDM,Fabry-RibaudoL,BoothJ,Topol
.
transient ischemic attack: a guideline for healthcare professionals from the . EJ, CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for
.
American Heart Association/American Stroke Association. Stroke . the prevention of atherothrombotic events. N Engl J Med
.
2014;45:2160(cid:2)2236. .. 2006;354:1706(cid:2)1717.
733. SteinerT,Al-ShahiSalmanR,BeerR,ChristensenH,CordonnierC,CsibaL, .. 749.DienerHC,BogousslavskyJ,BrassLM,CimminielloC,CsibaL,KasteM,Leys
.
ForstingM,HarnofS,KlijnCJ,KriegerD,MendelowAD,MolinaC,MontanerJ, . D,Matias-GuiuJ,RupprechtHJ,MATCHinvestigators.Aspirinandclopidogrel
. OvergaardK,PeterssonJ,RoineRO,SchmutzhardE,SchwerdtfegerK,StapfC, .. compared with clopidogrel alone after recent ischaemic stroke or transient
TatlisumakT,ThomasBM,ToniD,UnterbergA,WagnerM,EuropeanStroke .. ischaemicattackinhigh-riskpatients(MATCH):randomised,double-blind,pla-
. Organisation.EuropeanStrokeOrganisation(ESO)guidelinesforthemanage- . cebo-controlledtrial.Lancet2004;364:331(cid:2)337.
.
mentofspontaneousintracerebralhemorrhage.IntJStroke2014;9:840(cid:2)855. . 750.Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS,
.
734. OrnelloR,DeganD,TiseoC,DiCarmineC,PerciballiL,PistoiaF,CaroleiA, .. Lindblad AS, Palesch YY, Clinical Research Collaboration, Neurological
Sacco S. Distribution and Temporal Trends From 1993 to 2015 of Ischemic .. EmergenciesTreatmentTrialsNetwork,thePOINTInvestigators.Clopidogrel
.
Stroke Subtypes: A Systematic Review and Meta-Analysis. Stroke . and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med
.
2018;49:814(cid:2)819. . 2018;379:215(cid:2)225.
.
735. RodriguesMA,SamarasekeraN,LerpiniereC,HumphreysC,McCarronMO, .. 751.WangY,WangY,ZhaoX,LiuL,WangD,WangC,WangC,LiH,MengX,
.
WhitePM,NicollJAR,SudlowCLM,CordonnierC,WardlawJM,SmithC,Al- . Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC,
.
Shahi Salman R. The Edinburgh CT and genetic diagnostic criteria for lobar . CHANCEInvestigators.Clopidogrelwithaspirininacuteminorstrokeortran-
.
intracerebralhaemorrhageassociatedwithcerebralamyloidangiopathy:model .. sientischemicattack.NEnglJMed2013;369:11(cid:2)19.
development and diagnostic test accuracy study. Lancet Neurol .. 752.LiuM,CounsellC,SandercockP.Anticoagulantsforpreventingrecurrencefol-
.
2018;17:232(cid:2)240. . lowingischaemicstrokeortransientischaemicattack.CochraneDatabaseSyst
.
736. HartRG,PearceLA,AguilarMI.Meta-analysis:antithrombotictherapytopre- . Rev2000:CD000248.
.
ventstrokeinpatientswhohavenonvalvularatrialfibrillation.AnnInternMed .. 753.MohrJP,ThompsonJL,LazarRM,LevinB,SaccoRL,FurieKL,KistlerJP,Albers
2007;146:857(cid:2)867. .. GW,Pettigrew LC,Adams HP, Jr.,Jackson CM, PullicinoP, Warfarin-Aspirin
.
737. Riskfactorsforstrokeandefficacyofantithrombotictherapyinatrialfibrilla- . RecurrentStrokeStudyGroup.Acomparisonofwarfarinandaspirinforthe
.
tion.Analysisofpooleddatafromfiverandomizedcontrolledtrials.ArchIntern .. preventionofrecurrentischemicstroke.NEnglJMed2001;345:1444(cid:2)1451.
Med1994;154:1449(cid:2)1457. .. 754.Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M,
.
738. ConnollySJ,EzekowitzMD,YusufS,EikelboomJ,OldgrenJ,ParekhA,PogueJ, . LadenvallP,MolinaCA,WangY,JohnstonSC,THALESSteeringCommittee
.
ReillyPA,ThemelesE,VarroneJ,WangS,AlingsM,XavierD,ZhuJ,DiazR, . and Investigators. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic
.
Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering .. Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke
CommitteeandInvestigators.Dabigatranversuswarfarininpatientswithatrial .. 2020;51:3504(cid:2)3513.
.
fibrillation.NEnglJMed2009;361:1139(cid:2)1151. . 755.Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S,
.
739. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, . KnutssonM,LadenvallP,MolinaCA,WangY,THALESInvestigators.Ticagrelor
.
WaldoAL,EzekowitzMD,WeitzJI,SpinarJ,RuzylloW,RudaM,KoretsuneY, .. andAspirinorAspirinAloneinAcuteIschemicStrokeorTIA.NEnglJMed
BetcherJ,ShiM,GripLT,PatelSP,PatelI,HanyokJJ,MercuriM,AntmanEM, .. 2020;383:207(cid:2)217.
.
ENGAGEAF-TIMI48Investigators.Edoxabanversuswarfarininpatientswith . 756.Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, .
atrialfibrillation.NEnglJMed2013;369:2093(cid:2)2104. .. Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M,
740. GrangerCB,AlexanderJH,McMurrayJJ,LopesRD,HylekEM,HannaM,Al- .. DonnanG,FerroJM,GrondM,KallmunzerB,KrupinskiJ,LeeBC,LemmensR,
.
KhalidiHR,AnsellJ,AtarD,AvezumA,BahitMC,DiazR,EastonJD,Ezekowitz . MasjuanJ,OdinakM,SaverJL,SchellingerPD,ToniD,ToyodaK,RE-SPECT
.
JA,FlakerG,GarciaD,GeraldesM,GershBJ,GolitsynS,GotoS,Hermosillo . ESUS Steering Committee and Investigators. Dabigatran for Prevention of
.
AG,HohnloserSH,HorowitzJ,MohanP,JanskyP,LewisBS,Lopez-SendonJL, .. Stroke after Embolic Stroke of Undetermined Source. N Engl J Med
Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE .. 2019;380:1906(cid:2)1917.
.
CommitteesandInvestigators.Apixabanversuswarfarininpatientswithatrial . 757.Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD,
.
fibrillation.NEnglJMed2011;365:981(cid:2)992. .. SwaminathanB,LavadosP,WangY,WangY,DavalosA,ShamalovN,Mikulik
741. KlijnCJ,PaciaroniM,BergeE,KorompokiE,KorvJ,LalA,PutaalaJ,Werring .. R,CunhaL,LindgrenA,ArauzA,LangW,CzlonkowskaA,EcksteinJ,Gagliardi
.
DJ. Antithrombotic treatment for secondary prevention of stroke and other . RJ,AmarencoP,AmerisoSF,TatlisumakT,VeltkampR,HankeyGJ,ToniD,
.
thromboemboliceventsinpatientswithstrokeortransientischemicattackand . BereczkiD,UchiyamaS,NtaiosG,YoonBW,BrounsR,EndresM,MuirKW,
.
non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur .. BornsteinN,OzturkS,O’DonnellMJ,DeVriesBassonMM,PareG,PaterC,
StrokeJ2019;4:198(cid:2)223. .. Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A,
.
742. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, . Benavente OR, Joyner C, Themeles E, Connolly SJ, NAVIGATE ESUS
.
HalperinJL,HankeyGJ,PicciniJP,BeckerRC,NesselCC,PaoliniJF,Berkowitz . Investigators. Rivaroxaban for Stroke Prevention after Embolic Stroke of
.
SD,FoxKA,CaliffRM,ROCKETAFInvestigators.Rivaroxabanversuswarfarin .. UndeterminedSource.NEnglJMed2018;378:2191(cid:2)2201.
innonvalvularatrialfibrillation.NEnglJMed2011;365:883(cid:2)891. .. 758.PATS Collaborating Group. Post-stroke antihypertensive treatment study. A
.
743. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of rando- . preliminaryresult.ChinMedJ(Engl)1995;108:710(cid:2)717.
.
misedtrialsofantiplatelettherapyforpreventionofdeath,myocardialinfarc- .. 759.WangWT,YouLK,ChiangCE,SungSH,ChuangSY,ChengHM,ChenCH.
tion,andstrokeinhighriskpatients.BMJ2002;324:71(cid:2)86. .. ComparativeEffectivenessofBloodPressure-loweringDrugsinPatientswho
.
744. ESPRITStudyGroup,HalkesPH,vanGijnJ,KappelleLJ,KoudstaalPJ,AlgraA. . haveAlreadySufferedFromStroke:TraditionalandBayesianNetworkMeta-
.
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of . analysisofRandomizedTrials.Medicine(Baltimore)2016;95:e3302.
.
arterial origin (ESPRIT): randomised controlled trial. Lancet .. 760.OddenMC,McClureLA,SawayaBP,WhiteCL,PeraltaCA,FieldTS,HartRG,
2006;367:1665(cid:2)1673. . Benavente OR, Pergola PE. Achieved Blood Pressure and Outcomes in the
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 109 ---
ESCGuidelines 3335
.
.
Secondary Prevention of Small Subcortical Strokes Trial. Hypertension . 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial
.
2016;67:63(cid:2)69. . Diseases, in collaboration with the European Society for Vascular Surgery
.
761. White CL, Szychowski JM, Pergola PE, Field TS, Talbert R, Lau H, Peri K, .. (ESVS).Documentcoveringatheroscleroticdiseaseofextracranialcarotidand
Benavente OR, Secondary Prevention of Small Subcortical Strokes Study .. vertebral,mesenteric,renal,upperandlowerextremityarteries.Endorsedby:
.
Investigators.Canbloodpressurebeloweredsafelyinolderadultswithlacunar . theEuropeanStrokeOrganization(ESO).EurHeartJ2018;39:763(cid:2)816.
.
stroke?TheSecondaryPreventionofSmallSubcorticalStrokesstudyexperi- .. 776.BavryAA,AndersonRD,GongY,DenardoSJ,Cooper-DehoffRM,Handberg
ence.JAmGeriatrSoc2015;63:722(cid:2)729. .. EM, Pepine CJ. Outcomes Among hypertensive patients with concomitant
.
762. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, . peripheral and coronary artery disease: findings from the INternational
.
Rudolph AE,Sillesen H,SimunovicL, Szarek M, Welch KM, Zivin JA, Stroke . VErapamil-SR/TrandolaprilSTudy.Hypertension2010;55:48(cid:2)53.
.
Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) .. 777.HeartOutcomesPreventionEvaluationStudyInvestigators,YusufS,SleightP,
Investigators.High-doseatorvastatinafterstrokeortransientischemicattack.N .. PogueJ,BoschJ,Davies R,Dagenais G.Effects of anangiotensin-converting-
.
EnglJMed2006;355:549(cid:2)559. . enzymeinhibitor,ramipril,oncardiovasculareventsinhigh-riskpatients.NEngl
.
763. VermeerSE,HollanderM,vanDijkEJ,HofmanA,KoudstaalPJ,BretelerMM, .. JMed2000;342:145(cid:2)153.
RotterdamScanStudy.Silentbraininfarctsandwhitematterlesionsincrease .. 778.Shahin Y, Barnes R, Barakat H, Chetter IC. Meta-analysis of angiotensin
.
stroke risk in the general population: the Rotterdam Scan Study. Stroke . convertingenzymeinhibitorseffectonwalkingabilityandanklebrachialpres-
.
2003;34:1126(cid:2)1129. . sure index in patients with intermittent claudication. Atherosclerosis
.
764. BernickC,KullerL,DulbergC,LongstrethWT,Jr.,ManolioT,BeauchampN, .. 2013;231:283(cid:2)290.
PriceT,CardiovascularHealthStudyCollaborativeReseachGroup.SilentMRI .. 779.ParavastuSC,MendoncaDA,DaSilvaA.Betablockersforperipheralarterial
.
infarctsandtheriskoffuturestroke:thecardiovascularhealthstudy.Neurology . disease.CochraneDatabaseSystRev2013:CD005508.
.
2001;57:1222(cid:2)1229. . 780.Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary
.
765. Debette S,Beiser A,DeCarliC, AuR, HimaliJJ, Kelly-Hayes M, Romero JR, .. events in older persons with prior myocardial infarction and symptomatic
Kase CS,Wolf PA, Seshadri S.Association of MRI markers of vascular brain .. peripheralarterialdisease.AmJCardiol2001;87:1284(cid:2)1286.
.
injurywithincidentstroke,mildcognitiveimpairment,dementia,andmortality: . 781.BullenC.Impactoftobaccosmokingandsmokingcessationoncardiovascular
. theFraminghamOffspringStudy.Stroke2010;41:600(cid:2)606. .. riskanddisease.ExpertRevCardiovascTher2008;6:883(cid:2)895.
766. Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A, .. 782.MazariFA,KhanJA,SamuelN,SmithG,CarradiceD,McCollumPC,Chetter
. Vrettou AR, Ikonomidis I, Pikilidou M, Kargiotis O, Voumvourakis K, . IC.Long-termoutcomesofarandomizedclinicaltrialofsupervisedexercise,
.
AlexandrovAW,AlexandrovAV,TsivgoulisG.BloodPressureReductionand . percutaneoustransluminalangioplastyorcombinedtreatmentforpatientswith
.
Secondary Stroke Prevention: A Systematic Review and Metaregression .. intermittent claudication due to femoropopliteal disease. Br J Surg
AnalysisofRandomizedClinicalTrials.Hypertension2017;69:171(cid:2)179. .. 2017;104:76(cid:2)83.
.
767. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, . 783.FakhryF,SpronkS,vanderLaanL,WeverJJ,TeijinkJA,HoffmannWH,Smits
.
ConteMS,PomposelliFB,ClairDG,GeraghtyPJ,McKinseyJF,MillsJL,Moneta . TM,vanBrusselJP,StultiensGN,DeromA,denHoedPT,HoGH,vanDijk
.
GL, Murad MH, Powell RJ, Reed AB, Schanzer A, Sidawy AN, Society for .. LC,VerhofstadN,OrsiniM,vanPetersenA,WoltmanK,HulstI,vanSambeek
.
VascularSurgery.SocietyforVascularSurgerypracticeguidelinesforathero- . MR, Rizopoulos D, Rouwet EV, Hunink MG. Endovascular Revascularization
.
scleroticocclusivediseaseofthelowerextremities:managementofasympto- . and Supervised Exercise for Peripheral Artery Disease and Intermittent
.
maticdiseaseandclaudication.JVascSurg2015;61:2S(cid:2)41S. .. Claudication:ARandomizedClinicalTrial.JAMA2015;314:1936(cid:2)1944.
768. SinghS,ArmstrongEJ,SherifW,AlvandiB,WestinGG,SinghGD,Amsterdam .. 784.JansenSCP,HoorwegBBN,HoeksSE,vandenHoutenMML,ScheltingaMRM,
.
EA, Laird JR. Association of elevated fasting glucose with lower patency and . TeijinkJAW,RouwetEV.Asystematicreviewandmeta-analysisoftheeffects
.
increasedmajoradverselimbeventsamongpatientswithdiabetesundergoing . ofsupervisedexercisetherapyonmodifiablecardiovascularriskfactorsininter-
.
infrapoplitealballoonangioplasty.VascMed2014;19:307(cid:2)314. .. mittentclaudication.JVascSurg2019;69:1293(cid:2)1308e1292.
769. MomsenAH,JensenMB,NoragerCB,MadsenMR,Vestersgaard-AndersenT, .. 785.LawMR,MorrisJK,WaldNJ.Useofbloodpressureloweringdrugsinthepre-
.
LindholtJS.Drugtherapyforimprovingwalkingdistanceinintermittentclaudi- . ventionofcardiovasculardisease:meta-analysisof147randomisedtrialsinthe
.
cation:asystematicreviewandmeta-analysisofrobustrandomisedcontrolled .. context of expectations from prospective epidemiological studies. BMJ
studies.EurJVascEndovascSurg2009;38:463(cid:2)474. .. 2009;338:b1665.
.
770. KumbhaniDJ,StegPG,CannonCP,EagleKA,SmithSC,Jr.,GotoS,Ohman . 786.ManciaG,FagardR,NarkiewiczK,RedonJ,ZanchettiA,BohmM,Christiaens
.
EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL, . T,CifkovaR,DeBackerG,DominiczakA,GalderisiM,GrobbeeDE,Jaarsma
.
REACHRegistryInvestigators.Statintherapyandlong-termadverselimbout- .. T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM,
comes in patients with peripheral artery disease: insights from the REACH .. Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task
.
registry.EurHeartJ2014;35:2864(cid:2)2872. . Force Members. 2013 ESH/ESC Guidelines for the management of arterial
.
771. Murphy SA,CannonCP, Blazing MA, Giugliano RP, White JA, LokhnyginaY, . hypertension:theTaskForceforthemanagementofarterialhypertensionof
.
Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, .. theEuropeanSocietyofHypertension(ESH)andoftheEuropeanSocietyof
TershakovecAM,BraunwaldE.ReductioninTotalCardiovascularEventsWith .. Cardiology(ESC).JHypertens2013;31:1281(cid:2)1357.
.
Ezetimibe/SimvastatinPost-AcuteCoronarySyndrome:TheIMPROVE-ITTrial. . 787.OstergrenJ,SleightP,DagenaisG,DanisaK,BoschJ,QilongY,YusufS,HOPE .
JAmCollCardiol2016;67:353(cid:2)361. .. studyinvestigators. Impact of ramipril inpatients with evidence ofclinicalor
772.Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, .. subclinicalperipheralarterialdisease.EurHeartJ2004;25:17(cid:2)24.
.
MurphySA,JukemaJW,LewisBS,TokgozogluL,SomaratneR,SeverPS,Pedersen . 788.SarnakMJ,AmannK,BangaloreS,CavalcanteJL,CharytanDM,CraigJC,GillJS,
.
TR,SabatineMS.Low-DensityLipoproteinCholesterolLoweringWithEvolocumab . Hlatky MA, Jardine AG, Landmesser U, Newby LK, Herzog CA, Cheung M,
.
and Outcomes in Patients With Peripheral Artery Disease: Insights From the .. Wheeler DC, Winkelmayer WC, Marwick TH, Conference Participants.
FOURIERTrial(FurtherCardiovascularOutcomesResearchWithPCSK9Inhibition .. ChronicKidneyDiseaseandCoronaryArteryDisease:JACCState-of-the-Art
.
inSubjectsWithElevatedRisk).Circulation2018;137:338(cid:2)350. . Review.JAmCollCardiol2019;74:1823(cid:2)1838.
.
773. Schmit K, Dolor RJ, Jones WS, Vemulapalli S, Hasselblad V, Subherwal S, . 789.Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL,
. Heidenfelder B, Patel MR. Comparative effectiveness review of antiplatelet .. WassermanSM,DeedwaniaP,OlssonAG,SeverPS,KeechAC,GiuglianoRP,
.
agentsinperipheralarterydisease.JAmHeartAssoc2014;3:e001330. . FOURIER Steering Committee and Investigators. Efficacy and Safety of
.
774. AnandSS,BoschJ,EikelboomJW,ConnollySJ,DiazR,WidimskyP,AboyansV, . EvolocumabinChronicKidneyDiseaseintheFOURIERTrial.JAmCollCardiol
.
AlingsM,KakkarAK,KeltaiK,MaggioniAP,LewisBS,StorkS,ZhuJ,Lopez- .. 2019;73:2961(cid:2)2970.
JaramilloP,O’DonnellM,CommerfordPJ,VinereanuD,PogosovaN,RydenL, .. 790.Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ,
.
FoxKAA,BhattDL,MisselwitzF,VarigosJD,VanasscheT,AvezumAA,Chen . George JT, Green JB, Landray MJ, Baigent C, Wanner C. The potential for
.
E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S, COMPASS . improvingcardio-renaloutcomesbysodium-glucoseco-transporter-2inhibition
.
Investigators.Rivaroxabanwithorwithoutaspirininpatientswithstableperiph- .. inpeoplewithchronickidneydisease:arationalefortheEMPA-KIDNEYstudy.
eralorcarotidarterydisease:aninternational,randomised,double-blind,pla- .. ClinKidneyJ2018;11:749(cid:2)761.
.
cebo-controlledtrial.Lancet2018;391:219(cid:2)229. . 791.ProiettiM,RomitiGF,OlshanskyB,LaneDA,LipGYH.ImprovedOutcomes
.
775. The Task Force for the Diagnosis and Treatment of Peripheral Arterial .. byIntegratedCareofAnticoagulatedPatientswithAtrialFibrillationUsingthe
Diseases of the European Society of Cardiology (ESC) and of the European .. Simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med
.
SocietyforVascularSurgery(ESVS),AboyansV,RiccoJB,BartelinkMEL,Bjorck . 2018;131:1359(cid:2)1366e1356.
.
M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, . 792.YoonM,YangPS,JangE,YuHT,KimTH,UhmJS,KimJY,SungJH,PakHN,
.
Espinola-KleinC,KahanT,KownatorS,MazzolaiL,NaylorAR,RoffiM,Rother .. LeeMH,JoungB,LipGYH.ImprovedPopulation-BasedClinicalOutcomesof
J,SpryngerM,TenderaM,TepeG,VenermoM,VlachopoulosC,DesormaisI. . Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 110 ---
3336 ESCGuidelines
.
.
Fibrillation Better Care) Pathway for Integrated Care Management: A . 813.Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Levy P, Kalman JM,
.
NationwideCohortStudy.ThrombHaemost2019;19:1695(cid:2)1703. . SandersP.AssociationsofObstructiveSleepApneaWithAtrialFibrillationand
.
793. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated Care .. Continuous Positive Airway Pressure Treatment: A Review. JAMA Cardiol
Management of Patients With Atrial Fibrillation and Risk of Cardiovascular .. 2018;3:532(cid:2)540.
.
Events:TheABC(AtrialfibrillationBetterCare)PathwayintheATHERO-AF . 814.HolmqvistF,GuanN,ZhuZ,KoweyPR,AllenLA,FonarowGC,HylekEM,
.
StudyCohort.MayoClinProc2019;94:1261(cid:2)1267. .. Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP,
794. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation .. GershBJ,ORBIT-AFInvestigators.Impactofobstructivesleepapneaandcon-
.
Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The . tinuous positive airway pressure therapy on outcomes in patients with atrial
.
ATHERO-AFStudy.AmJMed2019;132:856(cid:2)861. . fibrillation-ResultsfromtheOutcomesRegistryforBetterInformedTreatment
.
795. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, .. ofAtrialFibrillation(ORBIT-AF).AmHeartJ2015;169:647(cid:2)654e642.
Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, .. 815.QureshiWT,NasirUB,AlqalyoobiS,O’NealWT,MawriS,SabbaghS,Soliman
.
SandersP.Effectofweightreductionandcardiometabolicriskfactormanage- . EZ,Al-MallahMH.Meta-AnalysisofContinuousPositiveAirwayPressureasa
.
ment on symptom burden and severity in patients with atrial fibrillation: a . Therapy of Atrial Fibrillation in Obstructive Sleep Apnea. Am J Cardiol
.
randomizedclinicaltrial.JAMA2013;310:2050(cid:2)2060. .. 2015;116:1767(cid:2)1773.
.
796. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, . 816.Shukla A, Aizer A, Holmes D, Fowler S, Park DS, Bernstein S, Bernstein N,
.
Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, . ChinitzL. Effect of ObstructiveSleep Apnea Treatmenton AtrialFibrillation
.
SandersP.Aggressiveriskfactorreductionstudyforatrialfibrillationandimpli- .. Recurrence:AMeta-Analysis.JACCClinElectrophysiol2015;1:41(cid:2)51.
cationsfortheoutcomeofablation:theARREST-AFcohortstudy.JAmColl .. 817.Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T,
.
Cardiol2014;64:2222(cid:2)2231. . CushmanW,GoffD,SolimanEZ,ThomasA,PapademetriouV.Impactofintensive
.
797. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, . glycemiccontrolontheincidenceofatrialfibrillationandassociatedcardiovascular
.
TwomeyD,ElliottAD,KalmanJM,AbhayaratnaWP,LauDH,SandersP.Long- .. outcomesinpatientswithtype2diabetesmellitus(fromtheActiontoControl
Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation .. CardiovascularRiskinDiabetesStudy).AmJCardiol2014;114:1217(cid:2)1222.
.
Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol . 818.DonnellanE,AagaardP,KanjM,JaberW,ElshazlyM,HoosienM,Baranowski
. 2015;65:2159(cid:2)2169. .. B,HusseinA,SalibaW,WazniO.AssociationBetweenPre-AblationGlycemic
798. VoskoboinikA,KalmanJM,DeSilvaA,NichollsT,CostelloB,NanayakkaraS, .. Control and Outcomes Among Patients With Diabetes Undergoing Atrial
. PrabhuS,StubD,AzzopardiS,ViziD,WongG,NalliahC,SugumarH,Wong . FibrillationAblation.JACCClinElectrophysiol2019;5:897(cid:2)903.
.
M,KotschetE,KayeD,TaylorAJ,KistlerPM.AlcoholAbstinenceinDrinkers . 819.PonikowskiP,VoorsAA,AnkerSD,BuenoH,ClelandJG,Coats AJ,FalkV,
.
withAtrialFibrillation.NEnglJMed2020;382:20(cid:2)28. .. Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C,
799. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, .. Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM,
.
Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. . Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members,
.
Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese . DocumentReviewers.2016ESCGuidelinesforthediagnosisandtreatmentof
.
Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J Am Coll Cardiol .. acuteandchronicheartfailure:TheTaskForceforthediagnosisandtreatment
.
2015;66:985(cid:2)996. . ofacuteandchronicheartfailureoftheEuropeanSocietyofCardiology(ESC).
.
800. LipGYH,CocaA,KahanT,BorianiG,ManolisAS,OlsenMH,OtoA,Potpara . Developed with the special contribution of the Heart Failure Association
.
TS,SteffelJ,MarinF,deOliveiraFigueiredoMJ,deSimoneG,TzouWS,Chiang .. (HFA)oftheESC.EurJHeartFail2016;18:891(cid:2)975.
CE,WilliamsB,Reviewers,DanGA,GorenekB,FauchierL,SavelievaI,Hatala .. 820.Forman DE, Maurer MS, Boyd C, Brindis R, Salive ME, Horne FM, Bell SP,
.
R,vanGelderI,Brguljan-HitijJ,ErdineS,LovicD,KimYH,Salinas-ArceJ,Field . Fulmer T, Reuben DB, Zieman S, Rich MW. Multimorbidity in Older Adults
.
M. Hypertension and cardiac arrhythmias: a consensus document from the . WithCardiovascularDisease.JAmCollCardiol2018;71:2149(cid:2)2161.
.
European Heart Rhythm Association (EHRA) and ESC Council on .. 821.TranJ,NortonR,ConradN,RahimianF,CanoyD,NazarzadehM,RahimiK.
Hypertension,endorsedbytheHeartRhythmSociety(HRS),Asia-PacificHeart .. Patternsandtemporaltrendsofcomorbidityamongadultpatientswithincident
.
RhythmSociety(APHRS)andSociedadLatinoamericanadeEstimulacionCardiacay . cardiovasculardiseaseintheUKbetween2000and2014:Apopulation-based
.
Electrofisiologia(SOLEACE).Europace2017;19:891(cid:2)911. .. cohortstudy.PLoSMed2018;15:e1002513.
801. Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial Fibrillation and .. 822.Buddeke J, Bots ML, van Dis I, Liem A, Visseren FLJ, Vaartjes I. Trends in
.
Hypertension.Hypertension2017;70:854(cid:2)861. . comorbidity in patients hospitalised for cardiovascular disease. Int J Cardiol
.
802. HuxleyRR,MisialekJR,AgarwalSK,LoehrLR,SolimanEZ,ChenLY,AlonsoA. . 2017;248:382(cid:2)388.
.
Physical activity, obesity, weight change, and risk of atrial fibrillation: the .. 823.Dunlay SM, Chamberlain AM. Multimorbidity in Older Patients with
Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol .. CardiovascularDisease.CurrCardiovascRiskRep2016;10:3.
.
2014;7:620(cid:2)625. . 824.JaniBD,NichollBI,McQueenieR,ConnellyDT,HanlonP,GallacherKI,LeeD,
.
803. ConenD,AlbertCM.Alcoholconsumptionandriskofatrialfibrillation:how . MairFS.Multimorbidityandco-morbidityinatrialfibrillationandeffectsonsur-
.
muchistoomuch?JAmCollCardiol2014;64:290(cid:2)292. .. vival:findingsfromUKBiobankcohort.Europace2018;20:f329(cid:2)f336.
804. LarssonSC,DrcaN,WolkA.Alcoholconsumptionandriskofatrialfibrillation: .. 825.Tisminetzky M, Goldberg R, Gurwitz JH. Magnitude and Impact of
.
a prospective study and dose-response meta-analysis. J Am Coll Cardiol . Multimorbidity on Clinical Outcomes in Older Adults with Cardiovascular .
2014;64:281(cid:2)289. .. Disease:ALiteratureReview.ClinGeriatrMed2016;32:227(cid:2)246.
805. LavieCJ,ThomasRJ,SquiresRW,AllisonTG,MilaniRV.Exercisetrainingand .. 826.Bell SP, Saraf AA. Epidemiology of Multimorbidity in Older Adults with
.
cardiacrehabilitationinprimaryandsecondarypreventionofcoronaryheart . CardiovascularDisease.ClinGeriatrMed2016;32:215(cid:2)226.
.
disease.MayoClinProc2009;84:373(cid:2)383. . 827.HallM,DondoTB,YanAT,MamasMA,TimmisAD,DeanfieldJE,JernbergT,
.
806. MontL.Arrhythmiasandsportpractice.Heart2010;96:398(cid:2)405. .. HemingwayH,FoxKAA,GaleCP.Multimorbidityandsurvivalforpatientswith
807. MenezesAR,LavieCJ,DeSchutterA,MilaniRV,O’KeefeJ,DiNicolantonioJJ, .. acute myocardial infarction in England and Wales: Latent class analysis of a
.
Morin DP, Abi-Samra FM. Lifestyle modification in the prevention and treat- . nationwidepopulation-basedcohort.PLoSMed2018;15:e1002501.
.
mentofatrialfibrillation.ProgCardiovascDis2015;58:117(cid:2)125. .. 828.KimDH,RichMW.Patient-CentredCareofOlderAdultsWithCardiovascular
808. KarjalainenJ,KujalaUM,KaprioJ,SarnaS,ViitasaloM.Loneatrialfibrillationin .. DiseaseandMultipleChronicConditions.CanJCardiol2016;32:1097(cid:2)1107.
.
vigorously exercising middle aged men: case-control study. BMJ . 829.RahimiK,LamCSP,SteinhublS.Cardiovasculardiseaseandmultimorbidity:A
.
1998;316:1784(cid:2)1785. . call for interdisciplinary research and personalized cardiovascular care. PLoS
.
809. BaldesbergerS,BauersfeldU,CandinasR,SeifertB,ZuberM,RitterM,JenniR, .. Med2018;15:e1002545.
OechslinE,LuthiP,ScharfC,MartiB,AttenhoferJostCH.Sinusnodedisease .. 830.WorldHealthOrganization.GlobalActionPlanforthePreventionandControlof
.
andarrhythmiasinthelong-termfollow-upofformerprofessionalcyclists.Eur . NCDs 2013-2020. https://www.who.int/publications/i/item/9789241506236 (22
.
HeartJ2008;29:71(cid:2)78. . June2021).
.
810. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J, Rebato C, .. 831.SongZ,JiY,SafranDG,ChernewME.HealthCareSpending,Utilization,and
ElosuaR.Long-termendurancesportpracticeincreasestheincidenceoflone .. Quality8YearsintoGlobalPayment.NEnglJMed2019;381:252(cid:2)263.
.
atrialfibrillationinmen:afollow-upstudy.Europace2008;10:618(cid:2)623. . 832.Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P,
.
811. NielsenJR,WachtellK,AbdullaJ.TheRelationshipBetweenPhysicalActivity .. Maggioni AP, Price S, Weston C, Casadei B, Gale CP. European Society of
and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. J Atr .. Cardiology methodology for the development of quality indicators for the
.
Fibrillation2013;5:789. . quantificationofcardiovascularcareandoutcomes.EurHeartJQualCareClin
.
812. Khan H, Kella D, Rauramaa R, Savonen K, Lloyd MS, Laukkanen JA. . Outcomes2020:[Onlineaheadofprint].
.
Cardiorespiratory fitness and atrial fibrillation: A population-based follow-up .. 833.SchieleF,AktaaS,RosselloX,AhrensI,ClaeysMJ,ColletJP,FoxKAA,Gale
study.HeartRhythm2015;12:1424(cid:2)1430. . CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M,
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
--- Страница 111 ---
ESCGuidelines 3337
.
MasoudiFA,PriceS,QuinnT,SwahnE,ThieleH,TimmisA,TubaroM,Vrints .. 835.WallentinL,GaleCP,MaggioniA,BardinetI,CasadeiB.EuroHeart:European
CJM, Walker D, Bueno H, ESC Scientific Document Group, Halvorsen S, .. UnifiedRegistriesOnHeartCareEvaluationandRandomizedTrials.EurHeartJ
.
JernbergT,JortveitJ,BlondalM,IbanezB,HassagerC.2020Updateofthequal- . 2019;40:2745(cid:2)2749.
.
ity indicators for acute myocardial infarction: a position paper of the . 836.CaseyDE,Jr.,ThomasRJ,BhallaV,Commodore-MensahY,HeidenreichPA,
.
AssociationforAcuteCardiovascularCare:thestudygroupforqualityindica- .. KolteD,MuntnerP,SmithSC,Jr.,SpertusJA,WindleJR,WozniakGD,Ziaeian
tors from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute .. B.2019AHA/ACCClinicalPerformanceandQualityMeasuresforAdultsWith
.
CardiovascCare2021;10:224(cid:2)233. . High Blood Pressure: A Report of the American College of Cardiology/
.
834. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, Hills MT, . AmericanHeartAssociationTaskForceonPerformanceMeasures.JAmColl
.
HindricksG,KusumotoFM,LaneDA,LauDH,LettinoM,LipGYH,LobbanT, .. Cardiol2019;74:2661(cid:2)2706.
.
PakHN,PotparaT,SaenzLC,VanGelderIC,VarosyP,GaleCP,DagresN, . 837.DrozdaJP,Jr.,FergusonTB,Jr.,JneidH,KrumholzHM,NallamothuBK,Olin
.
Reviewers,BovedaS,DenekeT,DefayeP,ConteG,LenarczykR,Providencia . JW,TingHH.2015ACC/AHAFocusedUpdateofSecondaryPreventionLipid
.
R,GuerraJM,TakahashiY,PisaniC,NavaS,SarkozyA,GlotzerTV,Martins .. Performance Measures: A Report of the American College of Cardiology/
OliveiraM.Qualityindicatorsforthecareandoutcomesofadultswithatrial .. AmericanHeartAssociationTaskForceonPerformanceMeasures.JAmColl
.
fibrillation.Europace2021;23:494(cid:2)495. . Cardiol2016;67:558(cid:2)587.
Downloaded
from
https://academic.oup.com/eurheartj/article/42/34/3227/6358713
by
guest
on
22
January
2026
